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THESIS ABSTRACT 
 
Background 
 
AML is one of the most common and acute diseases among the types of leukaemia. The 
treatment  costs  for  AML/APML  are  considerably  high  as  it  involves  the  use  of  
expensive treatments (such as stem cell transplantation). Over the past 20 years, the 
topic has attracted the interest of an increasing number of economic evaluation 
researchers, with the goal of reducing the related costs without compromising the quality 
of care and the clinical outcomes. However, no relevant overall/lifetime treatment cost 
study  has  been  carried  out  yet,  mainly  due  to  UK data  availability  constraints.  Taking  
the above into consideration, the aim of the study was to calculate the overall/lifetime 
treatment costs by applying the bottom-up method.  
 
Methods 
 
In order to obtain overall/lifetime cost for AML/APML treatments, an innovative 
three-phase costing study was conducted on 239 newly diagnosed (during September 
2004 to September 2006) adult AML/APML patients in Haematological Malignancy 
Research Network (HMRN). The study employed the bottom-up costing method and the 
retrospective treatment pathway. The involved patients were followed from diagnosis 
date onwards, until death or cure. Treatment pathways, and all the relevant clinical 
information (including treatments, tests, and duration) were extracted from patients’ 
medical  notes  on  a  regular  basis  by  well  trained  research  nurses.  Unit  costs  were  
determined from various sources, including the British National Formulary and the unit 
costs of health and social care from the Personal Social Services Research Unit 
(PSSRU). Finally, an exploratory analysis was carried out on the obtained cost results in 
order to uncover potential cost predictors. 
 
Results 
 
The average overall treatment cost per patient was found to be £27290. This cost was 
mainly  the  result  of  the  first-line  treatment  cost  and  the  number  of  AML  recurrences.  
The major cost driver throughout all disease phases was hospitalization, followed by 
drug  and  complication  treatment.  Age,  death  or  not,  number  of  treatments,  type  of  
primary induction treatment, and response to induction treatment were found to be 
highly associated with overall treatment costs.  
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Conclusion 
 
The results of the current study showed that the lifetime/overall costs of AML/APML 
treatments was considerably high (although variance between patients was high as well), 
and uncovered the potential existence of a number of cost predictors. It is expected that 
these findings could help to bridge the gap between the actual cost and the NHS reference 
costs, while the potential cost predictors could assist decision makers in relation to health 
policy or clinical guideline issues. 
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CHAPTER 1 INTRODUCTION  
 
1.1 Research Motivation 
 
1.1.1 Why AML/APML? 
 
Cancer care is often associated with intensive, ongoing treatment regimens and 
consequently has high associated costs. In this context, an important issue within the 
health care industry is the reduction of related costs without compromising the quality of 
care and the clinical outcomes. Better understanding of treatment costs facilitates 
evidence based decision making. 
 
Among all cancers, haematological malignancies are one of the most costly to treat, as it 
involves  expensive  treatments  (such  as  stem  cell  transplantation).  Traditionally,  the  
haematological malignancies are classified into three groups, namely lymphoma, 
leukaemia, and myeloma. Over the past 20 years, leukaemia treatments have advanced 
rapidly and, additional therapies are also expected to be introduced in the near future. 
Because of these developments, a number of economic evaluation researchers have 
increasingly focused on ‘leukaemia’ and the high costs associated with new treatments [1, 
2]. 
 
Following the increased interest in leukaemia it was decided that acute myeloid 
leukaemia (AML) was the target disease to study here. This was because AML is one of 
the most common and acute diseases among different types of leukaemia (acute 
lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML), and chronic 
lymphocytic leukaemia (CLL)) [3-5]. The current work was planned and carried out with 
the support of the Haematological Malignancy Research Network, (HMRN) [6]. 
 
1.1.2 What is AML/APML? 
 
Acute Myeloid Leukaemia (AML) is a form of cancer that affects the myeloid blood cells 
produced in the bone marrow. This includes red blood cells, platelets, and all white cells 
except lymphocytes. For the above reason, in some American publications, AML is also 
referred as acute non-lymphocytic leukaemia (ANLL) [7, 8]. In AML, blast cells start to 
accumulate in the bone marrow and can not differentiate properly. This leads to a large 
number of immature white blood cells in blood and bone marrow, with the amount of 
normal white blood cells significantly decreased. Therefore, this type of AML is also 
referred to acute myeloblastic leukaemia [9]. In cases where abnormal cells are red blood 
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cells or platelet, the term erythroleukaemia or acute megakaryocytic leukaemia are used 
respectively [8]. 
 
a. Classification 
 
AML  is  not  a  single  disease  but  a  set  of  phenotypically  similar  diseases  [10].  The  
traditional French-American-British (FAB) classification divides AML into eight 
subtypes ranging from M0 to M7 [11]. However, the more recent World Health 
Organization (WHO) classification sub-categorizes AML into five groups, in order to 
increase prognostic utility [10, 12-15]. In HMRN, which is the network involved in the 
current study, the WHO classification system was used. Further details on the above can 
be found in Appendix 1.1. 
 
b. AML epidemiology in the UK 
 
AML and APML account for approximately 6.7% of all newly diagnosed haematological 
neoplasms in the UK, with an incidence rate of 4.0 per 100,000 [16]. There are 
approximately 2000 new cases of AML diagnosed in the UK every year, with over 1400 
of these cases involving patients over 60 years of age [16-19]. AML can occur at any age, 
but the incidence rate increases with age. The median age of the AML is 68 [16]. It is the 
most common type of leukemia in adults and accounts for approximately 15-20% of 
childhood leukaemia [3]. 
 
c. Treatment 
 
AML is a quickly progressing disease. If left untreated, AML often lead to death within a 
few months from diagnosis [20, 21]. AML treatment can be divided into two phases: 
induction (remission induction) and consolidation (post-remission / maintenance / 
remission continuation) therapy. 
 
•Induction therapy 
Induction therapy is the first phase of treatment. Its purpose is to destroy the leukaemia 
cells in the blood and bone marrow, and to put the leukaemia into remission [9]. The 
conventional induction therapy for patients with good risk features is intensive 
chemotherapy (in combination with anthracycline and cytarabine) [22, 23]. To decrease 
the incidence and severity of infections induced by chemotherapy, sometimes 
additional cytotoxic agents (such as G-CSF) are used as adjuncts/supportive care [24, 
25]. For some elderly relapsing patients (with poor risk features), no intervention has 
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been proven to be better than others. Under such circumstance, low intensity 
chemotherapy may be given [24, 25]. 
 
•Consolidation therapy 
This is the second phase of treatment. It begins after the leukaemia is in remission. Its 
purpose is to destroy the remaining leukaemia cells, which might be inactive but they 
can potentially begin to re-grow leading to relapsed disease [26]. A number of types of 
interventions are used as consolidation therapies including intensive chemotherapy and 
allogeneic or autologous hematopoietic stem cell transplantation (HSCT) [24, 25]. 
However, relapsing patients are more likely to be candidates for hematopoietic stem 
cell transplantation [26]. 
 
•Supportive care/therapy 
Supportive care can be used as a main treatment option when patients’ conditions 
ccould not tolerate intensive therapies with cure intent, or as a treatment that is given in 
addition to the primary therapy. Supportive care contains a number of sub-type 
treatments, including blood or platelet transfusion, erythropoietin, granulocyte 
colony-stimulating factor, and steroids. 
 
d. Prognosis 
 
Prognosis is dependent on age, cell type, and the therapy given to patient [23-25]. It is 
generally accepted that older age is an adverse prognostic factor [23, 24, 27, 28]. 
Leukemic cell type is another strong prognostic factor in terms of both  response to 
induction therapy and survival [29, 30]. Patients with t(15;17), t(8;21), or inv(16) are 
expected to have better response to induction therapy and better overall survival [24, 
31-33]. Type of treatment also has an important role in prognosis. AML is known for its 
rapid progress, leading to death within weeks or months if untreated [34, 35]. However, 
approximately 60-70% of adults with AML are expected to achieve complete remission 
after induction therapy. More than 25% of adults with AML (about 45% of those who 
achieve complete remission) can be expected to survive 3 or more years [24, 36]. 
 
1.1.2 Why economic evaluation of AML/APML is important? 
 
Increased emphasis is being placed recently on the economic evaluations of AML/APML. 
This is mainly due to its progressively increasing cost of treating this disease. This trend 
is driven by the following three factors: 
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a. Increasing cases related to incidence 
 
The increasingly aging population in developed countries has resulted in increased 
incidence of AML. According to predictions based on an extrapolation of UK Leukaemia 
Research Fund epidemiologic data, the number of AML cases will increase 20% by 2031. 
This is mainly due to an increase of cases occurring in the elderly [37]. 
 
b. Increasing cases related to recurrence 
 
Major advances have occurred in treatment over the last 25 years. Modern therapy 
ensures that the great majority of patients achieve clinical remission. However, because 
AML/APML often relapses patients often require further courses of treament [38].  
 
c. Expensive to treat 
 
AML treatments have a very high associated cost, as they involve expensive interventions, 
such as prolonged hospital care, high level technological medical intervention, and 
provision of specialized facilities (such as those available on bone marrow transplant 
units) [39]. Moreover, new treatments/drugs under development often have high costs 
(such as Mylotarg). As a result AML is one of the most expensive diseases to treat among 
all cancers.  
 
Since the number of AML cases is expected to increase steadily and treatment costs are 
expected to remain high, economic evaluation of AML is important and necessary for 
more efficient healthcare resource allocation. However, only a small number of (three) 
AML  economic  evaluation  studies  have  been  carried  out  in  the  UK,  with  all  of  them  
focusing only on specific treatments (and not on lifetime treatments) due to data 
constraints. For this reason, the current study aims to explore methods to overcome these 
constraints and evaluate the lifetime treatment costs of AML, while also determining cost 
predictors for future health policy decision-making. 
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1.2 Determining a method for cost calculation 
 
 
1.2.1 Introduction of costing method 
 
Over the past few decades, researchers have tried to establish a ‘gold standard’ in order to 
provide the best estimate of ‘true cost’. However, this gold standard was difficult to 
establish  [40] as different costing methods are appropriate to specific situations and  no 
single methodology is appropriate for all circumstances. In the absence of a ‘gold 
standard’, the approaches for accurate estimations of the cost of specific healthcare 
services have been broadly classified into two categories: top-down and bottom-up 
[41-43]. 
 
a. Top-down approach 
 
Top-down methods use relative value units (RVU), such as hospital days, outpatient visits, 
or other metrics to assign total costs to individual services or healthcare products. They 
are often used when fine details are not available [43].  
 
The top-down method is an efficient approach. It is easy to conduct, less 
resource-demanding, and the implied data collection is relatively straightforward. Of 
greatest importance, the top-down method ensures that all expenses are included and no 
cost is overseen. This is because in this approach the basis is the “total cost”, which is 
later assigned to end products through a set of distribution formulas [44, 45]. However, 
the drawback of the top-down approach is that costs derived in this way might not 
accurately reflect actual resource use because total costs are allocated based on aggregate 
information [46]. Moreover, the result derived through the top-down costing method 
lacks a direct cause-and-effect relationship, as the top-down approach assigns the total 
costs by using “various weighting systems”. Therefore, any factor identified using the 
top-down approach might be associated but not causative [47]. 
 
b. Bottom-up approach 
 
The bottom-up approach is a method that assigns costs to health services or products, 
based on the actual contribution of the resource use and representing their proportion of 
total costs [43, 48, 49]. 
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This approach has many advantages. Firstly, many different issues can be addressed and 
the effect of each can be well understood as the conceptual design is built from scratch 
[47]. Secondly, the cost results are precise and reliable because they are derived in great 
detail. Thirdly, the bottom-up approach is transparent; it allows tracing and identifying 
the contribution of each element of the healthcare system to the cost of an individual 
healthcare service, while it also presents the subtle cost variations [43, 48-50]. Finally, it 
can reveal the cause and effect relationship [47]. 
However, there are also a number of disadvantages related with the bottom-up approach. 
Firstly, the whole analysis procedure is complex and time-consuming, something that 
make it more expensive to implement and difficult to use [42, 43, 49, 51]. Secondly, the 
bottom-up method is a resource-demanding approach. It requires a costing model that has 
to be designed from scratch, a detailed cost database, and analysts who are familiar with 
the study area involved in order that the method can be correctly applied [47].  
 
1.2.2 Why use the bottom up costing method? 
 
a. Capturing variations in cost 
 
The  bottom-up approach  emphasizes  time and  patient  differences  as  it  builds  up  costs  
based on resource use, which  can vary over time and between individuals [43]. In 
contrast, top-down approaches smooth out cost differences over time and between 
patients  as  they  apply  the  same  weights  to  similar  products  irrespectively  of  time  or  
patient differences [50]. Furthermore, the transparency and the strong cause-effect 
relationship associated with the bottom-up approach mean that the cost results can be 
further analyzed [43, 48-50]. 
 
b. Characteristics of the treatment/intervention cost 
 
An important characteristic of the hospital / treatment cost is that departments within the 
hospital work in collaboration with each other (not completely independent). Therefore, 
treatments processes are the result of complex interplay between many departments and 
thus cost units. In this context, the bottom-up costing method can be more precise than the 
top-down approach, as the former would not compromise the accuracy of the generated 
costs. 
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c. Exploring a method to overcome data constraints in the UK 
 
There is an increasing interest in costing life-time treatments for AML/APML patients, as 
life-time cost provides a clear overview of the total medical resource use for each patient. 
However,  no relevant life-time treatment cost  studies have been carried out in the UK. 
Moreover, in previous related studies, hospital billing systems and administrative claim 
databases were the main data sources for costing life-time treatments. However, in the 
UK, neither of the aforementioned data sources are available. The lack of previous data, 
specifically on life-time costs, and the inability of current top-down information systems 
to supply the detailed costings restricts the possibility of costing lifetime treatment for 
AML/APML in the UK. To resolve this issue, it was decided that bottom-up costing 
should be used, as this method is considered to be an alternative way to obtain the real 
cost without compromising the quality of the study. 
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1.3 Why cost the full history of treatment? 
 
Many previous economic evaluation studies of AML/APML have been restricted by 
setting a fixed time or study time period due to time, workforce, or data constraints. Such 
studies only use the ‘first line treatment phase’ or ‘induction treatment phase’ as study 
time period. This approach made their results more comparable, but fails to take two facts 
into consideration. Firstly, first-line treatment does not represent the whole range of 
treatments. Although cancer treatments generally are centered on the initial treatment 
episode, the outcome of induction treatment can only partly determine the whole range of 
treatments on the patient pathway. Secondly, AML/APML is a disease with a high rate of 
relapse. First line treatment cost therefore only accounts for part of the overall treatment 
cost. In order to have an overview of the total medical resource use and to uncover the 
long-term effect of cost predictors, it was decided to cost the entire pathway, including all 
treatments for AML/APML. 
 
1.4 Aim and objectives of the thesis 
 
The current study is an exploratory cost study, which forms the basis of a methodology 
for constructing life-time costs and illustrating the complexity of using a bottom-up 
methodological approach. The overall aim of this thesis is to provide the first detailed 
lifetime/overall costs of treating patients with AML/APML in the UK.  
 
The general objectives for this thesis are: 
a. To apply the bottom-up method in order to overcome the constraints of UK data and 
provide high-quality longitudinal cost data for economic evaluation studies. 
b. To explore phase-specific and lifetime treatment costs in order to identify patterns of 
resource utilization for AML/APML treatments in the UK. 
c. To explore possible cost predictors in order to provide useful information (on 
AML/APML) to policymakers or expert panels  
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1.5 Outline of the current thesis 
 
The current study was carried out in three main phases. In the first phase, the cost drivers 
that were commonly used in previous studies were explored in order that they could be 
integrated into the costing method of the current study. In the second phase, the 
bottom-up approach was employed in order to develop a costing method suitable for the 
UK setting. In the third phase, the costing method that had been developed was applied 
and the treatment costs were calculated. Finally, the cost results were further analyzed in 
order to uncover related cost predictors for AML/APML lifetime treatments. The 
breakdown of chapters is as follows. 
 
In Chapter two, the existing literature on economic evaluations of AML/APML is 
presented. The costing methods (such as data sources and measurement details) and the 
results of existing studies are presented.are possible cost drivers for the UK setting are 
then identified.  
 
In Chapters three and four, the three main databases which provided the data for this study 
are further discussed. Details related to database handling (such as data cleaning and 
missing data imputation) can be found in Chapter three. The results from the preliminary 
analysis of the three databases (such as treatment types and treatment durations) are 
presented in Chapter four.  
 
Chapter five presents an overview of the study methodology. This includes concepts such 
as deciding the costs that should be evaluated and determining the data sources to be used 
for costing. 
 
The three-phase costing method developed for the study is described in Chapters six, 
seven and eight. Phase one, which relates to the bottom-up costing methods for each cost 
driver, is presented in Chapter six, while Phase two, which relates to the costing methods 
for each treatment, is presented in Chapter seven. Finally, Phase three, which relates to 
the costing method for the overall treatments, is presented in Chapter eight.   
 
In Chapter nine, all the cost results are presented, ordered by treatment phases (including 
each treatment and overall treatment costs) along with the possible cost predictors. In this 
chapter, the challenges that arose during the costing and information related to data 
handling are presented. Also, the study results are further compared with those of other 
related studies in order to justify/validate the costing method and the cost results. 
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The final chapter (Chapter ten) summarizes the main findings of each chapter and the 
contribution of the current study to the existing literature. Finally, issues that require 
further analysis in the future in relation to the costings are listed.  
 
The structure of the thesis is illustrated below (Figure 1.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Illustration of the structure of the thesis 
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CHAPTER 2 LITERATURE REVIEW 
 
2.1 Objectives of the review 
 
Various cost measurement methods are generally available. For the purposes of the 
current work, it was decided that a systematic review would be conducted to explore the 
available costing methods for AML/APML and confirm the appropriateness of current 
practices. 
 
In the systematic review, all the costing studies that were relevant to AML/APML were 
reviewed. In the process, detailed information about the treatment costing methods, the 
data sources, and the cost results were extracted and sorted, in order to provide references 
for the costing methods used at later stages of the current study. 
 
The review questions focused on: 
 
a. The number of relevant cost studies that have been conducted on AML/APML. 
b. The costing methods used in the relevant studies (including the study time period, and 
the involved cost drivers). 
c. The results of the relevant studies. 
 
The review process is illustrated in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 The illustration of the review process 
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2.2 Study selection phase 1: selection criteria 
 
The research was limited to English language articles published between 1995 and 2007. 
All types of cost studies (such as cost analysis, cost effectiveness analysis, and cost utility 
analysis  studies)  on  AML/APML  were  included.  The  details  are  discussed  in  the  
following sections, while the summarized criteria are listed in Table 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.1 Participants 
 
Inclusion criteria: 
Studies in which patients were newly diagnosed with Acute Myeloid Leukemia 
(AML) and/or Acute Promyelocytic leukemia (APML / APL) were included, 
regardless of age and treatment phases. 
Exclusion criteria: 
Studies in which patients who were not diagnosed with AML or APML were 
excluded.  
 
a. AML /APML 
 
Studies that recruited both AML and APML patients were included. The reason for this 
was that the treatments and the clinical manifestations of APML were significantly 
different from the ones of AML, although APML is a common subtype of AML (accounts 
for 5-10% of cases of AML) [52, 53]. In the current review, studies focusing exclusively 
on APML or on both AML and APML were all included. It is worth noting that studies 
that included various haematological cancers (in which only a minor part concerned 
AML/APML) were excluded, as the relevant study designs, measurement methods, and 
results had little correlation with AML/APML.  
Table 2.1 Summary of the study selection criteria 
 Inclusion Exclusion 
Population Newly diagnosed AML / APL Not AML / APL studies or only a 
minor part discusses about AML 
Intervention Economic evaluation analysis Clinical management analysis 
Outcome Costing method No relevant methods 
Language English studies Non-English studies 
Publication status Published and unpublished - 
Publish year 1995-2008 Before 1995 
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b. Newly diagnosed 
 
Studies that recruited ‘newly diagnosed’ and ‘previously untreated’ patients were both 
included to allow the costing of the complete patient pathway from time of diagnosis. It is 
worth noting that the newly diagnosed criterion only applied to induction therapy studies. 
For studies focusing on consolidation therapy, complications of treatment, and supportive 
or palliative care, the newly diagnosed criteria was not applied, as it is not necessary to 
restrict with the newly diagnosed and previous untreated criteria.  
 
c. Age  
 
All the relevant economic evaluation studies on AML/APML were included regardless of 
the age of the study patients. The reason for not taking age into consideration was that 
AML/APML can occur in the young and the elderly groups [52, 53].  
 
2.2.2 Intervention and comparisons 
 
All AML/APML studies involving cost calculations were included. The reason for this 
was to reveal how the costing methods were carried out in previous studies. This included 
cost analysis, cost utility analysis, and cost effectiveness analysis. However, clinic 
management studies were not included as these studies were not related to cost estimation. 
Also, previous ‘review studies’ were excluded. The reason for this was that ‘review 
studies’ could not provide information related with the costing methodology, as these 
studies mainly focused on summarizing the cost results of other original studies. It is 
worth noting that the economic evaluations for single intervention or for comparison of 
multiple interventions were all included. The interventions were further categorized at 
later stages of the review.  
 
2.2.3 Outcome 
 
For the purposes of the current review, the primary outcomes were costing methods and 
costing details, while the secondary outcomes were cost results. 
 
a. For the objectives of the current review, costing methods and costing details (such as 
data sources and associated cost drivers) reported in previous studies were regarded 
as the primary outcomes. These details provided useful references for the costing 
method that was used at later stages of the current study. 
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b.  Cost  results  were  set  as  the  secondary  outcome  of  the  current  review.  Through  the  
transformation  of  the  cost  values  to  2007  USD,  cost  results  from  studies  from  
different countries, or those using different methods became comparable. The reason 
for converting currencies to US dollars, and not the opposite, was that most of the 
cost-study results were published in US dollars.  
 
2.2.4 Language 
 
Only relevant studies written in English were included in the current review. This was for 
2 reasons. Firstly, as English journals are a central point of the field in the present day, 
papers published in them are guaranteed to have been subjected to thorough reviewing. 
Therefore, papers written in English are considered to be of a higher quality standard than 
papers written in other languages [54]. Secondly, in most cases articles from non-English 
journals were very difficult to access/obtain, in contrast to study abstracts written in 
English that could be easily obtained through the main search engines of electronic 
databases for health care studies (such as MEDLINE, PUBMED, EMBASE). However, 
excluding non-English papers might cause language bias. Previous studies have shown 
that research reporting  effective interventions is more likely to be published in English 
[55-57]. Therefore, it was expected that the costing methods and results for ineffective 
intervention could be overlooked in the current review. 
 
2.2.5 Publication status 
 
Unpublished studies were considered to be of a lower quality standard than published 
ones (as they are likely not to have been reviewed thoroughly) and, thus, could bias the 
review results. However, both published and unpublished studies were included in the 
current review. This was mainly for two reasons. Firstly, excluding unpublished studies 
would cause publication bias, which effectively means that studies with significant 
findings are more likely to be published [58-62]. Therefore, excluding the unpublished 
studies could bias the results of the current review. Secondly, including the unpublished 
studies increased the amount of the reviewed studies. Therefore, it was considered that 
the inclusion of both published and unpublished studies would help in collecting as many 
relevant studies as possible, while it would also prevent publication bias. 
 
2.2.6 Year of publication 
 
In  order  to  include  as  many  relevant  studies  as  possible,  no  restriction  on  the  year  of  
publication was generally desirable in the current context. However, only studies 
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published between 1995 and 2008 were included here. This was for 3 reasons. Firstly, 
most of the available studies were published after 1994. Secondly, cancer treatments 
advanced rapidly. Treatments used before 1994 were not applicable in the present day. 
Thirdly, the Calman Hine Report (1995) introduced into the reconfiguration of cancer 
services in 1995 in order to ensure the quality of cancer services [63]. Therefore, it was 
decided the cut-off point of the year of publication to be set to 1995. 
 
2.2.7 Full text versus abstract 
 
Ideally, only full report studies should be included. However, due to the difficulty of full 
text access, abstracts were also included if they had sufficient relevant PICO information 
(population, intervention, control, and outcome). This ensured that the highest possible 
number of studies was identified.  
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2.3 Study selection phase 1: Search strategies for identifying studies 
 
To  identify  studies  potentially  related  with  the  current  work,  four  sources  were  
examined/searched. Details of the search process for each of these sources are presented 
in the following sections.  
 
2.3.1 Published studies 
 
Published studies were mainly identified via the search engines of the relevant electronic 
database, namely MEDLINE / PUBMED, EMBASE, and NHS Economic Evaluation 
Database (NHS EED) of Centre for Reviews and Dissemination. MEDLINE , the U.S. 
National Library of Medicine's bibliographic database, is one of the most complete 
databases, as it contains more than 18 million articles (with about 3/4 of these articles 
being recent) covering biomedicine and health from 1947 to the present day [54, 64, 65]. 
However,  it  was  not  the  only  database  that  was  examined.  This  was  because  previous  
research has shown that, on average, only 34% of papers are covered by both MEDLINE 
and EMBASE [66]. This indicated that a large number of studies were not included in 
MEDLINE. For this reason, it was decided that EMBASE (covering all areas of health 
care and index journal published from around the world), and the NHS EED (focusing on 
health economic evaluation) would also be searched/examined, in addition to MEDLINE. 
 
To  identify  relevant  studies,  several  filters  and  truncations  were  used  in  the  search  
engines, such as the Ovid economic evaluation filter, the filter designed by the SIGN [67], 
truncated  name  of  treatment  regiment  intervention,  and  truncated  name  of  the  AML  /  
APL. The key words and truncations of the search strategy are listed in Appendix 2.1, 
while the detailed search strategies for ‘AML/APML studies’ and ‘economic studies’ are 
described below. 
 
a. AML / APML studies 
 
The search strategy for AML / APML studies was derived from 3 sources: 
•From three previous AML / APML review papers in the Cochran library [68-70]. 
•From the full name of the textbook terminology [52, 53]. 
•From Ovid MEDLINE MeSH for AML / APML (derived from the MeSH search on 
the Cochran Library website [71].)  
The resulting search strategies for AML/APML studies are listed in Appendix 2.1. 
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b. Economic studies 
 
The search strategy for economic studies derived from 3 sources:  
•From the use of two filters, namely the Ovid MEDLINE filter and the SIGN’s filter. 
The ‘SIGN’s economic studies filter’ was an adaptation of the strategy designed by 
the  NHS  Centre  for  Reviews  and  Dissemination  at  the  University  of  York.  It  
provided less sensitive searches, but enabled retrieval of potentially relevant 
medical studies [67, 71-73]. 
•From the relevant MeSH terms [71] 
•From previous systematic review papers [74].  
The resulting search strategies for economic studies are listed in Appendix 2.1. 
 
2.3.2 Grey literature 
  
As mentioned earlier, unpublished studies (grey literatures) were examined in the current 
work in order to avoid publication bias [59-61, 75-77]. The following 3 types of such 
studies were examined. 
 
a. PhD and Master Theses: relevant topics were obtained using both electronic and hand 
searching. 
b. Government publication: relevant topics were obtained using both electronic and hand 
searching. 
c. Conference proceedings: relevant topics were obtained from several sources by using 
both electronic and hand searching (see Appendix 2.2 ). 
 
2.3.3 Ongoing trials 
 
Databases containing the latest trials (see Appendix 2.2)  were  also  searched;  as  such  
sources can occasionally provide useful albeit incomplete information. Secondly, 
ongoing trial searching can prevent the introduction of time period bias, which occurs 
when the search is conducted for an unrepresentative time period. 
 
2.3.4 Hand-search  
 
In order to avoid overlooking related articles, a manual search was performed on key 
journals, conference proceedings, and reference lists. 
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a. Key Journal 
 
Key journals are journals that specifically focus on haematology, or  leukemia treatment. 
(Key journals are listed in Appendix 2.2). To prevent overlooking important studies, 
hand-searching was applied to key journals. This helped in retrieving two types of useful 
information. Firstly, information that was not included in the electronic databases (as 
sometimes relevant information appeared in news columns, editorials, or letters). Second, 
relevant articles that were not indexed properly or not indexed with the term used in the 
search strategies of the current review (as sometimes these articles could be easily 
overlooked [58]). 
 
b. Conference proceedings 
 
Important conference proceedings were also searched manually. This was because of the 
following reasons. Firstly, most conference proceedings were not included in MEDLINE 
or any other electronic database. Secondly, according to previous research, over one-half 
of the work reported in conferences never reached full publication, while even work that 
was eventually published in full was observed to be systematically different from work 
that  was  not  [78].  Thirdly,  conference  abstract  is  a  type  of  grey  literature  that  is  more  
likely to generally contain ‘negative’ results, compared to studies published in journals 
[79].  
 
c. Reference list of the papers 
 
To avoid overlooking important studies, all the citations found in the identified studies 
(including the systematic review papers) were screened manually. This approach helped 
identification of the relevant studies quickly. However, a drawback related to this was that 
the authors of the identified studies could selectively cite studies with positive or coherent 
results [80, 81]. Therefore, hand searching the reference list of the related studies was 
used in combination with other searching approaches to identifypotential studies for the 
review. 
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2.4 Study selection phase 2: Eligibility check 
 
Studies obtained during searches were further screened/selected in order to retain the ones 
that addressed the review questions. For this task, two processes were employed: 
eligibility checks and quality assessment. Relevant details are presented in the following 
sections. 
 
The purpose of the eligibility checks was to screen studies and evaluate their relevance to 
the review purposes. An eligibility check form was built for this purpose, and all the 
candidate studies were assessed using this form. Studies that met the inclusion criteria 
were included in the current work. 
 
2.4.1 Building the eligibility form 
 
In order to identify relevant studies, an eligibility form that was built. The form, which 
can be found in Appendix 2.3, contained a number of questions related with the inclusion 
and  the  exclusion  criteria  (please  refer  to  sections  2.1.2,  2.1.2,  2.1.3).  Since  study  
selection involved subjective judgments, use of the eligibility form was expected to 
reduce the study selection bias caused by reviewers’ preference [54], and thus make the 
study selection procedure more transparent [54, 58]. 
 
2.4.2 Reviewer 
 
a. One reviewer 
 
Decisions regarding the inclusion and exclusion criteria of individual studies often 
involve some degree of subjectivity. Therefore, it is generally suggested that having at 
least two reviewers is desirable in order to reduce the possibility of subjective judgments 
[54] and the possibility of discarding important and relevant studies because of human 
errors (such as accidental exclusion, overlooking, or misunderstanding) [54, 58, 82]. 
However, in the current review, only one reviewer was involved in the candidate studies 
selection process. This was mainly because of time and workforce constraints. In order to 
maintain the transparency and reproducibility of the study selection, and to reduce the 
possibility of human errors, a second reviewer was invited to double-check the selection 
procedures of twenty random selected abstracts. It was expected that if the selection 
results of two reviewers were consistent, it would be safe to claim that the selection 
results of the current review were, by and large, robust. 
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b. Blind review 
The reviewer was unaware of the authors’ names, the institutions, the journals, and the 
results of the candidate studies when the eligibility check was applied. This was expected 
to help avoiding the introduction of the ascertainment bias, which occurs when false 
results are produced by a possible subjective selection by the reviewers [54, 58, 83]. 
 
2.4.3 Study selection process 
 
After the eligibility form was built, it was used for assessing the eligibility of all candidate 
studies. In cases where specific information (title and abstract) of the study was sufficient, 
decisions were made based on the eligibility criteria. When information was insufficient 
or doubtful, the full text of the study was retrieved and checked for further consideration 
[84]. However, related studies for which information validity was still doubtful after the 
examination of the full text, it was decided to be include in the current review. This was 
because once a study had been excluded it was impossible to be considered again. Also, 
this allowed doubtful studies to be further examined at later stages of the current work 
when further information became available [58].  
 
2.4.4 Keeping logs of excluded studies with reasons 
 
All the excluded studies, as well as the  reasons for their exclusion, were recorded. This 
was because keeping logs not only maintained the transparency of the selection process, 
but also could answer possible question regarding the exclusions [58]. 
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2.5 Study selection phase 3: Quality assessment 
 
Review results can be biased by poor internal and external validities of eligible studies 
(such as unsuitable interventions and inadequate follow-up time for internal validities, 
unreliable measurement techniques and inappropriate statistical analysis for external 
validities [54, 85-87]). Based on suggestions of the Cochrane Collaboration and other 
experts [83, 88], assessment of quality/validity was conducted by means of a quality 
assessment checklist. This was in order to minimize possible biases caused by poor 
validities of the eligible studies 
 
2.5.1 Developing the quality assessment checklist 
 
A number of checklists are available with each of them focusing on specific study designs 
(such as the checklist for randomized controlled trial and the checklist for observational 
studies) [54, 89]. In the context of the current review, the quality assessment checklist was 
constructed according to the following aspects (the checklist can be found in Appendix 
2.5). 
 
a. Modifying two existing checklists 
 
The quality assessment checklist was mainly based on Drummond’s and BMJ study 
quality checklist [90, 91], as both of these two checklists were capable of assessing the 
quality of economic evaluation studies. Since economic evaluation studies were not the 
only type of eligible studies for the current review, the checking questions derived from 
the aforementioned checklists were further divided into two categories/phases according 
to their characteristics.  
 
In the first phase, the checking questions focused on the quality of the reported costing 
method of all the eligible studies. The emphasis was placed on what and how the eligible 
studies measured the cost (for example: Were the costing measurement methods 
described comprehensively?). In the second phase, the checking questions focused on the 
quality of the economic evaluation studies (for example: were all the important and 
relevant costs and outcomes identified?). This was because the questions were important 
for economic evaluation studies but inadequate for judging the quality of non-economic 
evaluation studies.   
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Considering the above, after the two-phase quality assessment checklist was built, all the 
eligibility studies were assessed by means of the first-phase checklist, while economic 
evaluation studies were further assessed by means of the second-phase checklist. 
 
b. Two types of evaluation study  
 
Economic evaluation studies can be further divided into two categories: trial-based 
studies (using a single source of evidence) and model-based studies (using multiple 
literature sources) [83]. Generally, most reviewers show preference in designing separate 
quality checklists for different study bases [54]. However, in some occasions, joint 
checklists can be also considered [92]. In the current review, a joint checklist was used, as 
there was a large number of common checking questions. The checking questions were 
divided into two, only in the study design quality domain. In the part designed for 
trial-based studies, the checking questions focused on the quality of the study structure 
(such as inclusion / exclusion criteria, or data collecting method). In the part designed for 
model-based studies, the checking questions focused on the quality of the literature 
review (such as the method of deriving input parameters for the model, or the 
representativeness of the model in terms of clinical practice)[84]. 
 
c. Internal and external validity 
 
Internal and external validities are both important for quality assessment. In the current 
review, more emphasis was put on internal validity, as latter was a prerequisite for 
external  validity  [54,  84].  Internal  validity  focused  on  whether  results  of  a  study  were  
‘correct’ for the circumstances being studied. In contrast, external validity focused on 
whether results of a study were applicable to other circumstances (outside the study) [93]. 
Therefore, if the results of a study were invalid (internal validity), then the checking 
questions of its external validity became redundant. 
 
d. Simple checklists rather than quality scales 
 
There are two approaches for assessing the study quality. One is using the summary 
scores, and the other is examining the influence of the quality components by simple 
checklists [58, 94]. Although the use of summary quality scores can provide a useful 
overall quality assessment, it was decided that the simple checklist approach should be 
used (instead of the summary score) in the current review. This was for the following two 
reasons. Firstly, different measurement scales may lead to discordant results. Secondly, 
summary score was difficult to interpret, as associations between score results and quality 
2.5 Study selection 3 
(quality assessment) 
- 24- 
 
were unclear [58, 94]. In order to avoid the aforementioned issues and to ensure the 
transparency of the study selection process [89], it was decided that the simple checklist 
approach should be preferred.  
  
 
2.5.2 Quality assessment process 
 
After the quality assessment checklist was built, it was applied to the full texts in order the 
quality (validity) of the eligible studies to be assessed, while it was, also, judged by two 
un-blinded & independent reviewers. Because of time and workforce restrictions, only 
one reviewer assessed the qualities of all the eligible studies, while another independent 
reviewer only double-checked the results of twenty random eligible studies. This was in 
order to reduce possible bias caused by reviewer’s preference. Both of the reviewers were 
un-blinded, as blinded review was not necessary here [54, 58, 83]. It is worth noting that 
the quality assessment results of the two independent reviewers were consistent. Based on 
this, it is claimed that the selection results were robust.  
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2.6 Data extraction 
 
After the study selection, the next step was the extraction of the data. A specially designed 
data extraction form was used in order the data from the selected studies to be 
transformed to useful information suitable for further analysis at later stages of the current 
work. 
 
2.6.1 Rationales of using data extraction form 
 
a. The data extraction form provided clearer summaries than the study abstracts, as the 
design of the form was based on and linked to review questions [95].  
b. The data extraction form was a bridge between what was reported by the original 
investigators and what was ultimately reported by the review authors [96]. 
c. The data extraction form prevented collecting low or high amount of information. 
Collecting too much information might lead the length of the extraction form to be 
longer than that of the original study. On the contrary, collecting low amounts of 
information might result in missing important data and introduce a need for revisiting 
original study at later stages of the review process [96]. 
 
2.6.2 Design data extraction form 
 
The design of the data extraction form was based on three important aspects: 1) the 
review questions, 2) the eligibility criteria of the selected studies, 3) the informal collation 
of experiences from numerous review authors (published in Cochrane Handbook for 
Systematic Reviews of Interventions [96]). Moreover, according to suggestions found on 
the Cochrane Handbook [96], ticking boxes or coded responses were adopted into the 
data extraction form. This was in order to save time during the data extraction, while it 
also ensured that the same term was used for data categorization during the extraction. 
The data extraction form can be found in Appendix 2.5,  while  its  components  are  
discussed in the following sections.  
 
a. General information 
     
Information collected from the selected studies included: title, authors’ name, source 
information (year / volume / pages / journal or conference), contact E-mail address, 
country, the source type, study type (trial / observation / model), and data type (primary / 
secondary).  
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•The contact E-mail address was collected as a mean to contact the author regarding 
possible queries.  
 
•The country information was collected as a mean to identify the differences of the 
costing methods usage from country to country. Furthermore, the emphasis was put in 
UK studies, as information related with the costing methods and the data sources used 
in these studies was expected to be helpful at later stages of the research. 
 
•The ‘price year’ was collected for comparison reason, as the cost value changes over 
time because of the inflation (for example, £20 in 1998 has not the same value as £20 
in 2008). The price year information was useful for cost comparison at later stages of 
the current work. 
 
•Information related with the study type and the data type was collected because they 
could help in assessment of the costing methodologies and the data sources that were 
used in the selected studies. 
 
b. Participants 
   
The following information was collected from the selected studies: total number (initial 
sample size / number of AML or APML patients – when AML/APML was not the only 
one study population), setting of target population (description of inclusion and exclusion 
criteria / diagnostic criteria / baseline characteristics/treatment phase), study period, 
outcome sample size (withdrawals and losses to follow-up).  
 
•Three different sample sizes were collected. This was for two reasons. Firstly, the 
outcome sample size always differs from the initial numbers because of attrition or 
exclusions [96]. Secondly, if AML/APML was not the only study group (such as in 
case of hematological malignancy study), it was important to collect the number of 
AML/APML  patients,  as  this  number  could  affect  the  review  results  and  its  
generalization. 
 
•Age information was collected because AML/APML could occurred at any age [52, 53, 
97, 98]. Also, since treatment types and treatment tolerance differed between age 
groups [52, 53, 97, 98], it was expected that differences in cost between age groups 
could occur. Therefore, it was deemed that age information collection was necessary. 
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•Treatment phase information was collected because there were great different 
between treatment types and regimens in different treatments phases [97, 98], 
something that could the affect cost results. 
 
•Study period’ was also collected as it was associated with the costing methods and the 
cost results.  
 
c. Intervention 
 
Information related with study intervention was also collected from the selected studies. 
This included treatment type (overall treatment, chemotherapy, adjunctive treatment, 
transplantation, complication treatment, examination, supportive or palliative care), 
analysis type (Cost analysis, CEA/CUA), and objectives of selected studies.  
 
•Treatment types information was collected because different treatments required 
different methods to cost. The information not only helped to categorize the selected 
studies, but also assisted in uncovering the costing methods/data sources used for 
costing different treatments. 
 
•Objective information was collected because of its relation to the review questions. It 
not only helped to double check whether selected the studies were eligible, but also 
provided overviews of these studies. 
 
d. Outcome (Costing Methods) 
 
According to the review questions, the following information was collected: cost data 
sources (unit cost / charges / payments), cost drivers, costing methods, and cost results. It 
is worth noting that selected study results, mainly to be used as notes. 
 
•Cost data source information was collected because it was the main part of the costing 
methods, and also it determined the cost results. Therefore, the collected information 
not only helped to uncover the costing methods that were used in the selected studies, 
but also helped to distinguish whether cost results were comparable. 
 
•Information related with the costing method (such as method types, cost drivers, and 
data sources) was collected for three reasons. Firstly, it could uncover how previous 
studies measured the cost, which answered the review questions of the current review. 
Secondly, it could help to assess whether any costs have been omitted in the selected 
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studies. Thirdly, it could help to judge whether the study designs of the selected studies 
were applicable and replicable. 
 
•The results of the selected study were collected because they provided a clear, albeit 
simple, overview of the studies (irrespectively of how many outcomes were presented). 
Since variation in study results can be very large [99], it was decided only results that 
matched the review purposes to be collected.  
 
e. Note 
 
A blank footnote column was left for the purpose of keeping important notes relevant to 
the study. Also, following suggestions from the Cochrane Systematic review Handbook, 
another blank space was left for notes. This was placed near the beginning of the form, as 
opposed to its end, in order to avoid placing notes, questions or reminders in a position 
less noticeable [96]. Overall, two note-columns were included in the data extraction form. 
Important notes (such as reminders) were put in the column positioned in the beginning of 
the form, while less important notes (such as reference to other studies) were put in the 
column in the end of the form. 
 
2.6.3 Data extraction Process 
 
Using the designed data extraction form, data were extracted from the selected studies 
individually. It is worth noting that three data extraction principles were followed in order 
to avoid identified errors. Firstly, ‘raw’ data were preferred for the data extraction. For 
example, number was preferred to rate. Secondly, value range, confidence interval, or P 
value was also extracted, if available. This was in order to provide overviews of value 
variation. Finally, the extracted quantity formats should be consistent for comparison 
reason. 
 
After data extraction was completed, summaries of the review results were generated. 
The relevant details are presented in the following sections. 
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2.7 Results (characteristics of selected studies) 
 
The search strategies were practically applied in January 2008 and resulted in 333 
abstracts. After the eligibility check and the quality assessment of these articles in 
full-text, only 50 papers were found to match the review purposes of the current review. 
The relevant study selection details are discussed in the following sections. 
 
2.7.1 Number of studies for the review 
 
According to the set search strategies (please refer to section 2.3 for details), three main 
sources were examined. Relevant details are discussed in the following sections, while 
the results are summarized in Table 2.2. 
 
 
 
 
Table 2.2 The summarized results of study selection 
 
Name of source 
 
Number of papers 
indentified 
Number of papers 
after abstract 
screening 
Numbers of papers 
after detailed 
reviewing in full text 
    
Publish studies    
MEDLINE 277 85 41 
PUBMED 277 85 41 
EMBASE 279 85 41 
NHS EED 28 19 19 
Cochrane Library 2 2 2 
CancerLit 0 0 0 
Cochrane Center Register of 
Controlled trials 
0 0 0 
Subtotal 288 85 41 
    
Grey Literature    
Thesis 0 0 0 
ZETOC and ISI Conference 
Search 
0 0 0 
Conference Proceedings 26 26 2 
Subtotal 26 26 2 
    
Hand-searching     
Key journals 5 5 2 
Reference list of papers  25 15 6 
Subtotal 30 20 8 
    
Total   51-1=50* 
*One Mexico paper couldn’t be found because of wrong citation. 
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a. Published studies 
 
The electronic database searching strategies resulted in the collection of 288 abstracts. 
After the abstracts were screened using the eligibility form, 85 studies were found to be 
potentially relevant. The two main reasons for the exclusion of the 203 studies are 
described below. 
 
•Irrelevant studies 
A number of the obtained studies were found to be irrelevant, due to confusing key 
words and wrong indexed terms. The irrelevant studies were discarded, as they did 
not provide any answers to the review questions.  
 
•Case and review studies 
Although database searching confirmed to the inclusion and exclusion criteria (please 
refer to section 2.2), two case studies and 12 review studies were found in the 
obtained 288 published studies. According to the exclusion criteria, these studies 
were considered to be irrelevant to the review purposes. Therefore, they were all 
excluded. 
 
After the eligibility check, the eligible studies were further evaluated using the quality 
assessment checklist. Finally, 41 published studies were found to be relevant. The reason 
for excluding the remaining 44 studies was that costing methods were not included in the 
contents of these studies, although cost results were referred to briefly in their main body. 
Overall, 41 published papers were included in the current review study (Table 2.2).   
 
b. Grey literature 
 
Twenty-six studies considered through the grey literature electronic database or hand 
searching for relevant topics from PhD and Master theses, and through conference 
proceedings, were found to be potentially relevant. However, after the eligibility check 
and the quality assessment of the full text, only two conference studies were confirmed to 
be relevant. The two main reasons for excluding the remaining 24 studies are described as 
following:  
 
•Most of the reports included the term ‘cost-effectiveness’ in the last sentence in the 
conclusion. However, as a whole, these reports were irrelevant with cost analysis or 
economic evaluation. 
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•AML/APML cases only accounted for a minor proportion of the study population. 
Therefore, the results could not represent the real treatment and/or lifetime cost for 
AML/APML. 
 
Overall, two unpublished conference proceeding reports were included in the current 
review study (Table 2.2). 
 
c. Hand searching of key journals and reference list of papers 
     
Hand searching the key journals and the reference lists of the selected articles resulted in 
20 relevant articles. After excluding the repeated studies and the review studies, only 
eight articles remained (three conference reports and five published studies). It is worth 
noting that there were two non-English studies (one German study [100] and one Dutch 
study [101]) among these eight articles. The reason for the inclusion of these two studies 
was that they contained important information related with costing methods. In the 
German study, the bottom-up costing method was used and described, while in the Dutch 
study, the costing method that was used was described in detail. Since these two articles 
were considered to be important for the current review study, they were translated into 
English for further review use (Table 2.2). 
 
Overall,  there  were  51  studies  and  reports  were  recruited  in  the  current  review  study,  
including two non-English, but important studies. One of the aforementioned studies was 
a Mexico article [102] that could not be reached due to wrong citation from MEDLINE. 
Therefore, a total of 50 studies and reports were finally included in the current work. The 
study selection process is illustrated Figure 2.2.   
 
 
 
Figure 2.2 The illustration of study selection process 
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2.7.2 Overview of the selected studies 
 
The details of the study search and selection were approached by three different 
perspectives. Relevant details can be found in the following sections, while the 
summarized results are presented in Table 2.3 below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. Treatment types 
The data extracted from the selected studies were sorted and categorized into seven 
different treatment groups, namely overall/lifetime treatment (seven studies), 
chemotherapy (eight studies), transplantation (17 studies), complication treatment (eight 
studies), supportive /adjunctive care (11 studies), examination (two studies), and 
palliative or supportive care (five studies). Overall, 58 articles were ready for reviewing. 
It is worth noting that the additional 8 articles (50 studies in total were included in the 
current review) were obtained from five studies that compared costs and health outcomes 
of 13 different treatments. Relevant details can be found in Table 2.3. 
 
b. Publish year  
The selected studies were further subdivided by publish year (in 5-year intervals), namely 
1995-1999, 2000-2004, and 2005-2008. Between 1995 and 1999, 18 studies and report 
were found to have been published, while 24 and 16 studies were published between 2000 
and 2004, and between 2005 and 2008 respectively (Table 2.3). It is worth noting that the 
number of publications related with AML/APML economic evaluations increased 
Table 2.3 Number of selected studies 
Treatment type Number of studies  
1995-1999 2000-2004 2005-2008 Total 
Overall treatment 0 4 3 7 
Chemotherapy 1 3 4 8 
Transplantation 6 9 2 17 
Complication treatment 1 4 3 8 
Adjunctive trreatment 7 4 0 11 
Examination 1 0 1 2 
Palliative or supportive care 2 0 3 5 
     
Total 17 24 16 58* 
* Due to five studies that focused on more than one treatment. (1 study compared the costs of overall treatment, 
chemotherapy, supportive care, palliative care, and transplantation, 1 study estimated overall treatment costs and 
chemotherapy costs, 1 study estimated the costs of chemotherapy with / without adjunctive care, 1 study estimated the costs 
of chemotherapy, side effect treatment and supportive treatment, and 1 study estimated the costs of chemotherapy and 
transplantation. 
 
2.7 Results 
(general) 
- 33- 
 
progressively (3.6 papers per year were published during 1995-1999, 4.8 papers per year 
were published during 2000-2005, and 5.3 papers per year were published during 
2005-2008). This also underlined the increasing emphasis on AML/APML treatment cost 
analysis.   
 
Taking the ‘treatment types’ into consideration, the results showed that the focus was on 
different treatment type cost studies during different publish time periods. During 
1995-1999, most of the studies focused on growth factor cost saving and transplantation 
costs. During 2000-2005, most studies focused on transplantation costs. Growth factor 
cost studies were still highly emphasized, but meanwhile the researchers started paying 
more attention on overall/lifetime treatment costs and complication treatment costs. 
Between 2005 and 2008, the emphasis of the related studies started shifting from 
transplantation and growth factor costs to chemotherapy, complication treatment, and 
supportive or palliative cares costs (please refer to Table 2.3 for details). 
 
c. Country 
The country information of the selected studies (the location that the selected studies were 
carried out) was further divided into four main groups: America, Europe, Asia, and others. 
The relevant details are listed in Table 2.4 (Only countries with more than two studies are 
listed; the rest were categorized into ‘others’). 
 
 Table 2.4 Summarized country information of selected studies 
Treatment type Number of papers 
America Europe Asia Others  
USA CA UK FRA ESP ITA NED GER TUR IND JPN TWN  Total 
Overall treatment 4 0 0 0 0 0 1 1 0 0 0 1 0 7 
Chemotherapy 2 0 0 0 0 2 0 1 0 1 1 1 0 8 
Transplantation 4 2 0 3 1 0 3 1 0 1 0 1 1 Norway 17 
Complication 3 0 1* 0 1* 1 1* 0 1 0 1 0 1* Belgium 
1 Brazil 
8 
Adjunctive care 4 0 1 1 1 1 1 0 0 0 0 0 1 Australia 
1 unknown 
11 
Examination 0 0 0 1 0 0 0 0 1 0 0 0 0 2 
Palliative or  
supportive care 
0 0 0 0 0 2 0 1 0 0 0 1 1 Mexico 5 
Total 16 2 2 5 3 6 6 4 2 2 2 4 4 58 
* The study country of this paper covered UK, Spain, Netherlands, and Belgium. 
** CA: Canada, FRA: France, ESP: Spanish, ITA: Italy, NED: Netherlands, GER: Germany, TUR: Turkey, IND: India, JPN: Japan, 
and TWN: Taiwan. 
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As shown in Table 2.4, most of the selected studies (16 articles in total) were carried out 
in the USA, followed by Italy and Netherlands which had six relevant costing studies 
each. The rest of the countries had between one and five relevant cost studies since 1995.  
 
Taking the treatment type into account, the results showed that different countries focused 
on different treatment costs. USA focused on overall/lifetime treatment, transplantation, 
complication treatment, and adjunctive care cost. Italy focused on chemotherapy and 
palliative care; while Netherlands and France focused on transplantation costs (Table 
2.4). 
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2.8 Results (costing method review) 
 
In order to the review results to be presented systematically, the data extracted from the 
selected studies were categorized into the following seven groups: overall/lifetime 
treatment (seven papers), chemotherapy (eight papers), transplantation (17 papers), 
complication treatment (eight papers), growth factor (11 papers), examination (two 
papers), and supportive or palliative care (five papers). The review results of each 
treatment type are discussed in detail in the following sections. 
 
 
2.8.1 Overall treatment for AML/APML 
 
After categorization and data extraction, seven studies were found to be focusing on 
overall treatment costs. The summary of these seven studies can be found in Appendix 
2.8.   
 
a. Overview 
 
Four out of the seven overall treatment cost studies were published during 2001-2002 
[103-106], while three of them were published during 2005-2006 [107-109]. More than 
half of the studies (four papers) were carried out in the USA [103, 104, 108, 109].  
 
In terms of study population, four studies focused on elderly AML/APML patients (≧60 
or ≧65 years old) [103, 104, 108, 109], two studies on adult patients (≦60 years old) 
[104, 107], and only one study on pediatric patients [109]. Most of the studies applied 
cost analysis for costing the overall treatment, while only one study applied 
cost-effectiveness analysis [107]. In terms of study time period, most of the studies only 
estimated the inpatient costs either from admission (or diagnosis) to discharge or for a 
fixed  period  of  time  (such  as  three  years).  However,  there  were  three  studies  that  
measured not only the inpatient costs but also the follow-up costs [103-105]. It is worth 
noting that most of the studies used hospital charges for costing. Only two studies used 
the administrative claim payment data for costing [103, 104].  
 
b. Cost drivers 
 
The cost drivers that were used in the selected studies for costing overall AML/AMPL 
treatments were categorized into two main groups: medical-related and 
non-medical-related cost drivers. The related summary can be found in Table 2.5. 
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Table 2.5 Cost drivers for costing overall treatments 
 
 
 
Cost drivers Reference No. 
Medical cost drivers  
Inpatient condition  
Hospitalization [109], [103], [104], [105], [106] 
Pharmacy / IV therapy [109], [107] 
SNF [109] 
Laboratory / Pathology [109], [107], [105] 
OR / Anesthesia / Recovery room [109] 
Radiology [109] 
Respiratory services /  Pulmonary 
function 
[109] 
Physical therapy / Occupational therapy [109] 
Skilled nursing facility [103], [107], [106] 
Physician / supplier [103], [104], [107], [106] 
Procedure [107], [105] 
Relapse treatment [105], [106] 
First admission [108] 
Sequent admission [108] 
Outpatient condition  
Outpatient visit [103], [104], [105] 
Follow-up condition  
Home health care [103], [104] 
Hospice [103], [104] 
Overall follow-up cost [105] 
Non-medical cost drivers  
Durable medical equipment payments [103] 
Out-of-pocket [107] 
 
As shown in Table 2.5, the medical cost drivers were divided into three subgroups: 
inpatient condition, outpatient condition, and follow-up condition.  
 
•In inpatient condition, hospitalization was the most commonly used cost drivers. 
Personnel cost (such as skilled nurses and physicians) [103, 104, 107] and drug and 
examination costs [107, 109] followed. 
•In outpatient condition, outpatient visit costs was the only cost driver [103, 104]. 
•In follow-up condition, home health care and hospice were normally used as cost 
drivers for costing follow-up in the overall AML/APML treatment costs [103, 104].  
 
In relation to non-medical cost drivers, only a few studies took the latter into account for 
costing the overall treatments. Only Lang et al. [103] used capital overhead as 
non-medical  cost  driver,  and  Yu  et  al.  [107]  used  out  of  pocket  as  non-medical  cost  
drivers. 
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Table 2.6 Cost results for costing overall treatments 
c. Cost results 
 
By using the historical currency exchange rates [110] and inflation calculator [111], all 
the  overall  treatment  costs  were  converted  to  US  dollar’s  value  as  of  2007.  Relevant  
conversion information is listed in Appendix 2.6 and Appendix 2.7, while details of the 
results are presented in Table 2.6.   
 
 
Reference No. Country Study period Patients Year Cost per patient cost (in 2007USD) 
Rosenman [109] USA 3 years AML all ages 1997 $112,200 (13,500 – 217,600) 
per year 
$151,470 per year 
Lang [103] USA 2 years AML elder 2001 $25,944 + 27,413 per year $31,652 per year 
Menzin [104] USA 2 years AML   1998 $20,795 + 435 per year $27,657 per year 
Yu [107] Taiwan From diagnosis to the 
end of therapy 
AML adult 2003 $43,418 (1,494 – 172,332) 
per treatment cycle 
$51,233 per 
treatment cycle 
Katz [108] USA From first admission 
to the last discharge 
AML elder 2003 $115,471 + 334,581 per 
treatment cycle 
$136,256 per 
treatment cycle 
Uyl-de Groot [105] Netherlands From diagnosis to 2 
years follow-up 
AML adult  1995 $104,386 $148,228 
Kuse [106] Germany 2 inductions+1 
consolidation 
AML elder 1999 Young adult: 
105KDM (63-204 KDM) 
$65,500 per protocol 
cycle 
     Elderly patients: 
87.6KDM (56-147 KDM) 
$54,645 per protocol 
cycle 
 
As shown in Table 2.6, the result presentations were categorized into two groups: ‘costs 
per patient per year’ and ‘cost per patient per treatment cycle’. 
 
All studies in the ‘costs per patient per year’ group were from the USA [103-105]. One of 
them focused on elderly AML patients [104], while the remaining studied all age range of 
AML patients. It was observed that although only Lang et al. [104] and Menzin et al. [105] 
took follow-up and outpatient visits into consideration, their costs results were the lowest. 
On the contrary, although Rosenment et al. [103] only focused on inpatient costs, the cost 
result was the highest. A possible explanation for this was that different data sources and 
cost drivers were used in different studies (Appendix 2.8).   
 
Both of the studies in the ‘cost per patient per treatment cycle’ group were from 2003 [107, 
108]. One of these studies (Yu’s study) focused on adult patients [107], and the other 
(Katz’s study) on the elderly patients [108]. Although the study period of Yu’s study [107] 
was longer than Katz’s study [108], the cost result of the former was lower. This might be 
due to different study populations (elderly patients were considered to be more expensive 
to treat) and different country settings. 
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Table 2.7 Cost drivers for costing chemotherapy 
2.8.2 Chemotherapy for AML/APML 
 
After categorization and data extraction, eight studies were found to be focusing on 
chemotherapy costs. The summary of these studies can be found in Appendix 2.9. 
 
a. Overview 
 
Most of the studies were published after 2000 [100, 107, 108, 112-115] (only one study 
was published before 2000 [116]), and they were mainly carried out in the USA [108, 
114], Italy [112, 113], and Asia [107, 116]. In relation to study time period, only 
Takeshifa et al. [116] and Storti et al. [113] cost chemotherapies in fixed periods of time 
(first 2 months of hospitalization and one month respectively), while in the remaining 
studies,  chemotherapies  were  cost  by  cycles.  It  is  worth  noting  that  ‘hospital  charges’  
were the main data source for costing chemotherapies in most of the studies, with only 
Takeshifa et al. [116] using ‘payment data’ for the same purpose.  
 
b. Cost drivers  
 
The cost drivers used in the selected studies for costing chemotherapy were categorized 
into the following two main groups: medical-related and non-medical-related cost drivers. 
The related summary is shown in Table 2.7. 
 
 
 
Type of cost (cost driver)  (Reference No.) 
Medical cost drivers  
Inpatient condition  
Hospitalization [107], [113], [114], [115], [116] 
Pharmacy (drug/regimen) [107], [112], [113], [114] 
G-CSF [114], [112] 
Antiblastic drugs [112] 
Anticoagulants drugs [116] 
Infection treatment / antibiotic treatment [114], [112], [116], [113] 
Blood bank / transfusion [107], [114], [112], [116], [113] 
Laboratory / Pathology [107], [114], [112], [116] 
Surgery [114], [116]  
Radiology [114], [112], [116] 
Skilled nursing facility [107], [114], [112], [116] 
Physician / supplier [107], [114], [112], [116] 
Outpatient condition  
Outpatient visit [114] 
Emergency Room [114] 
Non-medical cost drivers  
Out-of-pocket [107] 
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Table 2.8 Cost results for chemotherapy 
In the medical cost driver groups, the cost drivers were further divided into two 
subgroups, namely inpatient setting and outpatient setting.  
 
•In inpatient condition, the most commonly used cost drivers were hospitalization, 
drug/regimen, transfusion, personnel, laboratory test and complication treatment. It is 
worth noting that the drug costs of chemotherapy were not always presented 
separately. In 4 of the studies [100, 108, 114, 116], the drug costs were included in the 
hospitalization cost.  
•In outpatient setting, only one study measured the outpatient visit costs and emergency 
room cost for costing chemotherapy [114]. 
 
In relation to the non-medical cost driver group, only Yu et al. [107] used hospital charges 
to estimate the out of pocket costs for costing chemotherapy. 
 
c. Cost results  
 
The cost results of the 8 chemotherapy cost studies are summarized in Table 2.8. 
 
 
Study Country Study period Patients Regimens Year Cost per patient per 
cycle 
Cost (in 2007 
USD) 
Yu [107] Taiwan Single therapy cycle AML adult 
≦60 (54) 
HidAC 2003 CC: $7,607 (546 – 
23,115) 
HiDAC: $13,668 
(1,538 – 29,180) 
CC: $8,976 
HiDAC: $16,128 
Katz [108] USA From first admission 
until last discharge 
AML elder 
≧ 60 (219) 
ADE 2003 Without chemotherapy: 
$80,541 (388,194) 
With chemotherapy: 
$163,159 (236,486) 
$97,490 
Berman [114] USA From diagnosis until 
the day before the 
next phrase of 
chemotherapy 
AML (79) Cytarabine+ 
Idarubicin 
1999 Standard: $124,868 
Protocol: $96,571 
Standard: $162,328 
Protocol: $125,542 
Clavio [112] Italy Beginning of therapy 
until discharge 
AML adult 
≦60 (18) 
AML10 
FLANG 
1997 AML10: $12,424 
FLANG: $9,269 
AML 10: $16,772 
FLANG: $13,513 
Jacob 
[115]** 
India Complete treatment AML DA, MidAC 2006 500,000 INR $11,845 
Takeshifa 
[116] 
Japan First 2 month of 
hospitalization 
APML 
adult 17-65 
(36) 
CC 
ATRA 
1993 CC: ￥4,164,026 + 
1,268,026 
ATRA: ￥2,906,825 + 
1,122,474 
CC: $56,402 
ATRA: $39,373 
Storti [113]** Italy 1 month AML elder 
65-80 (17) 
CC 
LDC 
2005 CC: €6500 
Low dose 
chemotherapy: 
€1806 
CC: $8,985 
LDC: $2,497 
Stabler [100] Germany 3 months Cancer (66) Conditioning 2002 - - 
* CC: conventional chemotherapy ; **conference report 
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As shown in Table 2.8, the cost results varied significantly. This was because the related 
regimens, study periods, and study populations were all different. Therefore, it was not 
possible for the cost comparisons to be carried out.  
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2.8.3 Transplantation for AML 
 
There were 17 studies found to be focusing on transplantation costs., a summary of these  
studies can be found in Appendix 2.10. 
 
a. Overview  
 
Only three of the transplantation cost studies were published before 2000 [117-119]. The 
rest of the studies were published after 2000 [120-127]. The studies were carried out in 
several countries, since transplantation cost is an important issue on a worldwide basis. 
The focus of the studies was on adult or pediatric patients or both but elderly patients. It is 
worth noting that only five studies specifically focused on AML patients [107, 118-120, 
127], while the remaining were case-mixed studies (AML/APML were part of the study 
populations). In relation to study time periods, fixed time period (such as one year and 
two year) costs were estimated in seven of the studies [118-122, 127], while in the 
remaining studies the estimation was for costs per cycle/event were [107, 117, 123-126, 
128]. It is also worth noting that hospital charges were used for costing in most of the 
studies, with the bottom-up costing method being used only in four of them [118, 121, 
124, 127].  
 
b. Cost drivers 
 
The cost drivers that were used in the selected studies for costing transplantation were 
categorized into the following three main groups: pre-transplantation, transplantation, 
and follow-up. 
 
The most commonly used cost drivers for costing pre-transplantation were: 
screen/laboratory test, harvest, conditioning chemotherapy and radiotherapy, while 
surgery, hospitalization, drugs, transfusion, and infection treatment were the most 
commonly used cost drivers for costing transplantation. It is worth noting that stem cell 
transplantation cost was not always reported separately. In many cases, the 
transplantation costs were included in the hospitalization cost. Only in five of the studies, 
the transplantation surgery costs were reported separately [107, 118, 119, 124, 128]. In 
relation to the follow-up group, only four studies took follow-up cost into consideration 
[121, 122, 124, 128]. The most commonly used cost drivers for costing follow-up were 
drugs, outpatient visits, and laboratory tests. Details relevant to the above matters can be 
found in Table 2.9. 
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Table 2.9 Cost drivers for costing transplantation  
 
Cost drivers Reference No. 
Pre-transplantation  
Screening cost  
Diagnostic test (investigation) [120], [127], [124], [125], [126], [128], [118], [100] 
Laboratory test (culture) [107], [120], [122], [124], [125], [126], [121], [118] 
Radiology evaluation [120], [124], [125], [128], [118], [122] 
Harvest (stem cell collection) [120], [124], [125], [128], [121], [119], [122] 
Pharmacy [128] 
Conditioning chemotherapy [120], [125], [121], [122], [100] 
TBI [120], [124], [125], [121], [122], [123] 
Hospitalization [121] 
Outpatient visit [120], [121] 
Personnel cost [128] 
Overheads: durable equipment & required spaces [124] 
Transplantation  
Inpatient setting  
Surgery [118], [107], [124], [119] [128], [100] 
Care expense  
Hospitalization [107], [120], [127], [125], [126], [121], [117], [118], 
[119], [100] 
Personnel cost [126], [128] 
Pharmacy [107], [124], [126], [128], [118], [119], [122] 
CSF [120], [124], [125] 
Parenteral nutrition [107], [120], [124], [125], [121] 
Infection treatment [120], [124], [125] 
Transfusion [107], [120], [124], [125], [126], [128], [121], [119], 
[122] 
Disposables [126] 
Overheads [127], [120], [107] 
Outpatient setting  
Outpatient visit [124], [121], [117], [122], [100] 
Acute care [118], [122] 
Personnel [127], [118], [100] 
Overheads: durable equipment and required space [127] 
Follow-up costs [119] 
Screening test  
Diagnostic test [124], [128] 
Laboratory test [124], [128] 
Radiology [124], [128] 
Hospitalization [124] 
Pharmacy [124], [128], [121] 
Transfusion [124] 
Day care [122], [124] 
Outpatient visit or consultation [124] 
Personnel costs [124], [128] 
Home health [122] 
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Table 2.10 Cost results for transplantation 
c. Cost results 
 
The cost results of the transplantation cost studies are summarized in Table 2.10. 
 
 
Reference No. Country Study period Patients Type of 
trans 
Costing 
year 
Cost per patient per year Cost (in 2007 USD) 
Agthoven et 
al.2002 [124] 
Netherlan
ds 
Pre-transplantatio
n until 2-year 
follow-up 
ALL and AML 
(97) 
BMT 
PBSCT 
MUD 
1998 BMT: €98,334 
PBSCT: €98,977 
MUD: €151,754 
BMT: $153,227 
PBSCT: $154,229 
MUD: $236,467 
Vicent et al. 
2001 [125] 
Spain From admission 
until discharge 
ALL, AML, 
NHL, HD 
children(131) 
PBPCT 
BMT 
1999 PBPCT: $7,895 
BMT: $11,820 
BMT: $15,366 
PBSCT: $10,264 
Cordonnier et 
al. 2005 [120] 
France 1 year AML (23) NMA 
alloSCT 
MA 
alloSCT 
2001 MA alloSCT: €74900 
+22600 
NMA alloSCT: €78700+ 
37300 
MA allSCT: $114,791 
NMA allSCT: 
$120,615 
Yu et al. 2006 
[107] 
Taiwan Single therapy 
period 
AML adult 
≦60 (54) 
AlloSCT 
ASCT 
2003 AlloSCT: 
$29,208 (9,100 – 106,212) 
ASCT: 
$10,037 (4,709 – 28,995) 
AlloSCT: $24,465 
ASCT: $11,644 
Esperou et al. 
2004 [122] 
France 6 months CML, AML, 
ALL (85) 
AlloSCT 2000 €70,479 (14761-183758) AlloSCT: $82,136 
Chandy et al. 
2001 [126] 
India From admission 
until discharge 
AML, CML, 
THAL children 
(4) 
AlloBMT 1999 AlloBMT: $16,666.75 AlloBMT: $21,666 
Mishra et al. 
2001 [128] 
Norway From 
pre-transplantation 
until 1 year 
follow-up 
CML, ALL, 
AML,MSD 
(17) 
AlloBMT 1999 AlloBMT: $106,825 
($24,375-$362,492) 
AlloBMT: $138,873 
Blaise et al. 
2000 [121] 
France 6 months AML, ALL, 
CML adult 
≦55 (98) 
AlloBMT 
AlloPBSCT 
1998 AlloBMT: €44531+15881 
AlloPBSCT: 
€37410+12109 
 
AlloBMT: $69,389 
AlloPBSCT:: $56,293 
Barr et al. 1996 
[118] 
Canada 5 years AML (2CR) 
adult 16-45 (7) 
AlloBMT 1992 AlloBMT: $CAN 
100,600+48380 
AlloBMT: $128,347 
Uyl-de Groot et 
al. 1995 [119] 
Netherlan
ds 
2 years AML (30) AutoBMT 1992 AutoBMT: $55,440 AutoBMT: $55,438 
Dagher et al. 
[123] 
USA Unknown ALL, AML 
children 9-17 
(10) 
IP TBI 
OP TBI 
1997 Inpatient TBI save $2,400 Save $3,240 
Farah et al.1998  
[117] 
USA From admission 
until discharge 
ALL, AML, 
CML children 
≦ 16 (19) 
IP TBI 
OP TBI 
1997 Inpatient TBI save $3,250 
per patient 
Save $4387.5 
Schimmer et al. 
2002 [127] 
Canada 1.5 year AML (18) Follow up 2000 $CAN 5,300 $4,500 
Stabler et al. 
2003 [100] 
Germany 3 months (66) SCT 2002 €16672 per op contact 
€45930 per hospital day 
€80820 per treatment day 
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As shown in Table 2.10, the transplantation cost results was categorized into three groups: 
‘BMT and AlloBMT’, ‘PBSCT and AlloSCT’, and ‘others’. 
 
•BMT and AlloBMT’ group: 
There were seven studies found to be focusing on BMT-related costing [118, 119, 121, 
124-126, 128]. Although five of the studies were carried out at a similar time 
(1998-1999), the cost results varied greatly. This was mainly due to differences in 
study settings, study populations, study time periods, and involved cost drivers. 
 
•PBSCT and AlloSCT’ group: 
There were six studies found to be focusing on BMT-related costing [107, 120-122, 
124, 125]. These six studies were carried out at a similar time (1998-2002). However, 
the cost results also varied greatly in this case for the reasons described previously in 
the ‘BMT and AlloBMT’ group. 
 
•Others’ group: 
There were three studies related to transplantation costing [117, 123, 127]. However, 
the authors only reported the amount of the cost saving, and, therefore, the cost results 
could not be compared with the study results (transplantation cost) of the previously 
mentioned groups.  
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2.8.4 Growth factor for AML  
 
 
As there were controversies regarding whether growth factor can save treatment costs, a 
number of economic evaluations of growth factors have been conducted. Therefore, 
despite the fact that growth factor is one of the types of supportive care, it was decided 
relevant studies to be discussed separately from other supportive care cost studies in the 
current review. For AML/APML, 11 studies related to growth factor treatment cost were 
found. The summary of these 11 studies can be found in Appendix 2.11. 
 
a. Overview  
 
Most of the relevant studies were published after 2002 [112, 129-138]. This underlined 
the increasing interest  on the topic.  The majority of the studies were carried out in the 
USA [131, 132, 135, 137], and in Europe [112, 129, 133, 134, 138] (one of them in the 
UK [129]). Elderly AML patients were the main focus study population [131, 132, 134, 
135, 137, 138], while no studies related with pediatric AML patients were found. 
Moreover,  five  out  of  the  11  relevant  studies  cost  growth  factors  ‘from start  date  until  
ANC (absolute neutrophil count) recover’ [112, 129-131, 138], while the remaining 
studies ‘from start date until discharge’ [132, 133, 135-137]. Long-term follow-up was 
taken into consideration in one study [134]. Among all of the relevant studies, ‘hospital 
charges’ was the only data source for costing. However, it is worth noting that in two of 
the studies (from the same study team) [132, 135], charge information was used for 
costing a limited number of study patients. The obtained information was further 
converted to relevant unit costs in order to cost whole study patients with the bottom-up 
method. 
 
b. Cost drivers 
 
The cost  drivers that  were used in the selected studies for costing growth factors were 
categorized into two main groups, namely inpatient and outpatient. Most of the studies 
focused on costing growth factors in inpatient condition. Hospitalization, drug, 
complication treatment, transfusion, laboratory test, and personnel were the most 
commonly used cost drivers for this purpose. It is worth noting that three of these cost 
drivers (hospitalization, drug, and complication treatment) were generally used in all the 
studies for costing in inpatient condition, while clinic visit (monitoring) was the key cost 
driver in outpatient condition. Relevant details are listed in Table 2.11. 
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Table 2.11 Cost drivers for costing supportive care (growth factor)  
Cost drivers  (Reference No.) 
Inpatient condition  
Hospitalization [112], [129], [130], [131], [132], [134], [135], [136], [137] 
CSF (G-CSF or GM-CSF) [112], [129], [130], [131], [132], [133], [134], [136], [137] 
Pharmacy  
Parenteral nutrition [133], [134] 
Other drugs [112], [129], [131], [132], [134], [135], [137] 
complication treatment  
Anti-infection treatment [112], [129], [130], [131], [133], [135], [136], [137] 
Other side-effect treatment [112] 
 Transfusion [112], [129], [131], [132], [133], [134], [135], [136], [137] 
Test or evaluation  
Diagnostic test [129], [132], [133], [134] 
Laboratory test [112], [129], [131], [132], [133], [134], [135], [137] 
Radiology [112], [131], [132], [133], [134], [135], [137] 
Respiratory service [132] 
Procedures (ex: surgery) [134] 
Personnel costs [112], [131], [133], [134], [135], [136], [137] 
Overhead and materials [131], [132], [134], [135], [137] 
Outpatient condition  
Monitoring [131], [134], [135], [137] 
Fluid administration [129] 
Long-term follow-up (outpatient visit) [134] 
 
 
c. Cost value  
 
The growth factor cost results were converted to the US dollar’s value as of 2007 by 
means of the historical currency exchange rates and the inflation conversion table (please 
refer to Appendix 2.6 and Appendix 2.7). These cost results are summarized in Table 
2.12 . As shown on the table, two main growth factors were studied, namely G-CSF and 
GM-CSF.   
 
•G-CSF group 
There were six studies found to be related to G-CSF costing [112, 129-131, 136, 137]. 
The cost results of these studies varied significantly from $16,603 to $69,253, due to the 
inclusion of different chemotherapy costs in the reported results. In terms of cost saving, 
Bradstock et al. [130], Bennet et al. [131], and Ojeda et al. [133] found that G-CSF 
increased treatment costs, while Lu’s study [136] and Clavio’s study [112] showed that 
G-CSF saved treatment costs. 
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Table 2.12 Cost results for growth factors  
•GM-CSF group 
A lower number of studies focused on GM-CSF costs [132, 134, 135, 138]. Similar to 
G-CSF,  the  cost  results  varied  (even  though  the  studies  were  carried  out  in  the  same  
countries with similar study populations, and by the same study team [132, 135]). Uyl-de 
Groot’s study [134] was the only study that took long-term follow-up into account. 
However, due to different settings, the cost results were lower than those of other relevant 
studies that only cost the GM-CSF from admission date until patient discharged [132, 
135]. 
 
 
Reference 
No. 
Country Study period Patients Type of 
Growth 
factor 
Costing 
year 
Cost per patient per year Cost ( in 2007 USD) 
Standaert 
et al. 
[129] 
UK 24 hours after 
chemotherapy 
until ANC 
recovery 
AML adult 
(82) 
G-CSF after 
chemotherapy 
 
1998 CRF methods: 
1st induction: £7531.67 
all cycles:£12,726.19 
PF method: 
1st induction: £9700.69 
all cycles: £14,861.09 
CRF methods: 
1st induction: $16,603 
all cycles: $28,057 
PF method: 
1st induction: $21,385 
all cycles: $32,763 
Bradstock 
et al. 
[130] 
Australia Start date until 
ANC recovery 
AML adult 
15-60 (114) 
G-CSF after 
induction 
chemotherapy 
2001 G-CSF increase the cost of A$ 
1494 
Increase $1,832 
Bennet et 
al. [131] 
USA Start date until 
ANC recovery 
AML elder 
55-70 (207) 
G-CSF after 
chemotherapy 
1998 Placebo group: $49,693 
G-CSF group: $50,593 
Placebo group: $66,092 
G-CSF group: $67,289 
Clavio et 
al. [112] 
Italy G-CSF: day 11 
until 
neutrophil 
recovery 
AML Adult 
≦60 (18) 
G-CSF after 
chemotherapy 
1997 CRT 1 (without G-CSF): 
$12,424 
CRT2 (with G-CSF): $9,269 
CRT 1 (without G-CSF): 
$16,772 
CRT 2 (with G-CSF): 
$12,513 
Lu et al. 
[136] 
Unknown Start date until 
discharge 
AML (521) G-CSF after 
chemotherapy 
1996 Cost saving: $2,230 Save $3,077 
Bennett et 
al. [137] 
USA Start date until 
discharge 
AML elder 
>55 (207) 
G-CSF after 
chemotherapy 
1998 G-CSF group: $52,070 G-CSF group: $69,253 
Woronoff-
Lemsi et 
al. [138] 
France Start date until 
ANC recovery 
AML elder 
55-75 (83) 
GM-CSF after 
chemotherapy 
1997 Overall survival : $97,841 
Disease free cost: $53,456 
Overall survival: $132,085 
Disease free cost: $72,166 
Bennett et 
al. [132] 
USA Start date until 
discharge 
AML elder 
55-70 (117) 
GM-CSF after 
chemotherapy 
1997 Overall: $38,412 
One cycle: $38,617 
Two cycle: $37,467 
Overall: $51,865 
One cycle: $52,133 
Two cycle: $50,584 
Bennett et 
al. [135] 
USA Start date until 
discharge 
AML elder 
56-70 (117) 
GM-CSF after 
chemotherapy 
1997 1 cycle: $66,757 
2 cycles: $62,728 
1 cycle: $90,122 
2 cycles: $84,683 
Uyl-de 
Groot et 
al. [134] 
Netherland
s 
Start date until 
2 year 
follow-up 
AML elder 
≧ 60 (103) 
GM-CSF after 
chemotherapy 
1992 Treatment cost: 
GM-CSF: $40,782 
Control: $34,465 
2 year follow-up cost: 
GM-CSF: $17,305 
Control: $17,402 
Total cost: 
GM-CSF: $58,087 
Control: $51,867 
Treatment cost: 
GM-CSF: $40,782 
Control: $34,465 
2 year follow-up cost: 
GM-CSF: $17,305 
Control: $17,402 
Total cost: 
GM-CSF: $58,087 
Control: $51,867 
Ojeda et al. 
[133] 
Spain Transplantatio
n inpatient day 
AML, NHL 
18-64 (62) 
G-CSF after 
PBSCT 
1998 G-CSF: €7,449 + 645 
Control: €6,689 + 480 
G-CSF: $11,607 
Control: $10,423 
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Table 2.13 Cost drivers for complication treatment 
2.8.5 Complication treatment for AML 
 
There were eight studies found to be related to complication treatment costs. A summary 
of these studies can be found in the following sections. 
 
a. Overview 
The relevant studies were published after 2000 [113, 139-144], with the exception of one 
that was published in 1996 [145]. In relation to treatment cost analysis, studies from the 
USA were still the main stream. The complication treatment cost studies were carried out 
in various countries (three in the USA [139, 143, 145], one in the UK [141], one in the 
Italy [113], one in the Japan [139], one in the Brazil[142], and one in the Turkey [144]), 
something that underlined a worldwide interest on the topic. It is worth noting that the 
related studies did not focus specifically on AML/APML patients, but they included 
AML/APML among various other diseases. The most commonly used study time period 
was ‘treatment time’ [140-145], with only one of the study costing complication from 
admission and until 30 days after discharge [139]. ‘Hospital charge’ and ‘administrative 
claim payment’ were still the main data sources for costing [113, 139, 140, 143-145], and 
only two studies used the ‘reference unit cost for bottom-up costing [141, 142].  
 
b. Cost drivers 
The cost drivers that were used for costing complication treatment are listed in Table 
2.13. 
 
 
 
Cost drivers  (Reference No.) 
Inpatient condition  
Hospitalization [139], [140], [141], [142], [143], [144], 
[145] 
Pharmacy [139], [141], [142], [143], [144] 
Nutrition [139] 
Anti-infection (antifungal, antibiotics) [113], [139], [140], [141], [142], [143], 
[145] 
 Transfusion [139], [142] 
Test or evaluation  
Diagnostic test [142] 
Laboratory test [139], [141], [142] 
Hemogram [142] 
Procedures (ex: surgery, chemotherapy) [139] 
Personnel costs [141] 
consultation [141], [142] 
Follow-up condition [140], [142] 
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As shown in Table 2.13,  the  cost  drivers  for  costing  complication  treatments  were  
divided into two conditions: inpatient and follow-up conditions. 
 
•Inpatient condition 
 
Most of the studies focused on costing complication treatment in inpatient conditions. 
The most commonly used cost drivers for this purpose were hospitalization, 
anti-infection treatment, drugs for non-infection complication and laboratory test. It 
is worth noting that anti-infection was a type of complication treatment that was used 
in all the complication treatment cost studies [113, 139-145].  
 
•Follow-up condition 
 
Among all the relevant studies, two studies were found to take follow-up costs into 
account, although the follow-up time periods were not very long (ranging from 20 
days to 30 days) [140, 142]. 
 
 
c. Cost results 
 
As shown in Table 2.14, the cost results varied significantly (from $60 per day to 
$147,320 per treatment plus 30 days follow-up). This was due to different study settings, 
study time periods, study populations, treatment strategies, and result presentations. 
Since there was no common ground for these studies, it was impossible to compare their 
costs and, thus, to derive meaningful comparison results. However, it is worth mentioning 
a number of observations related with the above. 
 
Firstly,  the  cost  results  tended  to  be  lower  when  the  study  populations  were  pediatric  
AML/APML patients. A possible explanation for this was that pediatric patients required 
lower dosages. Secondly, based on a number of the studies that reported the detailed cost 
results for each cost drivers, it was found that the drug costs for anti-infection were 
relatively consistent (range from $870 to $114 per episode) [139, 142, 145]. 
 
The cost results of the relevant studies are summarized in Table 2.14. 
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Table 2.14 Cost results for complication treatments  
Reference No. Country Study period Patients Type of 
treatment 
Costing 
year 
Cost per patient or per episode Cost (in 2007 USD) 
Nomura et 
al.[139] 
Japan Start of chemotherapy 
to CR or death 
AML 40 yrs (30) 3 strategies of 
antifungal 
treatment for 
chemotherapy 
2003 Strategy 1 (fluconazole): $25,900 
Strategy 2 (empirical amphotericin B): 
$25,400 
Strategy 3 (MCPG): $25,400 
Strategy 1: $30,562 
Strategy 2: $29,972 
Strategy 3: $29,972 
Menzin et al. 
[140] 
USA Inpatient time and 30 
days post discharge 
AML elder ≧65 (160) Antifungal 
treatment 
1998 Total charge for hospitalization: $110767 
Medicare payment for hospitalization: 
$34268  
Total charge: $147,320 
Medicare payment: $45,576 
Storti et al. [113] Italy Unknown AML elder 65-80 
(17) 
Antibiotics 1995 Total cost per month 
ST: €2900 
CC: €1100 
LDC: €300 
Total cost per month 
ST: $5,129 
CC: $1,945 
LDC: $531 
Costa et al. [142] Brazil Treatment time AML, ALL, NHL, HL 
children (22) 
Febrile 
neutropenia 
2000 Total cost per episode: $2660($2039) 
(AML: $2917) 
Total cost per episode: 
$3,675 
Rosenman et al. 
[143] 
USA Treatment time ALL, AML, CNS 
children (157 episodes) 
Fever and 
neutropenia 
1997 Total charges per episode: 
$11,967+$16,261 
($40,694+38,831in AML) 
Total charges per episode: 
$54,937 
Agaoglu et al. 
[144] 
Turkey Treatment time ALL, AML, solid 
children (87 episodes) 
Febrile 
neutropenia 
1999 Daily drug cost: 
C+N: $53.8 
C+A: $46.2 
M: $121.4 
Daily drug cost 
C+N: $69.9 
C+A: $60.1 
M: $157.8 
Horowitz et al. 
[145] 
USA Treatment time ALL, AML, NHL (10) Neutropnia 1994 Cost saved: $10,022 per patient (at home) Saved $14,632 
Annemans et al. 
[141] 
Belgium, 
Netherlands, 
Spain, UK 
Treatment time ALL, AML, NHL (144) Complication Unknown Incremental cost of prevention  
Adult: €1752 (1425-1924) 
Child: €492 (165-664) 
Incremental cost of treatment  
Adult: - €426 
Child: - €1686 
Incremental costs 
Prevention (adult): $2,340 
Treatment (adult): - $567 
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Table 2.15 Cost drivers for costing examination 
2.8.6 Examination for AML 
 
There were two studies found to be focusing on examination costs. The summary of these 
studies can be found in Appendix 2.13. 
 
a. Overview  
 
The two studies investigated different examination costs. Gonen et al. [146] studied 
‘fever investigation cost’, while Tonnaire et al. [147] studied ‘cytogeneic and molecular 
test cost’. Moreover, different costing sources and methods were used in these two studies. 
Gonen et al. [146] used ‘hospital charges’ for costing fever investigation, while Tonnaire 
et al. [147] used the ‘bottom-up method’ for costing laboratory tests.  
 
b. Cost drivers 
 
The cost drivers that were used for costing examination are listed in Table 2.15. 
 
 
Cost drivers  (Reference No.) 
Fever investigation test Gonen et al. 2005 [146] 
1. Blood cultures  
 
 
2. Urine cultures 
3. Chest X-ray 
4. Sinus X-rays 
5. Oral smear 
6. Sterile urine examinations 
7. urinalysis 
Cytogenetic and molecular test Tonnaire et al. 1998 [147] 
1. Equipment  
 
 
2. Labor 
3. Expenditure on reagents 
4. Other non expendable laboratory supplies 
5. stationery 
 
 
Since these two laboratory test cost studies focused on different screening tests and used 
different costing methods, the cost drivers that were used in both studies were very 
different. Gonen et al. used several examinations as cost drivers for costing, while 
Tonnaire et al. used equipments, personnel, and supplies as cost drivers for costing. 
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Table 2.16 Cost results for examination cost studies 
c. Cost results 
 
The cost results of these two examination cost studies are summarized in Table 2.16. 
 
 
 
Reference 
No. 
Country Study 
period 
Patients Type of 
screening 
Costing 
year 
Cost per patient or per 
episode 
Cost (in 2007 USD) 
Gonen et al. 
2005 [146] 
Turkey Per exam AML (33 
episodes) 
Fever 
investigation 
2004 cost of investigation of fever 
per episode: $64.76 
$74.47 
Tonnaire et 
al. 1998 [147] 
France Per 
exam 
ALL, AML 
16-91 (107) 
Cytogenetic 
and 
molecular 
test 
1995 Cytogenetic: $577.4 
PCR: $241.2 
Additional PCR: $94.8 
Cytogenetic: $819.9 
PCR: $342.5 
Additional PCR: 
$134.6 
 
 
Gonen’s study [146] showed that the cost of fever investigation test was $74.47 for each 
given time, while, in Tonnaire’s study [147], the costs of cytogenetic test was $819.9 (in 
2007 value), and the cost of PCR (molecular biology test) was $342.5 (in 2007 value). 
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2.8.7 Supportive or palliative care for AML  
 
There were five cost studies that have not been covered in the current review found to be 
related to non-curative interventions (supportive or palliative cares). Since the number of 
the studies was low and the study interventions had common character (non-curative), it 
was decided that they could be discussed as a whole. The summary of these five studies 
can be found in Appendix 2.14, while a related discussion follows in the next sections 
 
a. Overview   
 
As shown on Appendix 2.14, three studies focused on ‘supportive care’ [107, 148, 149], 
two on ‘palliative care’ [107, 113], and one on ‘home care’ [150] for AML/APML. 
 
For these three supportive care cost studies, only one was published after 2000 [107]. All 
of the studies focused on AML adult patients and used ‘hospital charges’ for costing. 
However, great differences were observed among the studies regarding the employed 
study time periods and the study interventions. Wandt et al. [148] only cost transfusions, 
with the study time period being unknown. Yu et al. [107] only cost inpatient-base 
supportive care from admission to discharge. Ruiz-Arguelles’s study [149] was the most 
complete of the three. The authors cost both inpatient-base and outpatient-base 
supportive care from the care start date and until granulocyte count recovery. 
 
In relation to the two palliative care cost studies, both were published after 2005 [107, 
113]. This showed a recently increasing interest on the topic. It is worth noting that both 
of the aforementioned studies used ‘hospital charge’ for costing, due to the complexity of 
the palliative care content. 
 
The single home care cost study [150] was published in 2007 and was carried out in Italy. 
The authors used the ‘bottom-up method’ for costing the home care. However, 
AML/APML was  not  the  only  cancer  type  included  in  the  study,  while  the  study  time 
period was, also, unknown.  
 
b. Cost drivers 
 
The cost drivers used for costing for the three different interventions are listed in Table 
2.17. 
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Table 2.17 Cost drivers for costing supportive and palliative cares  
Cost drivers Reference No. 
Supportive care  
Hospitalization [107], [149] 
Pharmacy   [107], [149] 
Laboratory test [107] 
Transfusion [107], [148], [149] 
Procedure [107] 
Personnel cost [107], [148], [149] 
Out-of-pocket [107] 
Palliative care  
Hospitalization [107], [113] 
Pharmacy   [107] 
Laboratory test [107] 
Infection treatment [113] 
Transfusion [107], [113] 
Procedure [107], [113] 
Personnel cost [107] 
Out-of-pocket [107] 
sHome care  
Personnel cost [150] 
Pharmacy and medical supplies [150] 
Transfusion [150] 
Laboratory test [150] 
 
 
•Supportive care [107, 148, 149] 
The most commonly used cost drivers were transfusion and personnel costs, followed 
by hospitalization and relevant drug costs. 
 
•Palliative care [107, 113] 
The most commonly used cost drivers for costing palliative care were hospitalization, 
transfusion and relevant procedure costs.  
 
•Home care [150] 
Only  one  study  was  found  to  be  focusing  on  costing  home  care.  The  authors  used  
personnel, pharmacy and medical supplies, transfusion, and laboratory test costs as 
cost drivers, to obtain cost of home care in Italy. 
 
c. Cost results 
 
The cost results of the three different intervention cost studies are summarized in Table 
2.18. 
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Table 2.18 Cost results for supportive and palliative care cost studies  
 
Refere
nce No. 
Country Study 
period 
Patients Type of care Costing 
year 
Cost per patient per 
year 
Cost (in 2007 USD) 
 
Yu et 
al. 
[107] 
Taiwan Single 
therapy 
period 
AML adult 
≦60 (54) 
Supportive care 
and palliative care 
2003 Supportive care: $3,013 
(120 – 25,581) 
Palliative care: $15,726 
(500 – 96,923) 
Supportive care: 
$3,555 
Palliative care: 
$18,557 
Cartoni 
et al. 
[150] 
Italy Unknown AML, 
lymphoma, 
myeloma 
(144) 
Home care 2005 Total monthly home care 
cost: 
Discharge early: €3986.4 
(241.2 - 6285.3) 
Terminal: €4232.5 (437 - 
14599) 
Chronic: €1488.3 (455.9 
- 4769.5) 
Home care per month 
Discharge early: 
$5,511 
Terminal: $5,851 
Chronic: $2,057 
Wandt 
et al. 
[148] 
Germany Unknown AML adult 
≦60 (105) 
Transfusion  
Trigger1: 
10╳109/L   
Trigger2: 
20╳109/L 
1996 Transfusion cost per 
treatment cycle: trigger 1 
is cost saved 
Lower trigger 
standard is cost saved 
Ruiz-A
rguelles 
et al. 
[149] 
Mexico Start date 
until 
recovery 
AML adult 
14-63 (24) 
Outpatient 
supportive care 
Inpatient 
supportive care 
1995 Outpatient setting cost 
saved by avoiding 
prolonged 
hospitalization: $1700 
per patient 
Outpatient setting 
saved $2,414 
Storti et 
al. 
[113] 
Italy Unknown AML elder 
65-80 (17) 
Palliative care  2005 Palliative care cost 
(monthly): €8900 
(transfusion include) 
$12,303 
 
•Supportive care 
Cost comparison was impossible to be conducted, due to differences in the study 
coverage for the three relevant studies, while two of the studies, also, did not report the 
cost results [148, 149].  
 
•Palliative care 
The cost results of the two related studies were generally consistent. Yu’s study [107] 
showed that the average cost of palliative care was $18,557 per treatment cycle, while 
Storti et al. [113] found that the average palliative care cost was $12,303 per month. 
 
•Home care 
Cartoni et al. [150] measured the home care cost for three different groups of patients. 
The average home care cost for ‘early discharge patients’ was $5,511. For patients in 
‘terminal stage’, the home care cost was similar to the cost of patients who discharged 
early  ($5,851),  but  higher  than  the  home  care  cost  of  patient  in  ‘chronic  stage’  
($2,057). 
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2.9 Discussion 
 
 
The current review examined cost drivers and costing methods used in previous relevant 
studies. Also, cost result comparisons were conducted when possible. The review results 
extended the methodologies of the previous relevant studies and provided 
ideas/recommendations of methodologies for future cost studies (as well as for the 
innovative costing method used at later stages of the current one). These 
recommendations and related significant findings are summarized as follows. 
 
2.9.1 Bottom-up costing method 
Most of the 50 relevant cost studies (42 out of 50 selected studies) made use of hospital 
charges or payments as costing data sources. The bottom-up costing method was applied 
only in ten of the studies (one for examination cost, two for complication treatment, four 
for transplantation, two for adjunctive treatment and one for home care). For countries 
where national level administrative claim database or hospital accounting system are 
unavailable (such as UK), the ‘bottom-up method’ is suggested to be the best alternative 
for costing. 
 
2.9.2 Overheads costs 
Since 40 out of 50 relevant cost studies used hospital charges or payments as costing data 
sources, overheads cost information was not reported in particular. This was because 
overheads costs were concealed in charges and payments. However, this was not the case 
for studies that used the bottom-up method. In order not to overlook overheads costs and 
not to underestimate overall treatment cost, it is important to take overheads into 
consideration, while applying the bottom-up method for costing. 
 
2.9.3 Follow-up costs 
Follow-up cost was usually overlooked. Among the 50 relevant cost studies, only a few 
overall treatment cost studies estimated follow-up costs [103-105]. In the remaining 
studies, follow-up cost was either completely overlooked or cost in a short period of time. 
In order not to underestimate overall treatment cost, it is suggested that follow-up should 
be considered as one of the important cost drivers, when costing.  
 
2.9.4. Important cost drivers for costing individual treatments 
The  current  review  uncovered  a  number  of  key  cost  drivers  for  costing  individual  
treatments, including ones that were actually, but not obviously, relevant. For example, 
complication  treatment  cost  is  one  of  the  key  cost  drivers  for  costing  growth  factors,  
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while infection treatment cost is one of the key cost drivers for costing complications. It is 
suggested that the aforementioned observations assist in broadening the scope when 
developing costing methods.   
 
2.9.5 Extrapolation for ‘resource uses’ 
 
During the review process, an innovative method for obtaining ‘resource uses’ (quantity) 
information was observed. Normally, hospital accounting system and administrative 
claim database are the main data sources for consumed amount of medical resources 
(quantity). However, Bennett et al employed a new approach for this [132, 135]. The 
authors firstly used the hospital accounting system to cost chemotherapy and growth 
factor for a small number of patients. Next, the obtained results were further used for 
extrapolating the rest of the remaining patients (the majority of the study patient). This 
provided a new way to obtain resource use information when the latter was unavailable, 
something important when using the bottom-up method for costing.  
 
 
The  review results  (cost  drivers  and  details  of  costing  methods)  and  related  important  
findings such as the ones mentioned above provided significant amount of information 
useful for developing costing methods. The information was also adopted in the costing 
method developed at later stages of the current study. 
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CHAPTER 3 THE STUDY DATABASES 
 
 
This study was carried out in the UK. Due to the complexity of the current study, three 
main databases (comprising HMRN) were employed in order to yield robust cost results. 
The three databases were Haematological Malignancy Research Network (HMRN) 
database, Palliative Care Database (PCD), and HMDS Integrated Laboratory Information 
System (HILIS) Database. The relationship between these three study databases is 
illustrated in Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 3.1, the HMRN database contained the health care details extracted 
from medical records. Therefore, it was used as the main data sources for costing. The 
HILIS database contained all the lab test results, while the PCD database, a subset of the 
HMRN database, contained detailed health care information in calendar-basis. Due to the 
information coverage, the PCD databases were used as supplementary data sources for 
costing.   
 
Although the three databases were all derived from the HMRN, these databases needed to 
be handled differently, as different databases contained different information, and used 
different formats. Therefore, in the current chapter, data handling of each study database 
is described respectively and analyzed preliminarily as follows. 
 
 
Figure 3.1 Illustration the relationship between three databases in HMRN 
 
3.1 Database description 
(HMRN) 
-60- 
 
DATABASE 1: HMRN database 
 
3.1Database description 
 
3.1.1 Data collection 
 
The data for treatment pathway building were mainly retrieved from the HMRN database. 
HMRN is a collaboration between five clinical teams based at 14 hospitals in Yorkshire 
and Humberside region (Figure 3.2) (which covers a population of around 3.6 million), a 
centralized diagnostic laboratory (Haematological Malignancy Diagnostic Service - 
HMDS) based in Leeds, and HMRN (Haematological Malignancy Research Network) 
researchers at the University of York [16, 151]. The clinical teams provide patient care, 
HMDS provides regional diagnostic service, while HMRN is responsible for collecting 
the detailed information about all the haematological malignancies diagnosed in the 
Network. This covers around 2,000 newly diagnosed haematological malignancy patients 
each year. All of the collected information about diagnosis, treatment and prognosis can 
be used for further clinical research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.2 Study time period 
 
All patients newly diagnosed with a haematological malignancy after 1 September 2004 
up to 1 September 2006 were included in the study. All identified patients were tracked 
from the time of diagnosis onwards until the study close date (30 May 2010). However, 
 
Figure 3.2 The Yorkshire and Humberside Haematology Network Coverage 
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patients were excluded when the disease was a transformation of another Haematological 
cancer originally diagnosed prior to September 2004 [151]. These decisions were made to 
allow retrospective tracking of the full course/episode of the disease for study patients. 
 
3.1.3 Data extraction 
 
The clinical data were abstracted from patients’ medical records by a group of well 
trained research nurses, who collected the relevant information on the standard forms 
from all the new cases in the Network from hospital records. This included hospital notes; 
however, notes held by private sector institutions were not included because of 
accessibility and availability constraints. Also, in cases where the patient went out to 
other cancer networks, notes were not included. All of the extracted data is centralized 
and stored in HMRN at the University of York, also called ‘HMRN database’. This 
database provides a large volume of clinical information. However, in the context of the 
current study, only required pieces of information were extracted selectively. 
 
a. Inclusion criteria 
 
The patients who were diagnosed with the following results were considered to be AML 
or APML patients and, thus, recruited into the study group: AML with adverse cellular 
features, AML inv(16)(p13;q22), AML arising from transformation of MDS, AML 
arising from transformation of MPD, AML with multi-lineage dysplasia, AML 
t(8;21)(q22;q22), AML with MLL (11q23) rearrangement, AML- probable therapy 
related, and APML t(15;17)(q22;q11-12). 
 
b. Exclusion criteria 
 
•Whenever  the  treatment  episode  was  not  for  AML /  APML,  the  episode  would  be  
removed from the database in order only the AML/APML-related treatment 
information to be retained in the database. For instance, the treatment episode would 
be excluded if it occurred before the patient was diagnosed, as this indicated that the 
treatment was given for other purposes rather than curing the mentioned disease. 
•Patients under 18 years of age were excluded. Given the significant differences in 
treatment response and prognosis between child and adult patients, it was decided 
only adult AML/APML patients would be included. The study included patients who 
were over 18 years old at the time of the diagnosis. The advantage of this was that the 
results would be more consistent and easy to extrapolate to the whole of the adult  
patients. 
3.1 Database description 
(HMRN) 
-62- 
 
 
c. Extraction of information items 
 
Although the HMRN database provides a large volume of clinical information, in the 
current study only the following fields were extracted: patient’s age, gender, diagnosis 
results, date of diagnosis, date of death, date of latest follow-up, name of each treatment, 
regimen of each treatment, start and end dates of each treatment. 
 
Based on the criteria mentioned above, 243 patients were found to be newly diagnosed 
with AML/APML.  
 
3.1.4 Remainder 
 
In the HMRN database, the start and end dates of each treatment episode were recorded to 
justify  the  delivery  of  medication.  The  duration  between  the  start  and  end  dates  was  
defined as the treatment time. It is worth noting that treatment time here does not reflect 
the actual days of the hospital stay, as patients may stay in hospitals for complication 
treatment or other purposes after treatment time.  
 
Another thing worth noting is that patients may have more than one cycle of the treatment 
during the reported treatment time, and, thus, treatment time could include treatment 
intervals or home leaves. This rendered the treatment time of identical treatments vary 
significantly. Since information related to actual treatment time was unavailable, ‘number 
of treatment cycles’ was required in order to transform the uneven treatment time into a 
consistent and comparable format. The information related to number of treatment cycle 
were not routinely recorded into the HMRN database. However, in most of cases, the 
relevant information can be found manually in the notes of the information extraction 
form (used by research nurses for extracting data from medical records). In the cases that 
relevant information could not be derived from data extraction forms, comparisons with 
similar cases under experts’ supervision to yield reliable number of cycles or frequency of 
usage.  
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3.2 Database cleaning 
 
Although all the clinical data were extracted by well trained research nurses, human 
errors/mistakes could have occurred at data input. Therefore, in order to prevent getting 
distorted results derived from analyzing a corrupted database and to enhance the accuracy 
of the analyzed results, data cleaning was needed before the database was used for further 
analyses. 
 
The following errors / mistakes were corrected or excluded from the study analysis for 
cleaning purposes. 
 
3.2.1 Excluding the problematic cases 
 
All  of  the  study  patients  were  followed  up  on  a  regular  basis,  and  their  clinical  
information were extracted by research nurses. However, there were four cases where 
either the relevant medical notes were unobtainable or the clinical information extraction 
forms had not been completed yet. These four cases were excluded from the study 
analysis completely in order not to be mistaken as untreated cases. 
 
3.2.2 Excluding the duplicate treatment records or integrating the treatment 
records that were likely to be the same 
 
Records duplication does not occur very frequently in the HMRN database. However, in 
treatment event/episode level, a number of duplicated events were observed. These 
duplicated cases were integrated into one record, with the wrongly added records being 
excluded. 
 
‘The event records that are likely to be the same’ are the records that are not presented in 
exactly the same way as others in the database but they have very high possibility to be 
the same events. This was because sometimes research nurses could be misled by the 
complexity or the purposes of the regimen / drug usage. For example, while cytarabine 
and daunorubicin could be given as a single agent, they could also be combined and given 
as a regimen called DA. To prevent this potential misleading information enter the 
database,  this  kind  of  records  needed  to  be  integrated  into  one  record  and  the  rest  of  
associated pieces of information to be excluded. 
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Identifying and integrating possible duplicate records was not an easy task as  it could 
not be done by the use of typical software logic procedures [152]. Therefore, potential 
duplicated records had to be cleaned up manually, with only the integrated data being kept. 
The details of the integration can be found in Appendix 3.1. 
 
3.2.3 Handling of records including in-equivalent information (observation event) 
 
Observation events were not routinely recorded. In order to ensure that all the patients’ 
records included equivalent amount of information, it was decided that observation 
should be defined as the outpatient based follow-up visit (during all gaps of treatments 
with the exception of supportive care).  
 
3.2.4 Ensuring the data is consistently formatted 
 
Correcting the format of the data not only helped the management of the database, but 
also it made further analysis work much easier, although this process was not as important 
as initially obtaining the correct data (as mentioned above). For example, since the 
missing data were recorded differently in the various fields of the HMRN database, blank 
fields were used for presenting all of the missing data, as a default. 
 
3.2.5 Summary 
 
After database cleaning process, 239 out of 243 patients were found to be eligible for 
further analysis, as the medical notes of four patients were not obtainable. In terms of 
event records, overall, 56 treatment events were excluded from the study database due to 
the duplication and inadequate information. Finally, 763 events remained in the database 
for further study. 
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3.3 Missing data imputation 
 
Despite the fact that research nurses tried to extract data from medical notes in as much 
detail as possible, in some cases the data were impossible to be obtained. In such cases, 
the missing data were coded separately. In the HMRN database, the missing data were 
divided into two types: those in the non-interest fields or those in the interest fields. When 
the missing data appeared in the non-interest fields (the fields that are not related to cost 
estimation), the most common value was used as a default for imputation. However, the 
situation was more complicated when the missing data appeared in the interest fields, as 
the missing data imputation could affect the final result - treatment cost. Therefore, a 
careful design for handling the missing value was needed. 
 
In the current study, an important field that had many missing data was the ‘treatment 
date’ (including ‘start date’ and ‘end date’). ‘Treatment date’ is considered to be 
associated with ‘treatment time’, which is an important parameter for cost measurement. 
In the HMRN database, among 763 treatment events, 241 events did not have sufficient 
date data for ‘treatment time’ calculation (either the treatment start or end date was 
missing, or both were missing). Therefore, an imputation for the missing dates was 
urgently needed. 
 
In this section, the imputation of the missing dates is discussed in detail. This includes 
two parts. First, the missing date of the treatment event was imputed. Second, the 
treatment events were broken down by treatment cycle. In the end, each treatment event 
would only have the information (including date and regimen) of one cycle/course of 
treatment. The benefit of this approach was that it made treatment overlapping easy to be 
identified, and, thus, made the further cost calculation and analyses easy to be carried out. 
The details are described in the following paragraphs. 
 
 
3.3.1 Imputation of missing date data 
 
a. Supplementary data for imputation 
 
In the current study, four sets of information (derived from five different sources) were 
used to serve the imputation purpose.  
3.3 Missing data imputation 
(HMRN) 
-66- 
 
•Fragments of actual ‘treatment date’: The non-missing ‘treatment date’ that derived 
from the HMRN database was retained as the main body of the imputation. 
•Number of treatment cycles: This information provided a general idea about the 
supposed length of the treatment, as some of the treatment event records contained 
more than one cycles of treatment. The ‘number of treatment cycles’ of each 
treatment was derived from the notes of the information extraction form.  
•Actual hospital stay: the additional information derived from a subset of the HMRN 
database - medical notes of 30 patients recruited in clinical trial. The ‘actual 
hospital stay’ provided the information about the number of bed days that a patient 
stayed in hospital (even after the delivery of medication). This was particularly 
useful for imputing when the treatment record contained more than one treatment 
cycles. 
•Standard treatment time: this information was derived from the AML 15 trial protocol 
and the BCSH treatment guideline. ‘Standard treatment time’ provided the 
information related with the general length of the treatment. This was useful when 
the treatment record contained more than one treatment cycles. 
 
After necessary refinement by clinical experts, all the information for imputation 
mentioned above was integrated into a table. The details can be found in Appendix 3.2. 
An abstract of the contents of the table is shown below. 
 
 
 
Table 3.1 Example of integrated information for imputation 
 Cycle 1 
Interval 
Cycle 2 
Imputed 
treatment time  Treatment time 
Hospital 
stays 
Treatment 
time 
Hospital 
stays 
ADE 10 30 13 8 25 30+13+8=51 
AraC (HD) 5 32 17 5 23 32+17+5=54 
DA 10 35 14 8 30 35+14+8=57 
FLA 5 28* 17* 5 46* 28+17+5=50 
Mylotarg 1 - 6 1 - One cycle (1) 
ATRA Till remission** -    Till remission** 
* The length was imputed by similar treatment  
** The length was imputed by expert opinions 
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As can be seen in Table 3.1, the inpatient chemotherapy of each cycle contained two 
pieces of information: ‘treatment time’ and ‘hospital stay’. Average treatment interval 
information for each chemotherapy regimen was also presented. As for the outpatient 
treatment, such as mylotarg, one cycle was set a default value if the information of 
numbers  of  cycle  was  not  obtainable.  No  hospital  stay  was  applied  to  outpatient  
treatment. 
 
 
b. Imputation methods 
     
After integrating the information for imputation, it was possible for the missing data to be 
imputed. The integration involved four steps. Details of the four steps can be found 
below. 
 
Step 1: Grouping treatment events. 
The treatments that used similar regimens or followed similar approaches were 
grouped together in such a way as the missing values to be possible to be imputed 
together at later stages. This way, not only the complexity of the imputation could 
be reduced, but also the imputed value could become more robust. 
 
Step 2: Ensuring that each event in the groups has only one date missing. 
In order to impute the missing ‘treatment date’ by means of ‘standard / imputed 
treatment time’, at least one of the ‘treatment dates’ (‘start date’ and/or ‘end date’) 
had to be known. Among 763 study events, eight events were found to have both 
the  ‘start-date’  and  the  ‘end-date’  missing.  To  deal  with  this  issue,  the  medical  
notes of these 8 cases were retrieved and re-extracted with the assistance of 
research nurses. Based on the above, it could be ensured that each treatment event 
in the groups had only one date missing. 
 
Step 3: Determining the ‘standard / imputed treatment time’ 
Based on the integrated information (Appendix 3.2) and on the ‘number of 
treatment cycles’, the ‘treatment time’ could be imputed in three different ways: 
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•When the ‘number of cycles’ was known (cycle=1) 
When the ‘number of cycles’ was one, then the standard treatment time (derived 
from guideline or protocol) was used for imputation. 
 
•When the ‘number of cycles’ was known (cycle>1) 
When the ‘number of cycles’ was more than one, the imputed treatment time was 
determined  by  the  lump  sum  of  the  hospital  stays  for  cycle  1,  interval,  and  
standard treatment time for cycle 2 (the details can be seen in Table 3.1) 
 
•When the ‘number of cycles’ was unknown 
When the ‘number of cycles’ was unknown, one cycle was set as the default value. 
The standard treatment time for one cycle (derived from the guideline or the 
protocol) was used for imputation. 
 
 
Step 4: Imputing the missing date. 
After applying the standard / imputed treatment time to the events that were found 
to have missing data, the missing date could be calculated by simple addition or 
subtraction. 
 
The imputation method is illustrated in the following figure (Figure 3.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 The illustration of missing data imputation method 
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3.3.2 Breaking down the treatment events (by cycles) 
 
Although at this stage each treatment event record had both a ‘start date’ and an ‘end date’ 
(either original or imputed), the treatment event records still could not be used directly for 
cost calculation. This was because they contained uneven information (some of the 
records contained 1 cycle of treatment information, while some contained more than 1 
cycle). To avoid confusion regarding the information one event record could contain, the 
treatment events were further broken down into cycles. This way, each cycle of treatment 
would be registered in one record in the database. This approach was expected to have the 
following four benefits: 
 
•It could give a better view of the time each treatment cycle was likely to have taken 
place. 
•It could help in avoiding over-counting the treatment cost in cases where the ‘treatment 
time’ contained more than one cycle and the ‘interval’ (also called ‘home leave’) 
should not be calculated.  
•It made treatment overlapping easy to identify. This made further cost calculation and 
analyses easier.  
•It enhanced the accuracy of the costing method, as the costs of all the cycles could be 
estimated in detail. 
 
It is worth noting that the ‘treatment dates’ of each cycle, deriving from the break-down 
method, were all imputed dates and not the actual occurrence dates. However, this was 
the closest estimation to the actual occurrence date that could be achieved. The details of 
the aforementioned break-down process are described below. 
 
a. In-patient treatment events 
 
All the treatment events that contained more than one cycle were further broken down 
into cycles,  according to the ‘number of treatment cycles’.  As for the events that  were 
found  to  have  missing  ‘number  of  treatment  cycles’,  the  breaking  down  number  was  
determined by comparing the treatment length with other cases with known ‘number of 
cycles’. After the above process was completed, only the newly generated event records 
were retained while all the original records (containing more than one cycle) were 
removed. The discussed process is illustrated in Figure 3.4. 
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b. Out-patient treatment events 
 
Unlike the inpatient treatment events, the records of the outpatient treatment event 
normally do not contain information related with the ‘number of cycles’. This is because 
many of them, such as Hydroxycarbamide, are given either on a daily or on a continuous 
basis. After careful consideration, it was decided that the outpatient treatment events did 
not need to be broken down. This was because of two reasons: 
 
Firstly, the pattern of the outpatient treatment delivery was not consistent. This was 
especially prominent when the outpatient treatment overlapped with the inpatient 
treatment, in which case the outpatient treatment (such as hydroxycarbamide) was carried 
out daily by hospital staff during the hospital stay while the delivery style changed after 
the patient discharged. In the latter case, the patient would only visit the hospital for 
getting medicine or receiving simple outpatient treatment on a regular basis. The 
inconsistent delivery pattern made the breaking down of the outpatient event difficult. 
 
Secondly, even in cases where the outpatient treatment did not overlap with the inpatient 
treatment, the frequency of outpatient visits could be changed when overlapping with 
other outpatient treatments occurred. This was because the medicines used for the 
outpatient treatment could be given at the same visit (there was no need for the patient to 
visit the hospital twice for getting different types of medicine as these could be provided 
at one visit). The discussed process is illustrated in Figure 3.5. 
 
 
 
 
Figure 3.4 The illustration of breaking down event 
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Based on the figure above, more information was needed in order to break down the 
outpatient events (such as the overlapping information). Therefore, the outpatient 
treatment records remained unaffected, at least for this particular phase of the study. 
 
3.3.3 Summary 
 
Overall, 763 events were broken down and, consequently, expanded to 1025 episodes. 
After the process described above was completed, all the missing treatment date data for 
each cycle were obtained and ready for cost estimation use.  
 
 
 
 
Figure 3.5 The illustration of outpatient treatment overlapping 
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3.4 Integration with other data sources 
 
 
3.4.1 Integration with NHS Central Register 
 
For the purposes of current study, additional information was obtained from the National 
Health Service Central Register (NHSCR) and was linked and integrated into the HMRN 
database with ethics approval (NHSCR is held by the Office for National Statistics on an 
agency basis for the Department of Health [153]). NHSCR compiles and maintains 
computerized records of all NHS registered patients, including information such as 
cancer  and  death  events  [153].  From the  NHS Central  Register,  ‘place  of  death’  fields  
were extracted and added into the study database for study purposes.  
 
The ‘place of death’ field mainly contained information related with the actual location of 
the patient’s death, for example at home, in hospital, or at nursing home. This information 
could be later used for calculating the dying cost, and mainly it could help to identify the 
ward cost for each of the above places. For example, the dying cost was considered to be 
zero if the patient died at home.  
 
3.4.2 Additional information was available on subset 
 
For a proportion of patients recruited to national clinical trials, additional data were 
obtained from medical records. The additional data relate to hospital stay and antibiotic 
use. 
 
a. Actual hospital stay 
 
Since ‘treatment time’ was not sufficient to provide the required information of the actual 
medical resource use, the actual hospital stay/bed day had also to be considered for 
estimating the treatment cost. In the context of the current study, it was initially intended 
all the actual hospital stays data to be obtained. However, this was not possible because of 
availability constraints. The only data that were possible to be extracted were those of the 
clinical trial arms. The aforementioned data were extracted from medical records of 30 
patients (including the information of admission date and discharge date). After the data 
were obtained, they were extrapolated and integrated into the study database. 
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b. Antibiotic use 
 
Antibiotic  is  a  common  supportive  care  or  complication  treatment  for  AML/APML  
patients. However, this information was not obtainable in the HMRN database. Since it is 
very expensive, the information of antibiotic use was needed to be additionally extracted 
in order to enhance the accuracy of the treatment cost estimation. Information related to 
the number of days the antibiotics were used for each clinical trial arm was extracted from 
30 available medical records. This information was extrapolated and added into the study 
database for further analysis. 
 
3.4.3 Summary 
 
The integration with other data sources enriched the HMRN database. A number of pieces 
of information became available for costing, namely place of death, index of deprivation, 
hospital stays, and days of antibiotic use. As the additional information derived from the 
integration did not alter number of cases, the study population remained the same: overall, 
239 patients with 1025 treatment events/episodes. 
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3.5 Preliminary analysis method 
 
In order to have a better understanding of the type of information contained in the HMRN 
database, a number of preliminary analyses were conducted. They were descriptive 
statistics, test of homogeneity, missing data analysis, and treatment pathway. The 
overview of preliminary analyses is illustrated in Figure 3.6, while the detailed analysis 
methods are discussed in the following sections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5.1 Descriptive statistics 
 
All statistical analyses were done by means of SAS/Stats program (SAS software 
program package, version 8.02, SAS Institute, Cary, NC) 
 
a. Characteristics of study population  
 
According to the information available in the HMRN database, the following 
demographic variables of the study population were analyzed: gender, age, diagnosis 
result, disease transformation, index of deprivation, mortality, and place of death. 
Information such as gender, mortality, place of death, disease transformation, diagnosis 
and index of deprivation is categorical data. Therefore, the analyses were descriptive in 
percentages for these variables.  
 
In the case of the ‘age’ variable, it was decided that the ratio scale should be applied, 
despite the fact that originally it was continuous data. The reason for this was that the age 
group was an important determinative factor for clinicians for deciding which was the 
optimal treatment to patients (Normally, old patients would have poorer response than 
 
Figure 3.6 Overview of preliminary analyses of HMRN database 
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younger adult patients [154]). Therefore, the results presented by continuous scale 
(‘average age’) would not be helpful enough for portraying the study population. 
Therefore, the analysis results were presented in age category format. The age data were 
categorized into three different age groups (based on the AML / APML treatment 
guideline [155, 156]), namely: less than 59, between 60 and 74, and over 75 year-old. The 
age of APML patients was divided into two categories: between 18 and 59, and over 60 
year-old. 
 
b. Types of treatment  
 
Different patients undertook different treatments, and also most of patients received more 
than one treatment for AML / APML. To portray the type of treatments that AML / APML 
patients received, three analyses were conducted. 
 
•Numbers of treatment 
•Types of treatment by diagnosis (AML/APML) 
Treatment type was an important piece of information for understanding what kind of 
treatment AML/APML a patient normally received. To reveal this information, all the 
treatment episodes that used for treating AML/APML were analyzed and presented in 
percentage. Since the diagnosis (AML / APML) also plays an important role in 
treatment decision making [155, 156], the analysis was further broken down into two 
parts by diagnosis. 
•Types of primary induction treatment by diagnosis and age groups 
Type of primary induction treatment has a strong connection with patient’s condition 
on their first diagnosis. Also, the types of primary induction treatment is considered to 
be  related  to  the  prognosis  (such  as  remission  rate)  and  mortality  according  to  the  
results of many clinical reports [97, 155, 157]. To reveal this connection, the primary 
induction treatment type was further analyzed with patient’s character, including age 
and diagnosis. 
 
c. The treatment duration 
 
In the HMRN database, there were three different types of treatment duration that were 
crucial for treatment cost estimation: 1) ‘treatment time’ which is the duration of the 
delivery of medication. 2) ‘hospital stay’ which is the number of bed days a patient stays 
in the hospital for treatment, including treatment time and other bed days involving 
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relevant supportive care or complication treatments. 3) ‘Antibiotic days’: days of 
receiving antibiotics, which could represent actual expenses of pricey complication 
treatment. These three different types of treatment duration were presented by types of 
regimen / arms of clinical trial. 
 
 
3.5.2 Missing data analysis (patterns of missing values) 
 
Missing data are commonly observed in patient-oriented research and studies [158, 
159].The HMRN database is not an exception, although the data were manually extracted 
by well trained research nurses.  
 
Missing data could produce substantial biases in analysis and reduce the precision of the 
statistic results, if it is not handled carefully [160, 161]. On this ground, it is very 
important to test and make sure that these occurrences of missing data are random and not 
systematical before starting analyzing the data. This was especially important in the 
context of the current study, as the interest variables (treatment start and end dates) 
contained significant amount of missing data, and also because these variables were the 
crucial  parameters  for  treatment  cost  estimation  at  later  stages.  In  current  study,  a  
two-stage simple missing data analysis was conducted in order to check the pattern of 
missing data and whether the missing values occurred systematically. 
 
 
a. Descriptive statistics 
 
In order to describe the distribution of the missing and non-missing values in the interest 
variables (treatment start-date and end-date), descriptive statistic analysis was conducted 
and missing and non-missing values were presented in numbers.  
 
b. Missing data analysis 
 
To check whether the missing values occurred randomly or systematically and whether 
the missing data were influenced by any other variables, a simple logistic regression 
method was conducted [162, 163]. 
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3.5.3 Treatment pathway 
 
The  tree  diagram of  the  treatment  pathway was  an  attempt  to  present  the  longitudinal  
history of main and relevant treatments, which took place not only within one hospital, 
but also within all the other relevant hospitals that were involved in the HMRN network. 
It  provided  a  holistic  view  of  the  entire  patient’s  treatment  pathway.  However,  the  
treatment pathway could not be portrayed as straightforward as in other leukemia cases 
because of rapid progression of the disease that caused complicated treatment processes. 
To make the tree diagram simple and easy to read, the treatment pathway was sorted and 
presented  according  to  treatment  start  date.  In  order  to  do  so  a  compromise  had  to  be  
made, as information regarding treatment overlapping could be lost. 
 
a. Purpose 
 
•Reveal the treatments which AML patients were received in real world 
Treatment pathway for two patients with the same illness could be entirely different 
depending on patients’ situation or physicians’ decisions. Therefore, the tree diagram 
allows the treatment pathway to be highly personalized. This made it a preferable way 
to calculate the ‘actual’ treatment cost, compared to the use of the clinical guidelines.  
•Transcend the hospital boundaries 
As the data were collected through the network, there were no hospital boundaries in 
this study. This allowed the collection of information from treatments of individuals in 
several different hospitals, rather than just form one hospital. 
•Display a graphic representation of the pathway in which costs can be later linked to. 
This is also known as ‘clinical process cost analysis’. 
b. Method 
 
The ‘treatment pathway’ was presented as a route that an AML/APML patient took from 
diagnosis, through treatments, to the completion of the treatments, follow-up or death. In 
this section, all the clinical information extracted from the database was plotted into a 
timeline. The events such as chemotherapy, clinical trial, palliative care, and 
transplantation were mapped to this timeline according to their treatment start date. 
However, events such as supportive care and observation/follow-up were not included 
because they were not given with curative intent. To plot the treatment pathway tree, four 
steps were followed: 
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Step 1: Identifying patients as AML /APML and dividing them into groups by their age: 
To plot the AML and APML treatment pathway, the patients were divided into 3 
main groups by age, as different age groups of AML / APML patients are suited 
for different treatment options due to different treatment response rate and 
treatment tolerance. According to the same definitions of the age groups used to 
present the descriptive statistics (referred to 3.1.2), AML patients were divided 
into 3 groups: ≤59, ≥60 and≤74, ≥75, and APML patients were divided into 2 
groups: ≥18 and≤59, ≥60 
 
Step 2: Excluding the treatments that were unsuitable to be presented: After the 
regrouping of treatment types, two treatment types were removed, namely 
observation/follow-up and supportive care. This was because these two 
inerventions could make tree diagram plotting problematic as supportive cares 
were usually given along chemotherapy or other treatments, and observation, and 
observation were given far too frequently and regularly then any other major 
treatments.  
 
Step 3: Presenting the main treatment information: Since it was impossible to show all the 
details in one tree diagram, only the main treatment types were shown in order to 
portray the whole range of the treatment activities given to a patient without 
compromising clarity. These treatment types were: chemotherapy, clinical trial, 
transplantation, palliative care, radiotherapy, and immunosuppressive care. 
 
Step 4: Plot tree diagrams: After identifying and grouping the patients and treatments, all 
the treatment data were summarized graphically by diagnosis, patient age, and 
treatment type. Each patient was traced from the diagnosed date onward, to the 
last follow-up date or death. Patients who died were given a square mark in the 
end of the branch in the tree diagram. All the sequences of treatments were 
visualized as a linear timeline according to the chronology of the HMRN records. 
However, overlapping treatments were not possible to be shown in this pathway 
tree diagram. 
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3.6 Overview of the work done on the HMRN database 
 
 
The HMRN database was used for defining the study population of the current study. In 
order to obtain the disease-specific information, the HMRN database was handled 
through several processes (discussed in sections 3.1 to 3.4). These processes were: data 
extraction, database cleaning, missing data imputation, event breakdown by cycle, and 
integration with other data sources. The whole process and number of cases are 
illustrated in Figure 3.7.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After the study database was set up, a number of preliminary analyses were conducted 
(please refer to section 3.5). The relevant results are presented and discussed in the next 
chapter (chapter 4). 
 
 
 
Figure 3.7 Illustration of data handling process on HMRN database 
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DATABASE 2: HILIS database 
 
3.7 Database description 
 
3.7.1 Data collection 
 
Information related with treatment phase distinguishing and laboratory cost estimation 
was mainly retrieved from the HILIS database, which was maintained by the 
Haematological Malignancy Diagnostic Service (HMDS), an organization based in Leeds 
Teaching Hospitals. HMDS, which was the first specialist haematopathology service in 
the UK, was established in 1993 in order to integrate the diagnostic techniques and 
experts  in  the  Yorkshire  and  Humberside  areas.  Since  then,  all  the  regional  diagnostic  
services are centralized and referred to HMDS. The number of tests, which increases 
annually, reached around 20,000 test requests in 2009. HMDS not only allows the 
diagnostic  resources  to  be  integrated,  but  also  enhances  the  precision  of  diagnosis  and  
helps to monitor both patient disease progression and response to treatment. Since this 
approach has been successfully carried out by HMDS and as the number of test requests 
increases year by year, a sophisticated and customized web-based laboratory IT system 
was applied in 2001 within the NHS intranet. The reason for this was to provide better 
services, better data usage, and a general source of information for potential and/or 
current users. The IT system is known as ‘HMDS Integrated Laboratory Information 
System (HILIS)’, and is used to integrate all the information related with clinical 
diagnosis, specimen or biopsy tracking, and reports produced in HMDS [164, 165]. In 
Figure 3.8, the reader can find a graphical representation of the data collection process of 
the HILIS database.  
 
 
 
 
 
Figure 3.8 Graphical representation of data collection process of the HILIS database 
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3.7.2 Study time period 
 
All the diagnoses are tracked and relevant reports of the study population (patients who 
were newly diagnosed with AML or APML between 1 September 2004 to 1 September 
2006) in the HILIS database were eligible to be included. However, only the test result 
information, reported between the diagnosis date and either the death date of the patient 
or the study close date (30th May 2010) was actually kept. This approach was expected 
not only to allow retrospective tracking for all the laboratory tests and relevant events, but 
also to assist in keeping the relevant events that were related to AML/APML treatment. 
 
3.7.3 Missing data 
 
In  the  HILIS database,  no  data  were  found to  be  missing  and  all  the  test  results  were  
reported in high detail. Even cases of inappropriate request or unsuitable specimen were 
recorded,  and  were  continuously  audited.  Therefore,  missing  data  analysis  was  not  
needed for the HILIS database. 
 
3.7.4 Database cleaning 
 
According to the guideline, when specimens or biopsies were referred to HMDS, they 
were investigated using standardized protocols rather than in response to individual 
requests for tests from referring clinicians [164]. Briefly, each patient-specific report 
generated by HMDS was derived from a maximum extent of cross validation information. 
This contained groups of samples received from clinicians rather than single samples of 
request for test. This was expected to assist in the investigation of the samples by 
co-ordinate experts at later stages, as it would allow focusing on specific clinical 
problems, and also assist in avoiding any duplicated test requests and conflicting reports 
from different sample types [164].  
Despite the fact that this specific approach introduced a number of advantages, a serious 
issue occurred while analyzing the data. A large amount of requests that were sent during 
a short period of time to produce one report were all reported and uploaded into the HILIS 
database. This means bunch of relevant request /sample reports had the same results. The 
above issue greatly increased the volume of the database rendering it inconvenient for 
further analysis. In order to have a clean database for analysis and not to double count the 
laboratory cost, all the duplicated information were summarized into one report 
according to the ‘report date’ field with all the unnecessary information being excluded. 
The information that was summarized contained the following fields: report date, test 
result, and specimen type.  
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a. Report date 
Without considering the screen date, only one patient-specific report was kept for each 
report date. Effectively, this meant that if the samples were collected on the same date 
(same screen date) but reported on different dates, these test results could not be 
combined into one. 
 
b. Test results 
Since the test results on the same report date would be consistent, the test results were 
summarized into one for each report date. 
 
c. Specimen/biopsy types 
The summary / combination of specimen of biopsy/specimen types mainly was 
conducted for laboratory cost estimation purposes, as summarized specimen data are 
easier to be linked by the unit cost and to be cost. The abbreviations of specimen are list 
below (Table 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Because  of  the  complexity  and  variety  of  specimen/biopsy,  the  combination  of  the  
specimen/biopsy information encompassed three steps: 
Table 3.2 Abbreviation of specimen test 
Full name of the specimen test Abbreviation 
Bone marrow aspirate BMA 
Bone narrow aspirate & Trephine biopsy BMAT 
Cerebral spinal fluid (CSF) CF 
Chimerism, allograft CHIA 
Chimerism, baseline CHIB 
Chimerism, mini-allograft CHIM 
Skin, block DBL 
Skin, fixed DF 
Skin, fixed & unfixed DFU 
Skin, unfixed DU 
Effusion EF 
Haematological slide HS 
Lymph node biopsy, fixed LF 
Lymph node biopsy, unfixed LU 
Peripheral blood PB 
Peripheral blood, stem cell PBS 
Spleen, unfixed RU 
Bone marrow trephine, fixed TBP 
Miscellaneous tissue aspirate XA 
Miscellaneous tissue, block XBL 
Miscellaneous tissue, unfixed XU 
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Step 1: The different sample results that were actually derived from the same specimen 
were combined. For example, as the LBL (Lymph node biopsy, block), the LF 
(Lymph node biopsy, fixed) and the LFU (Lymph node biopsy, fixed & unfixed) are 
similar methods used on the same biopsy (lymph note) they could be combined. In 
this  case,  the  specimen  types  were  combined  into  one  type,  and  the  rest  of  the  
information was removed in order to prevent double counting the lab cost. The 
specimen types that were combined in this group were: 
CHIA, CHIB, CHIM 
DBL, DF, DFU, DU 
LF, LU 
XA, XBL, XU 
BMA, BMAT 
PB, PBS 
 
Step  2: The duplicated specimen results that were examined for confirmation were 
combined. For example, ‘PB, BMA’ and ‘BMA, PB’ are actually the same methods 
used  on  the  specimens  so  they  could  be  combined.  In  this  case,  only  one  of  the  
specimen type sets of information was kept while the rest were removed in order to 
avoid double-counting the lab cost. The specimen types that were combined in this 
group were the following: 
BMA, TBP / TBP, BMA 
BMA / CF / CF, BMA 
PB, BMA / BMA, PB 
PB, BMAT / BMAT, PB 
TBP, HS / HS, TBP 
TBP, PB / PB, TBP 
 
Step 3: The remaining specimen type information was summarized into one record for 
each report date. After completing step 1 and step 2, only one specimen type was 
kept. However, on the same report date, the specimen type information from 
different test methods or different specimen still existed in the database and needed 
to be removed. For example, ‘BMA, PB’, ‘BMA, TBP’, and ‘CHIM’ were all on the 
same report date, and, therefore, they could be summarized into one record: “BMA, 
PB, TBP, CHIM”. All in all, the main task in step 3 was to summarize and combine 
all the remaining specimen types into one integrated specimen record. After step 3, 
each report date would only have one summarized specimen type, while the 
unnecessary pieces of information were removed from the database. 
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3.8 Preliminary Analysis Methods for the HILIS database 
 
 
All statistical analyses and data manipulation tasks, such as summarizing the duplicated 
data and calculating the lab cost, were done with the SAS/Stats application (SAS software 
program package, version 8.02, SAS Institute, Cary, NC) 
 
 
3.8.1 Treatment phase / Length of treatment phase 
 
Treatment phase (for example first remission or first relapse) is an important piece of 
information for describing the progression of AML treatment, while it is also relevant to 
the process of deciding the treatment types and calculating treatment costs. To identify 
the cutting-off date for the treatment phase, test result data from the HILIS database were 
used.  
 
To  identify  this  cutting-off  date,  two pieces  of  information  were  essential,  namely  the  
fields ‘test result’ and ‘date’. More specifically, the ‘report date’ was used as the 
cutting-off date instead of the screen date. Also, multiple test results were used for 
identifying the treatment phase. A breakdown of this can be found below: 
 
a. Remission date 
 
When the test result was firstly described as ‘remission bone marrow’ or ‘no evidence of 
disease’ based on specimen BMAT, then the report date could be defined as the first 
remission date. After that, all the following remission results could be treated as if the 
patient stayed in remission until the disease relapsed. If the disease relapsed, and the 
patient  achieved  remission  again  (that  is  if  the  patient  had  remission  diagnosis  again),  
then the report date for this remission would be defined as the next successive remission 
date (for example: second remission, third remission and similar).   
 
b. Relapse date 
 
Relapse is defined as the reappearance of leukemic cells after a patient achieved 
remission. Therefore, when a patient had previous remission record (achieved remission) 
and the test results were AML relevant diagnosis, then the first report date could be 
defined as the first relapse date. It is worth to note that ‘suspicious of malignancy’ was not 
considered as one of the AML relevant diagnoses. After that, if a patient had achieved 
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another  remission,  then  the  report  date  of  the  following  first  AML diagnosis  could  be  
defined as the next successive relapse date (for example: second relapse, third relapse and 
similar). 
 
It is also worth noting that a patient could have more than one remission and relapse dates 
depending on the diagnosis results in the HILIS database. All these dates were recorded 
with ordinal numbers according to the frequency of their appearances in the database (for 
example: 1st remission date, 2nd remission date, and 3rd remission date). 
 
After the remission dates and relapse dates were identified, the length of treatment phase 
was calculated in order to present the differences and characters of each treatment phase. 
 
3.8.2 Laboratory costs 
 
To estimate the laboratory costs, two pieces of information were needed, namely: 
‘quantity’ and ‘unit cost’. The details of these two elements are described below: 
 
a. Quantity 
 
The laboratory costs were calculated using 1767 test reports from the HILIS database, 
after the data had been cleaned. Based on the specimen type information (as shown in 
Table 3.2), each report had only one summarized specimen type. This summarized 
specimen information could be taken as ‘quantity’ in laboratory cost estimation. 
 
b. Unit cost 
 
For the laboratory cost calculation of each test request the price list was used as unit cost. 
The price list was derived from the ‘Provider-Provider Tariff 2006-7 of the 
Haematological Malignancy Diagnostic Service at St James’s Institute of Oncology, 
Leeds Teaching Hospital NHS Trust’. The detailed price list is shown in Table 3.3. 
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The  test  cost  of  each  report  could  be  obtained  simply  through  the  use  of  addition,  by  
linking the unit cost to the specimen type information in the HILIS database. The test 
costs were further summed up by patient level. Finally, each patient would be allocated 
one total lab cost, and the difference of the lab cost for each patient could then be revealed. 
In addition to considering the lab cost as a whole, the lab cost could be further divided by 
the treatment phase. This could provide a whole picture of the lab test usage in each 
treatment phase. 
 
 
 
Table 3.3 Price list of specimen test 
Full name of the specimen test Abbreviation Price 
Bone marrow aspirate BMA £148 
Bone narrow aspirate & Trephine biopsy BMAT £339 
Cerebral spinal fluid (CSF) CF £29 
Chimerism, allograft CHIA £265 
Chimerism, baseline CHIB 
Chimerism, mini-allograft CHIM 
Skin, block DBL £218 
Skin, fixed DF 
Skin, fixed & unfixed DFU 
Skin, unfixed DU 
Effusion EF £90 
Haematological slide HS £29 
Lymph node biopsy, fixed LF £90 
Lymph node biopsy, unfixed LU 
Peripheral blood PB £148 
Peripheral blood, stem cell PBS £148 
Spleen, unfixed RU £200 
Bone marrow trephine, fixed TBP £218 
Miscellaneous tissue aspirate XA £148 
Miscellaneous tissue, block XBL 
Miscellaneous tissue, unfixed XU 
 
3.9 Overview 
(HILIS) 
-87- 
 
3.9 Overview of the work done on the HILIS database 
 
 
The HILIS database was used for identifying treatment phase and for laboratory test 
cost calculation. In order to obtain the relevant information, the HILIS database was 
handled through several processes (discussed in sections 3.7). The whole process and 
number of cases are illustrated in Figure 3.9.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After the study database was set up, a number of preliminary analyses were conducted 
(please refer to section 3.8). The relevant results are presented and discussed in the next 
chapter (chapter 4). 
 
 
 
 
Figure 3.9 Illustration of data handling process on HILIS database 
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Database 3: Palliative care database 
 
3.10 Database Description 
 
3.10.1 Data collection 
 
The HMRN establishes a platform to conduct further researches into patients care. 
Currently, it is providing the research infrastructure for a portfolio of palliative and 
end-of-life care projects. This project is directed by the ‘HMRN Palliative Care and 
Haematological Malignancy Steering Group’, a group that was established in 2004 and 
comprises of academics from the University of York (including individuals from the 
fields of sociology, Health Sciences, and Epidemiology), the clinical director for cancer 
and clinical support at Castle Hill Hospital, consultant haematologists, specialist 
haematology nurses, consultants in palliative medicine, specialist palliative care nurses, 
GPs and patient representatives. The aim of the project is to examine specialist palliative 
care (SPC) referrals in patients with haematological malignancies. Special attention was 
given  to  the  investigation  of  the  patient  pathway,  the  palliative  care  input  and  the  
transition to a palliative approach. All the data related with the SPC referrals and with the 
transition from life prolonging to palliative approaches to care were routinely collected 
by well-trained research nurses. This was done for all newly diagnosed patients 
throughout the HMRN area. In total, approximately 350 medical notes of haematology 
patients who were diagnosed at two of the HMRN hospitals (York and Hull) between 1st 
April 2005 to 31st March 2008 and had died within the HMRN area by 2009 were 
examined and transcribed in detail.  
 
Among all the collected data, only 20 patients were found to have been diagnosed with 
AML / APML. Information such as delivery of medication, admission/discharge dates, 
units of blood and platelet transfusions, and the names of involving specialist teams were 
recorded on a day-to-day basis by means of a bespoke calendar approach (which was used 
extensively and extremely successfully in previous research projects). The above data 
were put in a database called ‘palliative care database (PCD)’. Screenshots and 
illustrations of the followed calendar approach (mentioned above) are shown in Figure 
3.10 and Figure 3.11.   
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Figure 3.10 Screenshots of bespoke palliative care database created to managed data 
abstracted using the day-to-day calendar approach 
 
Figure 3.11 Figure 3.10 Analyzed day-to-day data collected using the calendar approach 
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3.10.2 Data extraction 
 
Although  the  Palliative  Care  Database  provides  a  large  volume  of  detailed  clinical  
information on a calendar basis, unfortunately the limited number cases (20 AML / 
APML  cases)  restricted  the  possibility  of  data  use  for  further  analyses.  In  the  current  
study, only the transfusion relevant details from the records of the aforementioned 20 
patients  were  used  for  further  analysis  and  for  cost  estimation  at  later  stages.  This  
includes information related to units of transfusion (blood and platelet) and transfusion 
frequency. The rest of the clinical information was omitted for two reasons. Firstly, most 
of  the  clinical  information  could  also  be  found  in  the  HMRN  database  except  the  
transfusion  details.  Secondly,  the  case  numbers  were  not  high  enough to  cover  all  the  
treatments and conditions of the study population (239 patients from YHHN database). 
Therefore, it was very difficult to predict the treatment pattern or the patients’ conditions, 
such as the complication rate or the hospital  stays for specific treatments,  by using the 
detailed information from palliative care databases. 
 
Moreover, based on the infrastructure of HMRN and with the research nurses’ assistance, 
detailed information of the 20 AML/APML patients were further extracted ‘from 
diagnosed to death’. Therefore, the details of transfusion not only could be completely 
portrayed during the end-of-life period, which was the study time period of the original 
project, but also they could cover the whole treatment pathway time period, in such a way 
as the clear picture of delivery of transfusion could be revealed and analyzed. 
 
3.10.3 Missing data 
 
Since all information was extracted in a very detailed way and was continuously audited, 
no missing data were found to exist in the Palliative Care Database. 
 
3.10.4 Database cleaning 
 
In the palliative care database all the events are recorded by a day-to-day calendar 
approach with transfusion details not being an exception to this. All the units that had 
been transfused to patients were recorded unit by unit and day by day to the palliative care 
database. Since the transfusion unit and the frequency were the main concerns, three steps 
of data cleaning were applied to the palliative care database. This was to have an 
undisturbed database with no duplicated events in order to be use as a base for further 
analyses. 
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The first step in the data cleaning process was to keep all the transfusion-related 
information, such as the transfusion receiving date and transfusion unit. All irrelevant or 
unnecessary information was then removed from the database. 
 
The second step in data cleaning was to summarize all the transfusion details, including 
the details of delivered units which were presented separately and hospital stays, into one 
record per transfusion. This ensured that one transfusion would only have one record. 
Also, the summarized information provided a clearer view of how each transfusion was 
given, including the input and time spend. 
 
The third step in data cleaning was to keep the relevant transfusion records. Based on the 
transfusion time period information from the HMRN database, only records related with 
transfusion that occurred during the recorded time period were kept. Records of 
transfusions that occurred outside the given time period were removed, although these 
transfusions were actually given to patients. The reason for this was to ensure that only 
the transfusions that were actually delivered in the time period were considered while 
calculating the transfusion frequency (for later extrapolation use). This was expected to 
enhance the accuracy of the predictive frequency, although some of the transfusion 
information could have been lost because of this approach. 
 
 
After the above 3 steps of data cleaning were carried out, the palliative care database was 
prepared for transfusion frequency and unit use analysis. 
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3.11 Preliminary analysis methods for the palliative care database 
 
All statistical analyses and data manipulation, such as the summing of the duplicated data 
and the calculation of the transfusion frequency, were carried out using the SAS/Stats 
application (SAS software program package, version 8.02, SAS Institute, Cary, NC) 
 
3.11.1 Unit of transfusion 
 
Unit of transfusion is an important piece of information in order to reflect the input of the 
transfusion. To summarize how many blood units and platelet units were provided during 
each transfusion, the average unit was used in the results presentation. 
 
3.11.2 Transfusion Frequency 
 
Transfusion frequency is an important piece of information for cost calculation, 
especially in cases where the number of transfusions was not available. As research 
nurses working with the HMRN database tended to record only the first and the last dates 
of transfusions, the detailed number of transfusion was not obtainable. There was no 
further information regarding either the actual date for each transfusion or the number of 
transfusions between the first and last transfusion that could be gained from the HMRN 
database. Therefore, the frequency information that was extracted from the 20 
AML/APML  cases  in  the  palliative  care  database  was  used  as  an  alternative  way  to  
extrapolate the transfusion frequency of the study population (239 patients). 
 
Based on clinical suggestions and considering that the transfusion should only occur 
during the ‘disease time’ (which means patients would not receive transfusion when they 
are  in  remission),  the  patients  were  firstly  divided  into  two  groups:  patients  who  had  
achieved remission and patients who had not done so. Furthermore, each group was 
further divided into couples of subgroups according to its characters, in order to enhance 
the prediction power of transfusion frequency. This is further discussed in the following 
paragraphs. 
 
The group comprised of patients who had achieved remission, was further divided into 
two sub-groups according to the treatment response time: ‘quick response’ and ‘slow 
response’. The reason for dividing the group into these sub-groups was that the response 
time could reflect the disease severity, something that was also relevant to the transfusion 
frequency. The cut-off time of deciding good or poor response was set to 2 months 
according to expert suggestions. 
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The group comprised of patients who had not achieved remission was also further divided 
into two sub-groups according to the disease severity: those who died quickly and those 
who did not. The reason for this was that the rapid progress normally leads to more 
transfusions in a short time. The cut-off time for deciding whether a patient belonged to 
the rapid progress group or not was set to two months based on expert suggestions. 
 
After classifying patients into four subgroups, the transfusion frequency was calculated 
and analyzed by each sub-groups. 
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3.12 Overview of the work done on the PCD database 
 
 
The PCD database was used for extrapolating transfusion frequency. In order to obtain 
the relevant information, the PCD database was cleaned in three steps (discussed in 
sections 3.10). The whole process and number of cases are illustrated in Figure 3.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After the study database was set up, a number of preliminary analyses were conducted 
(please refer to section 3.11). The relevant results are presented and discussed in the next 
chapter (chapter 4). 
 
 
 
 
 
Figure 3.12 Illustration of data handling process on PCD database 
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3.13 Integration of all study databases 
 
3.13.1 Data Merging 
 
Although much of the useful information of each database was extracted, analyzed, and 
presented earlier (please refer to previous sections of this chapter), it was expected that 
some extra information could be revealed or extracted if the databases were integrated. 
This was especially prominent with the clinical evidence that required the treatment 
phase information (extracted from the HILIS database) in order to be defined. For this 
reason, database integration was conducted. The integration involved the combination of 
data from three different datasets (HMRN database, HILIS database, and palliative care 
database) by matching the patients studies ID, removing the duplicated information, and, 
finally, keeping the relevant information in the database. After integrating the information 
from the three databases, the data were ready for advanced analysis. 
 
3.13.2 Advanced Analysis Methods for the integrated database 
 
In order to provide clinical information that is both meaningful and understandable by 
haematologists/clinical staff, the analyses were divided into two domains. A breakdown 
of the details of each analysis in each domain follows: 
  
a. Treatment types / options in each treatment phase 
 
In section 3.5.1, the relationship between types of treatment and numbers of treatment 
was discussed, and details can be seen in next chapter (chapter 4). However, the number 
of treatments is not clinically meaningful. To make the results significant to 
haematologists/clinical staff, the type of treatment was further analyzed by each treatment 
phase, which was derived from supplementary database: HILIS. The frequency of each 
treatment in each phase was presented in numbers. 
 
b. Treatment response and prognosis 
 
•Complete remission rate 
 
Complete remission rate (CRR) is one of the indicators that could be used not only to 
reveal how effective a treatment is, but also to obtain the number of patients who 
responded to the treatment. In the current work, patient characteristics such as 
diagnosis, age, and gender, were used in order to test the kind of characteristics that 
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were more likely to lead patients to achieve remission. As for the primary induction 
treatment type, it was used to test the kind of treatment that was more effective. 
 
•Relapse 
 
Relapse is the reoccurrence of the disease after remission. It is another indicator that 
could be used to reveal the effectiveness of a treatment, the patients’ response to the 
treatment, and the severity of a disease. In the context of the current study, this was 
achieved by comparing the first relapse rates between patient characteristics and the 
primary induction treatment type. Similarly to the CRR analysis, the diagnosis, age, 
gender, and primary induction treatment type were used for analysis. Also, regression 
was conducted in order to determine whether any of these factors were associated with 
the relapse rate (i.e. what kind of patient or what kind of treatment was more likely to 
make patient relapse after remission) 
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3.14 Summary 
 
 
The current chapter involved the detailed description of data handling for the main study 
databases. The latter were thoroughly cleaned and all missing data were handled carefully 
in order to be ready for use for analysis at later stages of the current study. Furthermore, 
additional data from other sources were integrated into the study databases (place of death, 
hospital stays, and antibiotic days). The above data manipulation resulted in 1025 
relevant treatment events from the HMRN database, 1767 relevant test reports from the 
HILIS database, and 164 relevant transfusion records from the PCD database, which were 
analyzed and prepared for further use. The related results are further discussed in the 
following chapter (chapter 4). 
 
 
 -98- 
 
 
 
 
 
 
 
 
Chapter 4 Analysis Results of Study Databases 
 
 
HMRN, HILIS, and PCD databases 
 
 
 
 
 
 
 
 
 
 
4.1 Patient characteristics 
(HMRN) 
99 
 
CHAPTER 4 ANALYSIS RESULTS OF THE STUDY DATABASES 
 
Database 1: HMRN database 
 
243 patients were identified as newly diagnosed with AML and APML between 1st 
September 2004 and 1st September 2006. However, according to the inclusion and 
exclusion criteria, only 239 confirmed cases were finally retained for the current study. 
These cases comprised of 1025 treatment events (from 215 AML patients and 24 APML 
patients). 
 
4.1 Demographic characteristics of study population 
 
Summaries of the characteristics of the study population (the aforementioned 239 
AML/APML patients) are presented in the following paragraphs, while relevant details, 
such as numbers and percentages, are shown in below. 
 
4.1.1 Diagnosis 
 
As shown on Table 4.1, the most common subtype domain of diagnosis was the AML 
NOS. More specifically, nearly 83% of cases were diagnosed with ‘AML NOS’, while the 
rest of the subtypes for AML accounted for 7.53%. In relation to APML patients, ‘APML 
t(15;17)(q22;q11-12)’ accounted for approximately 10% of the total cases. The 
distribution was in line with previous reports both in the UK and worldwide [166-169]. 
 
4.1.2 Gender 
 
As shown in Table 4.1, 122 female patients (51.05%) and 117 male patients (48.95%) 
were identified in the current study. AML and APML accounted for 90.16% and 9.84% 
respectively for female patients, while for male patients 89.74% and 10.26%. This result 
was slightly inconsistent with the results of other previous studies [167, 168, 170-172]. 
Generally, AML/APML was more common in men than women, but the difference was 
not significant [167, 168, 170-172]. It is suggested that two factors contributed to the 
above. Firstly, four patients that were excluded from the study because of un-obtainable 
notes, were all male. Secondly, a higher number of male patients was observed among the 
children (<18 years old) that were excluded from the study. This suggests that no 
significant gender differences would exist if all the patients were included. 
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4.1.3 Age 
Age was an important risk factor for AML. According to the results of the current study, 
old patients (≥60 years old) were more likely to have AML/APML than young adult 
patients (<60 years old). However, further examination showed that the age distributions 
of AML and APML varied significantly. In AML patients, the incidence of AML 
Table 4.1 Demographic characteristics of study population 
 
 Frequency Percentage 
Gender   
  Male  117 48.95 
AML 105 89.74 
APML 12 10.26 
  Female  122 51.05 
AML 110 90.16 
APML 12 9.84 
Diagnosis    
AML 215 89.96 
AML NOS 197 82.43 
AML NOS 153 64.02 
AML arising from transformation of MDS 10 4.18 
AML arising from transformation of MPD 1 0.42 
AML with adverse cellular features 32 13.39 
AML with multi-lineage dysplasia 1 0.42 
AML with core binding factors 10 4.18 
AML inv(16)(p13;q22) 5 2.09 
AML t(8;21)(q22;q22) 5 2.09 
AML - probable therapy related 6 2.51 
AML - probable therapy related 6 2.51 
AML with MLL (11q23) rearrangement 2 0.84 
AML with MLL (11q23) rearrangement 2 0.84 
  APML 24 10.04 
APML t(15;17)(q22;q11-12) 24 10.04 
Age Mean: 63.62 (19-97), SD=18.11 
 <60 86 35.98 
AML 67 28.03 
APL 19 7.95 
  60≦y<75 73 30.54 
AML 72 30.13 
APL 1 0.42 
≧75 80 33.47 
AML 76 31.8 
APL 4 1.67 
Death (Mortality rate)   
  Yes  189 79.08 
At home 22 11.70 
At hospice 23 12.23 
At hospital 137 72.87 
At nursing residential home 6 3.19 
  No 50 20.92 
History of antecedent haematological disorder   
Yes 17 7.11 
No 222 92.89 
Total 239 patients 
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increased with age. AML patients over 75 years of age accounted for 31.8% and those 
between 60 and 75 for 30.13%, while younger AML patients (<60 years old) accounted 
for 28.03%. Unlike the distribution of AML, most of the APML patients (19 out of 24 
APML patients) belonged in the young age group (18-60 years old). APML patients over 
60 years of age only accounted for 20.83% of all the APML patients. This result is 
consistent with the results of other studies [166-169, 171]. 
 
4.1.4 Cases of fatality (percentage of death) 
The percentage of death of AML/APML was very high. As shown in Table 4.1, 79% 
patients died within a maximum of five years of follow-up (the median number of year of 
follow-up was 4 years). After cross-analysis, the relationships between the mortality rate 
and several patient characteristics were identified (Table 4.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Table 4.2, the mortality rate of AML (84.19%) was much higher than this of 
APML (29.17%). Moreover, older patients appeared to have poorer prognoses, both when 
they were diagnosed with AML and with APML. It is suggested that this could be because 
older  patients  were  either  less  likely  to  respond  well  to  the  treatments  or  less  able  to  
undertake/tolerate the treatments as a whole. This result is also in line with the results of 
previous studies [166-169, 171] 
Table 4.2 Mortality rate analysis 
 Frequency Percentage 
(among groups) 
Percentage 
(within group) 
Age    
AML:    <60  44 23.28 65.67 
     60≦y<75 63 33.33 87.50 
     ≧75 75 39.68 98.68 
APML:  18≦y<60 4 2.12 21.05 
     ≧60 3 1.59 60.00 
Deprivation    
Deprivation group 1 (most affluent) 40 21.16 74.07 
Deprivation group 2  34 17.99 77.27 
Deprivation group 3  49 25.93 81.67 
Deprivation group 4  35 18.52 87.50 
Deprivation group 5 (most deprived) 31 16.40 75.61 
Diagnosis    
AML NOS 168 88.89 85.28 
AML with core binding factors 7 3.70 70 
AML - probable therapy related 6 3.17 100 
AML with MLL (11q23) rearrangement 1 0.53 50.00 
APML t(15;17)(q22;q11-12) 7 3.70 29.17 
Primary induction therapy    
Intensive treatment with induction intent 90 47.62 64.75 
Intensive treatment without induction intent 39 20.63 97.50 
Support or palliative care only 60 31.75 100.00 
 189   
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Table 4.2 also shows the mortality rate results by primary induction therapy and 
deprivation. In regards to the primary induction therapy, the intensive treatments with 
induction intent (such as clinical trials or some intensive chemotherapies) provided a 
better prognosis for patients (lower mortality rate: 64.75%). Patients who only received 
supportive or palliative care had the worst prognosis (mortality rate was 100%). The 
results showed that AML/APML could be very fatal if left untreated or treated without 
induction intent. 
 
As shown in Table 4.2, the examination of the relationship between mortality rate and 
deprivation, uncovered an existing trend: increasing deprivation corresponded to higher 
mortality rates. The difference ranged from 74.07% for the most affluent group (group 1) 
to 87.50% for the second most deprived group (group 4). It is worth noting that the most 
deprived group (group 5) was not consistent with this trend. A possible explanation was 
that, compared to other groups, the most deprived group contained higher percentages of 
APML patients with lower mortality rate, compared to AML patients (as mentioned 
above).  
 
4.1.5 Place of death 
 
“Place of death” information is a useful factor for determining the dying cost, as well as 
for providing a broad picture of the location AML/APML patients received dying care 
during the final stages of their life. Table 4.1 lists the percentages of each possible place. 
Unsurprisingly, most of the patients died in hospitals (72.87%), a lower number in 
hospice or nursing residential homes, while only 11.70% of the patients died at home. 
 
4.1.6 Antecedent hematological disorder and therapy related AML 
 
Antecedent hematological disorder (AHD) and therapy related AML has been one of the 
most important AML/APML prognostic factors for years. In general, patients with a 
history of antecedent haematological disorder (MDS) or diagnosed with therapy related 
AML are more likely to have poor prognosis, such as lower CR rate and higher relapse 
rate after achieving remission [24, 173, 174]. As shown in Table 4.1, there were 17 
patients (7.11%) with antecedent haematological disorders and 6 patients diagnosed with 
therapy related AML. Cross-analysis showed that the aforementioned results were in line 
with the results of previous studies. 
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4.2 Number and type of treatment 
 
4.2.1 Number of treatments 
 
‘Number of treatments’ information can reveal the level of complexity and difficulty of 
the treatment for AML/APML. After the removal of treatments with non-curative or 
life-prolong intent, the results showed that there were 20.92% of patients receiving either 
only the observation or no treatment whatsoever. For patients who had received the 
treatments after being diagnosed, the number of treatments varied significantly. Most of 
the AML/APML patients received at least one treatment (79.08%), while around half of 
the patients (46.44%) received two treatments. 24.69% of the patients received three 
treatments, while the percentage decreased dramatically after this point, with only 3% (4 
patients) of the patients having received more than 10 different treatments. The maximum 
number of treatment was found to be 11. The relevant details can be found in Table 4.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.2 Treatments 
 
Treatments information (regimen and drugs) is useful both for understanding the 
haemotologists’ clinical decisions and for costing. The results were presented in 4 
different parts: regimens for chemotherapy, regimens for clinical trial, other types of 
treatment, and primary induction treatments. Relevant details can be found in the 
following paragraphs. 
Table 4.3 Numbers of the treatments 
 Number Percentage 
(%) 
Subtractive 
number 
Subtractive 
percentage (%) 
no treatment (follow-up only) 12 5.02   
Supportive care only 38 15.90   
1 78 32.64 189 79.08 
2 52 21.76 111 46.44 
3 15 6.28 59 24.69 
4 14 5.86 44 18.41 
5 7 2.93 30 12.55 
6 6 2.51 23 9.62 
7 5 2.09 17 7.11 
8 5 2.09 12 5.02 
9 3 1.26 7 2.93 
10 1 0.42 4 1.67 
11 3 1.26 3 1.26 
Total 239 100   
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a. Regimen for chemotherapy 
 
Chemotherapy accounted for 32.50% of a total of 763 treatment episodes. It was the 
second most commonly used treatment for AML/APML. The variety and the frequency 
of the regimens are discussed in the following sections. Relevant details can be found in 
Table 4.4, Appendix 4.1 and Appendix 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 Regimen for chemotherapy  
 AML APML Total 
 No. No. No. Percentage (%) 
Chemotherapy 232 15 247 32.50 
ADE 18 1 19 3.85 
AraC(HD) 11 - 11 2.23 
AraC(HD) + Mylotarg 2 - 2 0.40 
AraC(LD) 37 2 39 7.89 
Clofarabine 2 - 2 0.40 
DA 38 1 39 7.89 
DA + Mylotarg 1 - 1 0.20 
FLA 4 - 4 0.81 
FLAG 18 - 18 3.64 
FLAG-Ida 5 - 5 1.01 
FLAG-Ida + Mylotarg 1 - 1 0.20 
HAM 1 - 1 0.20 
MACE 9 1 10 2.02 
MidAC 12 - 12 2.43 
Mini-MIDAC 3 - 3 0.61 
Amsacrine 1 - 1 0.20 
Arsenic trioxide (ATO) - 2 2 0.40 
Campath 1 - 1 0.20 
Mylotarg - 1 1 0.20 
Daunorubicin 1 - 1 0.20 
Cyclophosphamide 5 1 6 1.21 
Cyclophosphamide / MESNA 2 - 2 0.40 
ETI 2 - 2 0.40 
FC 6 - 6 1.21 
Fludarabine 2 - 2 0.40 
Vincristine 1 - 1 0.20 
Melphalan 3 - 3 0.61 
ATRA - 3 3 0.61 
Anagrelide 1 - 1 0.20 
Clopidogrel 1 - 1 0.20 
Aspirin 2 - 2 0.40 
Hydroxycarbamide 39 - 39 7.89 
Hydroxycarbamide + Aspirin 1 - 1 0.20 
Chelating agent 2 - 2 0.40 
MRC like - 1 1 0.2 
Spanish like - 2 2 0.4 
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˙Types and frequency 
 
The 5 most commonly used chemotherapy regimens given to AML patients were (from 
the highest to the lowest): Hydroxycarbamide (39 episodes), DA (38 episodes), 
AraC –low dose (37 episodes), FLAG (18 episodes), and ADE (18 episodes). They 
accounted for 64.66% of the total chemotherapy episodes. It is worth noting that although 
Hydroxycarbamide and AraC –low dose were found to be the majority, they were mainly 
used for stabilizing the disease (not for induction intent). This could be an explanation for 
the exceptionally high frequencies. Another finding worth noting is that some regimens 
not suggested by the guideline or by the HMRN data manual were identified in the 
HMRN  database.  They  were  either  used  rarely  to  treat  AML  (such  as  Amsacrine  and  
Clofarabine that are mainly used for ALL), or for treating the complications after AML 
treatments (such as chelating agent for overflow of iron, and Anagrelide for rash). Also, a 
new, but rare, way to treat AML in the UK was identified: HAM (cytarabine 0.5 g/m2/12 
h i.v., days 1–3; mitoxantrone 10 mg/m2 i.v., days 2 and 3). In total, these regimens 
accounted for 4.74% (Table 4.4). 
 
Most  of  APML  patients  were  treated  in  clinical  trials  not  chemotherapy  outside  trial  
conditions. The most commonly used chemotherapy regimens (outside clinical trial) were 
ATRA, Arsenic trioxide (ATO), MRC approach like regimen, and Spanish approach like 
regimen. The regimen name ‘like’ was given when a patient was not eligible for entering 
clinical trial (usually because patients were too old), but received the same regimens as in 
clinical trial. These regimens accounted for 66.67% of total chemotherapy regimens. 
However, as shown in Table 4.4, a number of regimens that were normally used on AML 
patients were also used on APML patients, such as ADE, DA, and MACE. Although this 
was unusual, but the frequency of usage was very low (usually each of the regimens 
appeared only once). Therefore, it was decided these treatment episodes to be kept in this 
study. 
 
˙Number of occurrence on the timeline 
 
Appendix 4.1illustrates the regimen usage on a timeline. Most of the chemotherapy 
regimens were used for the first-five-time treatment episodes, and especially for the 
first-time treatment (34%). For the first-time chemotherapy, AraC (LD), DA and 
Hydroxyurea were the most commonly used regimens, with each of them accounting for 
more  than  25% in  the  first-time treatment  group.  After  the  first-5-time treatments,  the  
usage of chemotherapy decreased significantly, and none of the regimens appeared more 
than 4 times in such late stages. It is worth noting that Hydroxyurea was the only regimen 
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that appeared in all phases on the timeline, as it was used for stabilizing the disease. 
 
Similarly to the chemotherapy usage for AML patients,  in the case of APML patients,  
chemotherapy was only used for the first-five-time treatment episodes. The highest usage 
was for first-time treatment (40% of total chemotherapy episodes) and the used regimens 
were ATRA, MRC approach like and Spanish approach like. The rest of the regimens 
only appeared once or twice between 2nd and 5th treatments (Appendix 4.2). 
 
b. Regimen for clinical trial 
 
Clinical trial was the third most commonly used treatment for AML/APML patients. In 
total, clinical trials accounted for 23.56% of the total treatment episodes, and they were 
mainly used as induction treatment. The regimen options of clinical trials were limited. 
Basically, they could be divided into two main groups: AML 14 and AML15, the trials 
open for newly diagnosed patients between 2004-2006. The variety and the frequency of 
regimens are discussed in the following paragraphs, while all the relevant details are 
presented in Table 4.5, Appendix 4.1, and Appendix 4.2. 
 
 
 
 
 
Table 4.5 Regimen for chemotherapy 
 AML APML Total 
 No. No. No. Percentage (%) 
Clinical trial 155 25 180 23.56 
AML 14 AraC 4 - 4 0.81 
AML 14 AraC + Mylotarg 1 - 1 0.20 
AML 14 D35 C200 3 - 3 0.61 
AML 14 D35 C400 1 - 1 0.20 
AML 14 D50 C200 4 - 4 0.81 
AML 15 ADE 15 - 15 3.04 
AML 15 ADE + Mylotarg 9 - 9 1.82 
AML 15 AraC 20 - 20 4.05 
AML 15 AraC + Mylotarg 7 - 7 1.42 
AML 15 DA 16 - 16 3.24 
AML 15 DA + Mylotarg 6 - 6 1.21 
AML 15 FLAG-Ida 23 - 23 4.66 
AML 15 FLAG-Ida + Mylotarg 13 - 13 2.63 
AML 15 MACE 10 - 10 2.02 
AML 15 MACE + Mylotarg 9 - 9 1.82 
AML 15 MidAC 14 - 14 2.83 
AML 15 MRC approach - 12 12 2.43 
AML 15 Spanish approach - 12 12 2.43 
AML 15 Spanish Maintenance - 1 1 0.2 
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˙Types and frequency 
 
As shown in Table 4.5, most of the patients who agreed to join clinical trial were assigned 
to AML 15 trial (91.61%), while only 8.39% of the cases were assigned to AML 14 trial. 
In the HMRN database, the most common trial arms for AML 15 trial were: FALG-Ida, 
AraC, and ADE. FLAG-Ida arm (with and without mylotarg) accounted for 23.23%, and 
AraC and ADE arms accounted for 17.42 and 15.48% respectively. 
 
Table 4.5 shows  that  all  of  the  APML  patients  who  agreed  to  join  clinical  trial  were  
assigned to AML 15 trial. Furthermore, only two trial arms were given to APML patients: 
AML 15 APL (MRC) and AML 15 APL (Spanish). The percentage of the AML 15 APL 
(MRC) arm was 47.83%, while for AML 15 APL (Spanish) arm it was 52.17%. 
 
 
˙Numbers of occurrence on the timeline 
 
Most of the clinical trial arms (74.19%) took place in the first-two-time treatment. Only 
AML 15 AraC, MACE, and MidAC took place after the 2nd treatment, as they were the 
second-line  arms  of  the  clinical  trial.  The  results  were  consistent  with  the  clinical  
guideline (Appendix 4.1). 
 
Similarly to clinical trial arms for AML patients, the trial arms for APML patients were 
also given during the first occurrences of the treatments. 17 out of 28 arms took place in 
the first-time treatment, while the rest occurred between the 2nd to  the  4th time of 
treatments. No trial arms were found to have occurred later than the 4th time (Appendix 
4.2). 
 
 
 
c. Other treatments 
 
Treatments other than chemotherapy and clinical trial accounted for 39.30% of the total 
treatment episodes (refer to Table 4.6). 
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Supportive  care  was  the  most  commonly  used  treatment  for  AML  patients  (especially  
transfusion and G-CSF), among all types of treatments. It accounted for 58.50% 
(transfusion) and 14.63% (G-CSF). Palliative care followed with 10.55%, while the 
percentage for the rest of the treatments in this group was not very high. It is worth to note 
that, in this group, 12 patients were found to be either receiving no treatment or refusing 
treatment altogether. 
 
In  relation  to  the  APML  patients  group,  it  was  observed  that  only  a  small  number  of  
treatments were given. In this group, similarly to the case of AML patients, transfusion 
was  the  most  commonly  used  treatment  (60%),  followed  by  steroids  and  G-CSF  with  
33.33%. No APML patients were found to receive no treatment or to refuse treatment. 
 
Most of the treatments in this group occurred in the later phases of the timeline, as they 
were not carried out with curative intent. Details related with the occurrence of treatment 
on the timeline could be found in Appendix 4.1 and Appendix 4.2. 
 
 
 
 
 
 
Table 4.6 Other treatments 
 AML APML Total 
 No. No. No. Percentage (%) 
Supportive care 225 28 253 33.29 
Erythropoietin 3 - 3 0.39 
G-CSF 43 5 48 15.70 
Transfusion 172 18 190 24.87 
Steroids 9 5 14 1.83 
Immunosuppressive 6 - 6 0.79 
Palliative care 31 2 33 4.45 
Radiotherapy 14 - 14 1.83 
Transplantation 13 - 13 1.70 
Splenectomy 2 - 2 0.26 
Venesection 3 - 3 0.39 
No treatment 10 - 10 1.31 
Refused treatment 2 - 2 0.26 
Total 693 70 764 % 
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d. Types of primary induction treatment 
 
Primary induction treatment has been considered to be relevant to patient prognosis for 
years. Primary induction treatment was manually identified for each patient, and the 
related analysis results are shown on Table 4.7. Relevant details are also discussed in the 
following paragraphs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.7 Primary induction treatments 
 AML APML Total 
 18-60 
yr 
60-75 
yr 
>75 
yr 
 18-60 
yrs 
60-75 
yr 
>75 
yr 
 Number Percentage 
Intensive treatment with 
induction intent 
        139 58.16 
Chemotherapy 17 22 3 42 2 - 4 6 48 20.08 
ADE 2 1 - 3 - - - - 3 1.26 
ATRA - - - - - - 3 3 3 1.26 
DA 13 18 2 33 1 - - 1 34 14.32 
ETI - 1 - 1 - - - - 1 0.42 
Etoposide - 1 - 1 - - - - 1 0.42 
FC 1 - - 1 - - - - 1 0.42 
FLAG 1 1 - 2 - - - - 2 0.84 
MRC like - - - - 1 - - 1 1 0.42 
Spanish like - - - - - - 1 1 1 0.42 
Vincristine - - 1 1 - - - - 1 0.42 
Clinical trial 47 22 5 74 16 1 - 17 91 38.08 
AML 14 AraC - 1 4 5 - - - - 5 2.09 
AML14 DA - 8 1 9 - - - - 9 3.77 
AML 15 AraC 1 - - 1 - - - - 1 0.42 
AML 15 ADE 15 1 - 16 - - - - 16 6.70 
AML 15 DA 12 3 - 15 - - - - 15 6.28 
AML 15 FLAG-Ida 19 9 - 28 - - - - 28 11.72 
AML 15 MRC - - - - 9 0 0 9 9 3.77 
AML 15 Spanish - - - - 7 1 - 8 8 3.35 
Intensive treatment 
without induction intent 
1 9 30 40 - - - - 40 16.74 
AraC (LD) 1 7 19 27 - - - - 27 11.30 
Hydroxycarbamide - 2 11 13 - - - - 13 5.44 
Supportive or palliative  
care only 
2 19 38 57 1 - - - 60 25.10 
Observation 2 4 4 10 - - - - 10 4.18 
Supportive care - 14 25 39 - - - - 39 16.32 
Palliative care - 1 9 10 1 - - - 11 4.60 
Total 67 72 76 21
5 
19 1 4 24 239 100 
 
4.2 Number and type of treatment 
(HMRN) 
110 
 
As shown in Table 4.7, treatment with induction intent was the most common treatment 
for AML patients, especially for the young adult patients (18-60 year-old). Among all the 
regimens and trial arms, chemotherapy DA and clinical trial arm FLAG-Ida were the 
most common. They accounted for 78.57% and 37.84% respectively. Treatment with 
non-induction intent was commonly used as well, but less often than supportive care and 
palliative care. Both treatment with non-inductoin intent and supportive/palliative care 
were mainly given to older patients, especially patients older than 75 years of age. This 
might be because older patients showed poor response and decreased tolerance to the 
intensive curative treatment. Thus, treatment with non-induction intent and 
supportive/palliative care were given as alternatives 
 
In Table 4.7, it was observed that intensive treatment with induction intent was the only 
induction treatment option given to APML patients, with the exception of one patient who 
received palliative care. Among all the induction intent treatments, clinical trial was the 
most commonly used (70.83%), especially in the young adult patient group (18-60 years 
old). MRC approach arm and Spanish approach arm were also common, while 
chemotherapies (outside trial) only accounted for 25% of the induction treatment, and 
were mainly used for old patients (>60 years old) who were unable to enter the clinical 
trial. 
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Table 4.8 Summarized treatment time derived from the HMRN database 
4.3 Treatment duration 
 
For various purposes, the treatment duration related information was recorded in different 
forms and stored in different locations. In order to classify information from different 
sources, the treatment duration was categorized into 3 main groups: treatment time 
(duration of medication delivery derived from the HMRN database), hospital stays 
(actual hospital stays derived from subset of HMRN database), and antibiotics days (days 
for complication treatment derived from subset of HMRN database). 
 
4.3.1 Treatment time 
 
Treatment time is information related with the duration of medication delivery. Since the 
treatment time did not necessarily contain one cycle/course of treatment, the possible 
number of courses was determined according to the treatment time, on the basis of known 
cases (Table 4.8). For example, as shown in Table 4.8, 23 treatment episodes that ranged 
from 1 to 12 days contained one course of ADE, while in 12 treatment episodes that 
ranged from 37 to 74 days contained 2 complete cycles of ADE. This summary provided 
a broad view of how the treatment time was recorded. Also, it was expected to be useful 
for imputation of missing treatment dates. 
 
 
 
Type of treatment Treatment time 
 Number of course Number of 
episode for 
calculation 
Treatment time 
(Days) 
Means 
Chemotherapy and clinical trial     
ADE 1 23 1-12 9 
AML 15 ADE 2 12 37-74  
AML 15 ADE + Mylotarg missing 8   
AraC (HD) 1 30 4-29 8 
AML 15 AraC 2 6 36-72  
AML 15 AraC + Mylotarg 4 1 221  
 missing 3   
AraC (LD) 1 24 1-38 10 
AML 14 AraC 2 4 43-49  
 3 4 59-77  
 4 3 92-116  
 5 2 124-125  
 6 1 147  
 10 1 182  
 missing 5   
Clofarabine 1 1 5 5 
 2 1 38  
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 DA 1 39 2-41 11 
AML 14 D35 C200 2 14 42-74  
AML 14 D50 C200 3 4 88-112  
AML 14 D35 C400 4 1 152  
AML 15 DA missing 12   
AML 15 DA + Mylotarg     
FLA 1 1 5 5 
 2 2 42-48  
 missing 1   
FLAG 1 11 4-11 6 
 2 3 41-55  
 3 2 76-118  
 missing 2   
FLAG-Ida 1 18 5-11 6 
FLAG-Ida + Mylotarg 2 11 31-101  
AML 15 FLAG-Ida Missing 13   
AML 15 FLAG-Ida + Mylotarg     
HAM missing 1   
MACE 1 17 3-9 6 
AML 15 MACE 2 1 38  
AML 15 MACE + Mylotarg Missing 11   
MidAC 1 24 1-10 5 
Mini MidAC 2 2 47-58  
 missing 3   
MRC approach 1 5 4-11 8 
 2 - -  
 3 2 69-79  
 4 5 105-141  
Spanish approach 1 3 3-15 9 
 2 2 33-99  
 3 2 148-189  
 4 5 216-917  
 Maintenance 1 732  
 missing 2   
Amsacrine - 1 1 1 
Arsenic trioxide - 2 32-33 33 
Campath - 1 6 6 
Mylotarg missing 1   
Daunorubicin - 1 38 38 
Cyclophosphamide - 5 1-2 2 
 missing 1   
Cyclophosphamide / MESNA - 2 2 2 
ETI - 2 67-206 137 
FC - 4 1-29 10 
 missing 2   
Fludarabine - 1 2 2 
 missing 1   
Vincristine - 1 4 4 
Melphalan - 3 14-53 30 
ATRA - 3 3-40 16 
Anagrelide - 1 5 5 
Clopidogrel - 1 7 7 
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 Aspirin - 1 35 35 
 missing 1   
Hydroxycarbamide - 23 1-757 67 
Hydroxycarbamide / Aspirin missing 17   
Chelating agent - 1 593 593 
 missing 1   
Supportive care     
Erythropoietin - 2 15-274 145 
Steroids - 7 4-783 213 
 missing 6   
Transfusion - 101 1-1424 184 
 missing 89   
G-CSF - 26 1-805 86 
 missing 21   
Immunosuppressive treatment - 3 1-1310 610 
 missing 3   
Radiotherapy - 12 1-22 4 
 missing 2   
Stem cell transplantation once 9 1 1 
 missing 4   
Splenectomy once 2 1 1 
Palliative care - 16 2-34 12 
 missing 17   
Venesection - 3 99-888 479 
No treatment - 10   
Refused treatment - 2   
Total  776   
 
 
4.3.2 Hospital stays and antibiotic days 
 
Actual hospital stays (also known as ‘bed days’) information is very important for cost 
calculation. Unfortunately, this information was not required to record in the HMRN 
database, and, thus, 30 additionally available subset medical notes were used to obtain 
hospital stays and antibiotics day information. This information is summarized in Table 
4.9 below. 
 
As an example of the above, from 11 episodes of AML 15 ADE clinical  trail  arms, 1st 
cycle took an average of 30 days of stay in the hospital (please refer to Table 4.9). Among 
these 30 days, antibiotics were given for 14 days in total. In the 2nd cycle, the average 
hospital stays duration was 5 days shorter (25 days in total). Antibiotics were given in 7 
out of 25 days, while the average interval between 1st and 2nd cycle was 13 days.  This 
summary was also very useful for the imputation of missing treatment dates that was 
carried out at later stages of the current work. However, it must be stressed here that part 
of the actual hospital stays information of the trial arms was derived from a limited 
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number  of  treatment  episodes,  due  to  data  availability  constraints.  For  example,  AraC 
(HD), AraC(LD), MRC and Spanish approach were all derived from only 2 treatment 
episodes.  Therefore,  it  could  be  useful  that  the  reliability  of  these  results  to  be  further  
checked by experts or haematologists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.9 Hospital stays and antibiotic days derived from additional information of 30 medical notes 
 Cycle 1 Interval Cycle 2 Interval 
 No. 
of 
event 
Average 
hospital 
stays 
(day) 
Average 
antibiotic 
days 
(day) 
No. 
of 
event 
Average 
interval 
days 
(day) 
No. 
of 
event 
Average 
hospital 
stays 
(day) 
Average 
antibiotic 
days 
(day) 
No. 
of 
event 
Average 
interval 
days 
(day) 
AML 15 ADE 11 30 14 10 13 10 25 7   
AML 15 AraC (HD) 2 32 10 3 17 3 23 8   
AML 15 AraC (LD) 2 30 11 1 25 1 30 7   
AML 15 DA 8 35 16 5 14 7 30 12   
FLAG 1 33 21 1 19 1 45 26   
AML 15 FLAG-Ida 11 28 15 7 17 7 46 29   
AML 15 MACE 13 25 12        
AML 15 MidAC 9 30 10        
AML 15 MRC Cycle 1 Interval Cycle 2 Interval 
 2 32 13 2 11 2 25 23 2 15 
 Cycle 3 Interval Cycle 4  
 2 27 7 2 17 2 28 6 2  
AML 15 Spanish Cycle 1 Interval Cycle 2 Interval 
 2 31 14 1 0 1 23 14 1 0 
 Cycle 3 Interval Cycle 4  
 1 32 14 - - - - -   
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4.4 Missing data analysis 
 
Since treatment date information was crucial for cost estimation purposes, it was decided 
a missing data analysis to be conducted. This was in order to inspect whether the missing 
values occurred systematically or randomly. The analysis was separated into two parts. 
Firstly, ‘descriptive statistics’ was employed for portraying the picture of the distribution 
of the missing value, as a whole. Secondly, in order to determine whether the missing 
values occurred randomly, or were affected by specific factors, logistic regression was 
conducted. The results are shown on Table 4.10and Table 4.11.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.1 Descriptive statistics of missing data 
 
As shown in Table 4.10, supportive care had the largest amount of missing date data, 
among a total of 763 treatment episodes. More specifically, it accounted for 45.85% of a 
total of 253 supportive care episodes, and for 48.18% of a total of 763 treatment episodes. 
For chemotherapy and clinical trial, the number of missing data was lower than 50, and 
accounted for 36.1% (763 treatment episodes). The rest of the treatments only accounted 
for 15.72% of the total treatment episodes. It is worth noting that most of the missing date 
data occurred in the treatment end date rather than the start date. It accounted for 95.44% 
of the total missing data episodes. 
 
Table 4.10 Descriptive statistics of missing data 
 
Total 
Events 
Treatment start date Treatment end date Total 
No. of 
missing 
data 
(%) 
No. of 
missing 
data 
(%) 
No. of 
missing 
data 
(%) 
Chemotherapy 247 1 0.40 50 20.24 50 20.24 
Clinical trial 180 1 0.56 36 20.00 37 20.56 
Immunosuppressive therapy 6 1 16.67 2 33.33 3 50.00 
Radiotherapy 14 0 0 2 14.29 2 14.29 
Stem cell transplantation 13 0 0 4 30.77 4 30.77 
Supportive care 253 17 6.72 107 42.29 116 45.85 
G-CSF 46 1 2.17 20 43.48 21 45.65 
Erythropoietin 3 0 0 0 0 0 0 
Steroids 14 0 0 6 42.86 6 42.86 
Transfusion 190 16 8.42 81 42.63 89 46.84 
Venesection 3 0 0 0 0 0 0 
Splenectomy 2 0 0 0 0 0 0 
Palliative care 33 6 18.18 17 51.52 17 51.52 
No treatment / refused 
treatment 
12 12 100 12 100 12 100 
Total 763 37 4.85 230 30.14 241 31.59 
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4.4.2 Logistic regression 
 
Logistic regression was conducted in order to investigate the reason for the missing. After 
putting all the important interest variables in the model, the regression result is shown in 
Table 4.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is illustrated on the table that most of the variables were not associated with missing 
data (P value > 0.05). This indicated that no identifiable patterns existed in the missing 
data, with the exception of ‘death or not’. ‘Death or not’ was the only variable that had a 
significant effect (P=0.002). The results (Table 4.11) implied that patients who were still 
alive were less likely to have missing date data in the treatment episode record. A possible 
explanation for this is that the missing data of alive patients had more chances to be 
corrected, as the records were continuously audited by research nurses. In contrast, 
auditing stopped for dead case records, after patients died. This resulted in missing data to 
remain unknown. Overall, the results of the logistic regression suggested that the date 
data were missing at random. 
 
Table 4.11 Logistic regression result 
Parameters  Estimates P Odds ratio 
Intercept  -1.0904 <.0001  
Age group 18-60 yr 0.0324 0.7945 0.956 
 60-75 yr -0.1100 0.4193 0.829 
 >75 yr (reference group) - - - 
Gender Female -0.1724 0.0434 0.708 
 Male (reference group) - - - 
Diagnosis AML 0.1776 0.2906 1.427 
 APML (reference group) - - - 
Death or not Alive -0.3490 0.0020 0.498 
 Dead (reference group) - - - 
Treatment type Immunosuppressive 1.0590 0.1507 4.644 
 Radiotherapy -1.1270 0.0981 0.522 
 Stem cell transplant -0.0533 0.9234 1.527 
 Palliative care 0.6977 0.0608 3.236 
 Chemotherapy -0.7069 0.0037 0.794 
 Supportive care 0.6071 0.0082 2.955 
 Clinical trial (reference group) - - - 
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4.5 Pathway tree diagram 
 
 
Treatment pathway tree diagram provided the means to graphically represent the 
treatment pathway, to which the unit costs could be linked at later stages of the current 
work. After removing the ‘supportive care’ treatment episodes (the reasons are discussed 
in section 3.5.4), 510 treatment episodes remained. The latter were used for building the 
tree diagrams. Because of the large volume of the information, the tree diagram was 
divided into the following 4 parts (grouped by diagnosis and age group): 1) AML (18-59 
years old), 2) AML (60-74 years old), 3) AML (≧75 years old), and 4) APML. The four 
diagrams are presented in below Figure 4.1, Figure 4.2, Figure 4.3, Figure 4.4, and 
Figure 4.5. 
 
 
Taking the AML (60-74 years old) group as an example, the treatment pathway was 
plotted into a tree diagram that can be found in. As shown in Figure 4.3, a total of 72 
patients belonged in this group. Of these patients, 30 had chemotherapies and 21 had 
clinical trial as induction treatment. All patients who received either no treatment, or 
supportive/palliative care as first line treatment, eventually died. As expected the use of 
non-aggressive treatment did not lead to a better prognosis. Half of the patient who 
received chemotherapies as induction treatment died after the treatment, while the other 
half survived and had a second chemotherapy. Most of the patients who initially survived 
kept receiving chemotherapy until their death. Overall, only two patients were still alive 
at the time of the current work. Of the patients who received clinical trials as induction 
treatment, only one third died after the trial, with the surviving patients (2/3 of the overall 
number of patients) receiving further chemotherapy or clinical trial. After one to three 
cycles of clinical trials, all the patients started receiving chemotherapy until their death. In 
this group, 4 out of 21 patients were still alive at the time of the current work.  
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*chemo: chemotherapy; trial: clinical trial; radio: radiotherapy; immune: immunosupression; vene: venesection; erythro: erythropoietin; splen: splenectomy; no tx: no treatment; support: supportive care 
Figure 4.1 Treatment Pathway tree diagram-1 (AML 18-59 years old: part 1) 
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*chemo: chemotherapy; trial: clinical trial; radio: radiotherapy; immune: immunosupression; vene: venesection; erythro: erythropoietin; splen: splenectomy; no tx: no treatment; support: supportive care 
Figure 4.2 Treatment Pathway tree diagram-1 (AML 18-59 years old: part 2) 
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*chemo: chemotherapy; trial: clinical trial; radio: radiotherapy; immune: immunosupression; vene: venesection; erythro: erythropoietin; splen: splenectomy; no tx: no treatment; support: supportive care 
Figure 4.3 Treatment Pathway tree diagram-2 (AML 60-74 years old) 
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*chemo: chemotherapy; trial: clinical trial; radio: radiotherapy; immune: immunosupression; vene: venesection; erythro: erythropoietin; splen: splenectomy; no tx: no treatment; support: supportive care 
Figure 4.4 Treatment Pathway tree diagram-3 (AML≧75 years old) 
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*chemo: chemotherapy; trial: clinical trial; radio: radiotherapy; immune: immunosupression; vene: venesection; erythro: erythropoietin; splen: splenectomy; no tx: no treatment; support: supportive care 
Figure 4.5 Treatment Pathway tree diagram-4 (APML) 
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Database 2: HILIS database 
 
The HILIS database was used for identifying treatment phase and for laboratory test cost 
calculation. 
 
4.6 Descriptive statistics (HILIS) 
 
After mapping the study population (derived from the HMRN database) to the patient ID 
in the HILIS database, a total of 3058 reports were matched. After database cleaning and 
reported results integration, 1767 laboratory reports were obtained. The summarized 
specimen types of the 1767 reports can be found in Table 4.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As illustrated in Table 4.12, the most common specimen/biopsy test types were the 
specimen test: BMAT test alone (32.54%), BMA test alone (10.87%), and PB test alone 
(12.05%). The multi-specimen test types were found to be uncommon (less than 1%). 
Only four of the above accounted for more than 1%, with the two most common test types 
in this group being “BMAT, BMA, PB” and “BMA, PB”, accounting for 8.43% and 
4.30% respectively.
Table 4.12 Summary of specimen types and numberss 
Summarized test results Frequency Percentage 
BMA 192 10.87 
BMA, BMAT, HS, PN, TBP 47 2.66 
BMA, BMAT, PB 149 8.43 
BMA, CF 6 0.34 
BMA, HS, PB, TBP 24 1.36 
BMA, HS, TBP 15 0.85 
BMA, PB 76 4.30 
BMA, PB, TBP 3 0.17 
BMA, TBP 11 0.62 
BMAT 575 32.54 
BMAT, PB 13 0.74 
CF 95 5.38 
CHI group 177 10.02 
DF group 46 2.60 
EF 13 0.74 
HS 39 2.21 
HS, PB, TBP 3 0.17 
LF group 10 0.57 
PB 213 12.05 
PB, TBP 1 0.06 
PBS 25 1.42 
RU 25 1.41 
TBP 1 0.06 
TBP, HS 1 0.06 
XA group 7 0.40 
Total 1767  
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4.7 Length of treatment phases (HILIS) 
 
 
In order to provide a visual representation of the length of each treatment phase, the 
results had to be presented in a time axis format as shown in Table 4.13. As shown in 
Table 4.13, it took shorter time to achieve the 1st remission rather than the 2nd remission. 
Also, the patient stayed in the disease absence stage longer in 1st remission time rather 
than in 2nd remission  time.  This  implied  that  the  relapse  not  only  could  make  the  
remission more difficult to achieve, but also it could make the disease easier to relapse 
again. However, the above trends were only observed for the first and the second 
treatment phases, as the mentioned patterns did not appear during the third and fourth 
treatment phases. This change of pattern could be related with the fact that only few cases 
were found to have reached the third and fourth treatment phases, something that could 
make the available information insufficient for extracting consistent results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.13 The length of treatment phase 
From diagnosed to 1st relapse 1st relapse to 2nd relapse 2nd relapse to 3rd relapse 3rd relapse to 4th relapse 
Average length: 479 days Average length: 204 days Average length: 356 days Average length: - days 
(n=49) (n=6) (n=1) (n=.) 
Diagnosed to 
1st remission 
(induction) 
1st remission to 
1st relapse 
(consolidation) 
1st relapse to 
2nd 
remission 
2nd 
remission to 
2nd relapse 
2nd relapse 
to 3rd 
remission 
3rd 
remission to 
3rd relapse 
3rd relapse 
to 4th 
remission 
4th remission 
to 4th relapse 
Average 
length: 66 
days 
Average length: 
420 days 
Average 
length: 88 
days 
Average 
length: 154 
days 
Average 
length: 38 
days 
Average 
length: 300 
days 
Average 
length: 50 
days 
Average 
length: - days 
(n=107) (n=49) (n=23) (n=6) (n=3) (n=1) (n=1) (n=.) 
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4.8 Laboratory test cost (HILIS) 
 
 
The total and the individual lab costs for each treatment phase (at patient level) are 
presented in Table 4.14. Since the costs of transplantation-related tests (such as CHIA 
and CHIM) and the ‘stem cell harvest cost’ (derived from reference cost for calculating 
the  transplantation  cost  at  later  stages  of  the  study)  are  actually  the  same,  the  
transplantation-related test cost was removed from the database and the total treatment 
cost estimation. This was in order not to double count the harvest cost. However, in the 
context of the current work, information related with transplantation-related test cost was 
kept and presented separately in Table 4.14. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Table 4.14, irrespectively of whether the stem cell harvest cost was included 
or not, the lab cost increased gradually from phase to phase, with the exception of the 2nd 
relapse phase. It is suggested that this could be because of the significantly low numbers 
of cases for the 2nd relapse (n=6). However, the general trend indicated that increased 
relapse occurrences corresponded to increased lab costs (including the disease time and 
remission time). 
 
Table 4.14 Laboratory test cost 
Including the cost of transplantation-related tests Excluding the cost of transplantation-related tests 
Phase Number of 
patient 
Average cost 
per patient 
Phase Number of 
patient 
Average cost 
per patient 
First-line treatment 239 £1406.40 First-line treatment 239 £1385.89 
1st relapse 49 £2683.54 1st relapse 49 £2167.88 
2nd relapse 6 £2105.50 2nd relapse 6 £1780.17 
3rd relapse 1 £3706 3rd relapse 1 £2256.00 
Total  239 £2003.95 Total  239 £1867.35 
Average cost per report: £275.59 (n=1767) 
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Database 3: PCD database 
 
 
In the current study, the PCD database was used for extrapolating transfusion frequency. 
The latest update of the palliative care database used for analysis was made on January 
2010. In this database, there were 20 AML / APML patients, 14 of whom appeared to 
have had received once or more transfusions during the recorded transfusion time. Data 
summarizing and cleaning was carried out on 670 detailed records of transfusion, 
related to these 14 patients. In total, there were 164 summarized transfusion events that 
were ready for further analysis. 
 
 
4.9 Transfusion cost 
 
 
4.9.1 Unit of transfusion 
 
Based on the 164 summarized transfusion events, 1.87 blood units and 0.66 platelet 
units were assigned on each transfusion, on average. After rounding these values, about 
2 blood units and 1 platelet unit were found to have been given during each transfusion. 
 
 
4.9.2 Transfusion frequency 
 
The 164 summarized transfusion events were divided into 4 subgroups. Next, the 
transfusion frequency was calculated for each of these groups (defined in the previous 
section). Further analysis of the above can be found in the following paragraphs. 
 
Within a group comprising of patients who had achieved remission, 2 patients were 
found to have good treatment response (had achieved remission in less than 2 months), 
with the average transfusion frequency being once every 4 days (in round numbers) 
during the disease time, while 3 patients were found to belong to the poor response 
subgroup. In this subgroup, the average transfusion frequency was once every 14 days 
during the disease time. 
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In the group comprising of patients who had not achieved remission, there were 6 
patients who died quickly (within 2 months), with the average transfusion frequency 
being once every 4 days (in round numbers) during the disease time. In the group 
comprising of patients who had achieved remission, 3 patients were found not to have 
rapid progress (survived more than 2 months), with the average transfusion frequency 
being once every 14 days during the disease time. 
 
As the above results were highly consistent, it was possible the transfusion frequency to 
be summarized to the following statement: Transfusions would take place once every 4 
days when the disease time lasted less than 2 months, and once every 14 days when the 
disease time lasted longer than 2 months. The summary can be found in Table 4.15. 
 
 
 
 
 
 
 
 
Table 4.15 Summary of transfusion frequency extrapolation 
 Number of cases Transfusion frequency 
Had achieved remission   
Quick response to treatment (2 months) 2 Once every 4 days 
Slow response to treatment (2 months) 3 Once every 14 days 
Died before achieving remission   
Die soon (2 months) 6 Once every 4 days 
Die slowly (2 months) 3 Once every 14 days 
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Table 4.16 Treatment types by treatment phase 
Integrated database 
 
4.10 Preliminary analysis results of integrated database 
 
4.10.1 Types of treatment 
 
Treatment  types  in  each  treatment  phase  provided  an  indication  of  what  type  of  
treatment was normally given in specific treatment phases. Without considering the 
supportive care, most of regimens of chemotherapy or arms of clinical trial were used 
for first-line treatment (Table 4.16). Especially regimens or arms like ADE, FLAG-Ida, 
MRC, and Spanish approach normally were used as induction treatment, while 
AraC(HD), MACE, and MidAC were mainly used as consolidation treatment.  Other 
treatments, like radiotherapy, stem cell transplantation, and immunosuppressive 
therapy,  were  commonly  used  for  treating  relapse,  but  sometimes  were  also  used  as  
consolidation treatment. In relation to palliative care, it could be used at any treatment 
phase because of its nature of care. Overall, the timing of each treatment type use was in 
line with the guidelines [97, 151, 155, 156] and with previous review studies[24], 
which suggested that the treatment information in the study database was fairly reliable. 
 
 
 
 First-line 2nd 
relapse 
3rd 
relapse 
After 3rd 
relapse 
Total 
 Induction Consolidation 
Inpatient treatment 222 109 73 10 2 416 
ADE 28 4 11 - - 43 
AraC(HD) 6 22 11 1 - 40 
AraC (LD) 38 1 3 1 1 44 
DA 59 7 2 2 - 70 
Clofarabine - - 2 - - 2 
FLA 1 2 1 - - 4 
FLAG 6 6 6 - - 18 
FLAG-Ida 32 5 5 - - 42 
HAM - - 1 - - 1 
MACE 3 24 2 - - 29 
MidAC 5 22 2 - - 29 
MRC 11 2 - - - 13 
Spanish 10 4 - - - 14 
Amsacrine - - - 1 - 1 
Arsenic trioxide - - 2 - - 2 
Campath - - 1 - - 1 
Daunorubicin - - 1 - - 1 
Palliative care 23 2 6 1 1 33 
Radiotherapy - 2 10 2 - 14 
Stem cell transplant - 4 7 2 - 13 
Splenectomy - 2 - - - 2 
Outpatient treatment      84 (82) 
ATRA 3 - - - - 3 
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 Cyclophosphamid - 4 2 - - 6 
Cyclophosphamid / MESNA - - 2 - - 2 
ETI 1 - 1 - - 2 
FC 1 - 4 1 - 6 
Fludarabine 1 - - 1 - 2 
Melphalan 2 - 1 - - 3 
Mylotarg - - 1 - - 1 
Spanish maintenance - 1 - - - 1 
Vincristine 1 - - - - 1 
Aspirin - 2 - - - 2 
Hydroxycarbamide 30 4 4 1 1 40 
Hydroxycarbamide / Aspirin 1 1 - - - 2 
Chelating agents 1 - 1 - - 2 
Anagrelide - 1 - - - 1 
Clopidogrel - 1 - - - 1 
Immunosuppressive - 2 3 1 - 6 
Venesection - 3 - - - 3 
No treatment      12 
Total 275 128 92 14 3 512 
 
 
4.10.2 Treatment response and prognosis 
 
a. Complete remission rate 
CR rate is always one of the indexes of treatment effect. Based on information extracted 
from the HILIS database, the CR rate was further analyzed in the current study with the 
following prognostic factors: age, gender, diagnosis, and primary induction treatment. 
The results are shown in Table 4.17 and Table 4.18. 
 
 
 
 
 
 
 
Table 4.17 CR rate by gender, age, diagnosis, and primary induction treatment 
 CR cases CR rate (%) 
Gender   
Female 52 42.62 
Male 53 45.30 
Age group   
18-60 67 77.91 
60-75 33 45.21 
> 75 5 6.25 
Diagnosis   
AML NOS 76 38.58 
AML with core binding factors 8 80.00 
AML - probable therapy related 2 33.33 
AML with MLL (11q23) rearrangement 1 50.00 
APML t(15;17)(q22;q11-12) 18 75.00 
Primary induction treatment   
Intensive treatment with induction intent 102 73.38 
Intensive treatment without induction intent 1 2.50 
Support or palliative care only 2 3.33 
Total 105 43.9 
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As illustrated in Table 4.17, gender did not introduce any differences in CR rate. 
However, the rest of the factors did. According to the analysis results, older patients had 
worse outcome (lower CR rate). Also, in terms of diagnosis, ‘APML’ and ‘AML with 
core binding factors’ had better prognosis (higher CR rate). In relation to the primary 
induction treatment, treatments with induction intent resulted in much better CR rate. 
These results were consistent with the results of previous related studies [24, 157, 167, 
173]. 
 
Furthermore, in order to determine the effectiveness of each prognostic factor, a simple 
logistic regression was conducted. The regression result showed that both age and 
primary induction treatment had a significant effect to the CR rate (P<0.05), while 
‘diagnosis’ did not. There was no significant difference of the CR rate between AML 
and APML patients. The relevant details can be found in Table 4.18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. Relapse 
 
Based on the 104 patients who had achieved remission, the factors that had effect on 
relapse were tested by means of a simple logistic regression. As shown in Table 4.18, 
only diagnosis had significant effect. AML patients were more likely to relapse than 
APML patients, after achieving remission. The rest of factors did not have significant 
effects, even analyzed separately by AML and APML. 
Table 4.18 CR rate and relapse rate analysis 
  CR Relapse 
  Estimate P value Odd ratio Estimate P value Odd ratio 
Intercept  -1.7005 0.0006  -1.0147 0.9973  
Age group 18-60 0.9115 0.0014 8.832 0.3941 0.4023 1.658 
 60-75 0.3554 0.2298 5.065 -0.2827 0.5724 0.843 
>75 - - - - - - 
Gender Female 0.0720 0.7078 1.155 -0.2034 0.3435 0.666 
 Male - - - - - - 
Diagnosis AML -0.2145 0.4778 0.651 1.1975 0.0030 10.969 
 APML - - -   - 
Primary induction 
treatment 
With induction 
intent 
2.3832 <0.0001 35.503 -0.2224 0.9994 >999 
 With 
non-induction 
intent 
-1.1968 0.1034 0.990 13.3540 0.9197 >999 
 Palliative or 
supportive care 
only 
- - - - - - 
Case number  239 105 
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4.11 Summary 
 
 
The current chapter involved the analysis of the main study databases. Information from 
the  HMRN,  the  HILIS,  and  the  PCD  databases,  such  as  geographic  characteristics  of  
patients, types of treatments, treatment duration, treatment pathway, laboratory test, 
diagnosis, and transfusion frequency were discussed and summarized. The above formed 
the basis for costing, which is discussed in the following chapters (chapters 6, 7, 8). 
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Chapter 5 Costing Methodology 
 
 
Costing structure, data sources 
 
 
 
5.1 Overview of the costing structure 
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CHAPTER 5 STUDY METHODOLOGY 
 
The aim of this thesis is to explore how to obtain detailed costs of care per patient over the 
patient pathway from diagnosis to cure or death. Based on the review results discussed 
previously (chapter2) and Drummond et al. [175] suggest that costing care requires three 
stages: identification of items to cost, measurement of the amount of resource used for 
each item and thirdly valuation of each resource, an innovative five-step costing approach 
that contained three-phase costing method was designed. 
 
Information about the population on which the study was conducted has been described in 
the previous two chapters. In the current chapter, the overview of the costing methods and 
its data sources are discussed. The further details of the above three-phase costing method 
are described in the later chapters (respectively chapter 6, chapter 7, and chapter 8). 
 
5.1 Overview of the costing structure 
 
To calculate the overall/lifetime treatment costs of individuals, a five-step approach 
(adopted to cost the care the patients received) was applied  
 
Step 1. Cost items that were required to be calculated were identified.  
Step 2. Information for estimating the required cost items was collected.  
Step 3. Cost for each treatment episode/event was calculated.  
Step 4. Cost of each treatment episode was linked to the patient treatment pathway.  
Step 5. Overall treatment cost was estimated individually 
 
In the following sections, the preparation procedures employed before performing the 
actual costing (step 1) and the structure of the cost estimation methods (steps 2, 3, 4, 5) 
are presented and briefly discussed. 
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5.2 Defined and determine the cost drivers (three-level classification) 
 
Based on the review results of the relevant cost studies discussed in chapter 2, several key 
cost drivers were identified (such as drug cost and personnel cost). To ensure that all the 
resources were thoroughly considered, the cost drivers/items that should be estimated 
were further checked and identified by focus group meetings (composed by 
haematologists, research nurses, and the managers of financial department in hospital) 
with the application of three-level classification, according to three different and distinct 
characteristics. In each classification level, only one characteristic was used. This was 
done mainly in order to avoid problems in categorizing some resources, as it is easy to 
count the same resource twice or forget to count the resource altogether [176]. The details 
of the three-level classification and the cost items identified are described below: 
 
 
5.2.1 First level of cost classification by treatments/services 
 
Although there  are  many ways  to  classify  the  resource  input  (such  as  activity,  level  at  
which resources are used, currency and others), it was decided that the ‘classification by 
treatments/services (activity)’ should be used for the purposes of the current study. This 
decision was made for two reasons. Firstly, classifying or identifying the resource inputs 
by treatment/services is a relatively straight-forward process [44]. Secondly, classifying 
resources by treatment matches the main purpose of the study, which was to estimate the 
individual overall cost from the patient treatment pathway by summing up all the 
treatment event costs. Under the treatments/services classification, the costs were divided 
into 12 categories according to the types of treatment/service given to the AML/APML 
patients: 
 
a. Treatment costs identified from the HMRN database 
Ten treatment costs were identified from the HMRN database: costs of chemotherapy 
(including treatment given a part of a clinical trial), clinical trail, supportive care 
(including erythropoietin, steroids, G-CSF, and transfusion), venesection, splenectomy, 
palliative care, transplantation, radiotherapy, immunosuppressive therapy, and follow-up. 
These treatment costs occurred when they are given to patients.  
 
b. Service cost identified from the HILIS database 
Only one service cost item was identified from the HILIS database, namely the 
Laboratory  test  cost.  Test  costs  can  be  defined  as  the  costs  that  occur  when  patients  
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receive the lab testing service. Normally, the lab test is used for confirming the diagnosis, 
monitoring the effectiveness of treatment, and monitoring the progress of the disease. 
 
c. Care cost derived from the central register 
Only one care cost was identified from the central register: the end-of-life care. The care 
cost (dying cost) is the cost that occurs when a patient dies at healthcare institutes, such as 
hospitals and nursing homes, without receiving any aggressive treatment. The end-of-life 
care normally only involves basic daily care and emotional / psychological support. 
 
 
5.2.2 Second level of cost classification by information availability 
 
According to the availability of the detailed treatment information, the treatment costs 
were further divided into two types: the cost can be estimated by bottom-up costing and 
the cost that can not. 
 
a. cost type 1: cost that can be estimated by bottom-up costing method 
The costs can be estimated by bottom-up costing method when the treatment details 
are available. For example, chemotherapy treatment cost falls into this category as 
the regimen details are available in the HMRN database. 
 
b. cost type 2: cost that can not be estimated by bottom-up costing method 
The cost can not be estimated by bottom-up costing method when the treatment 
details are not obtainable. For example, transplantation cost falls into this category as 
the treatment details of transplantation are not available from any of the databases 
used in the current study.  
 
Based on the cost type, the treatment costs that can not be obtained by bottom-up costing 
method were estimated by substituting their values with the national average cost (from 
‘Reference Cost Schedule’). As for the treatment costs that can be estimated by 
bottom-up costing method, they were further identified with the third level classification. 
 
5.2.3 Third level of cost classification by functions 
 
According to the cost functions (derived from practical experience, expert opinions, 
literature mentioned in Chapter 2, and relevant publications [44, 176, 177]), the cost 
drivers/items that had to be estimated for all the treatments were listed below. 
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a. Drug costs (product costs): the costs for the delivered medicine/products of the 
treatment, such as the drug costs, regimen costs, and cost of blood products. 
b. Personnel costs: the costs of human resources used for the treatment, but not for care or 
support duties/purposes. 
c. Overheads and capital overheads costs: overheads costs are the resources serving 
different departments or treatments for supporting purposes (for example, 
administration, management, utility, central laundry, porter, outsource cleaning, and 
even infectious medical waste treatment expenditure or similar [44]). Capital 
overheads costs are the resources that are used to purchase the capital assets required 
by the treatment, such as equipment, buildings, vehicles, and land. 
d. Ward/clinic costs: the resources that are used in ward or outpatient clinic for care duties, 
such as changing beddings, providing medicine and meals and space cost. 
e. Complication treatment costs: the resources that are used to treat the side effects caused 
by treatments. 
 
This three-level cost classification ensures that all the relevant activities are captured and 
reported. Once all the costs were identified, different types of costs for each treatment 
were able to be calculated through different methodologies. The structure of cost 
measurement methods is discussed below. 
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5.3 Structure of three-phase costing method 
– microcosmic to macrocosmic 
 
 
5.3.1 Item cost measurement 
 
After the range of the cost items had been identified, the values of individual cost items 
for each treatment were measured. The general item cost measurement encompassed two 
parts: assignment of unit cost/price and measurement of quantities of the used resources. 
 
For the purposes of the current study, consumed amount was set as the quantity unit. In 
general, quantity measurement was estimated by means of the data sources: database, 
medical notes, expert or staff survey, and literature review. To reflect the costs in the real 
world, information of ‘patient actual resource consumption’ (such as the information 
derived from database and medical notes) was mainly used as the quantity unit. Staff / 
expert surveys and literature review were only used whenever the actual patient data were 
not available. 
 
For the assignment of unit cost, tariffs and publications of national average prices and 
costs were used as information sources (official price lists such as BNF) in order to make 
the estimation methods coherent and the estimates close to actual unit costs.  
 
 
5.3.2 Treatment cost measurement 
 
Assuming that the treatment cost is the bridge between the item cost and the patient total 
pathway cost (as treatment cost is the sum up of the item costs while it is also a chunk of 
the patient total pathway cost), then the bridge between the item cost and the treatment 
cost  is  ‘number of uses (frequency)’.  To estimate the treatment cost,  all  the item costs 
under each treatment were summed up according to the ‘frequency’ information. For 
example, the transfusion cost (treatment cost) was calculated from a multiplication of a 
lump sum of the item costs (such as blood product s and personnel) of each transfusion 
and the delivery frequency (once every four days when the disease time is less than two 
months) during the treatment (episode) time. 
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Figure 5.1 Illustration of the relationship between cost identification and measurement 
 
In the current study, a number of data sources were used to obtain the adequate frequency 
information for each treatment. Generally, patient treatment pathway databases were the 
main and most reliable sources for frequency. If the frequency information was not 
available in the relevant databases, then guidelines and expert opinions were taken into 
account. 
 
For the treatment cost that was unobtainable by bottom-up costing (item costs were not 
available or frequency information were insufficient), the national average cost (derived 
from ‘Reference Cost’) was used instead. For example, in the case of transplantations (13 
treatment  episodes  were  found  in  the  HMRN  database),  the  ‘Reference  Cost’  of  
transplantation was used as a substitute for treatment cost because the treatment details 
(cost drivers) were not obtainable. This approach was expected not only to be more 
time-efficient, but also to provide better human resources management. 
 
5.3.3 Overall treatment cost measurement 
 
After each treatment cost had been identified, the final step to the total cost was to link all 
the treatment costs to the patient treatment pathway (derived from the HMRN database), 
and then sum them up in order to reflect the individual total cost in the real world. The 
illustration of the relationship between cost identification and measurement is shown in 
Figure 5.1, while the relationship between three-phase cost measurement and five-step 
costing approach is illustrated in Figure 5.2. 
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Figure 5.2 The illustration of the relationship between five-step costing approach and 
three-phase costing method 
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5.4 Relevant data sources for valuation 
 
A number of different sources were used to obtain the value information for costing. The 
valuation methods were chosen depending on the availability of information.  
 
˙If the quantity information could be derived from the study databases, the national 
sources of unit costs (such as the BNF price list) provided the representative 
information that could be used for bottom-up costing. 
 
˙If the quantity information for bottom-up costing could not be retrieved from the study 
databases, the national cost data (such as the ‘Reference Cost’) were considered, as 
they were an alternative but reliable source of information.  
 
In order to be consistent with the time in which the majority of events occurred in the 
HMRN database, the relevant data sources that were used for valuation were the ones 
published in 2006/07. The main relevant sources were used in the current study as 
detailed below. 
 
5.4.1 British National Formulary (BNF) [178] 
 
The BNF provides UK authoritative and practical information (including medical 
directions and drug price) on the selection and clinical use of medicines. In the current 
study, the BNF was used as a reliable ‘unit cost’ source for drugs and regimens. 
 
5.4.2 PSSRU Unit Cost [179] 
 
Unit Cost derived from the Personal Social Services Research Unit (PSSRU) provides 
detailed and comprehensive unit cost estimates in heath and social care in the UK. Thus, 
the unit costs of the staff and the overheads for cost estimations were derived from this 
document. 
 
5.4.3 NHS Reference Cost Schedules 2006/07 [180] 
 
‘NHS Reference Cost Schedules’ provides the national average cost data of different 
health groups in the UK. In cases where the treatment event failed to be calculated by 
means of bottom-up costing, the ‘Reference Cost Schedule’ was used as an alternative 
way to represent the cost. In the current study, it was decided data from the ‘NHS trust 
Reference Cost Index’ group to be used instead of data from ‘Primary Care (GP) Trust 
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Reference  Cost  Index’  group.  This  was  because  most  of  AML/APML  patients  were  
treated in a secondary care settings, and also the participating hospitals of the HMRN are 
all NHS trust. 
 
5.4.4 Other sources  
 
Except the national data sources mentioned above, other value sources, such as price list 
or tariff, were also used as ‘unit cost’ for cost calculation. For example, the ‘National 
blood and blood components price list’ from the National Blood Service[181] was used as 
‘unit cost’ for transfusion cost calculation, while the ’Provider Tariff 2006-7 of the 
Haematological Malignancy Diagnostic Service’ [182] was used for laboratory test cost 
calculation.  
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5.5 Relevant data sources for quantification 
 
HMRN  was  the  main  data  source  for  qualification.  However,  in  some  cases,  detailed  
information was not possible to be retrieved from the HMRN database, and, thus, a 
number of alternative available sources were used instead. The details regarding 
aforementioned data sources are presented in the following paragraphs. 
 
5.5.1 Database 
 
As mentioned previously (chapter 3 and 4), three main databases compromising HMRN 
were used, namely the HMRN, the HILIS, and the PCD databases. The HMRN database 
was the main data source of the current study. It provided the information related with 
patients’ baseline characteristics, which were used for defining the study population. The 
associated  treatment  details  in  the  HMRN  database  were  also  used  for  treatment  cost  
estimation at later stages. As for the HILIS and the PCD databases, they were used as 
supplement databases. The HILIS database provided the information related with the 
treatment progress, the diagnoses, and the details of laboratory resource use. The PCD 
database was used for predicting the transfusion frequency as this information could only 
be obtained from this particular database (please refer to chapter 3 for detailed reasons 
and methods of predicting). 
 
5.5.2 Medical notes 
 
As information gaps were found in the databases, additional information (such as 
antibiotic days, actual hospital stay) was alternatively extracted from available medical 
notes, with the assistance of research nurses. 
 
5.5.3 Clinical guideline for AML/APML treatment [183, 184] 
 
The clinical guidelines issued by the British Committee for Standards in Haematology 
(BCSH guideline) are widely used in the UK. It provides haematologists with up to date 
advice on the diagnosis and treatment of haematological disease [183]. Generally, the 
AML/APML treatments in the HMRN network followed the BCSH guideline. The AML 
15 clinical trial protocol [185] was also used to retrieve more details regarding the 
chemotherapy regimens administered to patients on this trial. AML 15 trial is a clinical 
trial held by The Medical Research Council with the aim of improving the AML/APML 
treatment. The protocol contains all the dosage and delivery details of the regimens that 
are used in the trial arms. These regimens of the trial arms cover the, well-established, 
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mainstream treatments in the UK at present (such as ADE and FLAG-Ida) and the latest 
developed treatments (such as the treatment combination with Mylotarg). In the current 
study, the BCSH guideline and the AML 15 protocol were used as supplement for 
obtaining the ‘quantity’ and the ‘frequency’ information for the calculation of 
chemotherapy and clinical trial costs. For example, the numbers of days the specific drugs 
were delivered for each cycle of the clinical trial (frequency) was derived from the AML 
15 trial guideline. 
 
5.5.4 Experts and clinical staff survey 
 
Expert opinion survey and staff survey were conducted when it failed to obtain 
information either from database or guidelines. This included the staff working time for 
each treatment delivery and some information for missing value imputation.  
 
5.5.5 Literature review 
 
Literature review was the last in order source option used for quantification in the current 
study. It was only used when data was impossible to be obtained from all the other data 
source options. Mainly, this data source (literature review) served as ‘quantity’ 
information for complication treatment cost calculation, as the complication (adverse 
event) incidence rate of each treatment for specific disease was difficult to be obtained 
from other sources. 
 
5.5.6 Summary 
 
The summary of the function that was served by each data source is listed below (Table 
5.1). 
 
 Table 5.1 Summary of the data sources 
1. Treatment cost that could be derived by bottom-up costing 
 Quantity Unit cost Frequency 
Data sources Database (5.5.1) National data (5.4) Database (5.5.1) 
 Medical notes (5.5.2) Tariff (5.4.4) Expert survey (5.5.4) 
 Clinical guideline (5.5.3)  Clinical guideline (5.5.3) 
 Expert survey (5.5.4)   
 Literature review (5.5.5)   
2. Treatment cost that failed to be derived by bottom-up costing 
Data sources National data (5.4) 
 
5.5 Relevant data sources for qualification 
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Figure 5.3 Illustration of the costing methods and data sources 
5.6 Conclusion 
 
The connections between the costing methods and data sources that are discussed above 
are visually illustrated in Figure 5.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As it can be seen in Figure 5.3, the three databases used in the current study provided the 
information about treatment details, lab test details, and transfusion frequency 
respectively (marked in red). Based on the information availability, treatment type can be 
divided into two categories: estimated by bottom-up method or not. The treatment costs 
that could be estimated by the use of the bottom-up method were further divided into a 
number of cost items, such as drug cost and personnel cost. These cost items/drivers are 
marked in green in Figure 5.3.  Also,  all  the  data  sources  that  provided  the  relevant  
information  for  cost  item  estimations  are  presented  in  rhombus  shapes.  As  for  the  
treatment costs that were impossible to be estimated by means of the bottom-up costing 
method, the ‘Reference Cost’ was used to represent the treatment cost. Finally, Figure 5.3 
shows  that  all  the  treatment  costs  were  linked  to  the  treatment  pathway,  and  the  total  
treatment cost for each individual was generated by summing up these treatment costs. 
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CHAPTER 6 COSTING METHOD PHASE 1 
 
 
 
Based on the study design presented in the previous chapter (chapter 5), 12 types of 
treatment/intervention were defined and the costs of these 12 treatments/interventions 
have to be calculated in order to obtain the lifetime/overall treatment cost of individuals. 
These 12 treatment costs were: chemotherapy, clinical trial, supportive care 
(erythropoietin, steroids, G-CSF, and transfusion), radiotherapy, transplantation, 
immunosuppressive therapy, splenectomy, venesection, palliative care, observation 
(follow-up), end-of-life care, and laboratory test. 
 
 
Given data availability, it was possible to calculate eight out of 12 
treatments/interventions by summing up five different cost items/drivers using a 
bottom-up costing method. These are, namely: drug cost (product cost), personnel cost, 
overheads cost (overheads, and capital overheads), ward cost (inpatient ward and place 
of outpatient visit), and complication cost. As for other 4 treatments (splenectomy, 
radiotherapy, transplantation, and palliative care), the ‘Reference Cost’ was used to 
represent the treatment cost.  
 
 
According to the study design (section 5.3.2), cost measurement could be divided into 
three  phases  (illustrated  below).  In  the  current  chapter,  costing  phase  1  for  the  eight  
treatments that can be estimated by bottom-up method is discussed. The general costing 
details of each of the five cost items/drivers are described in the following sections. 
Also, the specific details of the cost items/drivers for costing each 
treatment/intervention are discussed in next chapter (chapter 7) 
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Figure 6.1 The illustration of costing phases 
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6.1 Drug / product cost 
 
For the treatments/interventions that could be cost by means of the bottom-up method, 
drug costs were calculated based on the price lists (derived from published sources) and 
the quantity (derived from the HMRN database). Overall, 3 price list sources were used 
in the current study. These lists are discussed in the following paragraphs: 
 
6.1.1 BNF price list [178] 
 
Except transfusions and laboratory tests, all the drug /regimen prices included in the 
current study were based on the BNF price list (UK manufacturers price)[178]. These 
official prices may vary from (and generally be higher than) the real cost that hospitals 
actually spend on patients, depending on the contract between each given hospital and the 
manufacturers. Also, BNF prices include the VAT, given that hospitals are required to pay 
VAT on medicines. 
 
6.1.2 National blood and blood components price list [181] 
 
In order to obtain the unit cost of the blood products that were used for transfusion, the 
‘National blood and blood components price list’ from the National Blood Service[181]of 
the UK was used. The full version of the price list can be found in Appendix 6.1. Based 
on the above, the blood product cost of the transfusion was calculated by the 
multiplication of the unit cost and the quantity (derived from the HMRN database). 
 
6.1.3 Provider Tariff of the Haematological Malignancy Diagnostic Service[182] 
 
In order to obtain the unit cost of the laboratory test services, the ’Provider Tariff 
2006-7 of the Haematological Malignancy Diagnostic Service (HMDS) [182]’ (derived 
from the Leeds teaching hospital NHS trust) was used. The reason for using the HMDS 
tariff instead of the national price list was that all the regional laboratory test requests 
were not only centralized, but also referred to HMDS. Therefore, the application of the 
HMDS tariff provided closer estimates to the actual laboratory test cost. The detailed 
price list of the laboratory tests for haematological malignancy diagnosis that was used 
in the current study can be found below (Table 6.1) . Based on the above information, 
the laboratory test cost was calculated by the multiplication of the unit cost and the 
quantity (derived from the HILIS database, the subset of the HMRN database). 
 
 
6.1 Drug / product cost 
- 149 - 
 
Table 6.1 Provider Tariff 2006-7 of the HMDS 
Full name of the specimen test Abbreviation Price 
Bone marrow aspirate BMA £148 
Bone narrow aspirate & Trephine biopsy BMAT £339 
Cerebral spinal fluid (CSF) CF £29 
Chimerism, allograft CHIA £265 
Chimerism, baseline CHIB 
Chimerism, mini-allograft CHIM 
Skin, block DBL £218 
Skin, fixed DF 
Skin, fixed & unfixed DFU 
Skin, unfixed DU 
Effusion EF £90 
Haematological slide HS £29 
Lymph node biopsy, fixed LF £90 
Lymph node biopsy, unfixed LU 
Peripheral blood PB £148 
Peripheral blood, stem cell PBS £148 
Spleen, unfixed RU £200 
Bone marrow trephine, fixed TBP £218 
Miscellaneous tissue aspirate XA £148 
Miscellaneous tissue, block XBL 
Miscellaneous tissue, unfixed XU 
 
Table 6.2 The summary of the drug/product costing method 
Drug/product cost of each 
treatment/intervention 
Unit cost Quantity 
Chemotherapy 
BNF price list HMRN database 
Clinical trial 
Supportive care 
Erythropoietin 
Steroids 
G-CSF 
Immunosuppressive therapy 
Supportive care National blood and blood 
components price list 
HMRN database 
Transfusion 
Laboratory test Provider Tariff from the 
Leeds teaching hospital 
NHS trust 
HILIS database 
Follow-up / observation   
End-of-life care 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding the follow-up and the end-of-life care, no drug/product cost was applied, as 
these two interventions do not involve any treatments with curative intent. 
 
Overall, the drug/product/service cost can be simply summarized as the multiplication of 
the unit cost and the quantity. The summary of the drug/product costing method for each 
treatment is shown in Table 6.2. 
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6.2 Personnel cost 
 
 
Hospital personnel could be divided in two distinct categories: staff directly involved 
with the treatment (such as doctors and nurses) and other support staff (such as managers, 
cleaners, and porters). In the current context, personnel cost was specifically defined as 
the cost  related with the staff  directly involved in the ‘treatment’ (such as delivery the 
medicine or injection), and not that involved with ‘care duty’ (like change beddings) or 
any other ‘supportive services’. 
 
In order not to overlook the cost of human resources in the hospital, the human 
resources were separated into three categories. The ‘cost of human resource for the 
supportive service’ was counted in overheads cost, and the ‘cost of human resource for 
care duty’ was counted in the ward/clinic costs at later stages. The only cost that was 
calculated separately was the one related with the human resource that was devoted to 
the treatment delivery. This was for two reasons. Firstly, it was difficult to separate the 
human resource costs from the overheads cost and the ward cost. Secondly, it was not 
possible to obtain information regarding the usual amount of working time spent on 
supportive services and care duty from the clinical staff during the staff survey. Therefore, 
only the cost of working time for treatment was considered as personnel cost. Also, the 
personnel cost was calculated by multiplying the unit cost with the quantity. The details 
of the costing method for the personnel cost are described in the following paragraphs. 
 
6.2.1 Assumptions 
 
Regarding the required calculation, a number of assumptions were needed. In 
particular the following two assumptions were made: 
 
a.  It  was  assumed that  under  the  same chemotherapy  regimen,  the  working  time of  
each member of staff was constant every day. 
b. It was assumed that during the working time, the member of staff involved in the 
treatment activity was not on any other care or supportive duty.  
 
Under the above assumptions, the personnel cost was calculated by multiplying the unit 
cost with the working time. The unit cost was derived from the government founds the 
publication: ‘PSSRU: Unit Costs of Health and Social Care [186]’, and the staff working 
time was derived from staff working time survey. The details can be found as follows. 
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Table 6.3 The unit cost list of personnel cost 
 
Category 
Working time 
per year 
Total Working 
mins 
Wages 
Total Unit cost 
Nurse Band 2 42 weeks / year 
37.5 hours / week 
94500 minutes £16,332 £0.17 / min 
Band 5 42 weeks / year 
37.5 hours / week 
94500 minutes £30,366 £0.32 / min 
Band 6 42 weeks / year 
37.5 hours / week 
94500 minutes £36,633 £0.39 / min 
Band 7 42 weeks / year 
37.5 hours / week 
94500 minutes £43017 £0.46 / min 
Doctor Specialist registrar 41 weeks / year 
39.9 hours / week 
88578 minutes £93,617 £1.06 / min 
Consultant: medical 41 weeks / year 
48.2 hours / week 
118572 minutes £178,360 £1.50 / min 
Pharmacist  42 weeks / year 
37.5 hours / week 
94500 minutes £38,912 £0.41 / min 
 
6.2.2 Unit cost 
 
In order to obtain the personnel unit cost, the salary grade was used instead of the actual 
salary. This decision was made for three reasons. Firstly, the actual salary was unavailable 
because most individuals tended not to reveal their real income when asked. Additionally, 
since income has many different probable definitions, it could be claimed that some 
individuals could not fully understand the exact meaning of the term ‘gross (net) 
earnings’ in the current context, something that could lead to inaccurate answers. 
Secondly, the actual individual salary varied, so it could not be used to interpret or reflect 
the salary of other members of staff that were involved in the same treatment activity. 
Thirdly, the information of the national average salary amount for each salary grade could 
usually be obtained from the publications, something that rendered the staff unit cost 
estimates more robust, reliable and interpretable. 
 
For the above reasons, the salary grade and the government founds the publication: 
‘PSSRU: Unit Costs of Health and Social Care [186]’ were used for the estimation of the 
personnel unit cost. Furthermore, in order to bring the personnel unit cost estimates closer 
to the actual cost and to avoid overlooking any relevant costs, costs, such as allowances, 
bonuses and qualification were all taken into account (total salary). The salary unit cost 
list is shown on Table 6.3. 
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6.2.3 Quantity 
 
To obtain the information related with the staff working time for each treatment and each 
regimen, a scenario form was built (the example of this form can be found in Appendix 
6.2). In this form, staff was divided into three main groups: doctors, nurses, and 
pharmacists. Based on the salary band set in the current study and the clinical grading 
system, each group was further divided into the following sub-groups: 
 
a. Doctors: Foundation House Officer 1, Foundation House Officer 2, Specialty 
Registrar (StR), Clinical Practitioner, and Consultant. 
b. Nurses: Band 1, Band 2 (Clinical support worker), Band 3, Band 4, Band 5 (24-hour 
ward nurse), Band 6 (Nurse team leader), Band 7 (Nurse team manager), Band 8, 
and Band 9. 
c. Pharmacists: Pharmacist and pharmacy technician. 
 
After the scenario form for each regimen and treatment was completed (in line with 
expert opinions), it was further simplified by grouping together regimens and treatments 
containing similar medicines or processes. For example, all the mild outpatient-based 
chemotherapies  were  grouped  into  one.  After  simplifying  the  form,  a  staff  survey  was  
performed. For each simplified treatment group, the involved staffs were asked to state 
their position on a salary scale (or the clinical grade) and the time spent on the treatment 
for one patient per day (working time per patient on a daily basis). This included direct 
and indirect working time. The result of the survey was later checked by experts 
resulting in a final table (containing the personnel cost per day/visit per patient for each 
treatment.)The resulting table can be found on Appendix 6.2. An abstract of the 
complete table is also shown below (Table 6.4). 
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Table 6.4 The abstraction of the staff working time survey result 
 
Table 6.5 The summary of the personnel costing method 
Personnel cost of each 
treatment/intervention 
Unit cost Quantity 
Chemotherapy 
PSSRU unit cost Staff survey 
Clinical trial 
Supportive care 
Erythropoietin 
Steroids 
G-CSF 
Transfusion 
Immunosuppressive therapy 
Laboratory test 
Follow-up / observation 
End-of-life care   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is worth noting that the personnel cost was not applied to end-of-life care, as the latter 
did not involve any treatment process but only care, which, in the current study, was 
covered by ward cost.  
 
Overall, the personnel cost can be simply summarized as the multiplication of the ‘unit 
cost  of  staff  working  time’  and  their  ‘actual  working  time  for  treatment  purposes’  
(quantity).  The  summary  of  the  personnel  costing  method for  each  treatment  is  shown 
on Table 6.5. 
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6.3 Overheads cost 
 
 
Overheads (such as utility, management, or administrative personnel) and capital 
overheads (such as space, building or general equipment) were very important cost 
items/drivers for treatment cost estimation. However, it was impossible to itemize the 
above costs and reallocate them to each treatment separately. Therefore, another 
alternative reasonable way to estimate these costs had to be found. Considering the needs 
of the current work, it was decided that the use of the national average cost from the 
publication: ‘PSSRU: Unit Costs of Health and Social Care 2006-07 [186]’ provided the 
optimal alternative solution. 
 
In the ‘Unit Costs of Health and Social Care’, the overheads costs were allocated to staff 
working time. Therefore, overheads costs were estimated by multiplying the staff 
working time survey results with the unit cost. The unit cost list of overheads and capital 
overheads for each member of staff is shown on Table 6.6.  Also,  the table of the staff  
working time survey can be found on Appendix 6.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.6 The unit cost list of overheads and capital overheads costs 
 
 
Category 
Working time 
per year 
Total 
Working 
mins 
Overheads Capital overheads 
Total 
cost 
Unit cost 
(per min) 
Total 
cost 
Unit cost 
(per min) 
Nurse Band 2 42 weeks / year 
37.5 hours / week 
94500  £2,904 £0.03  £1,394 £0.015 
Band 5 42 weeks / year 
37.5 hours / week 
94500 £2,904 £0.03  £1,394 £0.015  
Band 6 42 weeks / year 
37.5 hours / week 
94500  £2,904 £0.03 £2,479 £0.026 
Band 7 42 weeks / year 
37.5 hours / week 
94500  £2,904 £0.03 £2,479 £0.026  
Doctor Specialist registrar 41 weeks / year 
39.9 hours / week 
88578 £2,904 £0.03  £3,084 £0.03 
Consultant: medical 41 weeks / year 
48.2 hours / week 
118572 £35,167 £0.30 £4,610 £0.04  
Pharmacist 42 weeks / year 
37.5 hours / week 
94500 £2,904 £0.03 £4,486 £0.05  
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Table 6.7 The summary of overheads costing method 
Overheads cost of each 
treatment/intervention 
Unit cost Quantity 
Chemotherapy 
PSSRU unit cost Staff survey 
Clinical trial 
Supportive care 
Erythropoietin 
Steroids 
G-CSF 
Transfusion 
Immunosuppressive therapy 
Laboratory test 
Follow-up / observation 
End-of-life care   
 
It is worth to note that overheads cost was not applied to end-of-life care, as end-of-life 
care  does  not  involve  any  treatment  processes.  Therefore,  no  overheads  cost  could  be  
allocated to the relevant staff working time information, as the latter was non-existent. 
 
Overall, the overheads cost was calculated with the assistance of the staff working time 
survey  results  (quantity)  and  the  PSSRU  unit  cost  (unit  cost).  The  summary  of  the  
overheads costing method for each treatment is shown on Table 6.7. 
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6.4 Ward/outpatient clinic cost 
 
 
Except the actual treatment activities, all the other activity costs that occurred in the 
‘place of treatment’ (including care, beddings change, meals, space and similar) were 
defined as the ward /clinic costs. For inpatients, the ward costs occurred in the ward. 
For outpatients, the ward costs occurred in the outpatient clinic. 
 
The ward cost was a key to the treatment cost calculation, as it encompassed two 
important parts missing from both the personnel costs and the overheads costs. Firstly, it 
contained all the care costs, including the human resources costs, which were excluded 
from the “personnel costs (for treatment purpose only)”. Secondly, it contained the cost 
of treatment space, which was not included in capital overheads in the ‘PSSRU Unit 
cost of Health and Social Care 2006-07 [179]’ (the source used in the current study to 
estimate the overheads costs). 
 
For similar reasons to the ones described in the overheads costs section (difficult to 
itemize the ward cost, and to re-allocate all the activities separately), the national price 
list was used as the unit cost for ward/outpatient clinic. The relevant details are 
described in the following paragraphs. 
 
6.4.1 Assumptions 
 
For the required calculation, a number of assumptions had to be made: 
 
a.  It  was  assumed  that  no  “single  /  multi  people”  or  “standard  /  specialist”  wards  
differences existed, as this information was not available in the study databases. 
b. It was assumed that each inpatient used the same amount of care resources in ward for 
every inpatient day, and also the same with each outpatient in the outpatient treatment 
place for every outpatient visit. 
c. It was assumed that under different inpatient-based treatments, all the inpatients used 
the same amount of care resources both with one another, and also with all the 
outpatients.   
d. It was assumed that all the outpatient visits occurred in the hospital. 
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6.4.2 Unit cost 
 
A number of different publications were used in order to obtain robust and reliable 
estimations  of  the  ward  unit  cost  for  the  inpatient  stay  and  of  the  clinic  unit  cost  for  
outpatient visit.  
 
a. Inpatient 
According to the ‘Nursing care for older people’ from the Personal Social Services 
Expenditure and Unit Costs England, 2006-07 [187], the cost of hospital stay was found 
to be £467 per week (£67 per day in round numbers). The reason for using this 
information as ward cost was that the cost of nursing care for older people could reflect 
the cost of simple care duty in the ward (which matches the study design of the current 
study).  Regarding  the  other  information  sources,  such  as  the  reference  cost  or  the  
national tariff, it was decided that they could not provide the precise cost of simple care 
duty in ward, as all the costs provided contained the care duty and the relevant treatment 
costs.    
 
b. Outpatient 
According to the “outpatient specialty code 324: Anticoagulant Service Total 
Attendances” from the ‘Reference Cost Index’, the cost of an outpatient visit was found 
to be £19 per visit (based on Consultant Led Follow up Attendance Outpatient Face to 
Face for Adult Attendance). The reason for choosing this information as the outpatient 
clinic cost was that the anticoagulant service was the closest estimate to all the 
non-treatment  costs  that  occurred  in  outpatient  clinics.  This  was  because  the  
anticoagulant service involved the least treatments and examinations (compared to other 
outpatient visits mentioned in the ‘Reference Cost Index’). 
 
c. Sampling 
According to the ‘Pathology Services’ from the ‘Reference Cost’, the cost of the blood 
sampling was £3 per sampling (Haematology - code: DAP823), while the cost of the 
tissue sampling (such as bone marrow sampling) was £26 per sampling (Histology / 
Histopathology– code: DAP824). 
 
6.4.3 Quantity 
 
The quantity for the ward/outpatient clinic cost calculation was based on ‘the number of 
use’. 
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Table 6.8 The summary of ward costing method 
Ward/space cost of each 
treatment/intervention 
Unit cost Quantity 
Inpatient treatments 
Nursing care for older 
people (£67) 
Hospital stays 
Chemotherapy 
Clinical trial 
End-of-life care 
Outpatient treatments 
Reference Cost Index 
(£19) 
Numbers of visits 
Supportive care 
Immunosuppressive therapy 
Follow-up / observation 
Laboratory test Reference Cost Index Numbers of sampling 
 
a. Inpatient 
For the inpatient treatments, the quantity for the ward cost calculation was defined as the 
‘hospital stays’. Because of information insufficiency reasons (as mentioned in Chapter 
5), the’ number of hospital stays’ for each cycle of treatment was derived from the 
relevant imputations (imputed by the assistance of ‘treatment time’ derived from the 
HMRN database, additional information from medical notes, and clinical 
guidelines/protocol). 
 
b. Outpatient 
For the outpatient treatments, the quantity for outpatient clinic cost calculation was 
defined as the ‘number of outpatient visits’. Since the exact visit dates were not 
obtainable from the HMRN database, the outpatient visit frequency was set to once per 
month during the ‘treatment time’ (according to expert opinions). Therefore, the number 
of outpatient visits was possible to be obtained by simple division. 
 
c. Sampling 
For the sampling, the quantity for the sampling place cost calculation was defined as the 
‘number of sampling’. This information could be easily obtained by simple addition, as 
the exact sampling/screen dates could be derived from the HILIS database (the subset 
database of HMRN database). 
 
Overall, the ward/space cost could be calculated by the multiplication of the unit cost 
(from  three  different  information  sources)  and  the  quantity  (number  of  uses).  The  
summary of the ward costing method for each treatment is shown on Table 6.8. 
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Figure 6.2 The illustration of complication treatment costing process 
6.5 Complication treatment cost 
 
 
Apart from the drug, personnel, overheads, and ward costs, complication treatment cost 
was  also  an  important  cost  item/driver  which  had  a  significant  effect  on  the  total  
treatment cost (based on the review results discussed in chapter 2). To be consistent with 
the cost estimation method discussed in the previous sections (section 6.1 to section 6.4), 
the complication treatment cost was estimated by the complication rate (quantity) and the 
unit cost of complication treatment (unit cost). It is worth to note that haematological 
complication (such as haemorrhage and similar) was not taken into consideration, as the 
treatment (transfusion) had already been considered. 
 
According to expert opinions, the infection treatment (antibiotics use) was also 
calculated separately, as it was an important and costly complication treatment. The 
calculation process is illustrated in Figure 6.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The two different approaches for complication incidence rate and all of the details for the 
complication treatment cost calculation are discussed in the following section. 
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6.5.1 Non-infection complication rate derived from expert survey 
 
Based on the detailed information in the Palliative care database, the complications 
were classified into the following 10 categories: Digestion disorder, ENT disorder, renal 
disorder, respiratory disorder, cardiac disorder, ophthalmological disorder, Neurological 
disorder, Rheumatic disorders, and pain. After the complication categories had been 
identified, an expert survey was performed in order to obtain the incidence rate of each 
complication category for the treatments that did not include the complication cost into 
the treatment cost. The result is shown below (Table 6.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.5.2 Non-infection complication rate derived from literature review 
 
Expert survey provided a general idea of the complication incidence rate of each 
treatment as detailed information for each regimen was not available. To obtain detailed 
complication rates for each treatment and each regimen, both a comprehensive system 
review and a meta-analysis of all reported complication rates in AML / APML patients 
were carried out, without language restriction. The details are described below. 
Table 6.9 The expert survey results of the complication incidence rate 
 chemotherapy Clinical trial Transfusion Venesection 
Supportive care 
Immunosuppressive 
End-of-life care 
Follow-up 
ENT disorder 1% 1% - - 
Renal disorder 2% 2% - - 
Cardiac disorder 5% 5% - - 
Respiratory disorder 10% 10% - - 
Skin disorder - - - - 
Ophthalmological 
disorder 
5% 5% - - 
Pain 10% 10% 10% - 
Digestion disorder 5% 5% - - 
Neurological disorder 2.5% 2.5% - - 
Rheumatic disorders 2.5% 2.5% - - 
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a. Literature search strategy 
 
Three sources were used for searching for relevant literature: electronic databases, 
conference proceedings, and hand-searching relevant articles. A systematic review was 
firstly performed by searching the following electronic databases and conference 
proceedings (from 1990 to 2009): Medline, EMBASE, Cochrane Database of Systematic 
Reviews, and Cochrane Central Register of Controlled Trials. The standard search 
strategy recommended by the Cochrane Collaboration was used for different databases 
after being modified. As for the references from the included papers and relevant journals 
were hand searched. There was no language restriction used in the search process. Subject 
headings and keywords used included the following: 
 
˙Adult AML / APML: The definitions and keywords of AML / APML used in 
Chapter 2 (literature review) were applied to this search process. 
˙AML / APML treatment: All the relevant treatment names and regimen names 
mentioned  in  previous  sections  were  used,  such  as  AraC,  ADE,  G-CSF  and  
similar. 
˙Complication: complication, side effect, adverse effect, toxicity, and all the 
relevant complication terms (such as vomit, infection or similar) were used. 
 
In total, 193 relevant studies were found. 
 
b. Inclusion and exclusion criteria 
 
˙Inclusion criteria 
 
Eligible studies were defined as those that could provide the detailed numbers or 
percentages about the complication incidence cases, even if the complication 
report was not their main study purpose/subject. 
 
To maximize the amount of review study sources, studies in which the AML / 
APML patients received relevant treatment or regimen only in one arm (either the 
study arm or the control arm) were also permitted. 
 
˙Exclusion criteria 
 
Studies that failed to provide the detailed numbers and percentages of the 
complication cases were excluded. Moreover, studies were excluded if they 
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Figure 6.3 The illustration of relevant paper searching process 
included more than one treatment or one regimen in one research arm. This was in 
order to keep the complication rate simple and to avoid using the numbers that 
were affected by more than one treatment or regimen. However, this exclusion 
criterion could not be applied to the supportive care regimen (G-CSF). Previous 
studies and guidelines concluded that G-CSF is usually used as a subside regimen. 
Therefore, studies were eligible if the regimen G-CSF was combined with other 
treatments or regimens in any trial arms, in the perspective study design. However, 
the extracted complication rates for G-CSF had to be further analyzed and sorted 
by the regimens that were subsided by G-CSF before summarizing the results. 
 
Also, the studies were excluded if they only provided the “haematological 
complication rate”. This is because the haematological complication treatment 
cost  had  already  been  calculated  in  ‘transfusion’,  and,  therefore,  it  would  be  
double counted if this cost was considered again here. 
 
In addition, pediatric studies were also excluded because the main study 
population in the current research consisted of adults, rendering pediatric 
information unsuitable for our purposes. However, studies were permitted / 
included if they included patients under 18 years old as part of their study 
population (but not only patients under 18 years old). 
 
Overall, 77 studies were found to be suitable for analysis. 116 studies were 
excluded because they failed to provide the details of complication rate or because 
all  the  study  arms  were  applied  with  more  than  one  treatment  or  regimen.  The  
details of the searching process are illustrated in Figure 6.3. 
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c. Data extraction 
 
The following data were extracted from each of the included studies: general 
information, participants, intervention, and complication rates. 
 
˙General information 
Title, authors, source (year / volume / pages / journal or conference), country, and 
study design (RCTs or not) information was collected. 
˙Participants 
Number of study population (‘initial sample size’ or ‘number of AML or APML 
patients’ if AML / APML is not the only study population), setting of target 
population /patients’ baseline characteristics (age and cancer treatment stage), and 
study period. 
˙Intervention 
The following information was included: treatment or regimen type (such as regimen 
AraC, transplantation, and similar) and the dosage used in the study arm. 
˙Complication:  
Details related with all the reported complications were collected. This included 
main domains of complications, the grade of complication, numbers or percentages 
of complications. 
 
Since the authors of the related literature presented/reported the rates in various formats, 
it  is  worth  to  note  that  two  rules  were  applied  in  order  to  extract  and  report  the  
complication rates systematically: 
 
˙Categorizing the reported complications into 11 domains 
According to the WHO Common Toxicity Criteria [188] and the National Cancer 
Institution (NCI) Common Terminology Criteria for Adverse Events v3.0 [189], the 
reported complications were divided into 11 domains: cardiovascular disorder, 
dermatological (skin) disorder, gastrointestinal disorder, hepatic disorder, Renal / 
genitourinary disorder, pulmonary disorder, neurological disorder, edema, local, pain, 
and infection. 
 
˙Grading the severity of each reported complication 
According to the WHO Common Toxicity Criteria [188] which grades complications 
into 5 levels (grade 0 to 4) and the National Cancer Institution (NCI) Common 
Terminology Criteria for Adverse Events v3.0 [189], each reported complication was 
further divided into three levels: unspecified, mild, severe. If the reported 
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complication was graded between 0 and 2 in the WHO Common Toxicity Criteria or 
graded between 1 and 3 in the NCI toxicity criteria, then the complication was 
classified as ‘mild’. If the reported complication was graded between 3 and 4 in the 
WHO  Common  Toxicity  Criteria  or  graded  between  4  and  5  in  the  NCI  toxicity  
criteria, then the complication was classified as ‘severe’ All the remaining situations 
(including the ones labeled as ‘not specified’) were classified as ‘unspecified’. 
 
˙Ensuring the reported result is consistently formatted 
To ensure that the formats of each of the reported results were consistent, the ‘exact 
number of patients’ was set as the only representation format for this review 
(although ‘numbers’ and ‘percentages’ are both common formats for complication 
reports). Therefore, all the percentages extracted from the reviewed studies were 
converted to numbers, according to their study sizes. 
 
After all the required information had been extracted from the respective studies, it was 
sorted by treatment type, regimen, domains of complications, and grades of 
complications. The systematic review result is shown on Appendix 6.3. 
 
d. Meta analysis 
 
After the systematic review had been performed, the results from multiple studies needed 
to be summarized into a single estimate in order to be used later for cost calculation. 
According to Glasziou P [110] and to the opinions of other leading figures in the 
meta-analysis field, the result synthesis for the complication rate was simply pooling the 
results altogether if the complication incidence rate was considered to arise from a single 
common population  (fixed  effect  model).  Therefore,  it  was  assumed that  all  the  study  
results found arose from a common group of population, and that the synthesis of 
complication rate was calculated as the total cases in the total population. The relevant 
summary is shown on Appendix 6.3, while an abstract of the summary table is shown 
below (Table 6.10). 
 
As it can be observed in Table 6.10, the complication incidence rates for regimen ADE 
(chemotherapy) were derived from 12 previous clinical studies. After data extraction and 
systematic report, a total of 18 different types of complications were found and reported. 
With the application of the meta-analysis method, all the complication rates were 
summarized into a single estimate. For example, nausea was found to be the adverse 
event  of  ADE from 4  study  arms  in  3  studies.  After  the  results  were  summarized,  the  
nausea incidence rate for ADE treatment was found to be 34.5%.
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Table 6.10 The abstract of the summarized literature review for complication rates 
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6.5.3 Unit cost of complication treatment 
 
In order to obtain the unit cost of the complication treatment and to be consistent with the 
cost estimation methods mentioned in previous sections, the national average cost (NHI 
Reference Cost Index [180]) was used. The 4-step procedure is discussed in detail in the 
following paragraphs. 
 
Step 1: Selecting relevant adverse events from Common Toxicity Criteria 
 
Although all the adverse events were listed in the WHO or NCI Common Toxicity 
Criteria tables, not all of them could be related to the AML / APML treatment. In 
the  current  study,  only  the  adverse  events  that  were  caused  by  AML/APML  
treatments were taken into consideration. Therefore, the adverse events listed in 
the Common Toxicity Criteria were re-selected by experts, with only the relevant 
adverse events being kept. 
 
Step 2: Translating all the selected adverse events into HRG 4 codes 
 
To obtain the unit cost, the HRG 4.0 code for each selected adverse event was 
needed. Since ICD-10 code is the linkage between disease and HRG 4.0, ‘matching 
ICD-10 to each selected adverse event’ was performed. After ICD-10 for each 
adverse event had been identified, the codes were further translated into HRG 4 
codes with the use of HRG 4 Chapter Listing [190]. The details are shown in 
Appendix 6.4. 
 
Step 3: Linking the national average cost to each adverse event 
 
After  the  HRG  4  code  for  each  adverse  event  were  identified,  the  final  step  for  
obtaining the unit cost was linking these HRG4 codes to the National average cost 
index (NHS Reference Cost Index 2006/07 [180]). However, before obtaining the 
unit cost estimation (by applying the NHS reference cost directly to each adverse 
event),  some  assumptions  and  adjustments  had  to  be  made.  The  relevant  details  
are discussed below. 
 
˙Using the ‘lower quartile’ data 
The ‘lower quartile cost’ (from ‘Reference Cost Index [180]’) was decided to 
be used as the unit cost, instead of the average cost. This was because the 
adverse events / complications were not the main reason that patients seek 
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Table 6.11 The abstract of the summary of the unit cost list for complication 
 
Adverse event ICD-10 HRG 4.0 
No of 
cases 
Lower 
quartile 
× 70% 
Oedema Oedema, not elsewhere classified R60 WA18Y 299 £403 £282 
Cerebral oedema G93.6 AA25Z 2684 £649 £454 
Gestational oedema O12.0 NZ04A 629 £336 £235 
  NZ07A 382 £500 £350 
Pulmonary oedema J81 DZ20Z 76 £815 £571 
Pulmonary oedema due to heart disease I50.1 EB03I 904 £916 £641 
    £634 £444 
care in hospitals. Therefore, it was assumed that the “lower quartile cost” was 
the cost that was closer to the actual complication treatment cost rather than 
the average cost. 
 
˙Cost adjustment 
As the complication treatment usually took place during the main 
AML/APML  treatment,  some  medical  resources/cost  drivers  (such  as  the  
ward cost and the overheads cost) were shared between these two 
simultaneous treatments. In order not to double count these costs, it was 
assumed that the shared cost was 30% of the complication treatment cost, and 
also this shared cost was already included in the AML / APML treatment cost 
discussed in previous sections. Therefore, the adjusted complication treatment 
cost was set to 70% of the associated lower quartile NHS Reference Cost. 
 
The unit cost list for each selected adverse event can be found in Appendix 6.4. 
 
Step 4: Grouping and merging the cost by adverse event domains 
 
As mentioned earlier, the unit cost for each adverse event was identified as 
described in previous 3 steps. However, the grouping complication treatment cost 
was still needed. This was because, in many included studies, the authors only 
reported the complication rate in the main domain (such as cardiovascular disorder 
and hepatic disorder) instead of reporting it in detail (such as vomit and nausea). 
 
For grouping or merging the cost, the ‘weighted cost’ was used instead of averaging 
the  adverse  event  costs  belonging  to  the  same  domain.  The  domain  cost  was  
weighted  by  the  ‘reported  numbers  of  cases’  of  each  adverse  event  in  the  ‘NHS 
Reference Cost Index [180]’. The results can be found in Appendix 6.4, and an 
abstract of the table is shown below (Table 6.11). 
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Taking ‘oedema’ as an example (please refer to Table 6.11 above), when the reported 
complication was ‘pulmonary oedema’, the unit cost of the complication was £641. 
However, when the reported complication was ‘oedema (unspecified)’, then the 
weighted estimation (£444) was used as its unit cost. 
 
 
6.5.4 Infection complication: Antibiotic days 
 
Except the treatments for non-infection complication, another important complication 
treatment was the antibiotic use for treating infections. Since it is a widely used but very 
costly treatment, the costing is discussed separately. In order to be consistent with the 
costing methods discussed in previous sections, the bottom-up method was used for 
costing the ‘antibiotic use’. The number of antibiotic days (quantity) is discussed in the 
current section, while the cost of antibiotic day (unit cost) is discussed in section 6.5.5. 
 
The ‘number of antibiotic days’ was derived from additional information from a subset 
of the HMRN database (please refer to chapter 3 for details). However, information was 
not available for all the treatments/interventions due to data source unavailability. To 
overcome  this  issue,  an  expert  survey  was  carried  out  as  a  supplement  for  the  
treatments/interventions that were found to have missing ‘number of antibiotic days’ 
information. Relevant details can be found in Appendix 6.7. 
 
 
6.5.5 Infection complication: Unit cost of antibiotic day 
 
To ensure consistency when calculating treatment cost, the bottom-up costing method 
was  also  used  for  estimating  the  unit  cost  of  antibiotic  day.  The  aforementioned  unit  
cost contained three different cost drivers, namely drug cost, personnel cost, and 
overheads cost. Ward cost was not included, as it is a cost shared with the AML/APML 
treatment (mentioned in 6.5.4) and, thus, it had been already calculated in the treatment 
cost (mentioned in 6.4). Details of the three cost drivers are described below. 
 
1. Drug cost 
 
According to expert survey, 2 drugs are commonly given for antibiotic treatment, namely 
gentamicin (i.v.) and Tazocin (i.v). Based on the BNF price list [178], the unit cost for the 
former is £8.45 and for the latter £60.68 per day. Therefore, the sum of these two drug 
costs was set as the drug cost for each antibiotic day (£69.13). It is worth noting that the 
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Figure 6.4 The illustration of the complication cost integration process 
estimate was close to the ‘Band 2 anti-fugal drug cost (£67)’ from the ‘Reference Cost 
Index[180]’. Therefore, it is safe to claimthat the estimate was reliable. 
 
2. Personnel cost and overheads cost 
 
According to expert survey, the ‘extra staff time’ for delivering these two drugs as 
antibiotic treatment was 10 minutes for one Band 2 nurse, 5 minutes for two Band 5 
nurses, 10 minutes for one Band 6 nurse, and 5 minutes for one pharmacist. Based on the 
‘PSSRU unit cost’[179], the calculated amount of the personnel cost for antibiotic 
treatment was found to be £10.85, while the overheads cost was found to be £1.86. 
 
Overall, the unit cost of antibiotic day was found to be £81.84 per day. 
 
 
6.5.6 Integration of the complication cost 
 
After the unit costs and the quantities for ‘non-infection complication’ and for ‘infection 
complication’ had been identified, the non-infection and infection complication 
treatment  costs  were  calculated  by  multiplying  the  quantity  (complication  rate  /  
antibiotic days) with the unit cost of complication. The total complication cost was the 
sum of these two types of complication costs. The integration process is illustrated in 
Figure 6.4, and the details are described in the following paragraphs. 
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Table 6.12 The complication cost list (based on expert survey) 
 
chemotherapy Clinical trial Transfusion 
Venesection 
Supportive care 
Immunosuppressive 
End-of-life care 
Follow-up 
ENT disorder £1.0 £1.0 - - 
Renal disorder £1.9 £1.9 - - 
Cardiac disorder £18.2 £18.2 - - 
Respiratory disorder £30.1 £30.1 - - 
Skin disorder - - - - 
Ophthalmological 
disorder 
£5.1 £5.1 - - 
Pain £32.4 £32.4 £32.4 - 
Digestion disorder £15 £15 - - 
Neurological disorder £6.8 £6.8 - - 
Rheumatic disorders £4.6 £4.6 - - 
 £115.1 £115.1 £32.4 £0 
1. Non-Infection complication cost (approach one: based on expert survey) 
 
According to the complication rate derived from the relevant expert survey (please refer 
to Table 6.9), the non-infection complication treatment costs were calculated by 
multiplying  the  rates  by  the  unit  cost  calculated  earlier  (please  refer  to  section  6.5.3).  
However, there were three types of complication that could not be matched to any adverse 
event on the unit costs list. Therefore, the ‘NHS Reference Cost Index’ [180] was used to 
represent the cost. These three complications and their unit costs (after adjustment) were: 
ENT disorder £103, Ophthalmological disorder £101, and Rheumatic disorders £183. 
The cost list is shown below (Table 6.12). 
 
As it can be observed (Table 6.12), the non-infection complication cost of 
chemotherapy and clinical trial was £115.1, while the non-infection complication cost of 
transfusion was £32.4, without considering the regimen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Non-Infection complication cost (approach two: based on literatures) 
 
In relation to the non-infection complication treatment costs (based on the literature 
review), the costs were also calculated by multiplying the summarized complication 
rates with the unit cost. However, only the ‘severe’ complication rates were taken into 
account and used in the cost calculation. This was because of two reasons. Firstly, most 
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Table 6.13 The abstract cost list for non-infection complication (based on literatures) 
 Incidence rate Unit Cost Cost Total cost 
ADE    £188 
  Severe fever 10% £273 £27  
  Severe pain 3% £324 £10  
  Severe Nausea / vomiting 34.5% £120 £41  
  Severe Diarrhea 11.3% £130 £15  
  Severe Stomatitis 7% £97 £7  
  Severe Cardiac disorder 1.3% £364 £5  
  Severe Hepatic disorder 10.1% £224 £23  
Neurologic disorder (Severe) 22% £272 £60  
  Severe Cerebellum disorder 0.7% £393   
 
patients recovered from the mild complications without any treatment. Therefore, there 
was no need to take the cost of mild complication treatment into account. Secondly, 
when  the  complication  rate  was  reported  in  an  abstract  way  with  no  sufficient  details  
(for instance 2% of patients had headache including mild and severe cases) it was 
impossible to distinguish the percentage of mild and severe complications. Therefore, 
only the “severe” complication rate was used for cost calculation. 
 
Furthermore, when both the domain cost and its detailed adverse event costs of the 
severe complication treatment were available, the detailed severe adverse event cost 
belonging to the domain was not counted. This was in order to prevent double counting. 
The result can be found on Appendix 6.6, while an abstract of the appendix is shown 
below (Table 6.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
As it can be observed (Table 6.13), only the severe complication cost was calculated. 
Also,  when  the  unspecified  complication  domain  details  were  available,  the  subset  
adverse event cost was not calculated. After simple multiplication and addition, the 
non-infection complication of regimen ADE (chemotherapy) was found to be £188. 
 
3. Infection complication cost (antibiotic use) 
 
In relation to the infection complication treatment, the cost was calculated by 
multiplying  the  ‘number  of  antibiotic  days’  with  the  ‘unit  cost  of  antibiotic  day’.  The  
calculated amount was £81.84’ (please refer to 6.5.5 for details). The infection 
complication treatment cost for each treatment/intervention can be seen in Appendix 
6.7. 
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Table 6.14 An abstract of the cost list of complication treatment 
 
 
Non-Infection 
Complication cost 
Infection complication cost 
(Antibiotics Cost) 
Total complication cost 
Type 1  
(derived from 
literatures) 
Type 2 
(derived from 
expert survey) 
Antibiotics 
days 
Day cost 
Antibiotics 
cost 
Type 1 Type 2 
ADE £188 £115.1 12 / course ×81.8 £981 £1169 £1096 
Course 1  £94 £57.6 14 ×81.8 £1145 £1239 £1203 
Course 2 £94 £57.6 7 ×81.8 £573 £667 £631 
ADE + Mylotarg £188 £115.1 12 / course ×81.8 £981 £1169 £1096 
Course 1 £94 £57.6 14 ×81.8 £1145 £1239 £1203 
Course 2 £94 £57.6 7 ×81.8 £573 £667 £631 
 
 
4. Integrated complication cost 
 
After the non-infection and the infection complication costs were obtained, the 
complication treatment cost was calculated by simple addition of the aforementioned two 
costs. The integrated complication costs for each treatment/intervention are listed in 
Appendix 6.7, and an abstract of them can be seen below (Table 6.14). 
 
It is worth to note that complication rates were not provided for some of the treatment, 
such as chemotherapy regimen Aspirin and supportive care. This was because no 
relevant information (complication rates) could be found in the examined AML/APML 
studies. Therefore, it was assumed that no severe complication occurred due to these 
treatments. The integrated complication cost and the integration details for each 
treatment/intervention are listed in Appendix 6.7.  An  abstract  of  the  Appendix 6.7 is 
shown below (Table 6.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As it can be seen in Table 6.14, two approaches were used in order to derive the 
non-infection complication cost. Based on expert opinions, the cost was further broken 
down evenly into courses/cycles. Also, according to expert suggestions, it was decided 
that the cost of regimens was the same with or without the inclusion of Mylotarg. 
Overall,  the  total  cost  was  the  sum  of  the  non-infection  complication  cost  and  the  
infection complication cost. As it can be observed in Table 6.14, the complication cost 
of  regimen  ADE  course  1  was  found  to  be  £1239  based  on  literature  review,  while  it  
was found to be £1203 based on expert survey. It is worth to note that the complication 
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costs between the two different approaches (of non-infection complication cost 
calculation)  were  not  significantly  different  (£36).  Therefore,  it  is  quite  safe  to  claim  
that the estimates derived by using the two aforementioned approaches were highly 
consistent. 
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6.6 Reference cost 
 
In relation to the 4 treatments that were impossible to be cost using the bottom-up 
method, the ‘Reference Cost [180]’ was used for cost representation the cost. Further 
details related to the above can be found in the following chapter. 
 
 
 
6.7 Summary 
 
The current chapter dealt with the calculation of cost drivers. More specifically, the 
related calculation methodologies, data sources, and results were presented and briefly 
discussed. The work presented here formed the basis for the next phase of the study, 
which involved treatment/intervention costing (chapter 7).  
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Chapter 7 Costing Method Phase 2 
 
 
Treatment/intervention cost estimation 
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Figure 7.1 The illustration of costing phase 2 
CHAPTER 7 COSTING METHOD PHASE 2 
 
 
According to the study design (section 5.3.2), the cost measurement was divided into 
three phases (illustrated below). The current chapter covers costing phase 2, which is 
related to treatment/intervention cost estimation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the study design (discussed in chapter 5), it was decided that 12 types of 
treatment/intervention costs would be calculated in costing phase 2. These treatment 
costs were chemotherapy, clinical trial, supportive care (erythropoietin, steroids, 
G-CSF, and transfusion), radiotherapy, transplantation, immunosuppressive therapy, 
splenectomy, venesection, palliative care, observation (follow-up), end-of life care, and 
laboratory test. Each of the treatment/intervention is discussed in detail in the following 
sections. In the current chapter, the emphasis on the role of the ‘number of uses’ (usage 
frequency) as a means to calculate the treatment/intervention costs ( by multiplying it 
with the obtained values of the five cost divers as discussed in chapter 5). 
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Figure 7.2 The regimen costing process 
7.1 Chemotherapy 
 
In  the  HMRN  database,  twenty  eight  different  chemotherapy  regimens  were  found  to  
have been used on AML/APML patients. According to expert opinions, these twenty 
eight regimens could be divided into the following four groups: intensive inpatient 
chemotherapy, mild inpatient chemotherapy, intensive outpatient chemotherapy and mild 
outpatient chemotherapy. 
 
•Intensive inpatient chemotherapy includes regimens such as ADE, AraC, 
Clofarabine, DA, FLA, FLAG, FLAG-Ida, HAM, MACE, and MidAC. 
•Mild inpatient chemotherapy includes regimens such as Amsacrine, Arsenic trioxide, 
and campath. 
•Intensive outpatient chemotherapy includes regimens such as Daunorubicin, 
Cyclophosphamid, ETI, FC, Fludarabine, Etoposide, Melphalan, Mylotarg, 
Vincristine, ATRA, Anagrelide, and Clopidogrel. 
•Mild outpatient chemotherapy includes regimens such as Aspirin, 
Hydroxycarbamide and Chelating agent. 
 
The cost calculation methods used in each of the above groups varied. Details about the 
five cost drivers used for costing the chemotherapy can be found in the following 
sections.  
 
7.1.1 Drug/Regimen cost 
 
As there a large number of chemotherapy regimens was involved, it was decided the 
process of costing each regimen to be described separately in 3. 
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These three distinctive parts were: itemizing each regimen, costing drug items for each 
regimen, and costing each regimen. The costing process is illustrated above (Figure 7.2). 
 
a. Assumptions 
 
For the required calculation, a number of assumptions had to be made.  
˙The average patient body surface area required for the calculation of the dose and 
the actual cost was assumed to be 1.8m2 (based on 70 kg of body weight). This 
was  because  no  relevant  information  about  the  patient  body  weight  or  body  
surface was available in the HMRN database. Therefore, the assumption was 
made based on the experts’ suggestions. 
˙It was assumed that the regimen used for chemotherapy followed the clinical trial 
protocol. If the chemotherapy was not possible to be related to any clinical trial, 
then  the  regimen  usage  was  assumed  to  follow  the  BNF  suggestions  or  expert  
opinions. 
˙It was assumed that the full doses were given when the treatment time reached or 
exceeded the standard treatment time by the guideline/protocol. 
˙It was assumed that regimen Mini-MidAC used the same kind of drugs and the same 
amount of dosage as MidAC 
 
b. Itemizing the regimen 
 
According to the relevant information sources, the regimens of chemotherapy were 
divided into two categories in order to itemize the drugs used in each regimen. The 
categorization criteria were whether the regimen can be connected to the AML 15 trial 
protocol [184] / guideline [191] or not.  
When the regimen could be connected to the clinical trial, the AML 15 trial protocol / 
guideline was used for itemizing the drugs that were used in each regimen. This included 
the dosage and the length of usage of the drugs. The regimens that fell into this category 
were  ADE,  AraC,  DA,  FLAG,  MACE,  MidAC  and  similar.  In  our  context,  taking  
regimen ADE as an example (and according to the AML 15 trial protocol suggestions), 
the chemotherapy regimen ADE was decided to contain the  following drugs: 100mg/m2 
Cytarabine twice per day from day 1 to 10, 50mg/m2 Daunorubicin once per day on day 1, 
3, 5, 100mg/m2 Etoposide once per day from day 1 to 5, and some subside drugs, like 
300g Allopurinol, 8mg Dexamethasone 5 doses, 1mg Granisetron 5 doses, and 10mg 
Metoclopramide). 
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When the regimen could not be connected to the clinical trial, the BNF [178] as well as 
relevant published studies, and expert opinions were used for itemizing the drugs and 
dosages of each regimen. The regimens that fell into this category included HAM, 
Amsacrine, Clofarabine, Anagrelide, Chelating agent and similar. Taking regimen HAM 
as an example (and according to Buchner’s study [192], Schlenk’s study [193] and expert 
agreements), regimen HAM was assumed to contain the following drugs for our purposes: 
3g/m2 Cytarabine once per day for three days and 10mg/m2 Mitoxantrone once per day 
for 2 days for the current study. The same situation also applied to ‘amsacrine’ [183, 194]. 
 
c. Costing each drug item 
 
After the drug items of each regimen had been identified and confirmed by experts, the 
relevant BNF price (official market price) was applied to each drug item.  
 
Here, it is worth pointing out the costing method followed for regimen ‘Mylotarg’. 
Mylotarg is a common supplementary regimen in AML / APML chemotherapy treatment 
in the UK. Although it is particularly expensive, its efficiency cannot be easily argued. 
However, the UK price for Mylotarg was not obtainable because it was still under trial 
and, thus, it was paid from the pharmaceutical company while the current study was 
carried out. Therefore, for our purposes, Mylotarg cost was considered to be the shadow 
cost (term used when a resource has been subsidized or an input is paid partly from some 
other national source of funds or organization). Because Mylotarg is a significant cost that 
would inevitably affect the final total cost, it was decided that for our purposes the 
Mylotarg cost had to be counted in order to avoid the regimen cost appearing significantly 
lower than its actual value.  
 
To obtain the cost information for Mylotarg, worldwide prices were checked. However, 
this was not easy because this particular drug was still under trial in many countries and, 
thus, the prices were not available. For example, according to the official document, all 
the EU countries still refused Mylotarg’s marketing authorization application [195] while 
the current work was carried out. Also, even in countries that allowed Mylotarg to be up 
for sale, in most occasions only relevant local health professionals could access the 
official website and obtain the price. With the kind assistance of various individuals, the 
Mylotarg international price and source list was obtained (shown on Appendix 7.1).  In 
the  frame  of  the  current  work,  Mylotarg  international  average  price  was  set  as  the  
Mylotarg unit cost (£1619). 
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Table 7.1 The summarized list of the regimen cost and sources 
  Dose reference Cost reference 
Intensive Inpatient Treatment    
ADE 10+3+5 £1159 AML 15 trial protocol BNF 
ADE + Mylotarg £2780 AML 15 trial protocol BNF 
AraC (HD) £1700 AML 15 trial protocol BNF 
AraC (LD) £92 AML 15 trial protocol BNF 
Clofarabine £17071 AML 16 trial protocol BNF 
DA 10+3 £1016 AML 15 trial protocol BNF 
DA + Mylotarg £2637 AML 15 trial protocol BNF 
FLA £1979 AML 15 trial protocol BNF 
FLAG £2558 AML 15 trial protocol BNF 
FLAG-Ida £3790 AML 15 trial protocol BNF 
FLAG-Ida + Mylotarg £5411 AML 15 trial protocol BNF 
HAM £2831 Buchner T and Schlenk RF BNF 
MACE £1181 AML 15 trial protocol BNF 
MidAC £1204 AML 15 trial protocol BNF 
Mini MidAC £1204 As full dose of MidAC BNF 
Mild Inpatient Treatment    
Amsacrine £156/day BNF & Robert A BNF 
Arsenic trioxide £470/day Guideline BNF 
Campath £991/week BNF BNF 
Intensive Outpatient Treatment    
Cyclophosphamid £70/week Guideline: FC (remove F) BNF 
Cyclophosphamid/MESNA £132 Guideline: Cyclo (HD) BNF 
Daunorubicin £316/day Guideline BNF 
Mylotarg £1619 AML 15 trial protocol Appendix 7.1 
ETI £41/day Guideline BNF 
FC £157/day Guideline: F & C BNF 
Fludarabine £153/day Guideline  BNF 
Etoposide £13/day BNF & expert opinion BNF 
Melphalan £5/day Guideline BNF 
Vincristine £25/week BNF & Expert opinion BNF 
ATRA £16/day Guideline BNF 
Anagrelide £14/day BNF & expert opinion BNF 
Clopidogrel £1/day BNF & expert opinion BNF 
Mild Outpatient Treatment    
Aspirin £0.1/day BNF & expert opinion BNF 
Hydroxycarbamide £0.7/day AML 15 trial protocol BNF 
Hydroxycarbamide + Aspirin £0.8/day AML 15 trial protocol BNF 
Chelating agent £31/week BNF & expert opinion BNF 
 
The detailed drug item costs for each chemotherapy regimen are listed in Appendix 7.2, 
while the summarized list of the chemotherapy regimen cost and source is shown below 
(Table 7.1). 
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d. Costing each regimen 
 
After the regimen cost per cycle were obtained, the regimen costs were calculated by 
multiplying the unit cost with the ’treatment time’ (number of uses).  
For inpatient chemotherapies, the unit cost list of each regimen was further broken down 
into daily cost before multiplication in order to cost the incomplete chemotherapy. 
Incomplete chemotherapy was defined as the one that had a ‘treatment time’ shorter than 
standard treatment time suggested by the AML 15 trail protocol. This was because in this 
case the full dose of chemotherapy was not delivered. It is also worth mentioning here 
that incomplete chemotherapy was associated with factors related to patient tolerence, 
treatment complications, and similar. The cost details for regimen that were broken down 
by day can be found in Appendix 7.3. After the breakdown cost lists were built up, the 
inpatient chemotherapies were simply obtained by matching the ‘treatment time’ to the 
comparative breakdown cost lists. The matching process is illustrated in Figure 7.3. 
 
 
 
 
 
 
 
 
 
For outpatient chemotherapies, the regimen cost was calculated simply by multiplying 
the unit cost with the ‘treatment time’ (number of uses), as the regimens were given either 
daily or regularly with no difference between the ones that were complete and those were 
not. 
 
Figure 7.3 The illustration of the cost matching process for chemotherapy 
7.1 Chemotherapy 
- 182 - 
 
 
Figure 7.4 The illustration of costing process for personnel cost 
7.1.2 Personnel cost 
 
To estimate the personnel cost for each chemotherapy regimen, the costing method was 
divided into two parts according to the types of the treatment delivery, namely for 
inpatient or for outpatient chemotherapy. 
 
For inpatient chemotherapies, the personnel costs were calculated by multiplying the unit 
cost with the number of uses. The personnel cost per day for each regimen is discussed in 
earlier chapter (please refer to section 6.2 for descriptions and to Appendix 6.2 for details). 
Regarding the number of uses, the ‘treatment time’ was used in order to obtain robust cost 
estimations.  
 
For outpatient chemotherapies, the personnel costs were also calculated by multiplying 
the  unit  cost  with  the  number  of  uses.  The  personnel  cost  per  day  for  each  regimen is  
discussed in earlier chapters (please refer to section 6.2 for descriptions and to Appendix 
6.2 for details). However, instead of the ‘treatment time’, the ‘number of outpatient visits’ 
was set as ‘number of uses’. This is because the outpatient regimens did not need to be 
delivered by clinical staff on daily basis. Therefore, the personnel cost only occurred 
when the  patient  re-visited  hospital.  To  calculate  the  ‘number  of  outpatient  visits’,  the  
following assumption was made: outpatients returned to hospital to get the medicine, 
consultation and have simple treatments once per month, as no detailed information could 
be obtained from the HMRN database. On this ground, the ‘number of uses’ (number of 
outpatient visits) was calculated by dividing the ‘treatment time’ by 28 days (equivalent 
to 1 month / 4 weeks).  
The costing process for personnel cost calculation is illustrated in Figure 7.4. 
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Figure 7.5 The illustration of costing process for overhead cost 
7.1.3 Overheads cost 
 
Based on the study design (refer to chapter 5) and on data availability, the overheads and 
capital overheads costs were calculated by allocating the national average overheads cost 
to staff working time, as it was impossible to itemize the overhead costs and reallocate 
them (please refer to section 6.3 for details). On this ground, the overheads and capital 
overheads costs only occurred when clinical staff delivered the treatments, similar to the 
personnel cost. For inpatient chemotherapies, the overheads costs occurred during the 
‘treatment time’. For outpatient chemotherapies, the overheads cost occurred when the 
outpatient visit took place.  
 
Therefore, the overheads cost was calculated by ‘unit cost’ and ‘number of uses’ 
(‘treatment time’ or ‘number of visits’ depending on whether the chemotherapy was 
inpatient-based or not). The overheads cost per day for each regimen was obtained by 
multiplying the staff working time (from the staff survey) with the staff unit cost of the 
overheads (from ‘PSSRU Unit Cost’ [179]). For more details please refer to section 6.2, 
section 6.3, and in Appendix 6.2. The details regarding the ‘number of uses’ (‘treatment 
time’ and ‘number of visits’) can be found in the previous section (section 7.1.2). The 
costing process for overheads cost is illustrated below (Figure 7.5). 
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7.1.4 Ward and outpatient clinic cost 
 
According  to  the  study  design  (chapter  5),  ward  cost  and  outpatient  clinic  costs  were  
considered to be the costs that occurred in inpatient ward / outpatient clinic for care 
service and for other related supportive services. In this context, the inpatient ward and 
outpatient clinic costs were calculated by multiplying the ‘unit cost’ with the ‘number of 
uses’.  
 
The ward cost per day and the outpatient clinic cost per visit for each regimen have been 
obtained at earlier stages (details can be found in section 6.4). Regarding the ‘number of 
uses’, the calculation method was similar to the method used earlier (section 7.1.2 and 
7.1.3). The ‘number of outpatient visits’ was set as the ‘number of uses’. However, the 
‘number of uses’ was calculated differently for the inpatient chemotherapies. Instead of 
‘treatment time’, the ‘hospital stay’ was set as the ‘number of uses’ in order to reflect the 
actual resource consumption, 
 
7.1.5 Complication cost 
 
The ‘complication costs’ of each chemotherapy regimen were obtained at earlier stages 
(details can be found in section 6.5). It is worth to note that, the ‘non-infection 
complication cost’ based on literature review was used for treatment/intervention cost 
calculation. This was because, the complication cost list based on literature review 
provided more detailed information for each chemotherapy regimen (although both cost 
results were consistent with each other) comparing to the one based on the expert survey. 
Therefore, it was expected that, by employing this approach, the subtle complication cost 
differences between chemotherapy regimens could be captured at the later stage of the 
current work. 
 
Also, in order to calculate the complication costs for each chemotherapy cycle, the 
complication cost needed to be further broken down into cycles. Regarding the ‘infection 
complication cost’, the detailed cost information for each cycle was available from the 
subset of the HMRN database (please refer to Appendix 6.3 for details). However, this 
was not the case for ‘non-infection complication cost’, for which it was assumed that the 
non-infection complication cost shares of each chemotherapy cycle were the same. 
Therefore, the non-infection complication cost of each cycle was obtained by dividing the 
total non-infection complication cost evenly. For example, as demonstrated in Appendix 
6.3, the non-infection complication cost of regimen ADE was £188. Therefore, the 
non-infection  complication  cost  of  each  cycle  was  calculated  as  £94,  as  the  complete  
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Figure 7.6 The illustration of costing process for complication cost 
chemotherapy of regimen ADE contained two cycles (£188/2=£94). The costing process 
is illustrated below (Figure 7.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.1.6 Summary 
Considering the 5 cost drivers mentioned above, chemotherapy cost was considered to be 
the lump sum of drug/regimen cost (section 7.1.1), personnel cost (section 7.1.2), 
overheads/capital overheads cost (section 7.1.3), ward/clinic cost (section 7.1.4), and 
complication treatment cost (section 7.1.5). The summary of chemotherapy cost for each 
regimen is shown on Appendix 7.4, while an example is shown on Table 7.2. 
 
 
 
Table 7.2 Example of the summary of chemotherapy cost 
 
 
Treatment cost 
Drug cost Personnel cost Overheads cost Ward/clinic cost Complication 
(incl. antibiotic 
cost) 
Per Day Quantity Per Day Quantity Per 
Day 
Quantity Per 
Day 
Quantity 
ADE           
    10+3+5 £1158.46 (full 
course) 
£135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
    8+3+5 £1121.90 (full 
course) 
£135.6 × treatment time £20.5 × treatment time £67 × hospital stay £667 
ADE + Mylotarg         
Course 1 £2779.87 (full 
course) 
£135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
Course 2 £1121.90 (full 
course) 
£135.6 × treatment time £20.5 × treatment time £67 × hospital stay £667 
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7.2 Clinical trial 
 
 
In the HMRN database, ten different clinical trial arms were found to have been used on 
AML/APML patients. The details about the five cost drivers and their number of uses 
that were used for calculating the clinical trial cost are described in the following 
sections. It is worth to note that the costing methods used for calculating the clinical 
trial cost was very similar to the method used for costing the intensive inpatient 
chemotherapies. This was because the costing methods for calculating the costs of 
intensive inpatient chemotherapies were all based on the ‘AML 15 trial protocol [184]’ 
and ‘AML 14 trial protocol [196].  
 
7.2.1 Drug/Regimen cost 
 
Following the costing method and the assumptions made for intensive inpatient 
chemotherapy (discussed in section 7.1), the regimen cost of clinical trial was 
calculated by multiplying the ‘unit costs of clnical trial regimens’ with their ‘number of 
uses’. The ‘unit costs of clinical trial regimens’ were derived from the following 
sources: the ‘AML 15 trial protocol [184]’ , the ‘AML 14 trail protocol [196]’ and the 
‘BNF price list [178]’ (please refer to section 7.1.1 and section 6.1 for details). In 
relation to the ‘number of uses’, the calculation method was divided into two parts 
according to the completness of the treatment (please refer to section 7.1.1 for details 
and reasons): 
 
˙Treatment  completed:  When  the  ‘treatment  time’  derived  from  the  HMRN  
database was longer than the ‘standard treatment time’ derived from the AML 
15 trial protocol, the ‘standard treatment time’ was set as ‘number of uses’.  
˙Treatment incompleted: When the ‘treatment time’ was shorter than the 
‘standard treatment time’, the ‘treatment time’ was set as ‘number of uses’.  
 
The detailed unit costs, usage frequencies and total regimen cost for each clinical trial 
regimen are shown on Appendix 7.2. 
 
 
7.2.2 Personnel cost 
 
Following the costing method and the assumptions made for intensive inpatient 
chemotherapy (discussed in section 7.1), the personnel cost was calculated by 
multiplying the ‘personnel cost per day’ with the ‘number of uses’. The ‘personnel cost 
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per day’ was derived from the calculation based on the ‘PSSRU Unit cost’ and the ‘staff 
working time’ (derived from the staff survey). For more details regarding this please 
refer to section 6.2. In relation to the ‘number of uses’, the ‘treatment time’ or the 
‘standard treatment time’ (derived from protocols [184, 196]) was set as ‘number of 
uses’ depending on the completeness of the clinical trial (please refer to section 7.1.2 
for details and reasons): 
 
˙Treatment  completed:  the  ‘standard  treatment  time’  was  used  as  ‘number  of  
uses’.  
˙Treatment incompleted: the ‘treatment time’ was used as ‘number of uses’.  
 
The detailed unit costs, usage frequencies and total regimen cost for each clinical trial 
regimen are shown on Appendix 7.4 
 
 
7.2.3 Overheads cost 
 
Following the methodology discussed in the chemotherapy section (section 7.1.3), the 
overheads and capital overheads costs were caulculated by multiplying the ‘overheads 
cost per day’ with the ‘number of uses’. The ‘overheads cost per day’ is discussed in 
section 6.3. In relation to ‘number of uses’, it was identical with ‘number of uses’ that 
was used for the personnel cost calculation, as the amount of the overheads cost was 
related to the ‘staff working time’ (relevant calculation details can be found in sections 
7.1.3 and 7.2.1). The ‘overheads cost per day’ and the ‘number of uses’ for each clinical 
trial arm can be found in Appendix 7.4. 
 
 
7.2.4 Ward cost 
 
Following the costing method and the assumptions made for intensive inpatient 
chemotherapy (discussed in section 7.1.4), the ward cost was calculated by multiplying 
the  ‘ward  cost  per  day’  with  the  ‘number  of  uses’.  According  to  the  calculations  in  
section 6.4.2, the ‘ward cost per day’ was found to be £67 per day. Also, in order to 
reflect the actual resource consumption, the ‘hospital stay’ was set as ‘number of uses’, 
instead of ‘treatment time’. The ‘ward cost per day’ and the ‘number of uses’ for each 
clinical trial arm can be found in Appendix 7.4. 
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7.2.5 Complication cost 
 
The ‘complication costs’ of each chemotherapy regimen were obtained earlier (for 
related details please refer to section 6.5). The method that was followed for breaking 
down the complication cost into cycles was in line with the one used for chemotherapy 
(please refer to section 7.1.5). The cost details for each clinical trial arm can be found in 
Appendix 7.4. 
 
7.2.6 Summary 
 
According to the 5 cost drivers discussed earlier, clinical trail cost was considered to be 
the lump sum of drug/regimen cost (section 7.2.1), personnel cost (section 7.2.2), 
overheads/capital overheads cost (section 7.2.3), ward cost (section 7.2.4), and 
complication treatment cost (section 7.2.5). The summary of clinical trial cost for each 
regimen is shown in Appendix 7.4, while an example is shown on Table 7.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.3 Example of the summary of clinical trial cost 
 
 
Treatment cost 
Drug cost Personnel cost Overheads cost Ward/clinic cost Complication 
(incl. antibiotic 
cost) 
Per Day Quantity Per Day Quantity Per 
Day 
Quantity Per 
Day 
Quantity 
AML 15 ADE          
    10+3+5 £1158.46 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
    8+3+5 £1121.90 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £667 
AML 15 ADE + 
Mylotarg 
        
Course 1 £2779.87 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
Course 2 £1121.90 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £667 
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7.3 Supportive care - Transfusion 
 
 
Supportive care/therapy can be defined as a therapy that is given in addition to the 
primary therapy [197], or as a part of the main treatment [198]. Based on three sources 
(experts’ opinions, information from Macmillan Cancer Support [198], and the treatments 
used on AML/APML), supportive therapy was definded as a therapy that contained five 
different  sub-type  treatments  for  AML/APML.  These  five  treatments  were  transfusion  
(including blood and platelet transfusion), erythropoietin, haematopoietic grown factors 
(G-CSF), and steroids, the first of which (transfusion) is discussed in the current chapter. 
 
7.3.1 Introduction 
 
Transfusions in AML/APML treatment can be grouped into two types depending on the 
blood products transfused, namely whole blood and platelet transfusions. The whole 
blood transfusion mainly is  given for correcting anaemia and other similar side effects 
(haematological complications) caused by AML/APML treatments (such as 
chemotherapy), while the platelet transfusion mainly is given for haemorrhage and other 
similar side effects (haematological complications) again caused by AML/APML 
treatments. Therefore, costing the transfusion can be seen as costing the haematological 
complication, which was excluded from the complication cost (please refer to section 6.5 
for more details). The details about the five cost drivers and their usage frequencies used 
for calculating the transfusion cost are described below. 
 
7.3.2 Blood product cost 
 
Based on the relevant study design (discussed in chapter 5), the transfusion was 
calculated by multiplying the ‘blood product unit cost’ with the ‘number of transfusions’. 
The calculation details are described as follows. 
 
a. Blood product unit cost 
 
The transfusion unit cost was calculated by multiplying the‘unit cost’ with the ‘quantity’. 
The unit costs of the blood products were derived from the ‘National blood and blood 
components price list’ from the National Blood Service [181] (please refer to section 6.1 
for details). Based on the analysis result of the ‘Palliative Care Database’, the ‘quantity’ 
that was given for each transfusion was found to be two blood units and one platelet unit 
in round numbers (please refer to chapter 4 for details). Therefore, the unit cost of each 
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Figure 7.7 The illustration of blood product costing process for transfusion 
transfusion was the lump sum of each blood product cost, which in turn was found to be 
£512 in total for each transfusion. 
 
b. Transfusion frequency 
 
The actual ‘number of transfusions’ or actual ‘transfusion frequency’ was not obtainable, 
as  the  transfusion  date  was  not  routinely  recorded  by  the  research  nurses.  In  order  to  
overcome this issue, an extrapolated ‘transfusion frequency’ was needed. For our 
purposes, the detailed treatment records of 20 patients from ‘Palliative Care Database’ 
were used for extrapolating the ‘transfusion frequency’. The details of the extrapolation 
can be found in chapter 4. Based on the results of the extrapolation, it was observed that 
patients received transfusion once every four days when the disease time was less than 
two months, or once every 14 days when the disease time was longer than 2 months. 
 
After the extrapolated ‘transfusion frequency’ was obtained, the extrapolated ‘number of 
transfusions’ was calculated by dividing the ‘treatment time’ (derived from HMRN 
database) by the extrapolated ‘transfusion frequency’.  
 
c. Summary 
 
Overall, the blood product cost of transfusion was calculated based on the blood product 
unit cost and the extrapolated ‘number of transfusions’. The calculation process is 
illustrated below (Figure 7.7), while the detailed unit costs, frequencies and total blood 
product cost for transfusion are shown on Appendix 7.4. 
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7.3.3 Personnel cost 
 
Following the same definitions and assumptions made for the personnel cost for the 
chemotherapy treatment (discussed in section 7.1), the personnel cost was also 
specifically  defined  as  the  cost  of  the  ‘staff  working  time’  for  the  staff  who  involved  
directly  and  exclusively  in  the  ‘treatment  activities’.  To  be  consistent  with  the  costing  
method in pervious sections (sections 7.1.2 and 7.2.2), the personnel cost for transfusion 
event was calculated based on the ‘personnel cost for the transfusion’ and the ‘number of 
transfusions’.  The  ‘personnel  cost  for  each  transfusion’  was  derived  from  the  ‘staff  
working time survey’ (please refer to section 6.3). The ‘number of transfusions’ was 
derived from the extrapolated ‘transfusion frequency’. The calculation process can be 
found in section 7.3.2. Overall, the detailed unit costs (£42 per transfusion), number of 
transfusions and the total personnel cost for transfusion can be found in Appendix 7.4. 
 
7.3.4 Overheads cost 
 
To estimate the overheads cost with the bottom-up costing method, the ‘overheads cost 
per transfusion’ and the ‘number of transfusions’ were needed. The ‘overheads cost per 
transfusion’ was obtained earlier and is discussed in section 6.3. For the ‘number of 
transfusions’, the extrapolated ‘number of transfusions’ was used in order to be consistent 
with the method used for blood products and personnel costs estimation (sections 7.3.2 
and 7.3.3). In summary, overheads cost was estimated by the unit cost (£6 per transfusion) 
and the ‘number of transfusions’ (per transfusion event). The summarized details can be 
found in Appendix 7.4. 
 
7.3.5 Ward cost 
 
To be in line with the costing method used in previous sections (sections 7.1.4 and 7.2.4), 
the ward cost of transfusion event was also based on the ‘unit cost’ and the ‘number of 
transfusions’. Based on the analysis result of the ‘Palliative Care Database’, it was 
observed that most of the transfusions took place in inpatient setting and lasted for one 
day only (please refer to chapter 4). Therefore, according to the inpatient ward cost 
(discussed in section 6.4.2), the ward cost for each transfusion was found to be £67. With 
the assistance of the extrapolated ‘number of transfusions’ (discussed in section 7.3.1), 
the ward cost for transfusion event was obtained. The summarized details are shown in 
Appendix 7.4. 
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Figure 7.8 The illustration of transfusion costing process 
7.3.6 Complication cost 
 
Since the transfusion mainly was given for treating the haematological complications 
caused by the AML/APML treatments, it was not possible to calculate the costs of 
treating further complications caused by the transfusion due to time and human resources 
constraints. Therefore, the complication cost of transfusion was decided not to be 
included in the transfusion cost.  
 
7.3.7 Summary 
 
According to the five cost drivers discussed above, transfusion cost was considered to be 
the lump sum of the blood product cost (section 7.3.2), the personnel cost (section 7.3.3), 
the overheads and capital overheads cost (section 7.3.4), and the ward cost (section 7.3.5). 
The total cost of each transfusion event was found to be £628. The summarized costing 
details for the transfusion event can be found in Appendix 7.4, while the costing process 
is illustrated below (Figure 7.8).   
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7.4 Supportive care - Erythropoietin 
 
Erythropoietin  (or  EPO)  is  a  red  blood  cell  growth  factor  for  cancer  treatment.  It  
encourages the bone marrow to make more red blood cells. Therefore, it can help patients 
confront tiredness, beathlessness, dizziness, headaches and other side effects associated 
with cancer treatment-induced anemia [198, 199]. According to National Institute for 
Health and Clinical Excellence (NICE) recommendations, only people who could not 
have blood transfusions should have Erythropoietin, as an injection under the skin 
(subcutaneous injection) [199]. On the ground of the above information, the details of the 
cost estimation method and the information sources are discussed as follows. 
 
7.4.1 Drug cost 
 
The drug cost of erythropoietin was estimated based on the ‘drug cost for each 
erythropoietin’ and the ‘number of uses’.  
 
a. Drug cost for each erythropoietin injection 
 
Based on information from the HMRN database, it was found that the ‘Aranesp’ was the 
only erythropoietin drug used on AML/APML patients in the HMRN network. Based on 
expert opinions and BNF suggestions [178], the dosage of the ‘Aranesp’ was decided to 
be 300mg/ml injections once a week (assuming that the average body weight was 70Kg). 
On this ground, the drug cost of 300mg/ml ‘Aranesp’ for each erythropoietin treatment 
was found to be £467.55 (based on the BNF price list [178]). 
 
b. Number of uses 
 
The ‘number of the erythropoietin injections’ was used in order to calculate the drug cost 
of the erythropoietin. Based on the information discussed above (that the erythropoietin 
was  decided  to  be  given  once  a  week),  the  ‘number  of  erythropoietin  injections’  was  
calculated by divinding the ‘treatment time’ by the ‘usage frequency’ (once a week). 
 
The summarized details can be found in Appendix 7.4. 
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7.4.2 Personnel cost 
 
In accordance to the definitions and assumptions related with the personnel cost in 
chemotherapy treatment (section 7.1.2), the ‘personnel cost for each eyrthropoietin’ and 
the ‘number of uses’ were used for estimating the personnel costs of the erythropoietin 
treatment. Based on the results of the staff working time survey and the staff unit cost list 
from the ‘PSSRU Unit Cost’ [179], the ‘personnel cost for each erythropoietin’ was found 
to be £45.3 (please refer to section 6.2 for further details). Also, in line with the ‘number 
of uses’ used in drug cost calculation mentioned earlier (section 7.4.1), the ‘number of the 
erythropoietin injections’ was used for personnel cost calculation. The summarized 
details can be found in Appendix 7.4. 
 
7.4.3 Overheads cost 
 
Based on the results of the staff working time survey and on the unit cost of the overheads 
from the ‘PSSRU Unit Cost’ [179], the ‘overheads cost for each erythropoietin treatment’ 
was found to be £9.95. With the assistance of the ‘number of erythropoietin injections’, 
the overheads cost for erythropoietin was calculated by multiplying the ‘overheads cost 
for each erythropoietin treatment’ with the ‘number of erythropoietin injections’. The 
details can be found in Appendix 7.4. 
 
7.4.4 Outpatient clinic cost 
 
According to the BNF suggestions and expert opinions, the erythropoietin treatment 
usually takes place in outpatient clinics. Therefore, the outpatient clinic cost was needed 
to be calculated. To cost the outpatient clinic cost for erythropoietin, the ‘outpatient clinic 
cost for each erythropoietin’ and the ‘number of erythropoietin injections’ were used. The 
former was found to be £19 (please refer to section 6.4 for details), and the latter was in 
line with the ‘number of erythropoietin injections’ used in previous sections (sections 
7.4.1, 7.4.2, and 7.4.3). The details can be found in Appendix 7.4. 
 
7.4.5 Complication cost 
 
The erythropoietin was given mainly for treating the anaemia caused by the AML/APML 
treatments or the disease itself. In the current study it was not possible to calculate the 
costs of treating further complication caused by erythropoietin due to time and human 
resources constraints. Therefore, the complication cost of erythropoietin was decided not 
to be included in the erythropoietin cost.  
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7.4.6 Summary 
 
According  to  the  five  cost  drivers  discussed  above,  erythropoietin  treatment  cost  was  
considered to be the lump sum of the drug cost (section 7.4.1), the personnel cost (section 
7.4.2), the overheads and capital overheads cost (section 7.4.3), and the outpatient clinic 
cost (section 7.4.4). The total cost of each injection was found to be £542 in round 
numbers, and the summarized costing details for erythropoietin event can be found in 
Appendix 7.4. The costing process is illustrated in Figure 7.9. 
 
 
 
 
 
 
Figure 7.9 The illustration of erythropoietin costing process 
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7.5 Supportive care - Steroids 
 
It is widely accepted that steroids is one of the most widely used drugs in cancer 
treatment. Steroids can be used as part of the cancer treatment to help destroy cancer 
cells. Apart from treating cancer, it can be also used as a suppletment treatment in 
chemotherapy for reducing sickness and allergic reaction caused by the latter. 
Additionally, it helps in reducing inflammation and response of immunity after a 
transplantation, while it also increases appetite [198, 200]. Based on information from 
the HMRN database, the common types of steroids that were used as a single agent on 
AML/APML patients were the following three: Dexamethasone, Prednisolone, and 
Hydrocortisone. The details of the cost estimation for each of these drugs are described 
below. 
 
7.5.1 Drug cost 
 
According to BNF suggestions and expert opinions, the dosage of Dexamethasone was 
set to 40mg twice per day, while the dosage of Prednisolone to 20mg once per day, and 
the dosage of Hydrocortisone to 20mg per day. Based on the BNF price list, the cost of 
a 40mg Dexamethasone tablet was £0.29, the cost of a 20mg Prednisolone tablet was 
£0.14, and the cost of a 20mg Hydrocortisone tablet was £1.4. Since the steroids are 
normally given for continuous periods of time, it was decided that the ‘treatment time’ 
was used as ‘number of uses’. The summarized costing details are listed in Appendix 
7.4. 
 
7.5.2 Personnel cost 
 
When estimating the personnel cost for steroids, the ‘number of uses’ was a key factor. 
The steroids were considered to be the outpatient-based treatment, as they can be 
administered by patients at home (something that indicated that it is a treatment that 
required patients to go to hospitals to get medicines on a regular basis). Based on expert 
opinions, it was assumed that the outpatient visit frequency was once per month. 
Therefore, the ‘number of uses’ for personnel cost calculation was possible to be 
calculated by dividing the ‘treatment time’ by the outpatient visit frequency. After the 
‘number of uses’ was obtained, the personnel cost was calculated with the assistance of 
the ‘personnel cost for each outpatient visit for steroids treatment’ (£26.6, please refer 
to section 6.2 for details). The summarized costing details can be found in Appendix 
7.4. 
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7.5.3 Overheads cost 
 
The ‘overheads cost  for each outpatient visit  for steroids treatment’ was found to be 
£6.05 (refer to section 6.3). The overheads cost was calculated by multiplying the 
‘number of uses’ (also used for personnel cost calculation for steroids treatment 
discussed in section 7.5.2) with the ‘overheads cost for each outpatient visit for steroids 
treatment’. The summarized costing details are presented in Appendix 7.4. 
 
7.5.4 Outpatient clinic cost 
 
Similarly to the costing method mentioned above (sections 7.5.2 and 7.5.3), the 
outpatient clinic cost was estimated based on the ‘number of uses’ and the ‘clinic cost 
for each outpatient visit’ (£19, please refer to section 6.4 for details). The summarized 
costing details can be found in Appendix 7.4. 
 
7.5.5 Complication cost 
 
The steriods were mainly given for treating the side effects caused by chemotherapy or 
transplantation. In the current study it was not possible to calculate any costs for further 
complications caused by the steroids due to time and human resources constraints. Also, 
when steroids were used as a supplement treatment, they were usually given only for 
short periods of time, thus no side effects usually would occur [198]. Therefore, it was 
decided that the complication cost of steroids should not be included in the steroids 
cost. 
 
7.5.6 Summary 
 
According to the five cost drivers discussed above, steroids treatment cost was 
considered to be the lump sum of the drug cost (section 7.5.1), the personnel cost (£26.6, 
section 7.5.2), the overheads and capital overheads cost (£6.05, section 7.5.3), and the 
outpatient clinic cost (£19, section 7.5.4). The summary of steroids treatment is shown 
in Appendix 7.4, while an example is shown on Table 7.4. 
 
Table 7.4 Example of the summary of steroid cost 
 
Treatment cost 
Drug cost Personnel cost Overheads cost Ward/clinic cost 
Complicat
ion 
Per Day Quantity Per 
Day 
Qauntity Per 
Day 
Quantity Per 
Day 
Quantity 
Dexamethasone £0.58 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
Prednisdone £0.14 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
Hydrocortisone £1.4 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
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7.6 Supportive care – G-CSF 
 
G-CSF (granulocyte-colony stimulating factor) is a growth factor that can simulate the 
bone marrow to produce white blood cell quickly. Mainly, it is used to treat the 
chemotherapy-induced neutropenia [198]. G-CSF can be given either before or after the 
chemotherapy. Also, it can be administered by hospital nurses, GP practice nurses, and 
even patients themselves [198].  
 
Due to the complexity of the administration mentioned above and lack of relevant details 
in the HMRN database, some assumptions had to be made in order to calculate the G-CSF 
cost. Considering expert opinions, it was assumed that the G-CSF injection was given 
once per day, four days continuously after chemotherapy. Also, it was assumed that all the 
G-CSF injections took place in hospital only. 
 
Details about the five cost drivers and their usage frequency for costing the G-CSF 
treatment are described below. 
 
7.6.1 Drug cost 
 
Based on the treatment guidelines [183, 184], the dosage of the G-CSF was found to be 
300 microgram once per day. According to the BNF price list [178], the ‘drug cost for 
each G-CSF injection’ was found to be £80.38 per day and £321.52 for four days. In 
relation to the ‘number of uses’, the ‘number of chemotherapies’ that took place during 
the G-CSF ‘treatment time’ was used as the ‘number of uses’ for calculating the drug cost. 
The count of the ‘number of chemotherapies’ was carried out manully, as the G-CSF was 
only given after certain types of chemotherapy (such as intensive inpatient 
chemotherapies).  After  the  ‘drug  cost  for  each  G-CSF  cycle’  and  the  ‘number  of  
chemotherapies’ were obtained, the drug cost for the G-CSF treatment was calculated by 
a multiplication. The summary can be found in Appendix 7.4. 
 
7.6.2 Personnel cost 
 
Employing the method also used in previous sections for personnel cost (section 7.1.2, 
7.3.2,  and  similar),  the  personnel  cost  was  estimated  based  on  the  ‘personnel  cost  per  
cycle for the G-CSF treatment’ and the ‘number of uses’. The ‘personnel cost per cycle 
for  the  G-CSF  treatment’  was  found  to  be  £40.8  (please  refer  to  section  6.2),  and  the  
‘number of chemotherapies’ (mentioned above) was set as the ‘number of uses’ for 
personnel cost calculation. A relevant summary can be found in Appendix 7.4  
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7.6.3 Overheads cost 
The ‘overheads cost per cycle for the G-CSF treament’ (£8.9, please refer to section 6.3 
for details) and the ‘number of the uses’ were used for estimating the overheads cost for 
the G-CSF treatment event. Using the same method as for personnel cost (section 7.6.2), 
the ‘number of chemotherapies’ was set as the ‘number of uses’. The related summary can 
be found in Appendix 7.4. 
 
7.6.4 Ward cost 
Based on assumptions mentioned earlier (section 7.6), the inpatient ward cost was applied 
to the G-CSF cost, as in most of the cases patients still stayed in hospital four days after 
the chemotherapies. The ward cost per day was found to be £67 (refer to section 6.4), and 
the ‘number of chemotherapies’ was used as ‘number of uses’ for the ward cost 
calculation. The related summary is shown in Appendix 7.4. 
 
7.6.5 Complication cost 
Similarly to the decisions made for other types of the supportive therapy, it was decided 
the complication cost not to be counted in the G-CSF cost (refer to sections 7.3, 7.4, and 
7.5). 
 
7.6.6 Summary 
According to the cost drivers mentioned above, the G-CSF treatment cost was considered 
to be the lump sum of the drug cost (section 7.6.1), the personnel cost (section 7.6.2), the 
overheads and capital overheads cost (section 7.6.3), and the ward cost (section 7.6.4). 
The summary of the G-CSF treatment can be found on Appendix 7.4 (£640 for four days), 
while the costing process is illustrated below. 
 
 
Figure 7.10 The illustration of the G-CSF costing process 
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7.7 Immunosuppressive therapy 
 
Immunosuppressive  therapy  is  a  treatment  that  is  used  after  the  transplantation.  It  
employs drugs to suppress (weaken) the immune system in order to prevent the immune 
system attacking the transplanted cells. It is also used for preventing or treating the 
graft-versus-host  disease  [178].  In  the  HMRN  database,  only  six  cases  were  found  to  
make use of the immunosuppressive therapy.  
 
7.7.1 Drug cost 
 
In the HMRN database, it was observed that the ‘cyclosporin’ was the only drug that was 
used on AML/APML patients in the network. Because of the complexity of the 
administration of each ‘cyclosporin’ sub-type, some assumptions had to be made in order 
to calculate the drug cost for immunosuppressive therapy. Based on BNF suggestions 
[178] and expert opinions, it was assumed that the ‘Neoral’ was the drug that was used for 
immunosuppressive therapy. Also, it was assumed that the dosage was 12.5mg/kg on a 
daily basis (by mouth) from day before transplantation onward. Moreover, it was 
assumed that the ‘Prednisolone’ was used as an adjunct therapy with a dosage of 10 mg 
daily (by mouth). Therefore, based on the BNF price list [178], the ‘drug cost for 
immunosuppressive therapy per day’ was found to be £23.5. In relation to ‘number of 
uses’, the ‘treatment time’ was set as ‘number of uses’, as the immunosuppressive therapy 
was given continuously. The relevant summary can be found in Appendix 7.4. 
 
7.7.2 Personnel cost 
 
Since the drugs of the immunosuppressive therapy can be administered by patients at 
home, the immunosuppessive therapy was considered to be an outpatient-based treatment 
(same as steroids discussed in section 7.5.2). Based on expert opinions, it was assumed 
that patients went back to hospital for medicine once per month. Therefore, the ‘number 
of outpatient visits’ was set as ‘number of uses’ for the personnel cost calculation. Since 
the ‘personnel cost for each outpatient visit for immunosuppressive therapy’ was found to 
be £32.1 (refer to section 6.2), the personnel cost was possible to be calculated by a 
simple multiplication. The summary of the costing details can be found in Appendix 7.4. 
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7.7.3 Overheads cost 
 
The ‘overheads cost for each outpatient visit for immunosuppressive therapy’ was found 
to be £6.95 (refer to section 6.3). By using the ‘number of outpatient visits’ that was used 
earlier for personnel cost calculation (section 7.7.2), the overheads cost were calculated 
by a simple multiplication.The summary of the costing details can be found in Appendix 
7.4 
 
7.7.4 Clinic cost 
 
Using the same method as for costing the steroids (section 7.5.4), the clinic cost was also 
calculated by multiplying the ‘outpatient clinic cost for each visit’ with the ‘number of 
outpatient visits’. The ‘outpatient clinic cost for each visit’ was found to be £19 (please 
refer to section 6.4). The summary of the costing details is shown in Appendix 7.4. 
 
7.7.5 Complication cost 
 
The immunosuppressive therapy was given mainly for treating the complications caused 
by the transplantation. In the current study it was not possible to calculate any costs for 
further complications caused by the immunosuppressive therapy due to time and human 
resources constraints. Therefore, the complication cost of immunosuppressive therapy 
was decided not to be included in the immunosuppressive therapy cost. 
 
7.7.6 Summary 
 
According to the five cost drivers mention above, the immunosuppressive therapy cost 
was considered to be the lump sum of the drug cost (section 7.7.1), the personnel cost 
(section 7.7.2), the overheads and capital overheads cost (section 7.7.3), the ward cost 
(section 7.7.4), and the complication cost (section 7.7.5). Take one-month 
immunosuppressive care as an example (with outpatient visit once per month), the 
immunosuppressive care cost was found to be £763 per  month.  The  summary  of  the  
immunosuppressive therapy costing method can be found in Appendix 7.4. 
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7.8 Venesection 
 
Venesection is a surgical incision process during which a vein is directly opened for 
giving an intravenous therapy. In the HMRN database, three cases were found to 
involve venesection treatment. Based on expert opinions, the venesection was 
considered to follow the same procedure as the transfusion, with the exception of 
transfused blood products. Therefore, the costing method was in accordance with the 
method used for costing the transfusion. The relevant details are described below. 
 
7.8.1 Drug cost 
No drug was given during the venesection, as it is a simple outpatient procedure. 
 
7.8.2 Personnel cost 
In line with the personnel cost of the transfusion (section 7.4.2), the personnel cost was 
calculated by multiplying the ‘personnel cost for each venesection’ (£41.8, please refer 
to section 6.2 for details) with the ‘number of venesections’ (section 7.4.2).  
 
7.8.3 Overheads cost 
Similarly to the transfusion (section 7.4.3), the overheads cost was calculated by 
multiplying the ‘overheads cost for each venesection’ (£9.4, please refer to section 6.3 
for details) with the ‘number of venesections’. 
 
7.8.4 Outpatient clinic cost 
To be in line with the transfusion, the clinic cost was estimated based on the ‘clinic cost 
per visit’ (£19, refer to section 6.4 for details) and the ‘number of venesections’. 
 
7.8.5 Complication cost 
In line with the transfusion, no complication cost was applied to the venesection cost. 
 
7.8.6 Summary 
According to the five cost drivers mention above, the venesection cost was considered 
to be the lump sum of the personnel cost (section 7.8.2), the overheads cost (section 
7.8.3), and the clinic cost (section 7.8.4). The summary of the venesection cost is shown 
on Appendix 7.4 (£70 per venesection). 
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7.9 Follow-up / observation 
 
Follow-up is a regular checking activity that monitors a patient's health over time, after 
treatment. Since there was no sufficient information related to the actual follow-up date 
in the HMRN database, an assumption was made in order to cost the follow-up. Based 
on expert opinions, it was assumed that the follow-up was carried out once per month 
between any gaps between treatments. Also, it was assumed that the patient who didn’t 
receive any treatments after diagnosed or refused to be treated still had observation 
interventions before they died. The costing details are described below. 
 
7.9.1 Drug cost 
Since follow-up is a simple consultation process, no drug cost was given. 
 
7.9.2 Personnel cost 
Based on the results shown in section 6.2, the ‘personnel cost for each follow-up visit’ 
was found to be £28. The ‘number of follow-up visits’ was calculated by dividing the 
‘treatment time’ by 28 days. Therefore, the personnel cost for follow-up was calculated 
by multiplying the two pieces information mentioned above. 
 
7.9.3 Overheads cost 
To calculate the overheads cost, the ‘overheads cost for each follow-up visit’ (£6.2, 
refer to section 6.3) and the ‘number of follow-up visits’ (mentioned in section 7.9.2) 
were used. The summary can be found in Appendix 7.4. 
 
7.9.4 Outpatient clinic cost 
The outpatient clinic cost was calculated by multiplying the ‘clinic cost for each visit’ 
(£19, refer to section 6.4) with the ‘number of follow-up visits’ (mentioned above). 
 
7.9.5 Complication cost 
No complication cost was applied to the follow-up cost, as there was no treatment took 
place. 
 
7.9.6 Summary 
According to the five cost drivers mentioned above, the follow-up cost (£53 per visit) 
was considered to be the lump sum of the personnel cost (section 7.9.2), the overheads 
cost (section 7.9.3), and the clinic cost (section 7.9.4). The summary of the follow-up 
cost is shown on Appendix 7.4. 
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7.10 End-of-life care 
 
In the HMRN database, end-of-life care was defined as the care that took place when a 
patient  died  at  the  hospital  or  nursing  home,  with  no  palliative  care  or  other  relevant  
treatment being carried out. In order to cost the end-of-life care, it was assumed that it was 
carried out 14 days before death. The assumption was made based on expert opinions. 
The costing details are described below. 
 
7.10.1 Drug cost 
Since end-of-life does not involve any treatments, no drug cost was applied to the 
end-of-life care. 
 
7.10.2 Personnel cost 
Since end-of-life does not involve any treatments, no personnel cost existed. 
 
7.10.3 Overheads cost 
Since no treatment was given, no overheads cost could be allocated to the relevant staff 
working time information, as the latter was non-existent.  
 
7.10.4 Ward cost 
Based on the results presented in section 6.4, the ward cost per day was found to be £67. 
Since it was assumed that patients received 14 days of end-of-life care before death, the 
calculated ward cost was found to be £938 in total. 
 
7.10.5 Complication 
No complication cost was applied to the end-of-life care cost. 
 
7.10.6 Summary 
According to the five cost drivers mentioned above, the end-of-life cost was considered to 
be the ward cost only (£938 for 14 days). The summary can be found in Appendix 7.4. 
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7.11 Laboratory test 
 
The Laboratory test cost can be divided into two parts: the cost of the test itself, and the 
sampling cost (including personnel, overheads, and clinic costs). The relevant costing 
details are described below. 
 
7.11.1 Test cost 
Based on the ‘Tariff of the Haematological Malignancy Diagnostic Service’ [182], the 
test cost was calculated by multiplying the ‘tariff cost’ with the ‘number of tests’ from 
the the HILIS database (please refer to chapters 3 and 4 for details about the calculation 
method and results). 
 
7.11.2 Personnel cost 
According to the sampling recources, the laboratory tests can be divided into two 
groups: blood sampling and bone-marrow sampling. Based on the results in section 6.2, 
the personnel cost for blood sampling was £7 and for bone-marrow was £20 each time. 
By using the ‘number of tests’ derived from the HILIS database, the personnel cost was 
possible to be calculated by a simple multiplication. 
 
7.11.3 Overheads cost 
Similarly to the personnel cost mentioned above, the overheads cost was calculated 
based on the ‘number of tests’ and the ‘overheads cost per test’ (Base on the results in 
section 6.3: £1 for blood sampling and £3 for bone-marrow sampling). 
 
7.11.4 Clinic cost 
Similarly to the costing method used for personnel cost mentioned above, the clinic 
cost was calculated by multiplying the ‘number of tests’ with the ‘clinic cost per test’ 
(based on the results in section 6.4: £3 for blood sampling and £26 for bone-marrow 
sampling). 
 
7.11.5 Complication cost 
No complication cost was applied to the laboratory test cost. 
 
7.11.6 Summary 
According to the five cost drivers mentioned above, the lab cost was considered to be 
the lump sum of the test cost (section 7.11.1), the personnel cost (section 7.11.2), the 
overheads cost (section 7.11.3), and the ward cost (section 7.11.4). 
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Figure 7.11 The illustraction of splenectomy costing process 
7.12 Splenectomy 
 
Splenectomy is a surgical procedure involving the partial or complete removal of the 
spleen. The reasons for removing the spleen can be various and the procedure can be 
performed either for diagnostic or for therapeutic reasons. In haematological malignancy, 
the spleen is commonly enlarged as a result of lymphatic cancer, such as lymphomas or 
leukemia. When the spleen becomes significantly large, it can be destructive to 
platelets/red cells. Therefore, a splenectomy is needed [201-203]. 
In the HMRN database, only two cases were found to involve the splenectomy treatment. 
Since the splenectomy was one of the four treatments that can not be cost with the 
bottom-up method (due to lack of detailed information, please refer to chapter 6), the 
‘Reference Cost Index’ was used as an alternative method.  
7.12.1 Code translation 
To identify the splenectomy cost from the “Reference Cost Index”, the HRG4 code 
(Healthcare Resource Group Code) of splenectomy was needed. According to the known 
ICD-9 code of splenectomy (41.43: partial splenectomy and 41.5: total splenectomy), it 
was matched to the ‘OPCS classification of interventions and procedures’ [204]. The 
matching showed that the corresponding OPCS codes was J69: partial splenectomy and 
J70: total splenectomy. Next, by using the “HRG4 Definitions” [205] , it was found that 
the corresponding HRG4 code was GA07 (Hepatobiliary Procedure Category 3). 
7.12.2 Treatment cost 
After the HRG4 code of the splenectomy was identified (GA07), the corresponding 
splenectomy  treatment  cost  was  obtained  by  using  the  ‘Reference  Cost  Index’.  It  was  
found that the treatment cost of the splenectomy was £4,010, including the complication 
cost. The reported cost included the same cost information (five cost drivers) as the other 
treatment costs derived from the bottom-up method. Therefore, the reference cost (£4,010) 
was used to represent the splenectomy treatment cost. The costing process is illustrated 
below. 
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7.13 Radiotherapy 
 
Radiotherapy is a treatment of blood cancers and it involvessupplying high but measured 
doses of radiation. Radiotherapy can damage the DNA of the cancer cells (stops cancer 
cells from growing/reproducing/dividing), improve the results of chemotherapy, and 
prepare the body for transplant. Total body irradiation (TBI) and non-TBI are the two 
main types of the curative radiotherapy [201]. 
 
In the HMRN database, 14 cases were found to involve radiotherapy treatment. Similarly 
to splenectomy (section 7.12), the radiotherapy was also one of the four treatments that 
could not be costed with the bottom-up method. Therefore, the ‘Reference Cost Index’ 
was used to represent the radiotherapy. The costing details are described below. 
 
7.13.1 Assumptions 
 
To decide the treatment cost of the radiotherapy, two assumptions were made: 
a.  Since  TBI  was  used  primarily  as  part  of  the  preparative  regimen  for  stem  cell  
transplantation, it was assumed that only radiotherapy used before the stem cell 
transplantation would be considered as the TBI. Rest of the unspecified radiotherapies 
considered to be non-TBI. 
b. It was assumed that radiotherapy planning was always carried out before the 
radiotherapy. This was because the treatment planning before the radiotherapy is a 
necessary procedure, as it helps in controlling the damage of the healthy cells near the 
cancer cells during the radiotherapy. 
 
7.13.2 Costing process 
Based on the assumptions and on expert suggestions, it was decided that the radiotherapy 
cost contained two parts: the pre-radiotherapy treatment planning and the radiotherapy 
itself. 
 
a. Pre-radiotherapy treatment planning 
Based on expert opinions, two medical services were found to be needed for the treatment 
planning before the radiotherapy, namely the ‘radiotherapy planning outpatient visit’ and 
the ‘preparation for the radiotherapy’.  
˙‘Radiotherapy planning outpatient visit’ : here the purpose is to measure the proper 
dose  and  control  the  radiation  damage  to  the  body.  Therefore,  based  on  the  
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‘Reference Cost Index’ and the expert opinions, ‘HRG SC05Z: Define volume for 
Radiation Therapy with imaging, Dosimetry and technical support’ (£117) was 
used to represent the planning visit cost. 
 
˙‘Preparation for the radiotherapy’: According to the types of radiotherapy, the 
‘HRG SC08Z: Prepare for intracavitary radiotherapy’ (£284) was used to represent 
the  cost  of  non-TBI  preparation,  and  the  ‘HRG  SC07Z:  Prepare  for  Total  Body  
Irradiation’ (£334) was used to represent the cost of TBI preparation. 
 
Overall, the pre-radiotherapy treatment planning cost was found to be £401 for non-TBI 
radiotherapy and £451 for TBI radiotherapy. 
 
b. Radiotherapy 
According to expert opinions, the ‘HRG SC26Z: Deliver a fraction of intracavitary 
radiotherapy without general anaesthetic’ (£250) was set as the cost of the non-TBI 
radiotherapy, and the ‘HRG SC25Z: Deliver a fraction of Total Body Irradiation (£184)’ 
was set as the cost of the TBI radiotherapy. 
 
7.13.3 Summary 
Overall, the radiotherapy treatment cost was the lump sum of the pre-radiotherapy 
planning cost and the radiotherapy cost. The treatment cost of non-TBI radiotherapy was 
found to be £651, and the treatment cost of TBI radiotherapy £635. The costing process is 
illustrated below (Figure 7.12). 
 
 
 
 
Figure 7.12 The illustration of the radiotherapy costing process 
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7.14 Stem cell transplantation 
 
Stem cell transplant is a treatment that infuses healthy stem cells into the patient’s body 
aiming to produce enough healthy blood cells in order to prevent life threatening infection 
or anemia. Two different approaches can be employed for the transplantation depending 
on the ways of harvest. One is the bone marrow transplantation (BMT), in which stem 
cells are drawn out of pelvic bone or, less frequently, from the sternum. Another approach 
is peripheral blood stem cell transplantation (PBSCT), in which the numbers of stem cells 
are drawn out from bloodstream. These two stem cell transplantation approaches are very 
similar. In addition, stem cell transplantation can use the stem cells from patient’s own 
body (autologous stem cell transplantation) or stem cells from donors (allogenic stem cell 
transplantation) [201]. 
 
In the HMRN database, 13 cases were found to involve transplantions. All of them were 
the allogenic BMT. Since the stem cell transplantation was one of the four treatments that 
can not be costed with the bottom-up method (refer to chapter 6), the ‘Reference Cost 
Index’ was used to represent the treatment cost. The costing details and the relevant 
information are presented below. 
 
7.14.1 Assumptions 
To decide the treatment cost of the radiotherapy, two assumptions were made. 
 
a. It was assumed that the patients who received the stem cell transplantation had to have 
three pre-transplant outpatient visits beforehand (based on expert opinions). 
b. It was assumed that the costs of the mini-BMT and BMT were the same. 
 
7.14.2 Costing process 
Based on the assumption a, the stem cell transplantation cost was divided into two parts: 
pre-transplantation cost and the transplantation cost. The post-transplantation follow-up 
cost was not taken into consideration, as the follow-up costs discussed in section 7.9 
covered all kinds of the follow-up event costs. 
 
a. Pre-transplantation cost 
According to assumption a, three outpatient consulting visits were found to be needed 
before the stem cell transplantation. Therefore, based on the outpatient clinic cost (£19, 
refer to section 6.4), the three outpatient visits were found to be £57. It is worth to note 
that all the exam/test/typing costs occurred during this period of time have been included 
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in  the  ‘Laboratory  cost’  (discussed  in  section  7.11).  Therefore,  the  exam  cost  was  not  
taken into account here in order not to double count the cost. 
 
b. Transplantation cost 
To calculate the allogeneic stem cell transplantation, two types of costs were taken into 
consideration: the cost of the stem cell harvest and the cost of the stem cell transplantation 
itself.   
 
˙The cost of the stem cell harvest 
Based on the ‘Reference Cost Index’, ‘HRG SA18Z: Bone Marrow or Stem cell 
Harvest’ (£7845) was used to represent the harvest cost. 
 
˙Stem Cell transplantation cost 
Depending on the stem cell sources, allogenic transplantation can be further divided 
into two types. They are 1) allogeneic graft from sibling and 2) allogeneic graft 
from volunteer unrelated donor. After reviewing the extraction forms manually, it 
was found that the stem cell sources of the 13 allogenic transplantations were all 
from siblings. Therefore, based on the ‘Reference Cost Index’, ‘HRG SD05A: 
Allogeneic Graft (sibling) 19 years and over’ (£36297) was used to represent the 
cost of the allogenic stem cell transplantation. 
 
7.14.3 Summary 
Overall,  the stem cell  transplantation cost  was the lump sum of the pre-transplantation 
visit cost and the cost of the allogeneic stem cell transplantation (sibling). Therefore, the 
treatment cost of transfusion was found to be £44199. The costing process is illustrated 
below (Figure 7.13). 
 
 
 
Figure 7.13 The illustration of the transplantation costing process 
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7.15 Palliative care 
 
Palliative care is a non-curative treatment for patients whose disease is not responsive to 
curative treatment. The goal of palliative care is to control symptoms and improve 
patient’s quality of life. In practice, palliative care involves many different approaches, 
including physical and psychological cares [201]. Unlike the ‘end-of-life care’, the 
palliative care involves the substantial interventions rather than simply care. 
 
In the HMRN database, 31 patients received the palliative care before death. To obtain the 
palliative care cost, the ‘Reference Cost Index’ was used, as the palliative care was one of 
the four treatments that can not be costed with the bottom-up method (refer to chapter 6). 
The costing details are described below. 
 
7.15.1 Assumptions 
 
a. It was assumed that all the palliative care episodes were inpatient treatments.  
b. It was assumed that the patients received the palliative care intervention three times per 
week during the palliative care period (based on the expert suggestions). As for the rest 
of the week, only the simple care was given (similar to the end-of-life care). 
c. It was assumed that the treatment content of the palliative care for each time was the 
same. 
 
7.15.2 Costing process 
 
a. Unit cost 
According to assumption b, the palliative care cost was divided into two parts: the cost of 
the palliative care day and the cost of no palliative care day. 
 
˙The cost of no palliative care day 
Since only simple care was given on the no palliative care days during the palliative 
care period, the ward cost (£67 per day, refer to section 6.4) was used to represent 
the cost of no palliative care day. 
˙The cost of the palliative care day 
Based on the ‘Reference Cost Index’, the ‘HRG 4 code in reference cost: SD01A: 
Inpatient Specialist Palliative Care 19 years and over’ (£336) was used to present 
the cost of the palliative care day 
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b. Number of uses 
The ‘treatment time’ derived from the HMRN database was set as the ‘number of uses’ for 
palliative care cost calculation. 
 
7.15.3 Summary 
 
Overall, the palliative care cost was estimated based on the unit cost and the number of 
uses. Take one-week palliative care as an example (three days under the palliative care 
and four days were not), the palliative care cost was found to be £1276 per week. The 
costing process is illustrated below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.16 Summary 
 
In this chapter, the detailed costing methods for 12 types of treatments/interventions were 
described. Each method contained the previously obtained five cost drivers (please refer 
to chapter 6), with an exception of four treatments (splenectomy, radiotherapy, stem cell 
transplantation, and palliative care). The Reference Cost was used to represent the costs 
of these four treatments. Finally, all of the treatment events were cost and the cost results 
were ready for individual overall/lifetime cost calculation, which is discussed in the 
following chapter (chapter 8). 
 
 
 
Figure 7.14 The illustration of palliative care costing process 
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CHAPTER 8 COSTING METHOD PHASE 3 
 
 
According to the study design (please refer to section 5.3.2), the total treatment costing 
process was divided into three phases, of which costing phase 3 is discussed in the current 
chapter. The costing process is illustrated below (Figure 8.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The costing phase 3 contained two important processes, namely total treatment 
calculation (for each patient) and predictive factors analysis. The details of each process 
(including the ones related with the treatment overlapping) are described in the following 
sections. 
 
 
Figure 8.1 The illustration of the costing phase 3 
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8.1 Total cost calculation (non-treatment overlapping) 
 
 
To capture the subtle cost differences between patients, the ‘patient treatment pathway’ 
(summarized the data in the HMRN database as described in chapters 3 and 4) was 
employed to render the total treatment cost results for each patient.  
 
The treatment events in the pathway were sorted by chronological order, then cost, and, 
finally,  summed  up  to  a  single  number,  namely  the  ‘total  treatment  cost’  (without  
considering the treatment overlapping). To cost each event, the treatment/intervention 
costs discussed in chapter 7 were linked to the corresponding events in the pathway, 
making use of the ‘treatment time’ or the ‘number of uses’ of each event. After all of the 
event costs were obtained, the total treatment cost was calculated as the lump sum of the 
treatment costs that occurred on the patients’ treatment pathway. 
 
It is worth noting that, in order to make the cost result comparable, the total treatment cost 
was further broken down into parts depending on the ‘treatment phase’ (chapter 3) it 
belonged to. The costing process is illustrated below (Figure 8.2).   
 
 
 
 
 
 
Figure 8.2 The illustration of the costing process for total treatment cost 
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8.2 Total cost calculation (treatment overlapping) 
 
 
The total treatment cost can be simply calculated by the required addition (please refer to 
section 8.1). However, it is suggested that the calculated result could not reflect the actual 
medical resource consumption accurately. This is because, practically, treatments 
frequently overlap with each other, and, thus, it is not always possible to sum up directly. 
The studied AML/APML treatments were not an exception to this as more than 100 
treatment events were found to be overlapping with other treatments in the HMRN 
database (763 events in total),.  
 
The overlapping issue had to be handled with caution for two reasons. Firstly, medical 
resources were shared between treatments when more than one treatment was performed 
simultaneously.  Therefore,  it  was  easy  to  overestimate  the  total  treatment  cost  if  these  
overlapping treatments were summed up directly without any deduction. Secondly, the 
hospital stays or the outpatient visit frequency (discussed in section 5.4.2) could change 
as the treatment overlapped with others. Since the actual medical resource consumption 
pattern changed, the costing method should change correspondingly in order to avoid the 
total treatment cost to be overestimated or underestimated. 
 
The issues discussed above can be difficult to uncovered if the individual events are cost 
separately and once at a time. Therefore, a macro costing method that took the 
overlapping issue into consideration was needed in order to yield more reasonable and 
accurate cost results. Details on how the overlapping issue and the relevant costing 
method were handled can be found in following sections. 
 
 
8.2.1 Identifying the overlapping events 
 
To identify the overlapping events, a number of definitions and assumptions were needed. 
Relevant details can be found below. 
 
a. Definitions 
 
˙Disjointed events: two treatments that did not overlap with each other.  
˙Touching events: two events that shared one end date (the end date of the first 
event). 
c. Overlapping events: two events that overlapped over a period of time. 
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d. Subset event: one event is a subset of another event. 
e. Interval less than 3 days: the period/gap between two events is less than 3 days 
f. Interval more than 3 days: the gap between two events is more than 3 days 
 
b. Assumptions 
 
Based on expert suggestions and on the aforementioned definitions, it was decided that 
the following situations had to be considered as overlapping events, and, thus, more 
caution was needed when costing these treatment events. 
 
˙If two inpatient treatments were touched, it was assumed that these treatments 
overlapped. 
˙If two treatments were overlapping events, it was assumed that these two treatments 
overlapped and had effects on each other (including hospital stays or outpatient visit 
frequency). 
˙If one treatment was a subset event, it was assumed that it overlapped with another 
treatment and had effects on each other. 
˙If the interval between two inpatient treatments was less than three days, it was 
assumed that the two events actually overlapped, and the hospital stays continued 
without stopping. 
 
The definitions and assumptions are illustrated below (Figure 8.3). 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 The illustration of the overlapping types 
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8.2.2 Handling the overlapping treatments 
 
In order to overcome above issue, the concept of ‘span’ was introduced. ‘span’ was set as 
a unique treatment length record that engulfed all the relevant overlapping treatment 
events. The details of the ‘span’ calculation are described in the following paragraphs. 
 
a. Inpatient span 
 
The length of hospital stay determined the medical resources utilization and cost. 
Therefore, as the length of hospital stay changed when inpatient treatments overlapped, 
an inpatient span that engulfed the overlapping inpatient treatments was needed. To 
obtain the ‘span’ of a batch of relevant overlapping inpatient treatments, two steps were 
involved. This was in order to yield an inpatient span that was expected to reflect the 
actual hospital stays more accurately. 
 
˙Grouping the relevant overlapping inpatient treatments 
Based on the extrapolated treatment admission and on the discharge dates 
(discussed in section 5.4.2), the inpatient treatments fell into the same group when 
they overlapped or when intervals between each other were less than 3 days. It is 
worth to note that the transfusion and the laboratory test were not included, as they 
did not affect the hospital stays. Also, treatment events that did not overlap with 
others formed one span by themselves. 
˙Determining the ‘span’ 
Based on the batch of relevant overlapping inpatient treatments (defined above), the 
start date of the ‘span’ was determined by the earliest point of the grouped inpatient 
treatments. Similarly, the end-date of the ‘span’ was determined by the latest point 
of the grouped inpatient treatments. An illustrated example can be found below 
(Figure 8.4).   
 
 
 
 
 
 
 
 
 
 
Figure 8.4 An illustrated example of determining the inpatient span 
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b. Outpatient span 
 
Similarly  to  the  hospital  stays,  the  number  of  outpatient  visits  determined  the  medical  
resources utilization and cost. Therefore, an outpatient span that could divide different 
visit frequencies was needed, as the outpatient visit frequency changed when outpatient 
treatment overlapped. To obtain the outpatient ‘span’, two steps were involved. This was 
in order to yield an outpatient span that could both separate different visit frequencies and 
render the number of outpatient visits more accurate in relation to the actual number. 
˙Grouping the relevant overlapping outpatient treatments 
Based on the ‘treatment time’ (derived directly from the HMRN database), the 
outpatient treatments fell into the same group when they overlapped with each other. 
It is worth to note that the transfusion and the laboratory test were not included, as 
they did not affect the outpatient visit frequency. Also, treatment events that did not 
overlap with others formed one span by themselves. 
˙Determining the ‘span’ 
Based on the batch of relevant overlapping outpatient treatments (defined above), 
the cut-off points of each span were determined by the dates that overlapping 
started or ended. A relevant illustrated example can be found below (Figure 8.5). 
 
 
 
 
 
 
 
 
c. Follow-up span 
 
Any gaps found between the spans (considering all the inpatient and outpatient spans) 
were defined as the follow-up spans. It is worth to note that the transfusion and the 
laboratory test were not taken into consideration for reason mentioned previously. 
 
 
 
 
Figure 8.5 The illustrated example of determining the outpatient spans 
 
 
Figure 8.6 The illustrated example of determining the follow-up spans 
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8.2.3 Costing method for overlapping treatment 
 
After all the spans were identified (involving stood along and overlapping treatment 
event), the treatments within the same spans were ready to be cost. Details related to the 
costing method and the principles of cost sharing are described below. 
 
a. Inpatient spans 
 
˙If the treatment events in the ‘spans’ were disjointed or touching events, the 
treatment cost was calculated normally, without considering the cost sharing.  
˙If the treatment events in the ‘spans’ were overlapping events, the ward cost was 
considered to be the shared cost, and it was calculated only once. The rest of the 
cost drivers were considered to be non-shared cost, as they were all directly 
related to the treatments themselves.  
˙If the inpatient treatment overlapped with any of the 4 treatments that their costs 
were directly derived from the ‘Reference Cost Index’, the overlapping ward cost 
was not counted for two reasons. Firstly, ward cost had already included in the 
reference cost. Secondly, it was impossible to separate the shared ward cost from 
the reference cost. Therefore, instead of calculating the shared ward cost 
separately, the overlapping reference cost was fully kept without considering 
other ward cost. This was in order not to over-count the ward cost. 
 
The costing process is illustrated below (Figure 8.7). 
 
 
 
 
Figure 8.7 The illustration of the shared cost calculation for overlapping IP treatments 
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b. Outpatient spans 
 
˙If the treatment events in the ‘spans’ were disjointed or touching events, the 
treatment cost was calculated normally without considering the cost sharing. 
˙If the treatment events in the ‘spans’ were overlapping events, the one with the 
highest outpatient visit frequency was set as the visit frequency for the span. 
˙If the outpatient events overlapped with the inpatient event/span, different costing 
methods were used, depending on the type of the outpatient events. 
 
Type 1: If the outpatient treatment involved only drugs, then only the drug and the 
complication costs were calculated, as the rest of the costs (personnel, 
overheads, and other costs) were covered by the hospital staff responsible for 
the inpatient treatment event/span. It is worth to note that the complication cost 
that was taken into consideration was the evenly divided complication cost 
(according to the numbers of the spans the treatment covered) and not the total 
complication cost. 
Type 2: If the outpatient treatment involved surgical or other medical procedures 
(such as Mylotarg and immunosuppressive therapy), then all costs except the 
outpatient clinic cost were calculated. This was because these costs (drug, 
personnel, and other costs) could not be covered by the hospital staff 
responsible for the inpatient treatment event/span. 
 
The costing process is illustrated below. 
 
 
 
 
Figure 8.8 The illustration of the change of visit frequency for overlapping OP treatments 
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c. Follow-up spans 
 
Follow-up span was defined as the gaps between any treatment spans, without 
considering the transfusion and the laboratory test event (the reasons for this are 
discussed in section 8.2.3). Meanwhile, the follow-up frequency was defined as once 
every month (please refer to chapter 3 for more details). Therefore, the number of 
follow-up visits was simply calculated by dividing the length of the follow-up span by 28 
days (1 month, 4 weeks). 
 
After the number of follow-up visits was obtained, the follow-up cost was calculated by 
multiplying the number of follow-up visits with follow-up cost per visit (£53.2, please 
refer to section 7.9 for details). The relevant costing details are illustrated below. 
 
 
 
 
 
 
 
 
 
 
8.2.3 Overall/lifetime treatment cost calculation 
 
After the costs for all the treatment spans were obtained, the total treatment cost of each 
patient was calculated by summing up these costs. To render the cost results more 
comparable and clinically meaningful, the total treatment cost was further broken down 
into ‘treatment phase’ (please refer to chapter 3).  
 
 
 
Figure 8.9 The illustration of follow-up span costing process 
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CHAPTER 9 RESULTS 
 
 
The current chapter aims at presenting the cost results and comparing them with previous 
study results. This includes the results of estimated treatment and overall treatment costs. 
Furthermore, the result of the cost predictor analysis is also included in this chapter.  
 
After the three costing phases of the calculation process discussed in chapters 6, 7, and 8, 
the cost results for each treatment and the estimated total cost for each patient were 
obtained.  
 
In costing phase 1, the unit costs of five cost drivers for each treatment were calculated. 
Several important procedures were carried out in order to obtain robust values. This 
included staff working time survey for personnel cost and meta-analysis for complication 
treatment cost (please refer to chapter 6 for details). 
 
In costing phase 2, the costs for each treatment were calculated by summing up the five 
cost drivers mentioned above. To resolve the issues caused by the complexity of different 
drug delivery types and patient conditions, several assumptions for the treatment use 
frequency were made under experts’ guidance (please refer to chapter 7 for details).  
 
Finally, in costing phase 3, the total treatment costs for each patient were calculated by 
linking the treatment costs (mentioned above) to the patient treatment pathway (discussed 
in chapter 4). Costing the overlapping treatments can be challenging, as the AML/APML 
treatment combinations varied and no sufficient detailed information was possible to be 
obtained regarding the way each treatment was carried out. Overall, two different types of 
total cost results were generated: the total cost for non-treatment overlapping, and the 
total cost for treatment overlapping (please refer to chapter 8 for costing details).  
 
Before proceeding to the cost results, a summary of the data handling is presented in order 
to provide an overview of the costing process (section 9.1). Next, the estimated costs for 
each treatment, the total cost results for both the non-treatment and for the treatment 
overlapping costing are presented in the subsequent sections. Finally, the possible cost 
predictive factors are discussed in section 9.5. 
 
9.1 Summary of the data handling 
-225- 
 
9.1 Summary of the data handling 
 
For purposes of the current study, a total of 239 patients who were newly diagnosed with 
AML/APML from September 2004 to September 2006 in the HMRN network were 
recruited and studied. This included 215 patients with AML and 24 patients with APML. 
All the patients were followed from the diagnosis onward, and until mortality or the latest 
follow-up date. By the close date of the study (05/31/2010), 763 treatment records had 
been obtained from the HMRN database (please refer to chapter 4 for details). 
 
After imputing all the missing data, the 763 obtained treatment records were further 
broken down into 1025 treatment cycle records for calculation reasons (please refer to 
chapter 4 for details and reasons). Up to that stage, the 1025 treatment cycle records were 
ready for the 3-phase cost calculation (described in chapters 6, 7, and 8).  
 
9.1.1 Study material in costing phase 1 
 
In costing phase 1 (chapter 6), the number of treatment cycle records remained the same, 
as the aim of the costing phase 1 was to obtain the unit cost of the five cost drivers for 
each treatment record.  
 
9.1.2 Study material in costing phase 2 
 
In costing phase 2 (chapter 7), the number of treatment cycle records increased to 2731, 
as the two intervention costs (the end-of-life care cost and the laboratory test costs 
derived from the HILIS database) were added or integrated into the study database. The 
end-of-life care (a care that patients received at terminal stage of life) was taken into 
consideration as it was an important cost driver, but, unlike palliative care, it has not been 
recorded on a regular basis In order to avoid underestimating the total treatment cost, the 
intervention was cost based on experts’ opinions as described in chapter 7. For 
convenience reasons, since the laboratory test events were collected from HILIS and 
stored in the HMRN database, the laboratory test events were firstly integrated into the 
study database and then cost. Based on the treatment cost definitions described in chapter 
7, 66 patients were found to have received the end-of-life care and 1640 laboratory test 
records were found to be related (please refer to chapter 4 for details). Overall, 2731 
treatment event records were cost for further analysis. 
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9.1.3 Study material in costing phase 3 
 
In costing phase 3, the number of treatment cycle records changed again as the treatment 
overlapping was taken into consideration. To resolve the treatment overlapping issue, the 
concept of the ‘span’ was introduced (please refer to chapter 8). Firstly, the inpatient 
spans were defined by considering the overlapping treatments. Based on the durations of 
each treatment, the 675 inpatient treatment cycle records were merged into 529 inpatient 
spans. Secondly, the outpatient treatment cycle events were taken into consideration. By 
composing different outpatient spans when the outpatient treatment overlapped with 
inpatient spans or other outpatient treatments, the 460 outpatient treatment cycle records 
were further cut into 884 outpatient spans. Finally, based on the definition described in 
section 7.9 and the method described in section 8.2.2, the follow-up spans were defined as 
the gaps between any treatment spans and 269 follow-up spans (out of 588 treatment gaps) 
were found on the 123 patients. It is worth to note that the laboratory test did not take part 
in the span calculation for reasons mentioned in section 8.2. Therefore, the intervention 
records remained the same and they were not merged into any other treatment spans. 
After a complicated calculation, 2731 treatment event records expended to 3322 
treatment span records. These treatment spans were further cost and the results were 
summed up as the final estimated total treatment cost for each patient.  
 
The process of handling the study material is illustrated below. (Figure 9.1) 
 
 
 
 
 
 
 
 
Figure 9.1 The process of handling the study material 
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9.2 Cost results of each treatment 
 
In the current section, the cost results of each treatment are presented. According to the 
costing method described in chapter 7, the treatment/intervention costs were calculated 
based on the patient conditions (completed treatment or not) and the different types of 
drug delivery.  
 
In order to make the result section concise and easy to follow, only the costs for the most 
commonly used or the most important treatments are discussed. This includes 
chemotherapy, clinical trial, supportive care, radiotherapy, stem cell transplantation, 
immunosuppressive care, palliative care, and follow-up intervention. Analyses of each 
treatment cost can be found in the following sections. For the rest of the treatments, the 
calculated cost values can be found in Appendix 9.1. 
 
 
 
9.2.1 Chemotherapy and clinical trial 
 
Since the regimen used in the clinical trial arms were also used in chemotherapies, the 
regimen costs for the clinical trial and the chemotherapy were discussed together. 
Regarding the patient conditions and the differences of each drug/regimen delivery,  all  
the regimen costs were calculated separately and the main cost results are discussed in the 
following sections. This includes nine inpatient chemotherapy regimen costs and four 
outpatient chemotherapy regimen costs.  
 
 
a. ADE  
 
ADE was one of the most commonly used regimens in the HMRN network. In total, 47 
cycles of ADE and ten cycles of ADE + Mylotarg were used on the study patients. The 
cost results for the ADE regimen are illustrated in Figure 9.2.   
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Figure 9.2 The illustration of the ADE regimen cost results 
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As it can be observed in the relevant plot, the ADE regimen costs mainly fell into two 
groups. This was because ADE regimen contained two cycles. The cost of cycle one was 
slightly higher than the cost of cycle two, as the full course of cycle one was longer than 
the one of cycle two. The proportion of the five cost drivers that were used for costing and 
the proportion of the regimens used in the chemotherapy or in the clinical trial are also 
illustrated in the related pie charts. As indicated in Figure 9.2, the ward cost accounted 
for the highest percentage (36%), which was much higher than drug cost (21%) or 
personnel cost (23%). 
 
As shown in the detailed cost result table (Table 9.1), the average ADE regimen cost per 
cycle was £5284 (including the complication treatment cost). Specifically, the average 
cost for ADE cycle one was found to be £5799 and £4790 for cycle two. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. AraC (High Dose) 
 
AraC (HD) is the fifth most commonly used chemotherapy regimen in the network. The 
related cost results are illustrated in Figure 9.3.   
Table 9.1 The detailed cost results of the ADE regimen 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
ADE 47 courses £4367 £2553 £4797 £5284 £2677 £6036 
Course 1 23 courses £4625 £2553 £4797 £5799 £2677 £6036 
Course 2 24 courses £4120 £3938 £4287 £4790 £4522 £5037 
Chemotherapy 26 courses £4395 £2553 £4797 £5361 £2677 £6036 
Course 1 16 courses £4562 £2553 £4797 £5708 £2677 £6036 
Course 2 10 courses £4310 £4113 £4287 £4805 £4779 £5037 
AML 15 21 courses £4331 £3938 £4797 £5189 £4522 £6036 
Course 1 7 courses £4768 £4596 £4797 £6007 £5835 £6036 
Course 2 14 courses £4113 £3938 £4287 £4779 £4522 £5037 
ADE + Mylotarg 10 courses £6132 £4113 £6418 £7290 £4779 £7657 
Chemotherapy - - - - - - - 
AML 15 10 courses £6132 £4113 £6418 £7290 £4779 £7657 
Course 1 9 courses £6357 £6069 £6418 £7568 £7060 £7657 
Course 2 1 course £4113 - - £4779 - - 
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Figure 9.3 The illustration of the AraC (HD) regimen cost results 
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As it can be observed in the relevant plot, AraC (HD) costs were divided into two groups. 
This was because the AraC (HD) regimen contained two cycles, and the hospital stays of 
cycle one were longer than the ones of cycle two (please refer to section 5 for details). 
Also,  as  shown on  the  relevant  pie  chart,  the  ward  cost  still  accounted  for  the  highest  
percentage (39%) similar to the ADE regimen. Compared to other regimens, the drug cost 
of AraC (HD) accounted for relatively high percentage (34%), while the personnel cost 
accounted for relatively low percentage (9%). It is also worth noting that the AraC (HD) 
regimen was used more frequently in clinical trial (63%) rather than in non-clinical trial 
(37%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The detailed cost results are shown in Table 9.2. As it can be observed, the average AraC 
(HD) regimen cost per cycle was £4919 (including the complication treatment cost). 
More specifically, the average cost for AraC (HD) cycle one was found to be £5299 and 
£4499 for cycle two. 
 
 
c. AraC (Low Dose) 
 
AraC (LD) was the second most commonly used regimen. The cost results are illustrated 
in Figure 9.4 below.  
Table 9.2 The detailed cost results of the AraC (HD) regimen 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
AraC (HD) 40 courses £4091 £3092 £4405 £4919 £3689 £5315 
Course 1 21 courses £4389 £4204 £4405 £5299 £5114 £5315 
Course 2 19 courses £3761 £3092 £3802 £4499 £3689 £4548 
Chemotherapy 15 courses £4199 £3735 £4405 £5055 £4481 £5315 
Course 1 10 courses £4405 £4405 £4405 £5315 £5315 £5315 
Course 2 + 5 courses £3788 £3735 £3802 £4535 £4481 £4548 
AML 15 25 courses £4025 £3092 £4405 £4838 £3689 £5315 
Course 1 11 courses £4374 £4204 £4405 £5284 £5114 £5315 
Course 2 14 courses £3751 £3092 £3802 £4487 £3689 £4548 
AraC(HD) + Mylotarg 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Chemotherapy - - - - - - - 
AML 15 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Course 1 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Course 2 - - - - - - - 
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Figure 9.4 The illustration of the AraC (LD) regimen cost results 
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As shown on the plot, the Arac (LD) costs varied. A possible reason for this could be that 
the full course was not given when the AraC (LD) was used for prolonging life rather than 
using for an intensive induction treatment. However, when the full dose was given, cost 
patterns could be found in the plot. As it can be seen in the relevant plot, the costs could 
be categorized into two groups. The AraC (LD) cost used for clinical trial was slightly 
higher than the one used for standard chemotherapy, as the hospital stays of the clinical 
trial were higher than the one of the standard chemotherapy (please refer to section 4.3.2 
for details). As it can be observed in the relevant pie chart, the ward cost accounted for the 
highest percentage (35%). The rest percentages of the cost drivers were consistent with 
the percentages of the ADE regimen. It is worth noting that AraC (LD) was used mainly 
as the standard chemotherapy (87%). The AraC(LD) was used in clinical trial only in a 
few cases. 
 
The cost results are shown in Table 9.3 below. It can be observed that the average AraC 
(LD) regimen cost per cycle was £4088 (including the complication treatment cost). Thus, 
it  was  slightly  cheaper  than  AraC  (HD).  Specifically,  the  average  cost  for  AraC  (LD)  
cycle one was found to be £4022 and £4164 for cycle two. 
 
It is worth noting that it was assumed that all the patients received AraC(LD) in 
inpatient setting in the current study, although, clinically, AraC(LD) can be delivered in 
inpatient setting and outpatient setting. This assumption was made due to lack of the 
relevant information about where the patient received the treatment. Therefore, the 
AraC(LD) cost results here were considered to be overestimated, compared to the actual 
treatment cost. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.3 The detailed cost results of the AraC (LD) regimen 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
AraC (LD) 83 courses £3396 £638 £4895 £4088 £729 £5852 
Course 1 39 courses £3226 £638 £4895 £4002 £729 £5852 
Course 2 44 courses £3547 £1285 £4359 £4164 £1348 £4989 
Chemotherapy 72 courses £3267 £638 £4895 £3951 £729 £5852 
Course 1 35 courses £3096 £638 £4895 £3851 £729 £5852 
Course 2+ 37 courses £3430 £1285 £4359 £4045 £1348 £4989 
AML 14 11 course £4237 £3019 £4359 £4986 £3649 £5316 
Course 1 4 courses £4359 £4359 £4359 £5316 £5316 £5316 
Course 2+ 7 courses £4168 £3019 £4359 £4798 £3649 £4989 
AraC (LD) + Mylotarg 2 courses £5170 £4359 £5980 £5963 £4989 £6938 
Chemotherapy - - - - - - - 
AML 14 2 courses £5170 £4359 £5980 £5963 £4989 £6938 
Course 1 1 course £5980 - - £6938 - - 
Course 2 1 course £4359 - - £4989 - - 
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d. DA 
 
DA was the most commonly used regimen among all the chemotherapy regimens. In total, 
91 cycles of DA and eight cycles of DA + Mylotarg were used on the study patients. The 
cost results are illustrated below (Figure 9.5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.5 The illustration of the DA regimen cost results 
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As  shown  in  the  plot,  the  costs  were  divided  into  two  groups.  Similarly  to  the  ADE  
regimen, the cost of cycle one was slightly higher than the one of the cycle two, as the full 
course of the cycle one was longer. Also, it was observed that the dosage differences did 
not have significant effect on the cost results. As illustrated in the relevant pie chart, the 
ward cost still accounted for the highest percentage (38%). However, the personnel cost 
(20%) accounted for relatively higher percentage, while the drug cost (17%) accounted 
for relatively low percentage. The low percentage drug cost provided a possible 
explanation for the little effect that the dosage differences had on the regimen cost. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The detailed cost results are shown in Table 9.4. As listed, the average DA regimen cost 
per cycle was £5738 (including the complication treatment cost). More specifically, the 
average cost for cycle one was found to be £5913 and £5501 for cycle two. The costs of 
different dosages were similar. However, it is worth noting that the costs of DA used in 
the clinical trials were higher than the cost of DA used in the non-clinical trail. Also, 
Table 9.4 The detailed cost results of the DA regimen 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
DA 91 courses £4458 £750 £4918 £5738 £819 £6405 
Course 1 52 courses £4559 £750 £4918 £5913 £819 £6405 
Course 2 39 courses £4322 £2774 £4751 £5501 £3688 £6055 
DA (D50 C200) 85 courses £4454 £750 £4918 £5726 £819 £6405 
Course 1 48 courses £4542 £750 £4918 £5885 £819 £6405 
Course 2 37 courses £4340 £2774 £4751 £5520 £3688 £6055 
Chemotherapy 57 courses £4349 £750 £4918 £5591 £819 £6405 
Course 1 34 courses £4397 £750 £4918 £5689 £819 £6405 
Course 2 + 23 courses £4279 £2774 £4751 £5447 £3688 £6055 
AML 14 7 courses £4631 £4248 £4918 £5977 £5408 £6405 
Course 1 4 courses £4918 £4918 £4918 £6405 £6405 £6405 
Course 2 3 courses £4248 £4248 £4248 £5408 £5408 £5408 
AML 15 21 courses £4679 £4248 £4918 £6008 £5408 £6405 
Course 1 10 courses £4884 £4751 £4918 £6341 £6089 £6405 
Course 2 11 courses £4492 £4248 £4751 £5704 £5408 £6055 
DA (D35 C200) 5 courses £4470 £3854 £4792 £5826 £5014 £6278 
AML 14 5 courses £4470 £3854 £4792 £5826 £5014 £6278 
Course 1 3 courses £4792 £4792 £4792 £6278 £6278 £6278 
Course 2 2 courses £3988 £3854 £4122 £5148 £5014 £5282 
DA (D35 C400) 1 course £4707 - - £6194 - - 
AML 14 1 course £4707 - - £6194 - - 
Course 1 1 course £4707 - - £6194 - - 
Course 2 - - - - - - - 
DA+Mylotarg 8 courses £6253 £4248 £6539 £7699 £5408 £8026 
Chemotherapy 1 course £6539 - - £8026 - - 
Course 1 1 course £6539 - - £8026 - - 
Course 2 + - - - - - - - 
AML 15 7 courses £6212 £4248 £6539 £7652 £5408 £8026 
Course 1 6 courses £6539 £6539 £6539 £8025 £8025 £8025 
Course 2 1 course £4248 - - £5408 - - 
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among the clinical trial arms, the costs of DA in the AML 14 trial were higher than the 
costs of DA in the AML 15 trial. 
 
e. FLAG-Ida 
 
FLAG-Ida regimen was the third most commonly used chemotherapy regimen. The cost 
results are illustrated in Figure 9.6.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.6 The illustration of the FLAG-Ida regimen cost results 
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As illustrated, the FLAG-Ida was used mainly in clinical trial (85%). As shown on the 
plot, the costs were divided into two groups. Cycle two was more costly than cycle one, as 
the hospital stays of cycle two were much longer (please refer to chapter 5). It is worth 
noting that, compared to other regimen cost drivers, the FLAG-Ida complication 
treatment cost was the only complication treatment cost that accounted for such high 
percentage (56%). A possible reason for this was that more antibiotic days were 
prescribed during the FLAG-Ida treatment (refer to section 4.3.2 for details). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The detailed cost results are shown in Table 9.5. As listed, that the average FLAG-Ida 
regimen cost per cycle was £8403 (including the complication treatment cost). More 
specifically, the average cost for cycle one was found to be £7551 and £9344 for cycle 
two.   
 
 
 
f. MACE 
 
MACE was the one of the most commonly used consolidation chemotherapies for AML. 
The related cost results are illustrated below (Figure 9.7).   
Table 9.5 The detailed cost results of the FLAG-Ida regimen 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
FLAG-Ida 40 courses £6575 £5505 £7582 £8403 £6909 £10131 
Course 1 21 courses £6243 £5505 £6376 £7551 £6909 £7780 
Course 2 19 courses £6943 £5572 £7582 £9344 £7139 £10131 
Chemotherapy 6 courses £6503 £6153 £7582 £7963 £7155 £10131 
Course 1 5 courses £6287 £6153 £6376 £7530 £7155 £7780 
Course 2 + 1 course £7582 - - £10131 - - 
AML 15 34 courses £6588 £5505 £7582 £8480 £6909 £10131 
Course 1 16 courses £6230 £5505 £6376 £7558 £6909 £7780 
Course 2 18 courses £6907 £5572 £7582 £9300 £7139 £10131 
FLAG-Ida + Mylotarg 19 courses £7807 £7037 £7998 £9449 £8040 £10131 
Chemotherapy 1 course £7774 - - £8777 - - 
Course 1 1 course £7774 - - £8777 - - 
Course 2 + - - - - - - - 
AML 15 18 courses £7809 £7037 £7997 £9486 £8040 £10131 
Course 1 13 courses £7896 £7037 £7997 £9238 £8040 £9401 
Course 2 5 courses £7582 £7582 £7582 £10131 £10131 £10131 
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Figure 9.7 The illustration of the MACE regimen cost results 
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As shown in the plot, the MACE cost was quite consistent, as most of the patients were 
given one full dose cycle of MACE. As shown in the pie chart, the ward cost still account 
for the highest percentage (38%), while the drug cost was next (25%). The detailed cost 
results are shown in Table 9.6 below. As shown on the table, the average MACE regimen 
cost per cycle was found to be £4583 (including the complication treatment cost).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
g. MidAC 
 
MidAC was another commonly used consolidation chemotherapy for AML normally 
used after MACE. The cost results are illustrated in Figure 9.8. 
Table 9.6 The detailed cost results of the MACE regimen 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
MACE 21 courses £3519 £2829 £3553 £4583 £3480 £4638 
Chemotherapy 11 courses £3488 £2829 £3553 £4533 £3480 £4638 
Course 1 10 courses £3481 £2829 £3553 £4522 £3480 £4638 
Course 2 + 1 course £3553 - - £4638 - - 
AML 15 10 courses £3553 £3553 £3553 £4638 £4638 £4638 
Course 1 10 courses £3553 £3553 £3553 £4638 £4638 £4638 
Course 2 - - - - - - - 
MACE + Mylotarg 9 courses £5175 £5175 £5175 £6259 £6259 £6259 
AML 15 9 courses £5175 £5175 £5175 £6259 £6259 £6259 
Course 1 9 courses £5175 £5175 £5175 £6259 £6259 £6259 
Course 2 - - - - - - - 
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Figure 9.8 The illustration of the MidAC regimen cost results 
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As it can be observed in the relevant plot, the MidAC cost was generally consistent when 
the full dose was given. As illustrated in the pie chart, the ward cost accounted for the 
highest percentage (44%) and the drug cost was next (24%). The ward cost percentage 
was also the highest percentage among all the chemotherapy regimens.  
 
The detailed cost results are shown in Table 9.7 below. As illustrated, the average MidAC 
regimen cost per cycle was found to be £4771 (including the complication treatment 
cost). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
h. Spanish Approach 
 
The Spanish approach was one of the most commonly used regimens for APML. The cost 
results are illustrated in Figure 9.9.   
Table 9.7 The detailed cost results of the MidAC regimen 
 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
MidAC 31 courses £3967 £3038 £4094 £4771 £3389 £4971 
Chemotherapy 17 courses £3913 £3038 £4094 £4687 £3389 £4971 
Course 1 15 courses £3889 £3038 £4094 £4649 £3389 £4971 
Course 2 + 2 courses £4094 £4094 £4094 £4971 £4971 £4971 
AML 15 14 courses £4032 £3518 £4094 £4872 £4044 £4971 
Course 1 14 courses £4032 £3518 £4094 £4872 £4044 £4971 
Course 2 - - - - - - - 
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Figure 9.9 The illustration of the Spanish approach regimen cost results 
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The  Spanish  approach  costs  contained  four  cycles.  Generally,  cycle  one  cost  was  the  
highest  followed by  cycle  two,  while  the  cycle  four  cost  was  the  lowest.  As  it  can  be  
observed in the pie chart, the ward cost still accounted for the highest percentage (33%) 
followed by the drug cost. It is worth noting that the Spanish approach was used mainly in 
clinical trial (82%) for patients who met the required criteria. For patients who did not 
meet the criteria, only few cases were found to have received the Spanish approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.10 The illustration of the Spanish maintenance cost results 
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Except the intensive four-cycle inpatient treatment, the Spanish approach also contained 
long term outpatient maintenance. The cost results are illustrated Figure 9.10. As it can 
be observed in the plot, the costs varied depending on the maintenance time. Also, since 
the maintenance was outpatient based, the drug cost accounted for the highest percentage 
(65%) 
 
The detailed cost results are shown in Table 9.8. As it can be seen in the table, the average 
Spanish regimen cost per cycle was found to be £5799 (including the complication 
treatment cost). More specifically, a rise in the number of treatment cycles resulted in a 
progressive decrease in average costs. The average costs for cycle one to cycle four were 
found to be £7094, £5743, £5211, and £4608 respectively. For the maintenance cost, only 
five patients were found to receive the Spanish maintenance treatment, and the average 
maintenance cost was found to be £3165. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i. MRC approach  
 
The MRC approach was another commonly used regimens for APML. The cost results 
are illustrated in Figure 9.11. As illustrated in the relevant plot, unlike the Spanish 
approach, the costs did not decrease progressively. In general, the cost of cycle one was 
the highest, followed by the one of cycles two and four, while the cycle three was the 
Table 9.8 The detailed cost results of the Spanish approach / maintenance regimen 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
Spanish 33 courses £4636 £3339 £6403 £5799 £3964 £7595 
Course 1 10 courses £5975 £3508 £6403 £7094 £3964 £7595 
Course 2 9 courses £4579 £3339 £4734 £5743 £4285 £5926 
Course 3 7 courses £4019 £3789 £4057 £5211 £4981 £5249 
Course 4 7 courses £3416 £3377 £3645 £4608 £4569 £4837 
Spanish-like  6 courses £4951 £3645 £6403 £6143 £4837 £7595 
Course 1 2 courses £6403 £6403 £6403 £7595 £7595 £7595 
Course 2 2 course £4734 £4734 £4734 £5926 £5926 £5926 
Course 3 1 course £3789 - - £4981 - - 
Course 4 1 course £3645 - - £4837 - - 
AML 15 27 courses £4566 £3339 £6403 £5722 £3964 £7595 
Course 1 8 courses £5868 £3508 £6403 £6968 £3964 £7595 
Course 2 7 courses £4534 £3339 £4734 £5691 £4285 £5926 
Course 3 6 courses £4057 £4057 £4057 £5249 £5249 £5249 
Course 4 6 courses £3377 £3377 £3377 £4569 £4569 £4569 
Spanish maintenance 5 patients £3165 £914 £4563 £3165 £914 £4563 
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lowest. Similarly to the Spanish approach, the MRC approach was also used mainly in 
clinical trial (89%). As it can be observed in the pie chart, the ward cost still accounted for 
the highest percentage (33%) followed by the drug cost (23%).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.11 The illustration of the MRC approach cost results 
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The detailed cost results are shown in Table 9.9. As it can be seen in the table, the average 
MRC approach regimen cost per cycle was found to be £5606 (including the complication 
treatment cost). Consisted with the plot result, the costs did not decrease progressively. 
The average costs were £6575, £6143, £4300, and £5216 respectively for cycles one to 
four. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
j. Hydroxycarbamide 
 
The hydroxycarbamide was the most commonly used outpatient based regimen. In total, 
39 events of using hydroxycarbamide were used. The cost results are illustrated in Figure 
9.12.   
Table 9.9 The detailed cost results of the MRC approach regimen 
 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
MRC 35 courses £4283 £3511 £5500 £5606 £4300 £6795 
Course 1 10 courses £5301 £3511 £5500 £6575 £4594 £6795 
Course 2 9 courses £4160 £4041 £4175 £6143 £6024 £6158 
Course 3 9 courses £3617 £3617 £3617 £4300 £4300 £4300 
Course 4 7 courses £3841 £3841 £3841 £5216 £5216 £5216 
AML 15 31 courses £4283 £3511 £5500 £5606 £4300 £6795 
Course 1 9 courses £5279 £3511 £5500 £6550 £4594 £6795 
Course 2 8 courses £4159 £4041 £4175 £6141 £6024 £6158 
Course 3 8 courses £3617 £3617 £3617 £4300 £4300 £4300 
Course 3 6 courses £3841 £3841 £3841 £5216 £5216 £5216 
MRC like 4 courses £4283 £3617 £5500 £5617 £4300 £6795 
Course 1 1 course £5500 - - £6795 - - 
Course 2 1 course £4175 - - £6158   
Course 3 1 course £3617 - - £4300 - - 
Course 4 1 course £3841 - - £5216 - - 
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Figure 9.12 The illustration of the Hydroxycarbamide cost results 
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As illustrated in the plot, the hydroxycarbamide cost varied depending on the treatment 
time. Also, as shown in the pie chart, the composition of the hydroxycarbamide cost was 
very different from the inpatient-based regimens. The drug cost only accounted for a very 
low percentage (10%), with the complication treatment cost and the personnel costs 
dominating the percentage shares (41% and 27% respectively). 
 
The detailed cost results are shown in Table 9.10 below. As it can be seen in the table, the 
average hydroxycarbamide regimen cost per event was found to be £226 (including the 
complication treatment cost). No hydroxycarbamide was used in clinical trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
k. FC related regimens 
 
The FC related regimens were the second commonly used outpatient based regimen. The 
drugs of the FC regimen can be used separately as a single agent or combined. The cost 
results are illustrated in Figure 9.13.   
Table 9.10 The detailed cost results of the hydroxycarbaminde regimen 
 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
Hydroxycarbamide 39 events £132 £59 £384 £226 £63 £506 
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Figure 9.13 The illustration of the FC related regimen cost results 
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As illustrated in the plot, the cost of the combination of Fludarabine and 
Cyclophosphomide was the highest, followed by the cost of Fludarabine (used alone), 
while the cost  of cyclophosphomide (used alone) was the lowest.  As shown in the pie 
chart, it was observed that cyclophosphamide (37%) and FC occupied the largest 
percentage share (38%). After further breaking down, it was found that drug costs were 
the most important cost drivers for cyclophosphamide (55%) and for FC (91%) 
 
The cost results are shown in Table 9.11. As shown in the table, the average FC regimen 
cost per event was found to be £775. For the single agent, the average costs for 
Fludarabine and Cyclophosphamide were found to be £594 and £128 respectively. 
 
 
 
 
 
 
 
 
 
 
 
l. Summary 
 
The costs of chemotherapies and clinical trial arms varied depending on several factors. 
From the results discussed in previous sections, it was observed that, among all the 
chemotherapy regimens, the cost of clinical trial was slightly higher than the cost of 
non-clinical trial (chemotherapy), except ADE, AraC (HD), and the Spanish approach. 
The possible reason for this could be that the patients who entered the clinical trial were 
selected with specific criteria. Therefore, they had higher possibility to tolerate full 
course of treatment compared to other patients, something that caused the average cost of 
the clinical trial to be increased.   
Furthermore, taking the clinical trial arms and chemotherapies as a whole, regimen costs 
were driven by the five cost drivers. For inpatient chemotherapies, it was found that the 
ward cost was the largest fraction (from 33% to 44%) and followed by the drug cost (from 
18% to 34%), and then all the others. The FLAG-Ida was the only exception to the above. 
Possible reason for this might be that the relatively high level of the antibiotic needs (refer 
to chapter 6) compressed the percentages of other cost drivers. For the cost distribution of 
Table 9.11 The detailed cost results of the FC related regimens 
 
Events 
No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
FC 6 £775 £215 £1687 £775 £215 £1687 
Fludarabine 2 £594 £364 £823 £594 £364 £823 
Cyclophosphamide 6 £128 £128 £128 £128 £128 £128 
Cyclophosphamide + MESNA 1 £173 - - £173 - - 
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the outpatient chemotherapies, the composition percentages of cost drivers varied. This 
was because the drug costs of outpatient chemotherapies varied extremely from very low 
(i.e. Hydroxycabarmide at £0.72 per day) to very expensive (i.e. Daunorubicin at £316 
per day). Therefore, the composition percentage patterns of outpatient chemotherapies 
were not as consistent as the inpatient based chemotherapies. 
Based on the whole of the regimen cost results, it is worth noting that the cost results of 
the regimens along with Mylotarg equated to the costs of the regimen alone plus the 
Mylotarg cost. Taking ADE + Mylotarg as an example, the average cost for cycle one was 
found to be £7290. This value was close to the summation of the ADE cycle one cost  
(£5799) with the Mylotarg cost (£1619).  
Overall, the average cost per inpatient chemotherapy cycle was found to be £5829 and the 
cost  per  outpatient  chemotherapy  event  £640.  The  summary  of  the  costs  of  all  the  
regimens used on the study patients (including regimen costs that are not covered in detail 
in section 9.1) can be found in the Table 9.12 below, while the relevant details  can be 
found in Appendix 9.1. 
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 Table 9.12 The summary of the cost results of all the chemotherapy regimens 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
Chemotherapy 329 courses £3440 £59 £13770 £4284 £60 £15030 
Clinical trial 265 courses £5010 £914 £7997 £6220 £914 £10131 
Chemotherapy + trial 594 courses £4140 £59 £13770 £5148 £60 £15030 
Inpatient chemotherapy 516 courses £4678 £638 £13770 £5829 £729 £15030 
Outpatient chemotherapy 78 events £587 £59 £5112 £640 £60 £5112 
ADE 47 courses £4367 £4797 £2553 £5284 £2677 £6036 
Course 1 23 courses £4625 £2553 £4797 £5799 £2677 £6036 
Course 2 24 courses £4120 £3938 £4287 £4790 £4522 £5037 
ADE + Mylotarg 10 courses £6132 £4113 £6418 £7290 £4779 £7657 
Course 1 9 courses £6357 £6069 £6418 £7568 £7060 £7657 
Course 2 1 course £4113 - - £4779 - - 
AraC (HD) 40 courses £4091 £3092 £4405 £4919 £3689 £5315 
Course 1 21 courses £4389 £4204 £4405 £5299 £5114 £5315 
Course 2 19 courses £3761 £3092 £3802 £4499 £3689 £4548 
AraC(HD) + Mylotarg 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Course 1 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Course 2 - - - - - - - 
AraC (LD) 83 courses £3396 £638 £4895 £4088 £729 £5852 
Course 1 39 courses £3226 £638 £4895 £4002 £729 £5852 
Course 2 44 courses £3547 £1285 £4359 £4164 £1348 £4989 
AraC (LD) + Mylotarg 2 courses £5170 £4359 £5980 £5963 £4989 £6938 
Course 1 1 course £5980 - - £6938 - - 
Course 2 1 course £4359 - - £4989 - - 
DA 91 courses £4458 £750 £4918 £5738 £819 £6405 
Course 1 52 courses £4559 £750 £4918 £5913 £819 £6405 
Course 2 39 courses £4322 £2774 £4751 £5501 £3688 £6055 
DA+Mylotarg 8 courses £6253 £4248 £6539 £7699 £5408 £8026 
Course 1 7 courses £6539 £6539 £6539 £8025 £8025 £8025 
Course 2 1 course £4248 - - £5408 - - 
Clofarabine 3 courses £13256 £12631 £13770 £14516 £13891 £15030 
FLA 7 courses £4713 £3565 £5709 £6551 £4865 £7909 
Course 1 4 courses £4503 £4503 £4503 £6294 £6294 £6294 
Course 2  3 courses £4994 £3565 £5709 £6894 £4865 £7909 
FLAG 25 courses £5305 £4474 £6283 £7100 £5759 £8615 
Course 1 16 courses £5303 £4661 £5479 £6951 £5759 £7402 
Course 2  9 courses £5308 £4474 £6283 £7365 £6233 £8615 
FLAG-Ida 40 courses £6575 £5505 £7582 £8403 £6909 £10131 
Course 1 21 courses £6243 £5505 £6376 £7551 £6909 £7780 
Course 2 19 courses £6943 £5572 £7582 £9344 £7139 £10131 
FLAG-Ida + Mylotarg 19 courses £7807 £7037 £7998 £9449 £8040 £10131 
Course 1 14 courses £7896 £7037 £7997 £9238 £8040 £9401 
Course 2 5 courses £7582 £7582 £7582 £10131 £10131 £10131 
MACE 21 courses £3519 £2829 £3553 £4583 £3480 £4638 
MACE + Mylotarg 9 courses £5175 £5175 £5175 £6259 £6259 £6259 
MidAC 31 courses £3967 £3038 £4094 £4771 £3389 £4971 
HAM 1 courses £5883 - - £6949 - - 
Spanish 33 courses £4636 £3339 £6403 £5799 £3964 £7595 
Course 1 10 courses £5975 £3508 £6403 £7094 £3964 £7595 
Course 2 9 courses £4579 £3339 £4734 £5743 £4285 £5926 
Course 3 7 courses £4019 £3789 £4057 £5211 £4981 £5249 
Course 4 7 courses £3416 £3377 £3645 £4608 £4569 £4837 
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 MRC 35 courses £4283 £3511 £5500 £5606 £4300 £6795 
Course 1 10 courses £5301 £3511 £5500 £6575 £4594 £6795 
Course 2 9 courses £4160 £4041 £4175 £6143 £6024 £6158 
Course 3 9 courses £3617 £3617 £3617 £4300 £4300 £4300 
Course 4 7 courses £3841 £3841 £3841 £5216 £5216 £5216 
Amsacrine 1 courses £2155 - - £3300 - - 
Arsenic trioxide 2 courses £10391 £10391 £10391 £11537 £11537 £11537 
Campath 1 courses £2211 - - £3357 - - 
ATRA 3 events £334 £106 £757 £405 £124 £922 
Anagrelide 1 events £152 - - £152 - - 
Clopidogrel 1events £92 - - £92 - - 
Cyclophosphamide 6 events £128 £128 £128 £128 £128 £128 
Cyclophosphamide + MESNA 1 events £173 - - £173 - - 
Daunorubicin 1 events £768 - - £768 - - 
ETI 2 events £1440 £786 £2095 £1440 £786 £2095 
FC 6 events £775 £215 £1687 £775 £215 £1687 
Fludarabine 2 events £594 £364 £823 £594 £364 £823 
Mylotarg 1 events £1712 - - £1909 - - 
Melphalan 3 events £228 £128 £382 £228 £128 £382 
Aspirin 2 events £90 £60 £120 £90 £60 £120 
Hydroxycarbamide 39 events £132 £59 £384 £226 £63 £506 
Hydroxycarbamide / Aspirin 1 events £2244 - - £2366 - - 
Chelating agents 2 events £3874 £2636 £5112 £3874 £2636 £5112 
Vincristine 1 events £374 - - £374 - - 
Spanish maintenance 5 events £3165 £914 £4563 £3165 £914 £4563 
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9.2.2 Supportive therapy 
 
Supportive care had four different sub-types, namely G-CSF, erythropoietin, steroids and 
transfusion (please refer to chapter 7 for details). The three most commonly used 
supportive therapies are discussed in the following paragraphs, while the detailed cost 
results are listed in Table 9.13 below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. G-CSF 
 
G-CSF was the second most commonly used supportive therapy. As shown on Table 9.13, 
the average cost of G-CSF per event was found to be £827. According to the purposes of 
using G-CSF, the G-CSF can be further divided into two sub-types: inpatient and 
outpatient G-CSF (please refer to chapter 7 for details). When inpatient G-CSF was used 
as the adjunctive therapy of curative chemotherapy, the average cost was found to be 
£748. When outpatient G-CSF was used for long-term maintenance purposes, the average 
cost was found to be £1447. The cost results are illustrated in Figure 9.14. As shown in 
the pie chart, the inpatient G-CSF treatments were the most common (89%). Since the 
G-CSF was an expensive drug, the drug cost accounted for the highest percentage for 
both inpatient and outpatient G-CSF treatments.  
 
 
Table 9.13 The detailed cost results of the supportive therapies 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
Transfusion 267 events £8861 £530 £67282 £8861 £530 £67282 
 190 patients £12453 £530 £75229 £12453 £530 £75229 
G-CSF 62 events £827 £197 £4765 £827 £197 £4765 
 41 patients £1251 £197 £4765 £1251 £197 £4765 
 55 IP events £748 £197 £1182 £748 £197 £1182 
 7 OP events £1447 £596 £4765 £1447 £596 £4765 
Steroids 13 events £300 £59 £1733 £300 £59 £1733 
Dexamethasone 5 events £110 £62 £289 £110 £62 £289 
Prednisolone 7 events £467 £59 £1733 £467 £59 £1733 
Hydrocortisone 1 event £79 - - £79 - - 
Erythropoietin 3 events £1628 £111 £4440 1628 £111 £4440 
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Figure 9.14 The illustration of the G-CSF cost results 
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b. Steroids 
 
Steroids was another commonly used supportive therapy. Table 9.13 shows the average 
costs of the three different drugs that were used on the study patients. Without taking the 
drug types into consideration, the average steroids cost per event was found to be £300. 
Taking the drug types into consideration, the average cost result per cycle for 
Hydrocortisone  was  the  lowest  and  for  the  Prednisolone  the  highest,  in  sharp  contrast  
with the unit costs of these two drugs which were the exact opposite. This was because 
the average treatment time per cycle of Hydrocortisone was the shortest, compared to 
Prednisolone which was the longest. The cost results are illustrated in Figure 9.15.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.15 The illustration of the steroids cost results 
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As shown on the pie chart, Prednisolone was the most commonly used drug among three 
steroids drugs. Also, it can be observed that the personnel cost (51%) and the clinic cost 
(30%) accounted for the majority of the cost percentage share, while the drug cost 
accounted for the lowest percentage share, as the unit cost of the drug was low. 
 
c. Transfusion 
 
Transfusion was the most commonly used supportive therapy on the study patients. Based 
on the unit cost of the transfusion (£414/transfusion as described in chapter 7), Table 9.13 
illustrates the average transfusion costs per event (£8861) and per patient (£12453). The 
cost results are also illustrated in Figure 9.16 below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.16 The illustration of the transfusion cost results 
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As shown on the relevant plot, although the transfusion cost varied widely, most of the 
transfusion costs per person were below £10000. The breaking down pie chart shows the 
components accounted for the highest percentage (78%). 
 
 
 
9.2.3 Palliative care and end-of-life care 
 
189 out of 239 study patients died because of AML. According to the information in the 
HMRN database, 33 patients had received palliative care before death while 68 died 
during the treatments. However, the situation of the rest of 88 patients when they were at 
terminal stage was unknown. In order to avoid underestimating the care cost, the end-of 
life cost was applied to all cases with the exception of the 22 patients who died at home 
(please refer to section 7.10 for costing details). The estimated cost results are listed in 
Table 9.14 below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown on the table, the average palliative care cost was £2223, while the average cost 
for the estimated 14-day end of life care was £938.  The cost results are illustrated below 
(Figure 9.17).   
Table 9.14 The detailed cost results of the palliative and end-of-life care 
 
 
Events No 
Cost 1 (exclude 
complication cost) 
Cost 2 (include 
complication cost) 
Mean Min Max Mean Min Max 
Palliative care 33 patients £2223 £336 £6313 £2223 £336 £6313 
End of life care 66 patients £938 - - £938 - - 
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Figure 9.17 The illustration of the palliative and end-of-life care cost results 
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9.2.4 Stem cell transplantation related treatments 
 
 
Stem cell transplantation was one of the most important consolidation treatment options 
for  AML/APML.  According  to  the  information  from  the  HMRN  database,  three  
treatments were related to stem cell transplantation, namely radiotherapy (before 
transplantation), stem cell transplantation, and immunosuppressive therapy (after 
transplantation).  The  cost  results  of  each  treatment  are  listed  in  Table 9.15, while the 
relevant details are discussed in the following sections.  
 
 
 
 
 
 
 
 
 
 
a. Radiotherapy 
 
According to the HMRN records, 14 radiotherapies were used among 13 patients who 
received stem cell transplantation. Since no treatment details were avaliable, the 
radiotherapy cost was directly retreived from the ‘Reference Cost Index’ (please refer to 
section 7.13 for costing details). The cost results are illustrated below (Figure 9.18).   
Table 9.15 The detailed cost results of the stem cell transplantation related treatments 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
Radiotherapy 14 events £1318 £635 £2771 £1318 £635 £2771 
Stem cell transplant 13 patients £44199 - - £44199 - - 
Immunosuppressive 6 patients £5302 £82 £16684 £5302 £82 £16684 
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Figure 9.18 The illustration of the Radiotherapy cost results 
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As illustrated, two types of radiotherapy were used. TBI was slightly more common 
(57%). The average cost was found to be £1318 per event. This cost included the 
treatment planning cost (12%), the preparation cost for the radiotherapy (34%), and the 
radiotherapy itself (54%). 
 
 
b. Stem cell transplantation 
 
According  to  the  HMRN  records,  13  patients  were  found  be  received  the  stem  cell  
transplantation as their consolidation treatment. Since no treatment details were avaliable, 
the  transplantation  cost  was  directly  retreived  from the  ‘Reference  Cost  Index’  (please  
refer to section 7.14 for costing details).  
 
The cost results are illustrated below (Figure 9.19). As illustrated, the costs of all stem 
cell transplantions were the same (£44199). This was the consequence of direct applying 
the ‘Reference Cost Index’ as the treatment cost. Therefore, the difference between 
individuals were not possible to be captured. It is worth noting that the transplantation 
costconsisted three differe costs, namely consulting visit, stem cell harvest (18%), and the 
actual stem cell transplantation (82%). 
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Figure 9.19 The illustration of the stem cell transplantation cost results 
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c. Immunosuppressive therapy 
 
Immunosuppressive therapy was the treatment that was carried out after stem cell 
transplantation for preventing or treating the graft-versus-host disease. Among 13 
patients  who  received  stem  cell  transplantations,  six  were  found  to  be  involved  in  
immunosuppressive therapy. The cost results (illustrated in Figure 9.20) were obtained 
based on the assumptions and costing method discussed in section 7.7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in the relevant plot, the cost results varied heavily (£82~ £16684). This was due 
to  the  difference  of  the  lengths  of  the  treatment  time.  Finally,  the  average  cost  of  the  
immunosuppressive therapy was found to be £5302 (with drug cost accounting for 85%).  
 
Figure 9.20 The illustration of the immunosuppressive therapy cost results 
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9.2.5 Follow-up visit / observation 
 
Follow-up visit was one of the most commonly used interventions in the HMRN database. 
Since  many other  interventions  also  took  place  during  the  outpatient  visit  (such  as  the  
outpatient chemotherapy and immunosuppressive therapy), the follow-up time period in 
the current study was defined as the gap between any treatments, in order to avoid 
overestimating the cost (please refer to section7.9 for details). The cost results are 
illustrated in Figure 9.21 below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.21 The illustration of the follow-up visit cost results 
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As illustrated, the follow-up costs varied (£53~£4416) depending on the patients’ 
conditions. The average cost of follow-up visits per patient was found to be £1326, and 
the personnel cost and clinic cost accounted for the highest percentage (88% in total).  
 
Detailed cost results can be found in Table 9.16 below. 
 
 
 
 
 
 
Table 9.16 The detailed cost results of the follow-up visits 
 
Events No 
Cost 1 (exclude 
complication cost) 
Cost 2 (include 
complication cost) 
Mean Min Max Mean Min Max 
Observation 135 patients £1326 £53 £4416  
   No treatment 10 patients £335 £53 £1649 
   Refused treatment 2 patients £80 £53 £106 
Follow-up 123 patients £1427 £53 £4416 
 269 events £653 £53 £3564 
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9.2.6 Comparison with previous relevant studies 
 
The current section involves the comparison of the cost results and/or the costing methods 
of the current study with the results from previous related studies (please refer to chapter 
2).  The  reason  for  the  comparison  was  to  justify  the  reliability  of  the  costing  methods  
and/or the accuracy of the cost results of the current work. 
 
It must be stressed that there were cases where the comparison was not possible for 
various reasons, such as the use of different definitions, the inclusion of different cost 
drivers, differences in the dosages used in regimens, or unreported cost numbers. In cases 
such  as  ones  described  above,  detailed  cost  break  down information  was  not  available  
(such as palliative care), and thus, the comparison was omitted. 
 
a. Chemotherapy 
 
The comparison of the chemotherapy cost of the current work with the ones of other 
relevant studies was challenging, mainly because of three reasons. Firstly, the studies that 
focused on chemotherapy costing are limited (please refer to chapter 2 for details). 
Secondly,  the  regimens  or  the  dosages  of  the  regimens  that  were  used  in  the  relevant  
studies were different from the ones used in the current study. Thirdly, the cost drivers 
involved in each study were different. When the detailed cost information of each cost 
driver was not available, a comparison was impossible to be carried out. After careful 
matching, only one study was comparable. The comparison results are presented in Table 
9.17 below. 
 
 
 
 
 
 
 
 
 
 
As shown on the table above, in cases where the same cost drivers were involved, the cost 
results  of  both  studies  were  relatively  consistent.  In  other  wards,  Clavio’s  study  [112]  
validated the cost result of the ADE regimens. 
Table 9.17 The comparison of ADE cost with previous studies 
  Clavio’s study  The current study 
Country  Italy UK 
Regimen  AML 10 ADE cycle 1 
Cost drivers Personnel and services cost ˇ ˇ 
 Drug cost ˇ ˇ 
 Complication cost ˇ ˇ 
 Other costs ˇ ˇ 
Result  $6671 £5799 
Cost in 2007  £5940 £5799 
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b. G-CSF  
 
The G-CSF costing method contained several assumptions, as the treatment details were 
unavailable (please refer to section 7.6 for the costing details and assumptions). In order 
to validate the costing method and the cost result, a comparison with relevant studies was 
conducted (please refer to chapter 2 for details of the relevant study search). After 
converting the results into comparable forms, the comparison table was possible to be 
created (Table 9.18). 
 
 
 
 
 
 
 
 
 
As  shown  on  the  table  above,  compared  to  the  UK  study  [206],  the  cost  result  of  the  
current study (£1251 per patient) was much lower than the result of Standaert’s study 
[206] (£1435.8 per patient), regarding that ward and clinic costs have not included into 
Standaert’s result. Also, compared to Bradstock’s study [207] that was carried out in 
Australia, the average G-CSF cost in first remission time of the current study was much 
lower too (£1009 vs £1548), regarding that Bradstock et al. [207] calculated the drug cost 
only. A possible explanation for this significant difference might be the fact that the unit 
cost was retrieved from the different resources. Also, in the current study, protocol 
suggestions and expert opinions were used to predict the number of uses (please refer to 
chapter 7 for details), while in the Standaert’s [206] and Bradstock’s studies [207], the 
actual usage data was used as the quantity. Therefore, based on the comparison result, the 
G-CSF cost in the current study is possible to have been underestimated.  
 
c. Transfusion 
 
Comparing the transfusion cost of the current study with previous relevant studies was 
challenging, as the settings, the unit cost of blood products, and the involved cost drivers 
were all different. Therefore, for convenience and availability reasons, it was decided to 
compare the costing method (such as the uses of resource and the unit cost) instead of the 
transfusion cost results. 
Table 9.18 The comparison of G-CSF cost with previous studies 
Relevant studies 
The current study 
Study name Year Country G-CSF cost Value in 2007 
Standaert’s study  
(no ward cost) 
1998 UK £1413 per 
patient 
£1794 per 
patient 
£1251 per patient 
Bradstock’s study 
(drug cost only) 
2001 Australia A$3684  £1548 till 1st 
remission 
£1009 till 1st 
remission 
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Among all the relevant AML cost studies, only one UK study included information 
related  with  platelet  transfusion  cost  [206].  According  to  Standaert  et  al  [206],  it  was  
found that the cost of platelet products were £172.47/day, and the total platelet cost in the 
induction cycle was £1655.71 in 1998 (roughly 10 transfusions occurred in induction 
cycle). When compared to the costing method of the current study, the unit cost of the 
platelet was found to be similar (£153/day vs £172/day), as both studies used the same 
information resource [181]. Also, based on the extrapolated transfusion frequency of the 
current study (refer to chapter 5), it was found that the average number of transfusions 
given to the study patients in induction cycle was 8.5, which is close to the transfusion 
number in the result of the Standaert et al study [206]. The relevant details can be found in 
the following table (Table 9.19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cartoni et.al [150] has also cost transfusion in Italy in 2007. The study showed that the 
number of transfusions in disease time or end of life stage was 6.1 (+ 3.5) transfusions per 
month, and in the rest of time were 1.6 (+ 1.4) transfusions per month. After a comparison 
of Cartoni’s results [150] with the number of transfusions per month of the current study 
(7 transfusions per month in short disease time, and 2 transfusions per month in long 
disease time), it was observed that the numbers of transfusions in both studies were very 
close. More details can be found in Table 9.19 above. 
 
Based on the above, it was safe to claim that the extrapolated transfusion frequency used 
in the current study was close to the real frequency, and thus, it was a reliable piece of 
information suitable for costing the transfusion. 
Table 9.19 The comparison of transfusion cost with previous studies 
Comparison 1 
Standaert et al study  The current study 
Unit cost Resource use Unit cost Extrapolated frequency 
(refer to chapter 5) 
Retrieved from the 
National Blood 
Service  
10 transfusions in 
induction cycle 
Retrieved from the 
National Blood 
Service  
8.5 transfusions in induction 
cycle 
 
Comparison 2 
Cartoni et.al study  The current study 
Unit cost Resource use Unit cost Extrapolated frequency 
(refer to chapter 5) 
 Disease time /end of life stage:  
6.1 (+ 3.5) transfusions per month 
 Disease time<2 months: 
7 transfusion per month 
 Other status: 
1.6 (+ 1.4) transfusions per month 
 Disease time>2 months: 
2 transfusion per month 
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d. Immunosuppressive therapy 
 
Although there was no relevant immunosuppressive therapy costing study on AML, it 
was decided that it could be worthwhile to look at the cost from other types of 
transplantations. According to the NHS report [208], the immunosuppressive therapy 
cost after kidney transplantation was found to be £870 for first six weeks, which means 
£145 per week. After comparing the aforementioned cost with the unit cost of the 
immunosuppressive therapy used in the current study (£23.5 per day, £164.5 per week), it 
was  observed  that  the  cost  difference  between the  two studies  was  small.  This  finding  
support the validity of the costing method used in the current study for 
immunosuppressive therapy. 
 
e. Transplantation 
 
The  transplantation  cost  was  directly  derived  from  the  ‘Reference  Cost  Index’,  which  
represented the average transplantation cost in the UK. In order to validate the current 
cost result, a comparison with related international studies was conducted. After the 
relevant adjustment for the study time period, the currency exchange and the inflation 
comparison results (please refer to chapter 2 for the details) were obtained (Table 9.20). 
 
 
 
 
 
 
 
 
 
Although the costing methods and costing data varied between different studies, the 
differences were explainable. As it can be seen in Table 9.20 above, the estimates from all 
the studies [209-213] were relatively consistent, except the ones from Vicent’s [210] and 
Mishra’s [211] studies. The particularly low estimate from Vicent’s study [210] can be 
explained by the fact that the personnel cost was excluded from the study results. The 
particularly  high  estimate  from  Mishra’s  study  [211]  can  also  be  explained  by  the  
inclusion of the pre-transplantation cost (which started costing from consulting outpatient 
visit). Therefore, it can be claimed that relatively consistent SCT cost estimates have been 
found between the current and most of other involved studies. This finding potentially 
validates the estimated cost of the current study. 
Table 9.20 The comparison of stem cell transplantation cost with previous studies 
 Year Country Transplantation cost (from 
admission to discharge) 
Value in 
2007 
The current study (Reference cost) 2007 UK £44142 £44142 
Agthoven et al. study  1998 Netherland €39787 (£26880) £34138 
Vicent et al. study  1999 USA $11820 (£7319) £9002 
Mishra et al. study  1999 Norway $92272 (£57134) £70275 
Blaise et al. study  1998 France €37128 (£25084) £31857 
Uyl-de et al. study  1992 Netherland $51220 (£28101) £41028 
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9.2.7 Conclusion 
 
Section 9.2 brings the part of the study results and literature review results (chapter 2) 
together. In section 9.2, the estimated cost results of the main treatments (section 9.2.1 to 
section  9.2.5)  as  well  as  the  results  of  their  comparison  with  relevant  studies  (section  
9.2.6) were presented. The summarized cost result list of all the treatments can be found 
below (Table 9.21).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the limited number of related studies or incomparable cost information, not all the 
cost results or costing method could be appropriately compared. However, based on the 
cases that were possible to be compared (in section 9.2.6), it was found that most of the 
results  were  consistent,  with  the  exception  of  the  G-CSF  cost.  This  ensured  that  the  
overall  treatment  cost  calculation  (carried  out  at  later  stages  of  the  current  study)  was  
reliable. However, it must be stressed that the cases involving G-CSF treatment should be 
treated with caution when interpreting the results.  
Table 9.21 The summarized cost result list of all the treatments/interventions 
 
Events No 
Cost 1 (exclude complication 
cost) 
Cost 2 (include complication 
cost) 
Mean Min Max Mean Min Max 
Chemotherapy +clinical trial 594 courses £4140 £59 £13770 £5148 £60 £15030 
Inpatient chemotherapy 516 courses £4678 £638 £13770 £5829 £729 £5112 
Outpatient chemotherapy 78 events £587 £59 £5112 £640 £60 £5112 
Supportive care        
Transfusion 267 events £8861 £530 £67282 £8861 £530 £67282 
Erythropoietin 3 events £1628 £111 £4440 £1628 £111 £4440 
G-CSF 62 events £827 £197 £4765 £827 £197 £4765 
Steroids 13 events £300 £59 £1733 £300 £59 £1733 
Palliative care 33 patients £2223 £336 £6313 £2223 £336 £6313 
End-of-life care 66 patients £938 - - £938 - - 
Splenectomy 2 patients £4010 - - £4010 - - 
Venesection 3 patients £1168 £280 £2102 £1168 £280 £2102 
Immunosuppressive 6 patients £5302 £82 £16684 £5302 £82 £16684 
Stem cell transplant 13 patients £44199 - - £44199 - - 
Radiotherapy 14 events £1318 £635 £2771 £1318 £635 £2771 
Observation 135 patients £1326 £53 £4416 £1326 £53 £4416 
Laboratory test cost 239 patients £1746 £140 £16048 £1746 £140 £16048 
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9.3 Overall treatment cost results with no treatment overlapping 
 
The  current  section  describes  the  results  of  overall  treatment  cost  per  patient  without  
taking the treatment overlapping into consideration.  
 
Based on the costing method discussed in section 8.1, the cost results of each treatment 
(discussed in section 9.2) were linked to the corresponding events in the treatment 
pathway (please refer to chapter 4). Without taking the treatment overlapping into 
consideration, those events costs were directly summed up as overall treatment cost. The 
cost results are illustrated in Figure 9.22 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in the plot, the total cost distribution was like parabola, except two extreme 
estimates. The detailed cost results by treatment phases are listed in Table 9.22. 
 
 
 
 
 
Figure 9.22 The results of total treatment cost per patient (no treatment overlapping) 
Table 9.22 The detailed results of total treatment cost (no treatment overlapping) 
Treatment phase No. 
Cost results 
Average Min. Max. SD 
Total cost 239 £33192 £246 £254522 35326 
First line 239 £21826 £193 £103327 22726 
Induction  239 £13976 £193 £88795 17034 
Consolidation 103 £18215 £487 £78507 15030 
1st relapse-2nd relapse 42 £31749 £2350 £100967 25172 
2nd relapse-3rd relapse 6 £46846 £1589 £180446 69412 
3rd relapse + 2 £12250 £9257 £15242 4232 
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As shown in Table 9.22, the average cost increased progressively by the number of AML 
recurrences. The average cost of the first-line treatment was the lowest (£21826), 
followed by the treatment cost for the 2nd relapse (£31749). The treatment cost for the 2nd 
relapse period was the highest (£46846). It is worth nothing that the progressive cost 
increase did not apply to the cost after the 3rd relapse. As demonstrated in Table 9.22, the 
average cost for the 3rd relapse (£12250) was much less than the first line treatment cost. 
This inconsistence could be explained by two possible reasons. Firstly, the number of 
cases was too few in the current study (n=2). Therefore, the results might not be able to 
represent the whole resource use during the 3rd relapse. Secondly, patients might be very 
ill when they reached the 3rd relapse. Therefore, the average cost was much less as they 
died very quickly afterward.  
 
To conclude, the study found that the more times the AML recurred the higher the cost 
would be (before the 3rd relapse). Under this circumstance, the average overall treatment 
cost was found to be £33192. It is worth noting that all the overall treatment cost results 
discussed in this section were not the actual cost result, as the treatment overlapping issue 
was not taken in to consideration. However, these cost results gave a general idea of how 
the distribution of the overall cost results would be like. The overall cost that included the 
consideration of the treatment overlapping issue is discussed in the next section.  
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9.4 Overall treatment cost results with treatment overlapping 
 
The current section deals with the presentation of the results of the overall treatment costs 
per patient, including the consideration of the treatment overlapping issue.  
 
Based on the costing method discussed in section 8.2, a macro costing method that was 
included the consideration of the overlapping issue was applied in order to yield more 
reasonable and accurate cost results. There were two challenges in regards to this matter. 
Firstly, the overlapping treatments had to be identified and decisions had to be made on 
how the costs would be re-allocated/shared between them. To resolve this issue, a number 
of assumptions were made (please refer to section 8.2 for details). Secondly, the 
calculation (that integrated all the aforementioned definitions and assumptions) had to be 
executed with the statistical software. To resolve this issue, the SAS program (SAS 
software program package, version 8.02, SAS Institute, Cary, NC) was used. The cost 
calculation was carried out in three phases (please refer to section 8.2.3). Details 
regarding the calculation process can be found in section 9.1, while the cost results are 
presented in the following sections. 
 
9.4.1 Overall treatment  
 
The overall treatment cost results that were obtained from the aforementioned calculation 
are plotted in Figure 9.23 below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in the plot, the overall cost distribution was parabolic. The contributions of the 
costs for each treatment phase are illustrated below (Figure 9.24).
 
Figure 9.23 The overall treatment cost (with treatment overlapping) over the number of patient 
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Figure 9.24 The contributions of the costs for each treatment phase 
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As shown in Figure 9.24 above, the overall treatment costs were mainly driven by the 
first-line treatment cost and the number of AML recurrences. The detailed cost results 
ordered by treatment phases are listed in Table 9.23. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.23 demonstrates that the average cost increased progressively by the number of 
AML recurrences, with the exception of the treatment cost for the 3rd relapse (the reasons 
for this are discussed in section 9.3). The average cost of the first-line treatment was the 
lowest (£21340), followed by the treatment cost for the 1nd relapse (£28808). The 
treatment cost for the 2nd relapse period was the highest (£32582). The raising treatment 
cost values were caused mainly by the execution of the stem cell transplantation and of 
other related treatments and follow-up visits.  
 
9.4.2 Comparison with the cost results with no treatment overlapping 
 
The differences of the cost results between the two costing methods (with and without 
considering the treatment overlapping) are presented in Table 9.24.   
 
 
 
 
 
 
 
 
 
 
 
Table 9.23 The detailed results of overall treatment cost (with treatment overlapping) 
Treatment phase No. 
Cost results 
Average Min. Max. SD 
Total cost 239 £27290 £193 £174286 31025 
First line 239 £21340 £193 £105101 22226 
Induction  239 £12503 £193 £101205 14788 
Consolidation 102 £20505 £106 £73237 18035 
1st relapse-2nd relapse 42 £28808 £2063 £100416 26202 
2nd relapse-3rd relapse 6 £32582 £1589 £112594 43706 
3rd relapse + 2 £8251 £6380 £10121 2645 
 
Table 9.24 The difference of cost results between two costing methods 
 No. 
Average cost 
(no treatment 
overlapping) 
Average cost 
(with treatment 
overlapping) 
Difference 
Total cost 239 £33192 £27290 £5902 
First line 239 £21826 £21340 £486 
Induction  239 £13976 £12503 £1473 
Consolidation 102 £18215 £20505 £2290 
1st relapse-2nd relapse 42 £31749 £28808 £2941 
2nd relapse-3rd relapse 6 £46846 £32582 £14264 
3rd relapse + 2 £12250 £8251 £3999 
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As shown in Table 9.24, the cost results that included the consideration of the treatment 
overlapping  were  lower  than  the  ones  that  did  not.  This  was  probably  because  some  
medical resources were shared during the treatment overlapping. As demonstrated above 
(Table 9.24), the cost differences also increased progressively, with the exception of the 
cases at the 3rd relapse phase. The cost difference for first-line treatment was the lowest 
(£486)  while  the  one  for  the  2nd relapse treatment was the highest (£14264). Possible 
explanation for this was that most of the treatments that were used in the first line period 
were the inpatient treatments that had less overlapping problems. Therefore, although 
ward cost accounted for the highest percentage of inpatient treatments (discussed in 
section 9.2.1), the cost sharing (especially the ward cost sharing) was not significant. 
Moreover, plenty of the outpatient treatments were used in 2nd and 3rd relapse periods and 
they usually overlapped with inpatient treatments or other outpatient treatments. 
Therefore, more medical resources were shared, something that caused greater cost 
difference between the two costing methods. 
 
It is worth noting that the consolidation cost difference was not consistent with the 
aforementioned increasing trends. This was mainly because the cost attributes were 
slightly changed between two different costing methods when the treatment crossed the 
cut off point (between induction and consolidation). However, as a whole, the cost 
difference of first-line treatment cost still followed the increasing trend mentioned before. 
 
9.4.3 Comparison with relevant studies 
 
A small number of studies focusing on costing overall/lifetime treatment for AML (please 
refer  to  chapter  2  for  details)  were  available.  These  studies  made  use  of  the  hospital  
accounting system or the national-level database, but did not use the bottom-up costing 
method. Therefore, it was worthwhile comparing the results of the current study (derived 
from the bottom-up costing method) with the findings of aforementioned relevant studies. 
Based on the available cost breakdown information and study period, 3 studies were 
found to be comparable, after the relevant matching had been carried out. The comparison 
results are listed in Table 9.25. 
 
 
 
 
 
 
 
Table 9.25 The comparison of overall treatment cost with previous studies 
 Year Country Average cost Value in 2007 
The current study 2007 UK £27290 £27290 
   £21340 (first-line) £21340 
Lang’s study 2001 USA $50320 £29159 
Menzin’s study 1998 USA $40270 £31665 
Uyl-de’s study 1995 Netherlands $46387 (first-line) £39274 
Katz’s study 2003 USA $115471 £79596 
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As shown in Table 9.25, most of the studies were carried out in USA [35, 214, 215]. The 
cost results of the first two studies were consistent [35, 214]. Lang’s [214] and Menzin’s 
[35] studies showed that the overall treatment costs for AML were £29159 and £31665 
respectively. Their results were slightly higher than the one of the current study. This was 
possibly because the medical supplies / consumables were not included in the current 
study due to lack of relevant information. Another possible explanation is that there were 
differences in preferred treatments/regimens between the USA and the UK, with the ones 
used in the USA being more expensive. It is also worth noting that the cost results of 
Katz’s study [215], which was also carried out in the USA and has the same study period 
(from the first admission to the last discharge), was not possible to compare with other 
studies.  This  was  because  there  was  no  detailed  information  about  which  cost  drivers  
were included in the cost calculation. Uyl-de’s study [216] was the only one that carried 
out in Europe. The authors calculated that the first-line treatment cost was £39274, a 
value much higher than the cost result of the current study. This difference can be 
explained partly by the treatment protocol used in Netherlands (the country where the 
study took place). More specifically, Uyl-de studied the AML patients who were recruited 
in the HOVON 29 or the EORTC AML-10 trial. The suggested treatments and regimens 
of these two protocols were much different from the ones used in the UK at present. Also, 
according to these two protocols, the stem cell transplantation was set as the 
consolidation treatment for the eligible patients. Therefore, as would be expected, the cost 
result of Uyl-de’s study was much higher than any other studies. 
 
 
9.4.4 overall treatment cost vs. patient characteristics 
 
The relationship between the cost results and the patient characteristics are presented in 
Error! Reference source not found.. These patient characteristics included the 
baseline characteristics (age, gender, death or not, diagnosis, history of antecedent 
haemotalogical disorder, year of enrollment) and treatment related characteristics 
(number of treatments, type of primary treatment, achieving first remission). The 
correlation results are also presented in the Error! Reference source not found. below. 
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As show in Error! Reference source not found., the patient characteristics that were 
highly associated with the overall treatment cost were age (p<.0001), number of 
treatments (p<.0001), death (p<.0001), and type of primary induction treatment 
(p<.0001). Achieving first remission/response to primary induction treatment (p=0.0287) 
was also significantly associated with the total treatment cost. For the rest of the patient 
characteristics, although the cost differences existed between groups, these differences 
were not significant. 
 
Table 9.26 The comparison of overall treatment cost with previous studies 
 
 Case 
number 
Mean Correlation 
(P value) 
Age   <.0001 
age≦54 60 £53346  
54< age≦67 61 £29431  
67<age≦77 61 £18527  
age>77 57 £6847  
Number of treatments   <.0001 
1-3 167 £12911  
4-6 39 £43958  
7-9 20 £67322  
10-13 13 £100409  
Death   <.0001 
Yes 189 £20512  
No 50 £52908  
Achieving first remission   0.0287 
Yes 105 £49426  
No 134 £9944  
Type of primary induction treatment   <.0001 
With induction intent 132 £42407  
With non-induction intent 47 £12556  
Palliative care only 21 £2550  
Supportive care only 39 £7202  
Gender   0.8401 
Male 122 £25140  
Female 117 £29530  
Diagnosis   0.075 
AML NOS 197 £24976 * 
AML with core binding factors 10 £61057 * 
AML - probable therapy related 6 £13190  
AML with MLL (11q23) rearrangement 2 £22339  
APML 24 £36149  
Year of diagnosis   0.7182 
2004 29 £33342  
2005 122 £25269  
2006 88 £28095  
History of antecedent haematological disorder   0.7729 
Yes 11 25057  
No 228 27397  
 
9.4 Overall treatment cost results 
(treatment overlapping) 
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As would be expected, patients who were young, still alive at the time of current work, 
and received many times of treatments were highly associated with high overall treatment 
cost. It was also observed that the patients who received intensive primary induction 
treatment and the patients who responded to the induction treatment (reached first 
remission) were greatly associated with high overall treatment cost. This was related to 
the common findings that AML progresses very quickly and leads to death very easily, if 
patients do not receive induction treatments or receive induction treatment but do not 
respond well [20, 21]. Therefore, these patients spent more medical resources as they 
survive longer. 
 
 
 
9.4.5 Conclusion 
 
The current study was the first attempt to cost the overall AML/APML treatments by 
using bottom-up method. The study finding showed that the average overall cost was 
£27290. This result was found to be slightly lower than those of other related studies, but 
this difference was explainable. By and large, it can be claimed that after comparing the 
results  of  the  current  study  with  those  of  other  related  studies,  they  were  found  to  be  
consistent. The comparison results not only justified the costing method used here, but 
also validated the accuracy of the cost results of the current study.   
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CHAPTER 10 DISCUSSION 
 
 
AML/APML is the most common form of acute leukemia. It is very expensive to treat, as 
it involves long hospital stays, expensive treatments (such as stem cell transplantation), 
and complex complications (such as infection and anemia) [3]. For such an important 
health issue, it is striking that only seven studies focusing on the lifetime treatment cost 
were identified since 1995.None of these studies involved discussion of the cost 
predictors and none was carried out in the UK. Furthermore, these studies used the 
charging system or the administrative claim database for costing, which had methodology 
drawbacks (discussed in chapter 1) and means that it is difficult to translate the findings to 
a UK setting. In this thesis, a bottom-up method was employed to obtain estimates of the 
total health care cost over the lifetime of care. The lifetime cost results were further 
analyzed in order to uncover possible cost predictors. The obtained cost results were 
expected to provide a different perspective from the NHS reference cost, while the 
possible cost predictor results to provide useful information for health policy makers. 
 
10.1 Contributions of the current study 
 
Several challenges arose during the AML/APML lifetime treatment costing. To overcome 
these challenges, some innovative methods that had not been used before were applied. 
This approach, which was unique among all the related studies, was expected to extract 
more robust results. The contributions of the current study were the following:   
 
10.1.1 First use of the bottom-up costing method on AML/APML lifetime 
treatment  
 
As it is commonly accepted, the bottom-up costing method produces more precise and 
reliable cost results [43, 48-50]. However, it was observed that no relevant lifetime 
treatment cost study has made use of this method in the world (please refer to chapter 2: 
literature review). Therefore, the current work was the first attempt to cost the 
AML/APML lifetime treatment by using bottom-up method. 
 
10.1.2. First cost predictor study for AML/APML lifetime treatment 
 
Cost predictor analysis has been used to investigate various other diseases. However, it 
was observed that no AML study has covered this area in the past. Therefore, the current 
study was the first attempt of determining the cost predictors. 
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10.1.3 Breakdown of the hospital barrier 
 
Most of the previous cost studies were restricted to single or specific two to three 
hospitals, as the detailed information (such as medical records and charging systems) was 
difficult to obtain from different hospitals. This restriction compromised the robustness of 
the results, as the cost that patients transfer from hospital to hospital could be overlooked. 
In the current study, the aforementioned hospital barrier was broken by using the 
databases covering the medical information of all the hospitals in the network to cost, 
something that was expected to produce more robust cost result. 
 
10.1.4 Transparency of the costing procedures 
 
Since the current study employed the bottom-up method to cost the AML/APML 
treatments, all the estimated costs were traceable and the contributions of each cost driver 
were identifiable. This approach not only prevented costing in black box, but also 
provided a common ground for comparison with other relevant studies. 
 
10.1.5 Consideration of the treatment overlapping 
 
With  the  exception  of  the  studies  using  the  charging  system  or  administration  claim  
database for costing, most studies employing the bottom-up costing method faced the 
treatment overlapping issue. However, no information regarding how the overlapping 
issue was dealt with was found in the relevant papers (according to the results of the 
literature review presented in chapter 2). In order to increase the reliability of the cost 
result, in the current study, the treatment overlapping and cost sharing were taken into 
account (The details and relevant costing methods can be found in the chapter 8). 
 
 
10.2 Summary of the main findings of the current study 
 
The methods used for identification, measurement, and valuation of cost in previous 
economic evaluation studies on AML/APML treatments were reviewed in chapter 2. The 
review showed that most of the available publications related with economic evaluation 
of AML/APML treatment made use of the charging system or the administration claim 
database. The common cost drivers that were used for costing single or overall treatments 
were hospitalization, drug, personnel, overheads, outpatient visit, transfusion, adverse 
event treatment, laboratory test, follow-up, materials, and out-of-pocket.  
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Chapter 3 outlined how the study material was handled. The challenge at this phase was 
to impute the missing data and the necessary, but insufficient, information for the 
treatment costing (such as treatment time, hospital stays, and transfusion frequency). In 
order to yield the robust estimations, the available and reliable information sources (such 
as the treatment guidelines, expert opinions, and the analysis of the additional data) were 
used. 
 
In chapter 4, the preliminary analysis results of the study material were presented. The 
most  important  finding  at  this  phase  was  the  treatment  pathway  for  AML  and  APML  
patients, which not only provided an overview of the AML/APML treatment history of 
AML/APML patients, but also formed a basis for costing at later stages of the study. 
 
In  chapter  5,  an  overview  of  the  methodology  that  was  used  in  the  current  study  is  
described. More specifically, three-level cost classification was applied in order to 
identify the costs that had to be estimated for the AML/APML lifetime treatments. Finally, 
13 treatment/intervention events, with their five cost drivers, were determined, based on 
cost classification and literature review. 
 
Chapter 6 outlined the derivation of each of the five cost drivers. There were two 
important challenges at this phase. Firstly, the staff working time had to be obtained in 
order to calculate the personnel cost. This was dealt with by conducting a staff working 
time  survey.  Secondly,  the  complication  treatment  costs  of  each  treatment  had  to  be  
obtained. In order to achieve this, both expert opinion surveys and the meta-analysis of 
the results of previous studies were used.  
 
Chapter 7 outlined how each of the 13 treatments/interventions were costed. The number 
of medical resource uses per treatment time was used in order to connect the five cost 
drivers (discussed in chapter6) to the treatment cost. The challenge in this phase to 
carefully define the number of uses per treatment time from treatment to treatment, as the 
relevant actual information was unavailable. To order to address this, all the available and 
reliable information courses (such as the treatment guidelines, expert opinions, and the 
database analysis) were used. 
 
Chapter 8 outlined how the lifetime treatment cost of each patient was complied from the 
components described in the previous chapters. In this phase, a refined cost sharing 
procedure was established in order to resolve the treatment overlapping issue. 
In chapter 9, the cost results of each treatment and the overall treatments per patient were 
presented. Also, the cost predictors were explored. It was illustrated that age, diagnosis, 
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deprivation, number of treatment, and death were the important predictors of the lifetime 
cost  for  AML/APML,  and  these  cost  predictors  explained  majority  part  of  the  cost  
variance.  
 
10.3 Study limitations 
 
The costing method used in the current study dealt with a number of difficulties 
successfully. However, it was also subject to a number of disadvantages. These 
disadvantages are briefly presented below. 
 
10.3.1 Lacking of the information about the cost incurred outside the study sites 
 
It can be claimed that the current work was more successful in ensuring all acute 
treatment costs were recoded as the data collection was based on a linked regional 
database rather than being based on data collected from a single hospital site. However, 
treatment costs from providers outside this network were excluded. For example, 
treatment of patients who received further intervention in private sectors or went out to 
other networks could not be costed. During the costing process, 5 patients who received 
treatments outside the network were detected. Therefore, their lifetime costs were 
excluded from the cost predictor analysis, in an attempt ensure the reliability of the study 
results. 
 
10.3.2 Lacking of the detailed information of medical supplies/consumables use 
 
The medical supplies/ hospital consumables / disposables (such as syringe and gloves) 
were part of the treatment cost. In studies that made use of the charging systems for 
costing,  the  consumables  were  easy  to  cost.  However,  in  studies  employing  the  
bottom-up method, the consumable costs were very difficult to identify, due to lack of 
detailed quantity information. The current study was not an exception to this. Although 
some of the relevant studies used the percentage of treatment or the overall cost to 
predict the consumable costs, during the current work it was decided not to take the 
consumable costs into consideration. The reason was that its consumable costs were too 
low, compared to the treatment cost as a whole. Also, restraint time and workforce made 
it not possible to extract all the consumable cost percentages for each treatment. 
Therefore, it was decided that the cost can be neglected. Based on cost result 
comparisons (discussed in chapter 9), the findings of the current study were found to be 
consistent with and close to the results of other relevant studies. Therefore, it is safe to 
claim that the omission of the consumable costs was acceptable. 
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10.3.3 Lacking of the actual unit cost information for estimating ward/clinic cost 
 
Several AML treatment cost studies (including the current study) concluded that the key 
cost driver of the treatment cost was the length of hospital stay. For such important key 
cost driver, unfortunately, there was no relevant tariff price or national average cost for 
basic ward care and clinic care that can be used to cost length of hospital stay in the UK. 
Therefore, the current study used the ward and clinic costs which involved the simplest 
treatment  from  the  ‘Reference  Cost  Index’  (please  refer  to  chapter  6  for  details)  as  
substitutes. However, this approach needed professional opinions in order to justify its 
accuracy. Moreover, it was impossible to identify the type of the ward (single/multi-bed 
ward, standard/special ward) patients stayed in for the duration of the treatment, as no 
relevant information was available. Therefore, all the ward costs used the same unit cost, 
with the exception of the treatment cost derived from the ‘Reference Cost Index’ (such as 
stem cell transplantation and radiotherapy). Although the cost result comparisons 
(presented in chapter 9) indirectly proved that the costing method for the ward was 
acceptable, it was believed that further refinements from experts were needed.  
 
10.3.4 Applying a large amount of required assumptions for the costing  
 
Due to the absence of some necessary information (such as transfusion frequency, 
hospital stays, and antibiotic use), a large number of assumptions and imputations had to 
be made during the costing.  
 
It is possible that some of these assumptions and imputations might have caused the 
cost results to be underestimated. For example, as the imputed working time of 
consultants was underestimated, the personnel cost of outpatient treatment could be also 
underestimated. This was because the number of consultants who were involved in the 
working time survey was low. Since the consultants’ answers tended to be more 
conservative than those of other staff, it was considered that the results might have been 
underestimated. 
 
In contrast, some other assumptions and imputations could have resulted in the cost 
results being overestimated. For example, due to the lack of detailed relevant 
information and for the convenience reason, it was assumed that some of the 
chemotherapy regimens (such as low dose AraC) were only given in inpatient setting, 
for consistency reasons. However, such regimens can actually be given in both inpatient 
and outpatient scenarios. In such cases, the treatment cost might have been 
overestimated.   
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In other cases, some of the assumptions and imputations (such as the extrapolated 
transfusion frequency and hospital stay) were justified in the cost result comparisons 
(please refer to chapter 9). Therefore, further refinements from haematologists and other 
clinical staff were needed in order to justify the accuracy of these assumptions. If the 
actual details of medical resource consumption are obtainable, the information would be 
more desirable for bottom-up costing. 
 
10.3.5 Using literature review to cost the complications of treating AML 
 
Complication treatment cost plays an important role in treatment costing. In the current 
study, the complication costs were calculated based on the literature review and on the 
meta-analysis results: incidence rates of complications (please refer to chapter 7). This 
was because the detailed information of medical resource usage for complication 
treatment was not available. The advantage of the employed approach was that the cost 
results of complication treatments were more robust than other estimation approaches, as 
they were based on a large number of clinical trial studies. However, the drawback of this 
approach was that it compromised the reliability of the cost results. Firstly, the 
complication cost results derived from the literature review results (incidence rates of 
complication)  and  ‘Reference  Cost  Index’  (unit  cost  of  complication  treatment)  could  
not reflect the actual consumption of medical resources. Secondly, the detailed 
incidence rates of complication that derived from the literature review were strongly 
determined by level of detail the authors reported in the relevant papers not the actual 
incidences. Although generally it was observed that the extrapolated results were close to 
those of other related results (chapter 7), approvals by more experts, a sensitivity analysis, 
or actual information of medical resource consumption would be desirable. 
 
10.3.6 The reliability of using the existing publications for costing 
 
In the current study, a number of existing publications were used for estimating 
treatment costs when the actual consumption details of medical resources were not 
available, such as BNF, PSSRU Unit cost, and NHS Reference Cost Index (please refer 
to section 5.4). The advantage of this approach was that the cost results were more robust 
than other estimation approaches, as these publications were based on a large number of 
UK populations or national data. However, the drawback of this approach was that the 
reliability of these publications was still controversial. For example, the drug prices 
from the ‘BNF’ are not always the prices that hospitals actually pay, and the treatment 
costs from the ‘Reference Cost Index’ are considered to be under estimated.  
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Although using the existing publications was not perhaps the optimal alternative, the 
cost results were still valuable for the current work. This was mainly because the 
detailed and actual cost data were not available from either the regional databases or the 
hospitals.  
 
 
 
10.4 Recommendations 
 
10.4.1 Recommendation based on the findings of the current study 
 
a. Reveal the gap between real cost and NHS reference cost  
 
The ‘Reference Cost Index’ is thought to be an alternative information source in relation 
to the treatment cost in the UK. However, it is always questionable how close its values 
are to the actual treatment cost. In the current study, relatively reliable treatment costs 
were obtained with different approach and different perspective from the ‘Reference Cost 
Index’. It was observed that the AML relevant treatment costs in the NHS ‘Reference 
Cost  Index’  was  lower  than  the  cost  results  of  the  current  study.  For  example,  for  the  
immunosuppressive therapy, the reference cost was £1408, while the cost result of the 
current study was found to be £5302 per treatment time (please refer to chapter 9). 
Although further and more detailed comparisons between both costing methods are 
needed,  it  is  suggested  that  the  NHS  should  re-measure  the  treatment  cost  for  
AML/APML in order to develop more robust and fair payments. 
 
b. Health policy decision making or clinical guideline development 
 
Based on the findings of the cost results (discussed in chapter 9), the overall treatment 
cost for AML/APML were very high. Regarding the low survival rate of AML/APML, it 
is a wasteful use of medical resources with no benefit in terms of increased outcomes. 
Therefore, it is suggested that the health policy makers or the clinical guideline 
developers could re-set the treatment guideline in order to conserve medical resources for 
better use.  
 
10.4.2 Recommendation for future research 
 
The study limitation discussed previously (section 10.2) form the basis of the suggestions 
for the future study for obtaining more robust results. Based on the costing experience, a 
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number of recommendations were made. The latter are presented in the following 
paragraphs. 
 
a. Unit cost 
 
Most of the cost drivers that were used in the current study were derived be means of the 
bottom-up costing method. This approach required great amounts of research time to 
obtain reliable results. During the costing procedure, it was observed that existing 
published national average cost data could be used as the cost drivers directly, as they 
were found to be very close to the cost results calculated with the bottom-up method. For 
example, the drug cost for antibiotic use was found to be £69.13 per day. Compared to the 
antibiotic drug cost in the ‘Reference Cost Index’, the cost difference was only £2.13. 
Therefore, it is suggested that the existing national average cost data can be used for the 
cost drivers for to time and workforce saving.   
 
b. Database improvement 
 
Bottom-up method is a resource-demanding approach. It needs a highly detailed database 
with a limited amount of unknown factors. In the current study, many challenges and 
difficulties arose because the detailed resource use information was not available. In 
order  to  obtain  more  robust  results  and  save  time/workforce,  it  is  suggested  that  more  
detailed information about the resource use (such as admission and discharge dates, 
transfusion date, transfusion unit, and so on) should be collected and recorded for 
costing. In addition, it is suggested that database covering more hospitals and more 
networks would be preferable. This is because the wide coverage of the database could 
assist in breaking both the hospital and the network barrier, something that can produce 
more robust cost results. 
 
c. Cost-effectiveness study 
 
In the current study, information related with the patients’ quality of life was not available. 
Therefore, it was impossible to determine whether the increased lifetime cost was caused 
by prolonged survival or by ineffective and expensive treatments. For better 
understanding of the causes of the high lifetime cost, it is suggested that further 
cost-effectiveness study would be preferable.  
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10.5 Conclusion 
 
During the current study, a number of tasks were completed. The costing methods used in 
previous relevant studies were reviewed, the relevant bottom-up method was developed 
and implemented, the treatment cost over patients’ lifetime was calculated, and the cost 
predictors were extracted. The current study not only employed an innovative approach to 
cost the lifetime treatment for AML/APML, but also overcome many of the difficulties 
that identified or overlooked in previous studies. It was observed that AML/APML was 
expensive to treat, but possible predictive factors actually existed. It is expected that these 
findings could help to bridge the gap between the actual and the NHS reference costs 
while the cost predictors could assist decision makers in relation with health policy or 
clinical guideline issues. Also, it is expected that the current study could stimulate the 
interest of other researchers for more and better economic evaluations of the AML/APML 
treatment.  
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Appendix 1.1 WHO classification of AML 
 
WHO Classification of AML 
AML with recurrent cytogenetic abnormalities 
AML with t(8;21)(q22;q22), (AML1/ETO) 
AML with inv(16)(p13;q22) or t(16;16)(p13;q22), (CBF/MYH11) 
AML with t(15;17)(q22;q12), (PML/RAR) (APL) 
AML with 11q23 (MLL) abnormalities 
AML with multilineage dysplasia 
With prior myelodysplastic syndrome 
Without prior myelodysplastic syndrome 
AML and MDS, therapy related 
Alkylating agent type 
Topoisomerase II inhibitor type 
AML, NOS (modified FAB classification) 
AML, minimally differentiated 
AML without maturation 
AML with maturation 
Acute promyelocytic leukaemia 
Acute myelomonocytic leukaemia 
Acute monoblastic and monocytic leukaemia 
Acute erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Source: Brunning’s study [15] 
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Appendix 2.1 Search strategies (MEDLINE and EMBASE) 
 
# Search History 
1 Leukemia, Myeloid, Acute.mp. or exp Leukemia, Myeloid, Acute/ 
2 Leukemia, Myelomonocytic, Acute.mp. or exp Leukemia, Myelomonocytic, Acute/ 
3 Leukemia, Erythroblastic, Acute.mp. 
4 Leukemia, Basophilic, Acute.mp. 
5 Leukemia, Eosinophilic, Acute.mp. 
6 Leukemia, Erythroblastic, Acute.mp. 
7 Leukemia, Mast-Cell.mp. 
8 Leukemia, Megakaryoblastic, Acute.mp. 
9 Leukemia, Monocytic, Acute.mp. 
10 (Acute Myelo$ Leuk$ or Acute Myelo$ Leuc$).mp.  
11 (Acute nonlympho$ Leuk$ or Acute nonlympho$ Leuc$).mp.  
12 AML.mp. 
13 acute disease.mp. or exp Acute Disease/ 
14 leukemia, myeloid.mp. or exp Leukemia, Myeloid/ 
15 13 and 14 
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 15 
17 Leukemia, Promyelocytic, Acute.mp. or exp Leukemia, Promyelocytic, Acute/ 
18 APML.mp. 
19 APL.mp. 
20 17 or 18 or 19 
21 ph1 negat$.mp.  
22 philadelphia negat$.mp.  
23 ph1 posit$.mp.  
24 philadelphia posit$.mp.  
25 21 or 22 or 23 or 24 
26 16 or 20 or 25 
27 economics.mp. or Economics/ 
28 Economics, Hospital.mp. or exp Economics, Hospital/ 
29 Economics, Medical.mp. or exp Economics, Medical/ 
30 exp Economics, Nursing/ or Economics, Nursing.mp. 
31 Economics, Pharmaceutical.mp. or exp Economics, Pharmaceutical/ 
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32 evaluation study.mp. or exp Evaluation Studies/ 
33 model, economic.mp. or exp Models, Economic/ 
34 (economic$ or pharmacoeconomic$ or pric$ or cost$).mp.  
35 
exp "costs and cost analysis"/ or exp "cost allocation"/ or exp cost-benefit analysis/ or exp "cost control"/ or exp 
"cost savings"/ or exp "cost of illness"/ or exp "cost sharing"/ or exp "deductibles and coinsurance"/ or exp 
medical savings accounts/ or exp health care costs/ or exp direct service costs/ or exp drug costs/ or exp 
employer health costs/ or exp hospital costs/ or exp health expenditures/ or exp capital expenditures/ or exp 
economics, hospital/ or exp hospital charges/ or exp economics, medical/ or exp fees, medical/ or exp 
economics, nursing/ or exp economics, pharmaceutical/ or exp "fees and charges"/ or exp capitation fee/ or exp 
fee-for-service plans/ or exp fees, dental/ or exp fees, pharmaceutical/ or exp prescription fees/ or exp "rate 
setting and review"/ 
36 budget.mp. or exp Budgets/ 
37 (low adj cost).mp.  
38 (high adj cost).mp.  
39 (health?care adj cost$).mp.  
40 (cost adj estimate$).mp.  
41 (cost adj variable).mp.  
42 (unit adj cost$).mp.  
43 (fiscal or funding or finacial or finance).mp.  
44 value of life.mp. or exp "Value of Life"/ 
45 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 
46 26 and 45 
47 limit 46 to (english language and yr="1995 - 2008") 
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Appendix 2.2 Sources of search strategy 
 
1. Published study: 
MEDLINE, PUBMED, NHS EED, EMBASE, The Cochrane Library, CancerLit, and 
the Cochrane Center Register of Controlled Trials. 
 
2. Grey literature: 
a. Theses: http://www.theses.com/ 
b. Conference proceedings: 
i ) ZETOC Conference Search & ISI Proceedings 
ii) Conference proceedings: 
The International Conference on Malignant Lymphoma (Lugano) 
http://annonc.oxfordjournals.org/supplements.dtl 
The National Congress of Medical Oncology 
http://annonc.oxfordjournals.org/supplements.dtl 
The European Conference on Clinical Oncology 
http://www.ecco-org.eu/Conferences-and-Events/page.aspx/7 
The European Society for Medical Oncology (ESMO) 
http://www.esmo.org/ 
European Hematology Association (EHA) 
http://www.ehaweb.org/ 
The American Society of Clinical Oncology 
http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Annual+Me
eting+Summaries 
The American Society of Hematology 
http://www.hematology.org/meetings/2008/index.cfm 
 
3. Ongoing trials 
http://www.doh.gov.uk/research/nrr.htm 
http://clinicaltrials.nci.nih.gov 
http://clinicaltrials.gov/ct/gui 
www.trialscentral.org/index.html 
 
4 Hand-searching of key journals 
Annals of Oncology, European Journal of Cancer, European Journal of Haematology, 
Journal of Clinical Oncology, and Blood. 
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Appendix 2.3 Study eligibility form 
 
Study eligibility form 
 
Study No: _________ 
 
 Yes Unclear No 
Type of study 
Q1: Was the study described as economic 
evaluation? 
   
    
Participants in the study 
Q2: Did the participants in the study suffer from 
AML / APML? 
   
    
Intervention 
Q3: Did the study contain the estimation of cost? 
   
    
Outcomes in the study 
Q4: Did the study report the measurement methods 
of costing and health outcome (including the 
effectiveness, utilities, or no outcome 
measurement)?  
   
    
Final decision Include Unclear Exclude 
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Appendix 2.4 Quality assessment checklist 
 
 
Quality Assessment Form 
Study ID: ________ 
 Adequate Unclear Inadequate Not used 
First Stage     
Definition of study question      
Q1: Was the cost-measurement the main part of the study?     
Q2: Did it mainly study AML/APML patients?     
Study Design 
Q3: Trial-based study: 
● Were inclusion/exclusion criteria of recruitments outlined 
clearly 
Q4: Model-based study:  
● Did it outline the model used? If so, did the model reflect 
the real clinical practice? 
●Were inclusion/exclusion criteria of papers outlined 
clearly if the data/ parameters collected through systematic 
review? 
    
Cost measurement     
Q5: Were the measurement methods of cost and outcome 
described comprehensively? 
    
Q6: Were the sources of measurement described clearly?     
Q7: Were costs valued credibly?     
Results Presentation     
Q8: Were the results presented by the raw value or unit-cost?     
Q9: Did the study provide the range or distributions of value 
for the key study parameters?  
    
Q10: Were costs adjusted for different timing?     
Q11: Were sensitivity analyses conducted to investigate 
uncertainty in estimates of cost? 
    
     
Second Stage (For Economic Evaluation Study Only) 
Q1: Did the study involve a comparison of alternatives 
(including do-nothing alternative)? 
    
Q2: Was the viewpoint for the analysis stated?     
Q3: Were all the important and relevant costs and 
consequence for each alternative identified? 
    
Q4: Were costs and consequences measured accurately?     
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Appendix 2.5 Data extraction form 
Data  Extraction  Form                      Study  ID:_____ 
Notes  
General Info.  
Title  
Author  
Contact E- 
mail 
 
Journal  Price Year  
Country  Source type published unpublished 
Study type Trial Observation Model 
Data type Primary 
(From:                     )  
Secondary 
(From:                       )  
Population  
Setting  
Study period  
Initial 
numbers 
 Outcome No.  
Age Elder 
(        )  
Young 
(        )  
Adult 
(        )  
All 
 
Treatment 
stage 
All 
Induction Consolidation 
 
Post remission Maintenance 
remission 
continuation 
Intervention  
Therapy type Overall Chemotherapy Supportive Palliative 
Complication Transplantation Others  
Analysis type Cost analysis CEA / CUA 
Objective  
Methodology  
Cost type Unit cost (Ref) Unit cost (charge) Payments charges 
Costs Categories Source Methods value 
    
Outcome Categories value 
  
Results  
Notes  
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Appendix 2.6 The relevant historical currency exchange rates 
 
From To Year Exchange rate 
Australia (A$) USD 2001 0.51822 
Canada ($CAN) USD 1992 0.82845 
Canada ($CAN) USD 2000 0.67398 
Euro (€) USD 1998 1.17160 
Euro (€) USD 2000 0.92492 
Euro (€) USD 2001 1.25622 
Euro (€) USD 2003 1.13208 
Euro (€) USD 2005 1.24539 
German (Mark) USD 1999 0.47985 
GBP (£) USD 1998 1.65763 
INR USD 2006 0.02214 
Yen (￥) USD 2005 0.00903 
 
Source: http://www.x-rates.com/cgi-bin/hlookup.cgi 
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Appendix 2.7 The inflation conversion table 
 
 Year Value in 2007 
$1 in 1992 1.46 
 1993 1.42 
 1994 1.38 
 1995 1.35 
 1996 1.31 
 1997 1.29 
 1998 1.27 
 1999 1.23 
 2000 1.19 
 2001 1.17 
 2002 1.15 
 2003 1.13 
 2004 1.09 
 2005 1.05 
 2006 1.03 
http://safalra.com/other/historical-uk-inflation-price-conversion/ 
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Appendix 2.8 The summary of overall treatment cost studies 
Study Country Patients Type of 
analysis 
Study period Cost type Costing Method Note 
Cost item Item content Data source Method Value 
Rosenman 
et al. 2005 
[109] 
USA AML 
Children 
(36) 
Cost 
analysis 
3 years Hospital 
charge 
1. Hospitalization Pediatric, Emergency room, 
Pediatric ICU, SCT room, 
Neonatal ICU, Burn unit 
Hospital 
accounting 
system 
Sum up $5,442,100 1. Only focus on 
inpatient cost. 
2. Total inpatient 
charges per patient 
(mean): 94,000 (SD: 
123,900) 
3. Total AML inpatient 
charges (mean): 
336,600 
(40,500-652,800) 
      2. Pharmacy / IV therapy  $3,431,300 
      3. Laboratory / Pathology  $2,102,500 
      4. OR / Recovery room  $1,186,200 
      5. Radiology Standard diagnostic, CT scan, 
Nuclear medicine, MRI 
$805,300 
      6. Respiratory services /  
Pulmonary function 
 $382,000 
      7. Physical therapy / 
Occupational therapy 
 $61,000 
      8. All other  $2,183,195 
      Total  $15,566,400 
Lang et 
al.2002 
[103] 
USA AML Elder 
≧65 
(3439) 
Cost 
analysis 
2 years Payments 1. Hospitalization  SEER and 
Medicare 
database 
Sum up $42,103 Payments per month: 
$9,226   2. Skilled nursing facility   $767 
  3. Outpatient visit   $2,254 
  4. Physician / supplier   $5,061 
  5. Home health   $890 
  6. Hospice   $678 
  7. medical equipment ayments   $135 
    Total Medicare payments  $51,888  
Menzin et al. 
2002 [104] 
USA AML Elder 
≧65 
(2657) 
Cost 
analysis 
2 years payments Hospitalization  SEER and 
Medicare 
database 
Sum up $34,823＋755  
  SNF   $653＋52  
  Outpatient visit   $1,799＋113  
  Physician   $2,994＋78  
  Home health care   $1,004＋52  
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  Hospice   $320＋22  
      Total Medicare payments   $41,594＋870  
Yu et al. 
2006 [107] 
Taiwan AML Adult 
≦60 yrs 
(94) 
CEA From 
diagnosis to 
the end of 
therapy, 
either cure or 
mortality 
charges 1. Hospitalization  Hospital 
accounting 
system 
Sum up $9,118 1. Only focus on 
inpatient cost. 
2. Post remission 
   2. Pharmacy (drug)   $15,196 
    3. Laboratory   $4,776 
    4. blood transfusion   $5,644 
    5. procedure   $6,079 
    6. Professional manpower   $1,737 
    7. out-of-pocket   $868 
      Mean total treatment cost    $43,418 (1,494 – 
172,332) 
 
Katz et al. 
2006 [108] 
USA AML Elder 
≧ 60 
(219) 
Cost 
analysis 
From first 
admission to 
last discharge 
charges 1. Mean charges of first 
admission 
 Hospital 
accounting 
system 
Sum up $70,305 + 
204,800 
 
    2. Mean charges of 
subsequent admission 
  $38,785 + 
142,166 
 
     3. Mean admission   $53,054 + 
173,901 
 
      Mean total charges per 
person 
   $115,471 + 
$334,581 
 
          HOVON EORTC 
Uyl-de Groot 
et al. 2001 
[105] 
Netherlands AML adult 
≦60 (84) 
Cost 
analysis 
From 
diagnosis to 2 
years 
follow-up 
 Diagnosis Lab tests, consultants   $2504 $4714 
  Treatment Phase I: Chemotherapy, G-CSF   $46113 $52409 
   Phase II: harvest   $6148 $7292 
   Phase III: BMT/PBSCT   $19503 $20619 
   Follow-up Outpatient visits, lab tests   $2470 $8127 
     Relapse treatment Chemotherapy, palliative care   $25010 $22770 
      Total cost    $101748 $115930 
Kuse et al. 
2001 [106] 
Germany AML elder 
≧60 
(100) 
Cost 
analysis 
Protocol (2 
inductions + 1 
consolidation) 
charges Cost (Young adults)    105KDM (63-204 KDM) 
   Cost (elderly patients)    87.6KDM (56-147 KDM) 
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Appendix 2.9 The summary of chemotherapy cost studies 
Study Country Patients Type of 
analysis 
Study period Cost type Costing Method Note 
Cost item Item content Data source Method Value 
Yu et al. 
2006 [107] 
Taiwan AML 
Adult 
≦60 
(54) 
CEA Single period of 
therapy 
Charges 1. Hospitalization  Hospital 
accounting 
system 
Sum up  1. Only focus on 
inpatient 
cost. 
2. post 
remission 
   2. Pharmacy (drug)   
   3. Laboratory   
   4. blood transfusion   
   5. procedure   
   6. Personnel   
   7. out-of-pocket   
    Mean total cost  CC: $7670 + 5865 
HiDAC: $13,668 + 6048 
Katz et al 
2006 [108] 
USA AML 
Elder ≧ 
60 (219) 
Cost 
analysis 
From first 
admission until 
last discharge 
charges 1. Mean charges of first 
admission without 
chemotherapy 
 Hospital 
accounting 
system 
Sum up $103,483 (211,388) 1. Induction 
treatment 
   2. Mean charges of first 
admission with 
chemotherapy 
 $46,118 (197,039)  
      Mean total cost without 
chemotherapy 
   $163,159 (236,486)  
      Mean total cost with 
chemotherapy 
   $80,541 (388,194)  
          Protocol Standard  
Berman et 
al. 2002 
[114] 
USA AML (79) Cost 
analysis 
From diagnosis 
until the day 
before the next 
phrase of 
chemotherapy 
charges 1. Inpatient bed  Hospital 
accounting 
system 
Sum up $34373 $44200 1. Induction 
treatment  2. pharmacy Antiemetics, antibiotics, 
chemotherapy, and G-CSF 
$29214 $25553 
 3. Professional fee  $14723 $16563 
 4. chemistry  $10848 $13061 
 5. Blood bank  $5273 $8537 
 6. All the other Emergency room, Hospital 
visit, Laboratory 
$13563 $21109 
      Median total cost    $96571 $124868  
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          AML10 FLANG 1. Induction 
therapy 
2. Only focus on 
treatment cost; 
diagnostic cost 
were excluded 
Clavio et 
al. 2001 
[112] 
Italy AML 
Adult 
≦60 
(18) 
Cost 
analysis 
Beginning of 
therapy until 
discharge 
charges 1. Personnel and 
services 
 Hospital 
accounting 
system 
Sum up $5,906 $3,970 
  2. Antiblastic drugs   $453 $1,057 
  3. Infection treatment   $1,366 $721 
  4. Antiemetic drug   $156 $52 
  5. G-CSF   $52 $506 
  6. Transfusion   $4,243 $2,784 
  7. Microbiological test   $70 $43 
  8. Radiological test   $23 $18 
  9. Other costs   $156 $113  
      Mean total cost    $12,424 $9,269  
          Conventional 
chemotherapy 
ATRA  
Takeshifa 
et al. 1995 
[116] 
Japan APML 
adult 
17-65 
(36) 
Cost 
analysis 
First 2 month of 
hospitalization 
payment 1. Antibiotics   NHI data Sum up ￥13,174 + 7136 ￥7,341  + 
6442 
1. remission 
induction 
  2. Blood products   ￥21,846 + 16,942 ￥14150 + 
10688 
 
  3. Anticoagulants   ￥7,492 + 7051 ￥6,788 + 5980  
  4. Other medical costs drugs, meals, fee for 
laboratory tests, basic 
room, surgery 
 ￥43510 + 17116 ￥34374 + 
13141 
 
      Total costs    ￥86032 + 33030 ￥62653 + 
22312 
 
Jacob et 
al. 2007 
[115]* 
India AML Cost 
analysis 
Complete 
treatment: 2 
inductions and 
3 consolidations 
charges Mean total cost of 
complete treatment 
 Hospital 
accounting 
system 
Sum up 500,000 INR 1. induction and 
consolidation 
treatment 
          Conventional 
chemotherapy 
Low dose 
chemotherapy 
 
Storti et al. 
2005 [113] 
Italy AML 
elder 
65-80 
(17) 
Cost 
analysis 
N/A charges hospitalization (monthly)  Hospital 
accounting 
system 
Sum up €3700 €1000  
   Antibiotic (monthly)   €1100 €300  
   Transfusion (monthly)   €1200 €500  
   Chemotherapy   €500 €6  
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(monthly) 
      Total cost (monthly)    €6500 €1806  
Stabler et 
al. 2003 
[100] 
Germany Cancer 
(66) 
Cost 
analysis 
3 months Bottom-up Hospitalization 
Personnel 
 Hospital 
accounting 
system 
 -  
CC: conventional chemotherapy 
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Appendix 2.10 The summary of transplantation cost studies 
Study Country Patients Type of 
analysis 
Study period Cost 
type 
Costing Method Note 
Cost item Item content Data source Method Value 
Yu et al. 
2006 [107] 
Taiwan AML 
Adult 
≦60 yrs 
(54) 
CEA Single period 
of therapy 
charges 1. Hospitalization  Hospital 
accounting 
system 
  1. Only focus on 
inpatient cost. 
2. post remission 
   2. Pharmacy (drug)   
   3. Laboratory   
   4. blood transfusion   
   5. procedure   
   6. Personnel   
   7. out-of-pocket   
    Mean total 
treatment cost 
 AlloSCT: 29,208 + 20,901 
ASCT: 10,037 + 7,291 
          MA NMA  
Cordonnier 
et al. 2005  
[120] 
France AML (23) Cost 
analysis 
1 year charges Care expense Average daily rate for 
personnel costs, supplies, and 
room costs 
Hospital 
accounting 
system 
 €59920 €62960  
      Pre-transplantation Family HLA typing / 
evaluation of the recipient 
and donor /conditioning 
chemotherapy / harvest 
 Cost of harvest: 
MA-8.6% of total 
cost; NMA-5% of 
total cost 
   
      Expensive drugs chemotherapy, cyclosporine, 
blood products, growth 
factors, antibacterial and 
antifungal drugs 
 Pharmacy expense = 
10% of total cost 
 
   
      Other resources TBI, expensive investigations 
(CT, MRI) 
 Blood bank = 10% of 
total cost 
   
      Overheads maintenance, administration  step-down method €100 €100  
      Mean total cost    €74900 +22600 €78700+ 37300  
Schimmer 
et al. 2002 
[127] 
Canada AML (18) Cost 
analysis 
1.5 year after 
transplantation 
Unit 
cost 
Space requirements Examination room*2, waiting 
area and staff work area 
1. hospital 
2. health 
insurance 
Resource counts * 
reference unit cost 
Fixed costs for overheads $2300  
      Durable equipment table, equipment, desk and     
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chairs (examining room) 
      General equipment 
and waiting area 
Standard office equipment 
and lounge furniture 
    
      personnel 1. operated 0.5 days / week 
2. administrative secretary 0.5 
FTE, receptionist 0.1 FTE, 
nurse 0.1 FTE, hematologist 
0.1 FTE 
FTE: annual 
full-time-equi
valent 
 Staff $33,300 
Physician fees $4,100 
 
      Incremental 
diagnostic tests 
(New patient tests) 
Complete blood count, liver 
function tests, bone mineral 
density, Mammogram 
  Initial diagnostic procedures $ 
13,200 
 
      Annual total cost of operating the clinic  Sum up $53,000 (Can)  
          BMT MUD PBSCT  
Agthoven 
et al. 2002 
[124] 
Netherla
nds 
ALL & 
AML 
adult (97) 
Cost 
analysis 
Pre-transplanta
tion until 
2-year 
follow-up 
Unit 
cost 
Pre-transplantation: 
screening cost 
HLA typing + confirmation, 
chemistry, antibody, 
screening, immunology 
Unit cost: 
Dutch tariff 
Resource counts * 
reference unit cost 
€2,342 (excluding haematologist) 1. HLA typing 
details: Table 5 in 
the article 
2. donor cost 
details: table 5 of 
the article 
     Pre-transplantation: 
donor cost 
Family HLA typing, requesting 
blood samples, donor graft, 
harvest 
Unit cost: 
Dutch tariff 
Resource counts * 
reference unit cost 
10843 47063 11137 
      Transplantation Hospitalization, consultations, 
antibiotics, blood 
components, 
immunosuppressants, TBI, 
laboratory test 
1. Unit cost: 
Dutch tariff 
2. wholesale 
prices 
3. the unit of 
hospital days 
(regular / 
isolation / 
ICU)   
1. Resource counts * 
reference unit cost 
2. Hospitalization,  
day care treatment, 
outpatient visit 
included overheads 
cost 
28944 35543 32255  
      Follow-up phase 1: 
 6 months  
outpatient visits, 
consultations antibiotics, day 
care, blood components, 
laboratory test 
16587 30292 15051  
      Follow-up phase 2: 
 6-12 months  
10157 18473 12265  
      Follow-up phase 3: 
12-24 months  
8093 13331 6313  
      Personnel cost See table 3 of the article Salary and 
full-time 
equivalents  
FTEs required * total 
employer costs  
    
      Average costs     98334 151754 98977  
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          PBPCT BMT  
Vicent et 
al. 2001 
[125] 
Spain ALL, 
AML, 
NHL, and 
HD 
children 
(131) 
Cost 
analysis 
From 
admission for 
transplantation 
until discharge 
charges Stem cell collection Mobilization, harvest, 
apheresis, cryopreservation 
Hospital 
accounting 
system 
Sum up $1218 $1071  
  Hospitalization Hematologic care unit,  
intensive unit 
$3117 $5106  
  Blood products Platelet transfusion, red blood 
cell transfusion 
$606 $1236  
      Pharmacy Growth factors, conditioning, 
antibiotics  
$1845 $2061  
      Laboratory test Blood count, culture $164 $257  
      Radiological  X-ray, CT $99 $9  
      Total cost    $7895 $11820  
            
Chandy et 
al. 2001  
[126] 
India AML, 
CML, 
THAL 
children 
(4) 
Cost 
analysis 
From 
admission to 
discharge 
charges Investigations  Hospital 
accounting 
system 
Sum up $1735.5  
 Physician fees  $133,475  
 Room charges  $2,866  
 Blood product  $2,112  
 Drugs  $6,869  
 Disposables  $6,362  
      Mean total cost    $16,666.75  
Mishra et 
al. 2001 
[128] 
Norway CML, 
ALL, 
AML, 
MSD (17) 
Cost 
analysis 
From 
pre-transplanta
tion until 1 
year follow up 
charges Pre-transplantation Personnel resource, 
pharmacy, blood products, 
diagnostic tests, donor 
evaluation 
Hospital 
accounting 
system 
1. personnel 
resource unit cost: 
with 4 levels of care 
(OC:IC:LIC:HIC = 
1:2:3:4) 
2. overhead unit 
cost: step down key 
cost and allocate to 
get the mean cost 
$12,077 1. use bottom up 
costing method 
2. outpatient costs 
were excluded 
    Transplantation Personnel, pharmacy, blood 
product, operation, 
laboratory test, radiology 
$80,195 
      Post-transplantation 
(1 year follow-up) 
Personnel resource, 
pharmacy, blood products, 
laboratory test, radiology 
$14,533  
      Total cost    $106,825  
          PBSCT BMT  
Blaise et al. 
2000 [121] 
France AML, 
ALL, CML 
Cost 
analysis 
6 months Unit 
cost 
Donor graft 
collection 
1. Blood cell collection 
2. BM collection: prior study 
Medical 
records 
1.Resource count * 
reference unit cost 
€2740+525 €2449+241  
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  adult 
≦55 (98) 
   Conditioning 
regimen (drugs and 
TBI) 
 prices of 
medical 
technical acts 
2. total yearly cost of 
consumable supplies, 
hotel cost, personnel 
cost, and 
depreciation of 
equipment (for 5 
years) were 
measured to 
calculate per diem 
cost   
3. step-down method 
to calculate the  
overheads 
 
€1280+453 €1370+367  
     Room cost Initial and secondary room  €17408+7363 €21759+10087  
      Outpatient visit  €1678+1051 €1463+991  
      Transfusion Platelet, erythrocyte Prices €1802+1957 €3193+3537  
      Post transplantation 
drug 
 price €6450+3193 €7403+2632  
      Parenteral nutrition  Price €783+832 €1008+1106  
      Laboratory tests  prices of 
medical 
technical acts 
€5220+1509 €5832+1769  
      Total cost    €37410+12109 €44531+15881  
Farah et al. 
1998 [117] 
USA ALL, 
AML, 
CML 
children 
≦ 16 
(19) 
Cost 
analysis 
Treatment 
period 
charges Hospitalization  Unit bed 
charges 
Sum up  1. TBI charge were 
similar whether 
performed in 
inpatient or 
outpatient setting 
   Ambulance 
transportation (to 
and from) 
 Round trip 
twice per day, 
 
   Clinical visit    
   Fluid administration    
      Total cost    Outpatient TBI save $3,250 per patient 
          AlloBMT Control  
Barr et al. 
1996 [118] 
Canada AML 
(2CR) 
adult 
16-45 (7) 
CEA 5 years Unit 
cost 
Diagnostic and 
therapeutic costs  
laboratory tests, radiologic 
investigations, clinic visits, 
emergency department visit 
 Resource counts * 
reference unit cost 
$32997 $14349 1. the cost to 
families and to 
BMT donors were 
not included, but 
typing costs were 
included 
2. nursing costs 
were included in 
ward costs 
     Ward costs Included nursing cost Nursing costs: 
nursing 
reports 
nursing time per 
patient per day in 
hour * nursing cost 
$51105 $23673 
      Professional fees Physicianconsultation, visits, 
laboratory medicine, 
radiology, and surgical 
procedures  
OHIP 
schedule of 
benefits. 
 $5231 $6682 
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      Drug cost    $11267 $7097  
      Total cost    $CAN: 100,600 
(SD:48380) 
$CAN: 51,800 
(SD:17370) 
 
          Unit treatment 
cost 
Total cost  
Uyl-de 
Groot et al. 
1995 [119] 
Netherla
nds 
AML (30) Cost 
analysis 
2 years Unit 
cost 
Option 1: no further 
treatment 
40% no relapse  Resource count * 
reference unit cost 
$4220 $1690 
(4220*0.4) 
 
   60% relapse     
   50% re induction cycle  $31160 $9350  
   50% no re induction cycle  0 0  
      Conventional treatment cost    $11040  
      Option 2: 
autologous BMT 
Autologous BMT: 
pre-transplantation, 
transfusion, hospitalization, 
medication,  
 Hospitalization 55%, 
Medication 14%, 
Transfusion 18% 
$51220 $51220  
       Follow up      
       60% no relapse   $4220 $2530  
       40% relapse   $4220 $1690  
      Total BMT cost     $55440  
Esperou et 
al. 2004 
[122] 
France CML, 
AML, ALL 
(85) 
Cost 
analysis 
6 months charges Room Acute care days, ICU days, 
outpatient visit, home care 
Hospital 
accounting 
system 
step-down method 
to allocate the 
overheads costs. 
€57703 (11444-149901) 1. Median cost 
    Blood bank  €5390 (834-26557)  
    Tests family HLA typing, 
pre-transplant evaluation 
 €791 (48-3947)  
      pharmacy    €4441 (524-34628)  
      Conditioning    €13285  
      Harvesting BMT, PBSCT   €8501  
      Total cost    €70479 (14761-183758)  
Dagher et 
al. 1997 
[123] 
USA ALL, AML 
children 
9-17 (10) 
Cost 
analysis 
Unknown charges Inpatient  Hospital 
accounting 
system 
   
   Daily bed charges     
   Transportation To and from the radiation 
facility 
   
      Outpatient      
      Clinic visit      
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      Home-care      
      TBI      
      Total difference    $2,400  
Stabler et 
al. 2003 
[100] 
German
y 
Cancer 
(66) 
Cost 
analysis 
3 months Bottom
-up 
Diagnosis  1. Hospital 
accounting 
system 
2. survey 
   
 SCT     
    Conditioning  
chemo 
    
      Total cost   €16672 per outpatient contact 
€45930 per hospital care day 
€80820 per inpatient treatment 
day  
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Appendix 2.11 The summary of adjunctive care cost studies 
Study Country Patients Type of 
analysis 
Study period Cost type Costing Method Note 
Cost item Item content Data source Method Value 
          induction Induction + 
consolidation 
 
Standaert et 
al. 2002 
[129] 
UK AML adult 
(82) 
Cost 
analysis 
24 hours 
after 
chemotherap
y until ANC 
recovery 
Unit cost 
charges 
CRF (case report method)      
 1.Hospital stay   Case report forms Resource count * 
unit reference 
cost 
£4455.10 £7774  
 2. anti-infective drug   £433.9 £727.16  
    3. Platelet use  £1457.37 £466.44  
     4. Lab test    £267.31 £2345.59  
      5. G-CSF    £918 £1413  
      Total cost    £7531.67 £12726.19  
      PF (medical chart)     
      1. Hospitalization  Hospital accounting 
system 
Sum up £4485 £7721.10  
      2. iv infective drug  £536.45 £600.25  
      3. Other drug   £308.1 £530.41  
      4. Diagnostic tests Haematology, 
biochemistry, 
microbiology, t 
  £1147.36 £1531.58  
      5. Blood products    £3223.78 £4477.75  
      Total cost    £9700.69 £14,861.09  
          G-CSF  Placebo    
Bradstock et 
al. 2001 
[130] 
Australia AML adult 
15-60 
(114) 
Cost 
analysis 
Start date 
until ANC 
recovery 
Payment Lenograstim Daily dose and 
duration of 
lenograstim 
Australian 
pharmaceutical 
benefits schedule, 
case record forms 
1. Sum up 
2. Exclude: 
chemotherapy, 
antibiotics, 
transfusions, 
1-day admission 
and outpatient 
visits  
A$3684 A$120 Exclude some 
costs because 
the authors 
considered 
there were no 
differences 
between two 
arms   
 Intravenous and oral 
antibiotics 
Duration of 
administration and 
standard doses 
hospital purchasing 
costs, case record 
forms 
  
    Inpatient admission   Reimbursement   
      Total    Mean increase: A$ 1494 (SE: 
1942) 
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Bennet et 
al. 2001 
[131] 
USA AML elder 
55-70 
(207) 
Cost 
analysis 
Start date 
until ANC 
recovery 
charges Daily cost without 
infection 
Blood bank, 
hospitalization, lab 
test, and pharmacy 
Unit cost: the 
hospital billing data 
of 24 pts at 5 centers 
Sum up $1476 (722) use 
cost-to-charge 
ratio to 
transform the 
charges to real 
cost 
    Daily cost with infection Blood bank, 
hospitalization, lab 
test, pharmacy, and 
antibiotics,  
Unit cost: the 
hospital billing data 
of 24 pts at 5 centers 
 $1742 (548) 
      G-CSF  Drug selling price  $200  
      Total cost    Placebo group: $49,693 
G-CSF group: $50,593 
 
          AML10 FLANG  
Clavio et al. 
2001 [112] 
Italy AML Adult 
≦60 (18) 
Cost 
analysis 
Chemo: 
admission 
until 
discharge 
G-CSF: day 11 
until 
neutrophil 
recovery 
charges 1. Personnel  Hospital accounting 
system 
Sum up $5,906 $3,970 1. Induction 
therapy 
2. Only focus on 
treatment cost; 
diagnostic cost 
were excluded 
3. Including 
chemotherapy 
cost 
  2. Antiblastic drugs   $453 $1,057 
   3. Infection treatment    $1,366 $721 
     4. Antiemetic drug    $156 $52 
     5. G-CSF    $52 $506 
     6. Transfusion    $4,243 $2,784 
     7. Microbiologic testing    $70 $43 
     8. Radiological testing    $23 $18 
      9. Other costs    $156 $113  
      Mean total cost    $12,424 $9,269  
          infection Un-infection  
Bennett et 
al. 1999 
[132] 
USA AML elder 
55-70 
(117) 
Cost 
analysis 
Start date 
until 
discharge 
charges Non GM-CSF  Hospital room, 
laboratory, 
pharmacy, blood 
products, 
24 patients’ hospital 
charges data (cost to 
charge ratio) 
Median per day 
cost(exclude the 
cost of GM-CSF) 
$1742 $1467 Use 24 patients’ 
charge data to 
estimate the 
mean 117 pts’ 
total cost      GM-CSF  Hospital charge  $190.8 $190.8 
      Total cost  Resource count * hospital charge unit cost Overall: $38,412 
One cycle: $38,617 
Two cycle: $37,467 
 
          G-CSF Control  
Ojeda et al. 
1999 [133] 
Spain AML, NHL 
adult 
Cost 
analysis 
Transplantati
on in-patient 
charges Occupied-bed days personal, laboratory 
test 
Patient medical 
records 
Sum up €4362 + 387 €4317 + 238 Only included 
in-patient time. 
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 18-64 (62) time Non-prophylactic 
antibiotics 
 €711 + 140 €601 + 76 Exclude: costs 
after discharge,  
conditioning 
chemotherapy, 
harvest and 
cryopreservation
. 
 TPN (total parenteral 
nutrition) 
   €511 + 38 €483 + 32 
 Transfusion RBC, Platelet   €995 + 133 €993 + 196 
      G-CSF    €553 + 37  
      Total cost    €7,449 + 645 
Median: 
€5,961  
€6,689 + 480 
Median: €5,751  
 
          GM-CSF Control  
Uyl-de 
Groot et al. 
1998 [134] 
Netherlands AML elder 
≧ 60 
(103) 
Cost 
analysis 
Start date 
until 2 years 
follow-up 
charges Induction I       
1. Hospitalization Personnel, overheads 
cost 
 Sum up $14,950 $14,270  
  2. Consultation    $101 $83  
    3. Laboratory services Routine test, blood 
culture 
  $2,854 $2,592  
      4. Medical procedures radiotherapy and 
surgery 
  $1,318 $1,437  
      5. Drug (excl. GM-CSF)  Wholesale price  $5,327 $4,412  
      6. GM-CSF  Wholesale price  $3314 0  
      7. Nutrition    $434 $328  
      8. Transfusion Blood products   $2,301 $2,113  
      Total induction I cost    $30,599  $25.236  
      Total induction II cost    $25,054  $22,965   
      Total consolidation cost    $15,384  $20,891  
      Treatment cost    $40,782 $34,465  
      1st year follow-up Outpatient visit, 
day-care   
  $11,266 $10,831  
      2nd year follow-up   $6,039 $6,571  
      Total cost    $58,087 $51,867  
          1 cycle 2 cycles  
Bennett et 
al. 1997 
[135] 
USA AML elder 
56-70 
(117) 
Cost 
analysis 
Start date 
until 
discharge 
charges 1. Daily cost without 
infection 
Blood bank, 
hospitalization 
laboratory test, 
hospital billing data 
of 7 pts at a center 
Sum up $2,100 $2,100 1. medical cost 
only 
2. use 
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pharmacy cost-to-charge 
ratio to 
transform the 
charges to real 
cost 
 2. Daily cost with 
infection 
Blood bank, 
hospitalization 
laboratory test, 
pharmacy, antibiotics 
Unit cost: the 
hospital billing data 
of 7 pts at a center 
 $3,600 $3,600 
      3. G-CSF  selling price  $200 $200  
      Mean total cost    $66,757 $62,728  
Lu et al. 
1996 [136] 
Unknown AML (521) Cost 
analysis 
1st induction 
(start day 
until 
discharge) 
charge 
sunit cost 
1. hospitalization  Baseline model with 
hospital accounting 
system 
Resource count * 
hospital charge 
unit cost 
  
 2. anti-infective therapy    
 3. transfusion    
     4. G-CSF administration    
      5. physician visit     
      Net cost saving    $2,230  
          G-CSM placebo  
Bennett et 
al. 1998 
[137] 
USA AML elder 
>55 (207) 
Cost 
analysis 
Start date 
until 
discharge 
charges 1. Median cost per day 
with infection 
   $1,840 $1,840  
 2. Median cost per day 
without infection 
   $1,370 $1,370  
      Total cost    $52,070 $51,950  
          G-CSF Placebo  
Woronoff-L
emsi et al. 
1997 [138] 
France AML elder 
55-75 (83) 
CEA Start date 
until ANC 
recovery 
charges Overall survival cost  Medical records and 
hospital accounting 
system 
 $97,841 
(36,704) 
$106,963 
(45,927) 
 
  Disease free survival 
cost 
  $53,456 
(20,940) 
$59,528 
(27,075) 
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Appendix 2.12 The summary of complication treatment cost studies 
Study Country Patients Type of 
analysis 
Study period Cost type Costing Method Note 
Cost item Item content Data source Method Value 
Nomura et 
al. 2006 
[139] 
Japan AML 40 yrs 
(30) 
CEA Start of 
chemothera
py to CR or 
death 
Payment 
and 
hospital 
charge 
1. Hospitalization  National 
health 
insurance 
Sum up $5093 (3644-5914) Strategy 1: Oral 
fluconazole 
Strategy 2:  
empirical 
amphotericin B 
Strategy 3:  
MCPG 
  2. chemotherapy   $7542 (5394-10600) 
  3. Laboratory test   $1404 (749-1729) 
    4. Medication 
(excluding antifungals) 
   $1053 (283-3536) 
      5. nutrition    $733 (518-972) 
      6. Transfusion    $8608 (1338-16211) 
          S1 S2 S3 
      7. Antifungal drug   Resource count * 
daily hospital charge 
$884 $112 $870 
      Cost per patient    $25900 $25400 $25400  
          case control  
Menzin et al. 
2005 [140] 
USA AML elder 
≧65 (160) 
Cost 
analysis 
Inpatient 
time and 30 
days post 
discharge 
Charges 
and 
payment 
Total charges for 
hospitalization 
Hospitalization, 
intensive care  
Accounting 
system 
Sum up $110767 
(95592) 
$55796 
(63462) 
 
 Medicare payments 
for hospitalization 
 SEER + 
Medicare 
Sum up $34268 
(31811) 
$21416 
(22449) 
 
          HU TLS  
Annemans 
et al. 2003 
[141] 
Belgium, 
Netherland
s, Spain, UK 
ALL, AML, 
NHL (144) 
CEA Treatment 
time 
Ref Unit 
cost 
1. Medication  Unit cost Mean of resource 
count * reference 
unit cost 
€218 (51) €446 (92) HU: hyper 
uricaemia 
TLS: tumour lysis 
syndrome 
 2. Interventions   €13 (6) €719 (185) 
 3. Consultations   €32 (3) €142 (19) 
  4. Laboratory   €32 (4) €115 (20) 
      5. Imaging   €1 (0) €83 (18) 
      6. Hospitalization    €376 (142) €5837 (1421)  
      Total cost     €672 (181) €7342 (1617) 
      Total cost per 
treatment with 
rasburicase 
 Unit cost Average body weight 
*dosage* number of 
days* unit cost 
Adult: €2220 
Child: €960 
 
      Incremental cost of 
prevention with the 
 Drug cost – (HU cost*HU 
incidence*%HU prevented) – (TLS 
Adult: €1752 (1425-1924) 
Child: €492 (165-664) 
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drug cost*TLS incidence*% TLS prevented) 
      Incremental cost of 
treatment with the 
drug 
 Drug cost – (HU cost*% HU 
prevented) – (TLS cost*TLS incidence 
in HU case*% TLS prevented) 
Adult: - €426 
Child: - €1686 
(-€965~-€3665) 
 
Costa et al. 
2003 [142] 
Brazil AML, ALL, 
NHL, HL 
children ≦21 
(22) 
Cost 
analysis 
Treatment 
time plus 20 
days after 
treatment 
Ref unit 
cost 
1. Antibacterial   Resource count * 
reference unit cost 
$41,523  
 2. drugs excludes 
disease treatment 
  $7,657  
  3. ambulatory visit   $5,337  
  4. cultures   $3,726  
     5. transfusions    $3,642  
      6. laboratory test    $4,420  
      7. Hemogram    $2,117  
      8. Hospitalization Personnel and 3 
types of ward 
  $112,383  
      Total direct cost   Sum up $180,805  
      total cost per episode   per treatment 
episode 
$2660($2039) (AML: $2917)  
Rosenman et 
al. 2002 
[143] 
USA ALL, AML, 
CNS children 
≦18 (157 
episodes) 
Cost 
analysis 
Treatment 
time 
charges Total hospital charges 
per episode 
  Mean $11,967+$16,261 
($40,694+38,831in AML) 
 
          C+N C+A M  
Agaoglu et 
al. 2001 
[144] 
Turkey ALL, AML 
children (87 
episodes) 
Cost 
analysis 
Treatment 
time 
charges Daily drug cost for 
30kg patient 
 Hospital 
accounting 
system 
 $53.8 $46.2 $121.4 1. cefepime + 
netilmicin 
2. ceftazidime + 
amikacin 
3. meropenem 
Horowitz et 
al. 1996  
[145] 
USA ALL, AML, 
NHL (10) 
Cost 
analysis 
Treatment 
time 
charges 1. Antibiotic cost 
differential 
Gentamicin, 
Ceftazidime, 
Vancomycin, 
Ciprofloxacin IV 
Hospital 
accounting 
system 
total cost of 
ciprofloxacin * 
number of days on 
ciprofloxacin 
$1,142 per patient 1. object is to 
compare the cost 
of ciprofloxacin in 
hospital and at 
home 
  2. Hospital day cost 
saved 
oncology bed Cost of oncology bed 
per day * the number 
$8,880 per patient  
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of  days   
      Total cost saved Antibiotic and 
hospitalization 
cost save 
  $10,022 per patient  
          ST CC LDC  
Storti et al. 
2005  [113] 
Italy AML elder 
65-80 
(17) 
Cost 
analysis 
unknown charges Antibiotic expense 
(monthly) 
   €2900 €1100 €300 ST: supportive 
care 
CC: Conservation 
chemotherapy 
LDC: low-dose 
chemotherapy 
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Appendix 2.13 The summary of examination cost studies 
Study Country Patients Type of 
analysis 
Cost type Costing Method 
Cost item Item content Data source Method Value 
Gonen et al. 
2005 [146] 
Turkey AML (33 
episodes) 
Cost 
analysis 
Hospital 
charge unit 
cost   
1. Blood cultures  Hospital accounting system Resource count * hospital 
charge unit cost 
$43*26 
 2. Urine cultures   $36*21 
 3. Chest X-ray   $5.8*6 
 4. Sinus X-rays   $4.9*2 
 5. Oral smear   $14.2*2 
     6. Sterile urine 
examinations 
  $14.2*11 
     7. urinalysis    $5.7*6 
     Total cost of  investigation of fever per episode  $2137/33=$64.76 
         cyto PCR PCR (add) 
Tonnaire et 
al. 1998 
[147] 
France ALL, AML 
adult 16-91 
(107) 
CEA Ref unit cost 1. Equipment Appliances and 
supplies 
 5 year depreciation rate for 
equipment (20%) and 10 year 
for materials (10%), average 
annual rate 8% 
$108 $26.6 $0 
  2. Labor technicians, 
physicians, white 
collar and 
maintenance workers 
1. White collar workers: annual 
laboratory charges / no. of 
analyses completed within the 
year 
2. physicians and technicians: 5 
exams per week + 1 hour work for 
physician to interpret. 
 $289.8 $123.1 $41.6 
     3. Reagents    $163.2 $88 $53.2 
     4. Other non 
expendable 
laboratory supplies 
   $15.8 $3 $0 
     5. stationery    $0.6 $0.5 $0 
     Total    $577.4 $241.2 $94.8 
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Appendix 2.14 The summary of palliative or supportive care cost studies 
Study Country Patients Type of 
analysis 
Study period Cost type Costing Method Note 
Cost item Item content Data source Method Value 
Yu et al. 
2007 [107] 
Taiwan AML Adult 
≦60 yrs 
(54) 
CEA Single period 
of therapy 
Charges 1. Hospitalization  Hospital 
accounting 
system 
Sum up  1. Only 
focus on 
inpatient 
cost 
2. post 
remission 
   2. Pharmacy (drug)   
   3. Laboratory   
   4. blood transfusion   
   5. procedure   
   6. personnel   
   7. out-of-pocket   
    Total treatment cost  Supportive care: $3,013+ 4,586 
Palliative care: $15,726+ 17,083 
          Discharge 
early 
Terminal Chronic  
Cartoni et 
al. 2007 
[150] 
Italy AML, 
lymphoma, 
myeloma 
(144) 
Cost 
analysis 
Unknown Ref unit 
cost 
1. Health care provider Physician, nurse,, and 
co-ordination team 
(direct cost and 
overheads in a 60:40 
ratio) 
 Resource 
count * 
reference 
unit cost 
€1354.9 €1513.6 €507.3  
      2. Medicines    €1432.2 €1442.6 €728.3  
      3. Transfusion     €1148.2 €1224.3 €227.3  
      4. laboratory hematology, blood 
chemistry, microbiology 
  €51.1 €52.0 €25.4  
      Total monthly cost    €3986.4 
(241.2 - 
6285.3) 
€4232.5 
(437 - 
14599) 
€1488.3 
(455.9 - 
4769.5) 
 
Wandt et 
al. 1998 
[148] 
Germany AML adult 
≦60 (105) 
Cost 
analysis 
Unknown charge   Platelet transfusion  Hospital 
accounting 
system 
Sum up Trigger 1 saved 1/3 cost  
  RBC transfusion  No difference  
    Leukocyte filters  No difference  
    personnel     
      Transfusion cost per treatment cycle   Trigger 1 is cost saved  
Ruiz-Arguel Mexico AML adult Cost Start date until charges Outpatient setting cost Transfusion,   $1700 per patient  
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les et al. 
1995 [149] 
14-63 (24) analysis granulocyte 
count recovery 
saved by avoiding 
prolonged hospitalization 
antibiotics, physician 
fee 
Storti et al. 
2005 [113] 
Italy AML elder 
65-80 
(17) 
Cost 
analysis 
unknown charges hospitalization (monthly)  Hospital 
accounting 
system 
 €5,100  
  Antibiotic (monthly)   €2,900  
   Transfusion (monthly)   €900  
     Chemotherapy (monthly)    €0  
      Total cost (monthly)   €8,900  
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Appendix 3.1 Database Cleaning 
 
Database Cleaning Number 
Removed problematic cases  
Medical note is not obtainable 2 
Extraction form has not been completed 2 
Removed duplicated events  
Duplicated records 1 
Integrated the records that are likely to be the same  
Integrating Mylotarg 2 
Integrating Spanish approach (like) 3 
Integrating MRC approach (like) 1 
Integrating FC 2 
Integrating FLAG 2 
Integrating FLAG-Ida 2 
Fixed the records that against the definition  
Removing observation record 91 
Removing “non-haematological” treatment record 10 
Removing “Bisphosphonates” which is not for AML treatment 1 
Change the extreme long palliative care to observation 3 
Fixed the field input error  
Immunosuppressive therapy miss-input as chemotherapy 1 
AraC(LD) miss-input as Cytarabine (IT) 2 
Fixing the missing data in the field: place of death 2 
Fixed the date input error  
Fixing the missing data in the field: Date of Follow-up 1 
Fixing the missing date in the field: treatment date 7 
Fixing the miss-input date in the field: treatment date 4 
Fixing the miss-input in the field: death date 18 
Total   156 
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Appendix 3.2 Integration information for imputation 
 Cycle one 
Interval 
Cycle two Imputed 
treatment 
time 
Numbers 
of 
imputed 
cases 
 Treatment 
time 
Hospital 
stays 
Treatment 
time 
Hospital 
stays 
Intensive inpatient treatment        
ADE 10 30 13 8 25 30+13+8=51 6 
AraC (HD) 5 32 17 5 23 32+17+5=54 3 
AraC (LD) – clinical trail 10 30 18 10 30 30+18+10=58 3 
DA 10 35 14 8 30 35+14+8=57 12 
FLA 5 28* 17* 5 46* 28+17+5=50 1 
FLAG 7 33 19 7 45 33+19+7=59 2 
FALG-Ida 7 28 17 7 46 28+17+7=52 15 
HAM 6 30*    30 1 
MACE 5 25    25 10 
MidAC 5 30    30 3 
Spanish Approach 4 31 0 4 23  2 
 5 32 0 1 28**   
MRC approach 10 32 11 8 25  0 
 5 27 17 5 28   
Clofarabine 5 30**    30  
Mild inpatient treatment        
Amsacrine 5 28    28 0 
AraC (LD) -chemotherapy 10 14 18 10 14 14+18+10=42 5 
Arsenic trioxide 25 33    33 0 
Campath 3 14**    14  
Intensive outpatient treatment        
Mylotarg 1 - 6 1 - One cycle (1) 1 
FC 5 - 23 5 - One cycle (5) 2 
Fludarabine 5 - 28 5 - One cycle (5) 1 
Cyclophosphamide 1 - 6 1 - One cycle (1) 2 
Cyclophosphamide / MESNA 1 -    1 0 
ETI 5 - 21 5 - One cycle (5) 0 
Etoposide 7 - 21 7 - One cycle (7) 2 
Vincristine 1 - 6 1 - 1 0 
ATRA Till 
remission*
* 
-    Till 
remission** 
2 
Melphalane 4 -    4 0 
Anagrelide 5 -    5 1 
Clopidogrel 7 -    7 1 
Mild outpatient treatment        
Aspirine 28** -    28** 1 
Hydroxycarbamide 28** -    28** 16 
Hydroxycarbamide / Aspirin 28** -    28** 0 
Chelating agent  28** -    28** 0 
Non-chemotherapy treatment        
Supportive care        
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Erythropoietin 1 - 6 1 - 3 months** 0 
G-CSF 4 after 
chemo** 
- - 4 after 
chemo** 
-  21 
Steroids       6 
Dexamethasone 14 days** -    14  
Prednisolone 14 days** -    14  
Hydrocortisone 14 days** -    14  
Transfusion       89 
Disease time < 2 months 1 - 4 1 - Till 
remission** 
 
Disease time > 2 months 1 - 14 1 - Till 
remission** 
 
Stem cell transplantation 1 28    28 4 
Immunosuppressive 14 weeks** -    98** 3 
Radiotherapy 1 -    1 2 
Splenectomy 1 8    8 0 
Venesection 1 -    1 0 
Palliative care       17 
<100 days till death Till death** Till 
death** 
   Till death**  
>100 days till death 2 weeks** 2 
weeks** 
   14**  
Follow up        
End-of life care 14** 14**    14**  
 
* The length was imputed by similar treatment  
** The length was imputed by expert opinions 
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Appendix 4.1 Types of treatment by numbers of treatment (for AML patients) 
 Tx 1 Tx 2 Tx 3 Tx 4 Tx 5 Tx 6 Tx 7 Tx 8 Tx 9 Tx 10 Tx 11 
Chemotherapy 84 48 21 25 21 17 10 2 3 1 - 
ADE 3 3 1 6 4 1 - - - -- - 
AraC(HD) - 1 1 - 5 3 - - 1 - - 
AraC(HD) + Mylotarg - - - - - 1 1 - - - - 
AraC(LD) 27 5 1 1 - 2 - - - 1 - 
Clofarabine - - - 1 - - 1 - - - - 
DA 27 8 - 1 1 - - 1 - - - 
DA + Mylotarg - - - - - - 1 - - - - 
FLA - - - 3 1 - - - - - - 
FLAG 2 5 3 7 1 - - - - - - 
FLAG-Ida 1 2 1 1 - - - - - - - 
FLAG-Ida + Mylotarg - - - - - 1 - - - - - 
HAM - - - - - 1 - - - - - 
MACE - 4 3 - 2 - - - - - - 
MidAC - 4 6 - - 2 - - - - - 
Mini-MidAC - 2 1 - - - - - - - - 
Amsacrine - - - - 1 - - - - - - 
Campath - - - - - 1 - - - - - 
Daunorubicin - - - - 1 - - - - - - 
Cyclophosphamide - - 2 1 1 - 1 - - - - 
Cyclophosphamide / MESNA - - - - 1 1 - - - - - 
ETI 1 1 - - - - - - - - - 
FC 1 - 1 - - 2 2 - - - - 
Fludarabine - - - 1 - - 1 - - - - 
Vincristine - 1 - - - - - - - - - 
Melphalan 1 1 - 1 - - - - - - - 
Anagrelide - - - - - - 1 - - - - 
Clopidogrel - - - - - 1 - - - - - 
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Aspirin - - - - 1 - - - 1 - - 
Hydroxycarbamide 21 10 1 1 2 1 1 1 1 - - 
Hydroxycarbamide + Aspirin - - - 1 - - - - - - - 
Chelating agent - 1 - - - - 1 - - - - 
Clinical trial 70 45 20 9 1 - - - - - - 
AML 14 AraC 4 - - - - - - - - - - 
AML 14 AraC + Mylotarg - 1 - - - - - - - - - 
AML 14 D35 C200 3 - - - - - - - - - - 
AML 14 D35 C400 1 - - - - - - - - - - 
AML 14 D50 C200 4 - - - - - - - - - - 
AML 15 ADE 7 7 1 - - - - - - - - 
AML 15 ADE + Mylotarg 8 1 - - - - - - - - - 
AML 15 AraC - 6 10 3 1 - - - - - - 
AML 15 AraC + Mylotarg 1 4 2 - - - - - - - - 
AML 15 DA 8 8 - - - - - - - - - 
AML 15 DA + Mylotarg 6 - - - - - - - - - - 
AML 15 FLAG-Ida 15 7 1 - - - - - - - - 
AML 15 FLAG-Ida + Mylotarg 13 - - - - - - - - - - 
AML 15 MACE - 3 7 - - - - - - - - 
AML 15 MACE + Mylotarg - 7 2 - - - - - - - - 
AML 15 MidAC - 1 7 6 - - - - - - - 
Immunosuppressive - - - 1 - 1 1 2 1 - - 
Radiotherapy - - - 2 1 3 2 3 1 1 1 
Stem cell transplantation - - - 1 3 - 2 3 2 2 - 
Splenectomy - - 1 - 1 - - - - - - 
Palliative care 11 9 1 2 1 2 2 1 - - 2 
Venesection - 1 1 - - - - 1 - - - 
No treatment 10 - - - - - - - - - - 
Refused treatment 2 - - - - - - - - - - 
Total 177 103 54 40 28 23 17 12 7 4 3 
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Appendix 4.2 Types of treatment by numbers of treatment (for APML patients) 
 Tx 1 Tx 2 Tx 3 Tx 4 Tx 5 Tx 6 Tx 7 Tx 8 Tx 9 Tx 10 Tx 11 
Chemotherapy 6 4 2 2 1 - - - - - - 
ADE - - 1 - - - - - - - - 
AraC(LD) - 2 - - - - - - - - - 
DA - 1 - - - - - - - - - 
DA + Mylotarg         - - - 
MACE - - - 1 - - - - - - - 
Arsenic trioxide (ATO) - 1 - 1 - - - - - - - 
Mylotarg - - - - 1 - - - - - - 
G-CSF         - - - 
Cyclophosphamide - - 1 - - - - - - - - 
ATRA 3 - - - - - - - - - - 
MRC approach (like) 1 - - - - - - - - - - 
Spanish approach (like) 2 - - - - - - - - - - 
Clinical trial 17 4 2 2 - - - - - - - 
AML 15 MRC approach 9 1 1 1 - - - - - - - 
AML 15 Spanish approach 8 2 1 1 - - - - - - - 
AML 15 Spanish Maintenance - 1 - - - - - - - - - 
Palliative care 1 - - - 1 - - - - - - 
Total 24 8 4 4 2 - - - - - - 
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Appendix 6.1 National blood and blood components price list 
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Appendix 6.2 The staff working time survey results 
 ADE DA / AML 15 DA / AML 14 DA 
In-patient period In-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)      1 15 £15.9 £0.5 £0.5      1 15 £15.9 £0.5 £0.5 
Clinical Practitioner                     
Consultant                     
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker 2 30 £10.2 £1.8 £0.9 2 30 £10.2 £1.8 £0.9 2 30 £10.2 £1.8 £0.9 2 60 £38.4 £3.6 £1.8 
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 20 £12.8 £1.2 £0.6 2 90 £57.6 £5.4 £2.7 2 10 £6.4 £0.6 £0.3 2 60 £38.4 £3.6 £1.8 
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 2 10 £7.8 £0.6 £0.5 2 10 £7.8 £0.6 £0.5 1 10 £3.9 £0.3 £0.3 1 10 £3.9 £0.3 £0.3 
Band 7 F,G Nurse team manager  1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
Pharmacist technician                     
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The staff working time survey results (continued) 
 
 AraC (HD) / AML 15 AraC AraC (LD) / AML 14 AraC 
In-patient period In-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)      1 15 £15.9 £0.5 £0.5      1 15 £15.9 £0.5 £0.5 
Clinical Practitioner                     
Consultant                     
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker 2 30 £10.2 £1.8 £0.9 2 90 £30.6 £5.4 £2.7 2 30 £10.2 £1.8 £0.9 2 90 £30.6 £5.4 £2.7 
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 10 £6.4 £0.6 £0.3 2 60 £38.4 £3.6 £1.8 2 30 £19.2 £1.8 £0.9 2 30 £19.2 £1.8 £0.9 
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 1 10 £3.9 £0.3 £0.3 1 10 £3.9 £0.3 £0.3 1 10 £3.9 £0.3 £0.3 1 10 £3.9 £0.3 £0.3 
Band 7 F,G Nurse team manager  1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
Pharmacist technician                     
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The staff working time survey results (continued) 
 
 FLA/ FLAG / FLAG-Ida AML 16 DClo / Clofarabine 
In-patient period In-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)      1 15 £15.9 £0.5 £0.5      1 15 £15.9 £0.5 £0.5 
Clinical Practitioner                     
Consultant                     
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker 2 30 £10.2 £1.8 £0.9 2 60 £38.4 £3.6 £1.8 2 30 £10.2 £1.8 £0.9 2 30 £10.2 £1.8 £0.9 
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 10 £6.4 £0.6 £0.3 2 15 £9.6 £0.9 £0.5 2 60 £33.6 £3.6 £1.7 2 60 £33.6 £3.6 £1.7 
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 1 10 £3.9 £0.3 £0.3 1 10 £3.9 £0.3 £0.3 1 30 £11.7 £0.9 £0.8 1 30 £11.7 £0.9 £0.8 
Band 7 F,G Nurse team manager  1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
Pharmacist technician                     
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The staff working time survey results (continued) 
 
 MidAC / AML 15 MidAC / HAM MACE / AML 15 MACE 
In-patient period In-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)      1 15 £15.9 £0.5 £0.5      1 15 £15.9 £0.5 £0.5 
Clinical Practitioner                     
Consultant                     
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker 2 30 £10.2 £1.8 £0.9 2 30 £10.2 £1.8 £0.9 2 10 £3.4 £0.6 £3.0 2 30 £10.2 £1.8 £0.9 
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 60 £33.6 £3.6 £1.7 2 60 £33.6 £3.6 £1.7 2 30 £19.2 £1.8 £0.9 2 60 £33.6 £3.6 £1.7 
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 1 30 £11.7 £0.9 £0.8 1 30 £11.7 £0.9 £0.8 1 10 £3.9 £0.3 £0.3 1 20 £7.8 £0.6 £0.5 
Band 7 F,G Nurse team manager  1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
Pharmacist technician                     
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The staff working time survey results (continued) 
 
 
 Campath / ATO / Mylotarg/ Immunosuprresive (IP) Amsarcrine / Idarubicin / Chelating agent (IP)  
In-patient period In-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)      1 15 £15.9 £0.5 £0.5      1 15 £15.9 £0.5 £0.5 
Clinical Practitioner                     
Consultant                     
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker      1 60 £10.2 £1.8 £0.9      1 15 £2.55 £0.45 £0.2 
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 5 £3.2 £0.3 £0.2 1 60 £19.2 £1.8 £0.9 2 5 £3.2 £0.3 £0.2 1 15 £4.8 £0.45 £0.2 
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader      1 30 £11.7 £0.9 £0.8      1 10 £3.9 £0.3 £0.3 
Band 7 F,G Nurse team manager                      
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
Pharmacist technician                     
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The staff working time survey results (continued) 
 
 APML 15 Spanish APML 15 MRC 
In-patient period In-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)      1 15 £15.9 £0.5 £0.5      1 15 £15.9 £0.5 £0.5 
Clinical Practitioner                     
Consultant                     
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker 2 20 £6.8 £1.2 £0.6 2 20 £6.8 £1.2 £0.6 2 30 £10.2 £1.8 £0.9 2 30 £10.2 £1.8 £0.9 
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 30 £19.2 £1.8 £0.9 2 60 £38.4 £3.6 £1.8 2 60 £38.4 £3.6 £1.8 2 60 £38.4 £3.6 £1.8 
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 2 10 £7.8 £0.6 £0.5 2 10 £7.8 £0.6 £0.5 2 20 £15.6 £0.6 £1.0 2 20 £15.6 £1.2 £1.0 
Band 7 F,G Nurse team manager  1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 1 10 £4.6 £0.3 £0.3 
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
Pharmacist technician                     
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The staff working time survey results (continued) 
 
 G-CSF / Vincristine / Cyclophosphamide + MESNA / Daunorubicin Cyclophosphamide / Etoposide / EIT / FC / Melphalan / ATRA / Chelating agent (OP) / 
Hydroxyurea / Aspirin / steroids 
Out-patient period Out-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)                     
Clinical Practitioner                     
Consultant      1 15 £22.5 £4.5 £0.8      1 15 £22.5 £4.5 £0.8 
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker      1 30 £5.1 £0.9 £0.5           
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 5 £3.2 £0.3 £0.2      1 5 £1.6 £0.15 £0.1      
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 1 10 £3.9 £0.3 £0.3 1 5 £2 £0.15 £0.1 1 10 £3.9 £0.3 £0.3      
Band 7 F,G Nurse team manager                      
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
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The staff working time survey results (continued) 
 
 
 Transfusion Venesection 
 
In-patient period Out-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)      1 15 £15.9 £0.5 £0.5           
Clinical Practitioner                     
Consultant                1 15 £22.5 £4.5 £0.8 
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker      1 60 £10.2 £1.8 £0.9      1 60 £10.2 £1.8 £0.9 
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 5 £3.2 £0.3 £0.2 1 10 £3.2 £0.3 £0.2      1 10 £3.2 £0.3 £0.2 
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 1 10 £3.9 £0.3 £0.3 1 5 £2 £0.15 £0.1 1 10 £3.9 £0.3 £0.3 1 5 £2 £0.15 £0.1 
Band 7 F,G Nurse team manager                      
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5                
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The staff working time survey results (continued) 
 
 Erythropoietin Immunosuppresive therapy 
 
Out-patient period Out-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)                     
Clinical Practitioner                     
Consultant      1 15 £22.5 £4.5 £0.8      1 15 £22.5 £4.5 £0.8 
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker      1 10 £1.7 £0.3 £0.2           
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 2 5 £3.2 £0.3 £0.2      1 5 £1.6 £0.15 £0.1      
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader 1 10 £3.9 £0.3 £0.3 1 5 £2 £0.15 £0.1 1 10 £3.9 £0.3 £0.3      
Band 7 F,G Nurse team manager                      
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist 1 10 £4.1 £0.3 £0.5      1 10 £4.1 £0.3 £0.5      
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The staff working time survey results (continued) 
 
 Sampling for blood Sampling for bone marrow 
 
Out-patient period Out-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)                     
Clinical Practitioner                     
Consultant      1 5 £7.5 £1.5 £0.2      1 30 £45 £9 £1.6 
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker                     
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse 1 5 £3.2 £0.3 £0.2      1 30 £19.2 £1.8 £0.9      
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader                     
Band 7 F,G Nurse team manager                      
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist                     
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The staff working time survey results (continued) 
 
 Follow-up / observation / outpatient visits Anti-biotic 
 
Out-patient period In-patient period 
Indirect contact Direct contact Indirect contact Direct contact 
No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital No Min wages overheads capital 
Doctor (Modernising Medical Careers)                     
  Foundation House Officer 1                     
  Foundation House Officer 2                     
  Specialty Registrar (StR)           1 5 £5.3 £0.2 £0.2      
Clinical Practitioner                     
Consultant      1 15 £22.5 £4.5 £0.8           
Nurse (Agenda for Change)                     
Band 1                       
Band 2 A Clinical support worker      1 5 £1.6 £0.15 £0.1 1 10 £1.7 £0.3 £0.2      
Band 3 B                      
Band 4 C                      
Band 5 D 24-hour ward nurse           2 5 £3.2 £0.3 £0.2      
Band 5 D Day ward nurse                     
Band 6 E Nurse team leader      1 10 £3.9 £0.3 £0.3 1 5 £1.8 £0.2 £0.2      
Band 7 F,G Nurse team manager                      
Band 8 H, I                      
Band 9 H, I                      
Pharmacist                     
Pharmacist           1 10 £4.1 £0.3 £0.5      
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Appendix 6.3 The literature review for complication rate of each treatment and regimen 
 
ADE 
 Heil 1995 
[217] 
Bishop 
1996 [218] 
Lee 1999 
[219] 
Heil 1995 
[217] 
Hann 1997 
[220] 
Heil 1997 
[221] 
Heil 1997 
[221] 
Heil 1997 
[221] 
Heil 1997 
[221] 
Heil 1997 
[221] 
Bishop 
1996 [218] 
 
Number of Patient  30 152 41 39 770 262 67 157 58 26 149  
Age 15-75 yr 15-60 yr ≥ 60 yr 15-75 yr All age ≥ 16 yr ≥ 16 yr ≥ 16 yr ≥ 16 yr ≥ 16 yr 15-60 yr  
Randomised trial Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes  
Controlled trail Yes No Yes Yes No Yes Yes Yes Yes Yes No  
Phrase - In In - In In 1 In 2 Con 1 Con 2 Con 2 In  
Regimens             
  AraC mg/m2 100 100 100 100 100 200 200 200 200 3000 3000  
 Days (dose) 7 7 7 8 10 7 5 5 5 6 4 (8)  
  Daunorubicin mg/m2 45 50 30 60 50 45 45 45 45 30 50  
 Days   2 3 3 3 3 3 2 2 2 2 3  
  Etoposide mg/m2 100 75 100  100 100 100 100 100 100 - 75  
 Days   5 7 3 5 5 5 5 5 5  7  
Complications             
  Fever       241 50 99 33 24  78% 
     Severe  5   2        10% 
  Infection  96    252 47 85 30 24 128 76% 
     Severe  2   2 46       6% 
  Pneumonia             
     Severe  2   2        6% 
  Pain              
     Severe  -   1        3% 
  Nausea / vomiting        144   137 91.8% 
     Severe  (grade  3-4)  0.5   1    49   79 34.5% 
  Diarrhea         25   34 19.3% 
     Severe  (grade  3-4)  -   1    13   25 11.3% 
  Severe Stomatitis         4   7% 
  Severe Cardiac disorder (failure) 0.5   2 8       1.3% 
  Severe Hepatic disorder 3   4        10.1% 
 Sever Bilirubin         16   27% 
 Cerebellum disorder        6 10  10 10.8% 
     Severe  (grade  3-4)       0     3 0.7% 
 Neurologic disorder       15     22% 
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The literature review for complication rate (continued) 
 AraC (LD) AraC (HD) 
 Winer 2005 
[222] 
Burnett 
2007 [223] 
Stone 2001 
[224] 
 Bassan 1998 
[225] 
Ossenkoppele 
2004 [226] 
Curtis 1987 
[227] 
Mayer 1994 
[228] 
Estey H 1990 
[229] 
 
Number of Patient  94 103 82  24 69 43 187 53  
Age ≥ 18 > 60  ≥ 60  15-60 ≥ 45 All age ≥ 16 ≥ 18  
Randomised trial No Yes Yes  No Yes No Yes No  
Controlled trail No No Yes  No Yes No No No  
Phrase In In Con  Con - Con con In  
Regimens           
AraC mg/m2 20 20 100   1000  2000  3000 3000 6000  
 Day (doses) 7 10 (20) 5  6 5 6 (12) 3 (6) 4  
Hydroxyurea mg/m2 500          
 Day 15          
GM-CSF Dose 250 µg/m2     5 µg/kg     
 Day   7          
Complications           
  Fever  54   57%       
     Severe  (grade  3-4)            
  Infection  46 80 68.1% 14     58% 
     Severe  (grade  3-4)  7  6 7%  40 9  17 40% 
Pneumonia / sepsis     2    37 50.6% 
     Severe  (grade  3-4)            
Diarrhea   80 98%       
     Severe  (grade  3-4)   6 8 7.6%       
 Nausea / vomiting           
     Severe  (grade  3-4)   8         
Malaise   80 98%       
     Severe  (grade  3-4)    1 1%       
 Severe mucositis  8  8%       
 Severe alopecia  8  8%       
 Serious CNS toxicity        41  22% 
 Severe neurotoxicity      2    3% 
 Severe cerebellar toxcitity       2   5% 
 Respiratory insufficiency 7   7%       
 Severe liver disorder      11    16% 
 Severe cardiac disorder  14  14%  11    16% 
 Renal disorder 8 5  6.6%   3   7% 
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The literature review for complication rate (continued) 
 DA (Part 1) 
 Atallah 2007 
[230] 
Dillman 
1991 [231] 
Takemoto 
1999 [232] 
Rai 1981 
[233] 
Rai 1981 
[233] 
Vogler 1992 
[234] 2006 
[235] 
Dillma
n 1991 
[231] 
Rai 1981 
[233] 
Mitus 
1995 
[236] 
Rai 1981 
[233] 
Stone 1994 
[237] 
Rowe 1995 
[238] 2008 
[239] 
 
Number of Patient  149 50 26 79 177 60 110 62 94 43 177 47  
Age All ≥ 60 15-60 < 60 ≥ 60 ≥ 14  15-60 < 60 ≤ 65 ≥ 60 ≥ 60 55-70  
Randomised trial No Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes  
Controlled trail No No No No No No No No No No Yes Yes  
Phrase In In In In In In In In In In In In  
Regimens              
 AraC mg/m2 - 100 100 100 100 100  100 100 100 100 100 100  
 Day (dose) - 7 7 5 5 7 7 7 7 7 5 (10) 7  
Daunorubicin mg/m2 - 35 40 45 45 45 45 45 45 45 50 60  
 Day  3 3 2 2 3 3 3 3 3 1 3  
Complications              
  Fever    19   17   93   35 72.2% 
     Severe  (grade  3-4)  36  7          24.6% 
  Infection   16 32 76 58  41  23  32 56.3% 
     Severe  (grade  3-4)  107 10 3    6    32 33 34.2% 
     Fungal  infection          12    13% 
  Pneumonia              
     Severe  (grade  3-4)             13 28% 
  Malaise   2          7% 
     Severe  (grade  3-4)               
 Weight gain            10 21% 
 Weight loss            13 28% 
 Mucositis      33   37  21  27.5% 
     Severe  (grade  3-4)       5     4  3.8% 
 Bacteremia         27    29% 
 Headache      14       24% 
 Pain   7          25% 
Digestive system              
  Nausea / vomiting   21   48     94 26 61% 
     Severe  (grade  3-4)    4   2     0  2.3% 
  Diarrhea    10   41     35 25 35.8% 
     Severe  (grade  3-4)    1   8     4  4.9% 
  Stomatitis   10         20 41% 
     Severe  (grade  3-4)               
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  Anorexia   20          75% 
     Severe  (grade  3-4)    6          21% 
Skin and appendages              
  Alopecia   21   43     122 24 67.7% 
     Severe  (grade  3-4)    6   16     50  27.4% 
  Rash       24     30  22.8% 
     Severe  (grade  3-4)       1     0  0.4% 
Metabolic disorder              
  Edema             11 23% 
Respiratory system              
  Pulmonary      23      10 30.8% 
  Dyspnea              
     Severe  (grade  3-4)               
Cardiovascular system              
  Hypertension            15 32% 
Hypotension            12 26% 
     Severe  (grade  3-4)               
  Cardiac disorder    0 2 14  3  0.9 7  4.5% 
     Severe  (grade  3-4)  3     13     7  8.4% 
  Severe heart failure   1          4% 
Renal disorder              
  Dialysis              
     Severe  (grade  3-4)  19            13% 
Renal disorder    4 4   6  4   5% 
     Severe  (grade  3-4)  6            4% 
Hepatic disorder              
  Hepatic disorder    4 4   2  0  39 12% 
     Severe  (grade  3-4)  40 1     -      20.6% 
  Bilirubinemia   9          36% 
     Severe  (grade  3-4)    0      9    7.5% 
  Creatinine      15     9  10.1% 
     Severe  (grade  3-4)       0.6     0  0.3% 
Neurologic disorder              
  Neurologic disorder      5       9% 
     Severe  (grade  3-4)               
  Cerebellar dysfunction      2   5    4.5% 
  CNS toxicity              
     Severe  (grade  3-4)   1     6      4.4% 
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The literature review for complication rate (continued) 
 DA (part 2) 
 Weick 
1996 
[240] 
Dillman 
1991 
[231] 
Lowenber
g 1997 
[241] 
Usui 
2002 
[242] 
Zittoun 
1996 
[243] 
Dillman 
1991 [231] 
Rubin 
1992 
[244] 
Weick 
1992 [245] 
Weick 
1996 
[240] 
Godwin 
1998 [246] 
Anderson 
2002 [247] 
Stone 1995 
[248] 
Dombret 
1995 
[249] 
 
Number of Patient  66 50 161 22 26 116 176 168 490 104 161 195 85  
Age ≤ 65 ≥ 60 ≥ 61 15-60 15-45 15-60 ≥ 18 ≤ 64 ≤ 65 ≥ 56 ≥ 56 ≥ 60 ≥ 65  
Randomised trial No Yes Yes No Yes Yes No Yes Yes Yes Yes Yes Yes  
Controlled trail No No Yes No Yes No No No No Yes No Yes Yes  
Phrase Con In In In In In In In In In In In In  
Regimens               
  AraC mg/m2 200 200 200 200 200 200 200 200 200 200 200 299 200  
 Day (dose) 7 7 7 7 7 7 7 7 7 7 7 7 7  
  Daunorubicin mg/m2 30 30 30 40 45 45 45 45 45 45 45 45 45  
 Day 3 3 3 7 3 3 3 3 3 3 3 3 4  
Complications               
  Fever    114           71% 
     Severe  (grade  3-4)              9 11% 
  Infection   124  19     67  125  68.9% 
     Severe  (grade  3-4)   10  22  10   49 15 24 35 41 16.8% 
     Fungal  infection                
  Pneumonia          25    24% 
     Severe  (grade  3-4)              14 16% 
  Malaise               
     Severe  (grade  3-4)             31  16% 
 Weight gain (≥ 5kg)     2         8% 
 Weight loss               
 Mucositis   39 6          24.6% 
     Severe  (grade  3-4)     1     20      
 Bacteremia               
Headache     0         0% 
Pain   10       5    5.7% 
Digestive system               
  Nausea / vomiting   56 18          40.4% 
     Severe  (grade  3-4)     0     15     2.9% 
  Diarrhea    66 13          43.2% 
     Severe  (grade  3-4)    29 2          9% 
  Stomatitis              41% 
     Severe  (grade  3-4)            6   10.9% 
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  Anorexia               
     Severe  (grade  3-4)                
Skin and appendages               
  Alopecia               
     Severe  (grade  3-4)                
  Rash                
     Severe  (grade  3-4)     10          45% 
Metabolic disorder               
  Edema    90  6         23% 
Respiratory system               
  Pulmonary              56% 
  Dyspnea               
     Severe  (grade  3-4)             35  18% 
Cardiovascular system               
  Hypertension               
Hypotension   21  1         11.8% 
     Severe  (grade  3-4)             14  7% 
  Cardiac disorder   35  0         18.7% 
     Severe  (grade  3-4)     1        27  12.9% 
 Dysrhythmia            27  14% 
  Severe heart failure               
Renal disorder   39            
  Dialysis   5           24% 
     Severe  (grade  3-4)               3% 
Renal disorder               
     Severe  (grade  3-4)                
Hepatic disorder   68            
  Hepatic disorder  5 18           42% 
     Severe  (grade  3-4)       -   29     7.4% 
  Bilirubinemia               
     Severe  (grade  3-4)             31  16% 
Neurologic disorder 11  18            
  Neurologic disorder 6      18 7      10.4% 
     Severe  (grade  3-4)          5     2% 
  Cerebellar dysfunction               
  CNS toxicity  3             
     Severe  (grade  3-4)       5        4.8% 
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The literature review for complication rate (continued) 
 HAM MidAC 
 Lofgren 2004 [250] Solary 1995 [251] Kern 1998 [252] Buchner 1991 [253]  Buchner 1999 [254] Buchner 1999 [254]  
Number of Patient  55 154 91 56  365 212  
Age ≥ 60 14-66 ≥ 17 ≥ 65  16-60 16-60  
Randomised trial Yes Yes No No  Yes Yes  
Controlled trail No Yes Yes Yes  No No  
Regimen         
Phrase - Both In Both  In Con  
AraC   mg/m2 1000 1000 1000 or 3000 1000 or 3000  3000 3000  
 Day (dose) 3 (6) 5 (10) 4 (8) 4 (8)  3 (6) 3 (6)  
Mitoxantrone mg/m2 12 12 10  10  10  10  
 Days 3 4 4 4  3 3  
Etoposide mg/m2 200        
 Days 3        
Complications         
  Fever     55 98%    
     Severe  (grade  3-4)     21 38%    
  Infection   91 47 93.9%    
     Severe  (grade  3-4)    44  48% 146 23 29.2% 
  Pneumonia / sepsis    24 43%    
Mucositis  48 36  34.3%    
     Severe  (grade  3-4)   15 8  9.4%    
  Weight gain    5 9%    
Digestive system         
  Nausea / vomiting  83 61  58.8%    
     Severe  (grade  3-4)   17 17  13.9% 80 19 17.2% 
  Diarrhea   79 45  50.6%    
     Severe  (grade  3-4)   25 14  15.9% 37 8 7.8% 
  Severe Stomatitis      33 6 6.8% 
Metabolic disorder         
  Edema     7 13%    
Renal disorder         
  Renal disorder 9 14   11%    
     Severe  (grade  3-4)   0   0%    
Hepatic disorder         
Liver disorder 15 51   31.6%    
     Severe  (grade  3-4)   12   8%    
  Bilirubinemia   35 36 48.3%    
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     Severe  (grade  3-4)    4 22 17.7%    
  Creatinine   17  19%    
     Severe  (grade  3-4)    4  4%    
Cardiovascular system         
  Cardiac disorder  2  24 12.4%    
     Severe  (grade  3-4)   2   1% 22 2 4.2% 
  Heart failure 6    11%    
Neurocortical disorder         
  Nurocortical  disorder       15 26%    
     Severe  (grade  3-4)     12 21%    
  CNS toxicity   10  11%    
     Severe  (grade  3-4)    6  7% 7 2 1.6% 
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The literature review for complication rate (continued) 
 FA FLAG FLAG-Ida 
 Estey 
1994 
[255] 
Atallah 
2007 
[230] 
 Marcucci 
2003 
[256] 
Ossenkopp
ele 2004 
[226] 
Huhma
nn 
1996 
[257] 
Estey 
1994 
[255] 
Visani 
1994 
[258] 
Clavio 
1996 
[259] 
Montillo 
1998 
[260] 
 Russo 
2005 
[261] 
Yavuz 
2006 
[262] 
Pastore 
2003 
[263] 
Martin 
2009 
[264] 
 
Number of Patient  85 278  20 65 22 112 28 51 38  57 56 46 23  
Age All ≥ 15  ≥ 18 45-75 18-65 All age 17-75 ≥ 18 11-70  18-60 - 15-60 18-70  
Randomised trial    No Yes No No No No No  Yes No No No  
Controlled trail    No Yes No Yes No No No  No No No Yes  
Phrase In -  - - - In - - -  In - Con -  
Regimen                 
  AraC (HD) mg/m2 2 -  1to2 2 2 2 2 2 2  2 2 2 -  
 Day (dose) 5 -  5 5 5 5 5 5 5  5 5 5 -  
  Fludarabine mg/m2 30   15to30 25 25 30 30 30 30  25 25 30 -  
 Day 5   5 5 5 5 5 5 5  5 5 5   
  Idarubicin mg/m2 - -     -     10 12 10 -  
 Day - -     -     3 3 3   
  G-CSF  - -  5 µg/kg 5 µg/kg 400 
µg/m2 
- 5mg/kg 300 
µg/day 
5 µg/kg  - - 5 µg/kg -  
Complications                 
  Fever       22   16  52% 56  27  80.5% 
     Severe  (grade  3-4)   92 33%   0    17 28%   13  28% 
  Infection 74  87%   20 102    91% 56  19  72.8% 
     Severe  (grade  3-4)  27 153 49.6%  44 5 25   17 38%   14 2 23% 
  Pneumonia / sepsis         10  20%  15 13  28% 
Mucositis    50%  55%           
     Mild  (<grade  2)             55  46  98% 
     Severe  (grade  3-4)       0    4 7%   30  65% 
  Headache    65%       65%      
     Severe  (grade  3-4)     15%       15%      
  Pain     2  15     40%      
     Severe  (grade  3-4)       14%     14%      
Digestive system                 
  Nausea / vomiting    13  14     64%      
     Mild  (<  grade  2)             53  10  61% 
     Severe  (grade  3-4)       32%     32% 3  8  10.7% 
  Diarrhea     16  8     57%      
     Severe  (grade  3-4)       2    3 8% 5%    5% 
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  GI disorder     14%      14%      
Skin and appendages                 
  Rash     30%       30%      
     Severe  (grade  3-4)     0%       0%      
  Skin disorder              17%  17% 
Metabolic disorder                 
  Edema     75%       75%      
     Severe  (grade  3-4)     1%       1%      
Respiratory system                 
  Dyspnea    65%       65%      
     Severe  (grade  3-4)     50%       50%      
  Lung disorder                 
Renal disorder                 
  Renal disorder      41%     41%      
     Severe  (grade  3-4)   11 4%   0%     0%      
Hepatic disorder                 
Liver disorder                 
     Severe  (grade  3-4)   61 22%  10     3 12.6%      
  Bilirubinemia    8  9     40%   26%  26% 
     Severe  (grade  3-4)     4  1     12%    22% 22% 
  creatinine    4  6     23.8%   4%  4% 
     Severe  (grade  3-4)     0%  0%     0%      
  Acute renal failure         1%  1%      
Cardiovascular system                 
  Cardiac disorder         8%  8%   4%  4% 
     Severe  (grade  3-4)   3 1%  16%      16%      
  Hypertension    2       10%      
  Hypotension    4       20%      
Neurocortical disorder                 
  Nurocortical  disorder         9   3  16%      
     Severe  (grade  3-4)      9 0%  1  1 7%      
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The literature review for complication rate (continued) 
 
 Mylotarg Clofarabine MACE Hydroxyurea Amsacrine 
 Bross 
2001 
[265] 
Bross 
2001 
[265] 
Bross 
2001 
[265] 
Martin 
2009 
[264] 
 Faderl 2008 
[266] 
Kantarjian 
2003 [267] 
 Cassileth 
1992 
[268] 
Sung 
2005 
[269] 
 Burnett 
2007 
[223] 
Harousseau 
2009 [270] 
 Lovie 1985 
[271] 
 
Phase 2 2 1       2   3    
Number of Patient  142 80 41 48  16 62  99 51  99 229    
Age ≥ 18 ≥ 60 16-70 18-70  ≥ 60  ≥ 15  15-65  15-65  > 60  ≥ 70    
Randomised trial No No No No  Yes No  Yes No  Yes Yes    
Controlled trail No No No Yes  No No  No No  No Yes    
Phrase Con Con -   In In  Con -  In     
Regimen    FLAG-
Ida 
 30 mg/m2 
for 5 days 
40 mg/m2 
for 5 days 
         
  AraC mg/m2         3 1       
 Day (dose)         6 (12) 3 (6)       
  amsacrine mg/m2         100 100       
 Day         3 3       
  Etoposide mg/m2          100       
 Day          5       
Complications                 
  Fever    44%  44% 4 19 30%         
     Severe  (grade  3-4)  10 4   6.3%            
  Infection       50% 50%         
     Severe  (grade  3-4)  40   9 26%    22%  22% 21%  21% 50% 50% 
  Pneumonia / sepsis      6 16 28%         
     Severe  (grade  3-4)  23 13   16%        19% 19% 20% 20% 
Mucositis      3 9 15%       32,40,46,80%  
     Severe  (grade  3-4)  4%    4% 6%  6%    3%  3%   
Malaise               80% 80% 
  Headache      38%  38%  10% 10%      
  Pain    4  10%            
  Hemorrage 15%    15%    5 4 6% 3%  3% 13% 13% 
     Severe  (grade  3-4)                  
Digestive system                 
  Nausea / vomiting   13  32% 13 42 71%  82% 82%    30% 30% 
     Severe  (grade  3-4)  11%    11% 0 2 2.5%  29% 29% 8%  8%   
  Diarrhea       12 13 32%  26% 26%    3-17%  
     Severe  (grade  3-4)       0%  0%    20%  20%   
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  Anorexia      19%  19%       29% 29% 
  GI disorder                 
     Severe  (grade  3-4)          4%  4%  9% 9%   
Skin and appendages                 
  Alopecia               4-20%  
     Severe  (grade  3-4)             5%  5%   
  Rash    12%  12% 9 29 49%  24% 24%      
     Severe  (grade  3-4)       2 6 10%         
Metabolic disorder             10% 10%   
  Edema       38%  38%         
Respiratory system                 
  Dyspnea                 
     Severe  (grade  3-4)  13 10   10%            
Renal disorder                 
  Renal disorder               1-5%  
     Severe  (grade  3-4)             3%  3%   
Hepatic disorder                 
Liver disorder               30-35%  
     Severe  (grade  3-4)          17%  1%      
  Bilirubinemia      10 31 53%         
     Severe  (grade  3-4)  33 18  6 21% 6 9 19%         
  Creatinine      32%  32%         
     Severe  (grade  3-4)  1 0   0.5% 13%  13%         
Cardiovascular system                 
  Cardiac disorder                 
     Severe  (grade  3-4)             16% 14% 15%   
  Hypertension                 
     Severe  (grade  3-4)  13 9   10%            
  Hypotension                 
     Severe  (grade  3-4)  11 6   7.7%            
Neurocortical disorder                 
  CNS toxicity               1-5%  
     Severe  (grade  3-4)  6    4%     2% 2%      
  Cerebellar toxicity                 
     Severe  (grade  3-4)          12%  12%      
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The literature review for complication rate (continued) 
 G-CSF  
 Heil 
1997 
[221] 
Heil 
1997 
[221] 
Heil 
1997 
[221] 
Heil 
1997 
[221] 
Heil 1997 
[221] 
Godwin 
1998 [246] 
Dombret 
1995 [249] 
Ohno 1994 
[272] 
Ohno 1990 
[273] 
Kern 
1998 
[252] 
Amadori 
2005 [274] 
Amadori 
2005 [274] 
Amadori 
2005 [274] 
 
Patient AML AML AML AML AML AML AML AML AML AML AML AML AML  
Number of Patient  262 67 157 58 26 104 88 28 48 68 172 173 177  
Age ≥ 16 ≥ 16 ≥ 16 ≥ 16 ≥ 16 ≥ 56 ≥ 65 15-65 13-70 ≥ 17 ≥ 61 yr ≥ 61 ≥ 61  
Randomised trial Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes  
Controlled trail Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes  
Phrase In 1 In 2 Con 1 Con 2 Con 2 In In In In In In In In  
Conjunction treatment ADE ADE ADE ADE DA (HD) DA DA (after) HAM 
(during) 
HAM HAM HAM 
(during) 
HAM 
(after) 
HAM 
(during & 
after) 
 
Complications               
  Fever  238 54 77 27 25   26 41     76% 
     Severe  (grade  3-4)       20 10    40 54 44 24% 
  Infection 249 52 69 21 23   14 5 65    70% 
     Severe  (grade  3-4)        42   29    46% 
     Fungal  infection       20%        20% 
  Pneumonia / sepsis      33  3      27% 
     Severe  (grade  3-4)        11  1     8.8% 
Mucositis         5 33    33% 
     Severe  (grade  3-4)           15%    15% 
  Pain       1%        1% 
     Severe  (grade  3-4)            0% 2 2 0.8% 
Digestive system               
  Nausea / vomiting          36    53% 
     Severe  (grade  3-4)           21 40 29 28 20% 
  Diarrhea           24    35% 
     Severe  (grade  3-4)           11 3 9 7 5% 
  Stomatitis        14%      14% 
Skin and appendages               
  Severe Rash           3 7 7 3.3% 
Hepatic disorder               
Liver disorder        4%      4% 
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     Severe  (grade  3-4)            14 21 21 11% 
  Bilirubinemia          27%    27% 
     Severe  (grade  3-4)           6%    6% 
  creatinine          12%    12% 
Cardiovascular system               
  Cardiac disorder               
     Severe  (grade  3-4)            10 16 19 8.6% 
  Hypotension               
     Severe  (grade  3-4)            2 9 7 3.4% 
Neurocortical disorder               
  CNS toxicity          4%    4% 
     Severe  (grade  3-4)           3%    3% 
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The literature review for complication rate (continued) 
 ATRA MRC approach 
 Shen 
et.al 
2004 
[275] 
Tallma
n et.al. 
1997 
[276] 
 Medeiro
s et al 
1998 
[277] 
Mandelli 
et al 
1997 
[278] 
Tallmanet 
al  2000 
[279] 
 
Castaign
e et al 
1990 
[280] 
Kanamar
u et al. 
1995 
[281] 
 Botton 
et al 
1998 
[282] 
Jacom
o et al 
2007 
[283] 
Fenau
x et al 
1993 
[284] 
Fenau
x et al 
1999 
[285] 
Ades 
et al 
2005 
[286] 
 Bahar et 
al 2004 
[287] 
 
Number of Patient  20 172 94 37 240 167 22 109  413 114 54 208 129 404 24  
Age 17-74 1-81 1-81 9-69 2-74 1-81 19-68 15-74  ≦65 yr 5-79 6-63 2-64 ≧ 60 18-60 17-55  
Randomised trial Yes Yes Yes No Yes Yes No No  Yes No Yes Yes No No No  
Controlled trail Yes Yes Yes No Yes Yes No No  Yes No Yes Yes No No No  
Phrase Con In M In In In In In  In Con In In In In In  
Regimen                  
    Dosage (mg/m2) 45 45 45 45 45 45 45 45          
Complications                  
  Retinoic Acid Syndrome  45 34   44  7 24% 64   33 16 60 2 15% 
  Fever    10     27%         
  Severe infection   43 7      19%  4 3     4% 
  Headache 4  5  31   23 14%   16     30% 
      Severe             1     2% 
  Severe Pain     14  11 2 7%         
  Dryness of mouth 11   28     68%         
Degestive system                  
  Severe Nausea / vomiting  11       6%         
  Severe Diarrhea  6       3%         
  Severe Stomatitis  12       7%         
Skin and appendages 4        20%         
  Skin dryness     70    29%   26     48% 
  Sever skin disorder  5       3%         
Respiratory system                  
  Severe Dyspnea        4 4%         
  Severe lung disorder  36       21%         
Hepatic disorder                  
  Liver dysfunction            46     85% 
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     Severe  1 34 5 1     13%         
Cardiovascular system                  
  Severe hypertension     17    7%         
  Severe cardiac disorder  19       11%         
Nervous system (Severe)  16 11  5    6%         
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The literature review for complication rate (continued) 
 Spanish approach 
 Miguel et al [288] Jacomo et al [283] Mandelli et al 
[278] 
Avvisati et al 1996 
[289] 
Montesinos  et al 
2009 [290] 
Mandelli et al 
2003 [141] 
Girmenia et al 
2003 [291] 
Serna et al 2008 
[292] 
 
Number of Patient  103 157 240 20 739 134 89 732  
Age 1-74 5-79 2-74 ≦ 70 2-83 60-75 1-77 2-83  
Randomised trial No No Yes No No No No Yes  
Controlled trail No No Yes No No No No Yes  
Phrase Con In In In In In In In  
Complications          
  Retinoic Acid Syndrome 7 4  2 183 5  10 18% 
  Fever     17     85% 
  Severe infection  2  6  2 19 17 3% 
  Severe Mucositis 15      22  19% 
  Severe headache    2     10% 
  Pain     2     10% 
  Skin dryness    3     30% 
Degestive system          
  Severe Nausea / vomiting   12      5% 
  Severe Diarrhea 2  5      2% 
  Severe stomatitis   14      6% 
Skin and appendages          
  Severe skin disorder 2        2% 
Metabolic disorder          
  Severe Edema     75    10% 
Respiratory system          
  Severe Lung disorder 17        17% 
Hepatic disorder          
  Severe liver disorder 5  7      3% 
Cardiovascular system          
  Hypotension    1     5% 
  Severe cardiac disorder 6  6      3% 
Urogenital sysem          
  Severe renal disorder 1  1      0.6% 
Nervous system          
  Severe  2        2% 
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Appendix 6.4 The unit cost list of complications 
 
 
Adverse event ICD-10 HRG 4.0 
No of 
cases 
Lower 
quartile 
× 
70% 
 
Cardiovascular 
(Arrhythmia) 
dysrhythmias (Nodal, junctional arrhythmia) I49 EB07I 4567 £448 £314  
Atrioventricular heart block (type I / II) I44.0-I44.3 EB07I 4567 £448 £314  
Sinus bradycardia R00.1 EB07I 4567 £448 £314  
Sinus tachycardia R00.0 EB07I 4567 £448 £314  
Supraventricular tachycardia (SVT) I47.1 EB07I 4567 £448 £314  
Atrial fibrillation (flutter) I48 EB07I 4567 £448 £314  
Ventricular tachycardia I47.2 EB07I 4567 £448 £314  
Premature ventricular contraction (PVC)  I49.3 EB07I 4567 £448 £314  
    £448 £314  
Cardiovascular 
(general) 
Hypertension I11 EB04I 303 £521 £365  
Hypotension I95.2 / I95.8 EB01Z 5396 £508 £356  
Acute myocardial infarction  I21 EB10Z 5999 £758 £531  
Myocardial ischaemia I24.x, I25.6 EB10Z 5999 £758 £531  
Myocarditis I40, I41, I51.4 EB01Z 5396 £508 £356  
Pericarditis (pericardial effusion) I30,I31,I32 EB01Z 5396 £508 £356  
Phlebitis I80 EB11Z 685 £424 £297  
Thrombosis / embolism I80, I82 EB11Z 685 £424 £297  
Congestive heart failure (CHF) I50.0 EB03I 904 £916 £641  
Left ventricular function decrease I50.1 EB03I 904 £916 £641  
Peripheral artery occlusive disease I73.9 QZ17C 4322 £447 £313  
Peripheral arterial ischemia I73.9 QZ17C 4322 £447 £313  
    £520 £364  
Oedema Oedema, not elsewhere classified R60 WA18Y 299 £403 £282  
Cerebral oedema G93.6 AA25Z 2684 £649 £454  
Gestational oedema O12.0 NZ04A 629 £336 £235  
  NZ07A 382 £500 £350  
Pulmonary oedema J81 DZ20Z 76 £815 £571  
Pulmonary oedema due to heart disease I50.1 EB03I 904 £916 £641  
    £634 £444  
Dermatology / 
skin 
Alopecia L65.8 JD04C 670 £429 £300  
L65.9 JD06B 1217 £349 £244 £264 
Rash R21.x JD05C 834 £359 £251  
Flushing R23.2 WA18Y 299 £403 £282  
Desquamation R23.4 JD05C 834 £359 £251  
Pruritus L29.8 JD04C 670 £429 £300  
L29.3, L29.9 JD06B 1217 £349 £244  
L29.1 LB35B 1340 £352 £246  
L29.2 MB01Z 412 £379 £265 £257 
Urticaria L50.8 JD04C 670 £429 £300  
L50.0 JD05C 834 £359 £251 £273 
Stevens-Johnson syndrome L51.1 JD03C 654 £498 £349  
Toxic epidermal necrolysis L51.2 JD03C 654 £498 £349  
Vesicular / macular / papular erythema 
(eruption) 
L53.0 JD03C 654 £498 £349  
Nail disease L60.1 JD04C 670 £429 £300  
L60.3 JD05C 834 £359 £251  
L60.4 JD06B 1217 £349 £244 £260 
Pigmentation change L80.x JD05C 834 £359 £251  
    £389 £272  
Gastrointestinal 
disorder 
Anorexia R63.0 KC03C 983 £174 £122  
Diarrhea A09.x FC06C 161 £195 £137  
 K59.2 FC04C 13526 £168 £130 £130 
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Nausea / Vomiting R11.x FC02C 4891 £171 £120  
Stomatitis K12.2 CZ22Y 1048 £139 £97  
Mucositis L23.5 JD04C 670 £429 £300  
Ascites R18.x FC05C 5545 £474 £332  
Colitis K50-K52 FC07C 2071 £568 £398  
Constipation K59.0 FC04C 13526 £168 £118  
Dehydration E86.x KC02F 27 £308 £216  
Gastric and duodenal ulcer K25.0,2,4,6 FC08C 303 £352 £247  
 K25.1,3,5,7,9 FC02C 4891 £543 £380  
 K26.1,3,5,7,9 FC02C 4891 £543 £380  
 K26.0,2,4,6 FC08C 303 £352 £246  
 K27.0,2,4,6 FC08C 303 £352 £246  
 K27.3,5,7,9 FC02C 4891 £543 £380  
 K27.1 FC05C 5545 £474 £332 £362 
Dyspepsia, dysphagia R13.x FC01C 6232 £557 £390  
Heartburn R12.x FC01C 6232 £557 £390  
Fistula-intestinal K63.2 FC05C 5545 £474 £332  
Fistula-anal K60.3 FC11C 3226 £532 £372  
Fistula-rectal K60.4 FC04C 13526 £562 £393  
Flatulence R14.x FC02C 4891 £543 £380  
Gastritis K29.x FC02C 4891 £543 £380  
Taste disturbance R43.8 AA26Z 4580 £525 £368  
Smell disturbance R43.8 AA26Z 4580 £525 £368  
Pancreatitis K85.x GC02C 166 £409 £286  
Atrophy of salivary gland K11.0 CZ23Y 957 £508 £356  
Ileus K56.0, 3, 7 FC05C 5545 £474 £332  
Fistula-esophageal or pharyngeal K38.3 FC10Z 84 £359 £251  
Procitis K51.2 FC07C 2071 £568 £398  
    £429 £300  
Hepatic 
disorder 
Bilirubinemia E80.4, 80.6 GC07C 1761 £307 £215  
Elevated alkaline phosphatase R74.8 WA19Y 318 £311 £218  
Elevation of levels of transaminase R74.0 WA19Y 318 £311 £218  
Liver failure K72.9 GC02C 166 £409 £286  
Decrease portal vein flow  K76.5,7 GC02C 166 £409 £286  
    £320 £224  
Pulmonary 
disorder 
Dyspnoea R06.8 DZ19C 1268 £395 £277  
Cough R05.x DZ19C 1268 £395 £277  
Hiccoughs R06.6 DZ19C 1268 £395 £277  
Apnea R06.8 DZ19C 1268 £395 £277  
Acute respiratory distress syndrome J80.x DZ27F 86 £461 £323  
Pneumothorax J93 DZ26B 121 £411 £288  
Pulmonary fibrosis J84.9 DZ25B 375 £590 £413  
Pleural effusion J90.x-J91.x DZ16C 802 £616 £431  
Laryngitis J04.0 CZ22Y 1048 £437 £306  
Stridor R06.1 DZ19C 1268 £395 £277  
Voice change R49.8 CZ22Y 1048 £437 £306  
    £430 £301  
Renal / 
genitourinary 
disorder 
Creatiniemia R79.8 WA19Y 318 £311 £218  
Renal failure N17.x LA07C 83 £296 £207  
 N18.x,N19.x LA08B 965 £974 £682 £644 
Bladder spasms N32.8 LB19B 1885 £361 £253  
Hematuria R31.x LB38B 539 £376 £263  
dialysis X40.x LC02A 1854429 £133 £93  
Haemoglobinuria R82.3 LB37B 393 £338 £237  
Urinary incontinence R32.x LB16C 1054 £353 £247  
Proteinuria R80.x LB37B 393 £338 £237  
Polyuria / urinary frequency R35.x LB37B 393 £338 £237  
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Urinary retention R33.x LB16C 1054 £353 £247  
Urinary electrolyte wasting E72.0 KC04Z 1506 £355 £247  
Urine color change R82.9 LB37B 393 £338 £237  
    £134 £94  
Neurology- 
Sensory 
Paresthesia (abnormal touch sensation) R20.2 AA26Z 4580 £525 £176  
Arachnoiditis G03.9 AA22Z 2221 £710 £497  
meningismus R29.1 AA22Z 2221 £710 £497  
Radiculitis M54.1 HC22C 286 £438 £307  
     £476 £333  
Neurology- 
Motor 
Paralysis G81 AA25Z 2684 £649 £454  
G82 HC25C 277 £701 £491 £458 
Extrapyramidal G20-G26 AA25Z 2684 £649 £454  
Involuntary movement R25.x AA25Z 2684 £649 £454  
Torticollis M43.6 HC26C 187 £379 £265  
     £644 £415  
Neurology- 
cortical 
Confusion (disorientation) R41.0 WA18Y 299 £403 £282  
delusion F22 WD22Z 8195 £199 £139  
Somnolence  R40.0 AA25Z 2684 £649 £454  
Stupor R40.1 AA25Z 2684 £649 £454  
Coma R40.2 AA22Z 2221 £710 £497  
dizziness R42.x AA26Z 4580 £525 £368  
Hallucination R44 WD22Z 8195 £199 £139  
Restlessness R45.1 WD22Z 8195 £199 £139  
Seizure (convulsion) G40-41, R56.8 AA26Z 4580 £525 £368  
     £357 £250  
Neurology- 
cerebellar 
Ataxia  R27 AA26Z 4580 £525 £368  
Locomotor ataxia R26 AA26Z 4580 £525 £368  
Dysdiadochokinesia (incoordination) R27 AA26Z 4580 £525 £368  
Dysmetria R27 AA26Z 4580 £525 £368  
Tremor R25.1 AA25Z 2684 £649 £454  
Slurred speech R47.8 AA25Z 2684 £649 £454  
Dysphasia or aphasia R47.0 AA22Z 2221 £710 £497  
Nystagmus H55 BZ24C 2115 £341 £239  
Cerebellar necrosis I67.8 AA22Z 2221 £710 £497  
    £561 £393  
Neurology- 
hemarrhage 
Transient ischemic attack G45.9 AA29Z 157 £539 £377  
Stroke (Cerebral vascular accident) I61-I62 AA23Z 1249 £980 £686  
     £931 £652  
Neurology- 
Mood 
anxiety F40, F41 WD22Z 8195 £199 £139  
Agitation R45.1 WD22Z 8195 £199 £139  
Depression F32-F33 WD22Z 8195 £199 £139  
Euphoria F02.0 WD22Z 8195 £199 £139  
Suicidal ideation R45.8 WD22Z 8195 £199 £139  
     £199 £139  
Neurology- 
general 
Syncope R55.x EB08I 445 £413 £289  
Fatigue, malaise, asthemia R53 WA18Y 299 £403 £282  
     £409 £286  
     £389 £272  
Local Weight gain R63.5 KC03C 983 £174 £122  
Weight loss R63.4 KC03C 983 £174 £122  
swelling R22 CZ22Y 1048 £437 £306  
Pain (R52) Headache R51, R43, R44 AA31Z 765 £231 £162  
Bone pain M89.8 HD24C 5876 £436 £305  
Chest pain M07.3, M07.4 HD23C 1403 £480 £336  
Back pain M54.5 HC24C 5876 £453 £317  
Abdominal pain or cramping R25.2 AA25Z 2684 £649 £454  
Arthralgia (joint pain) M25.5 HD26C 850 £351 £246  
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Arthritis M00-M25 HD24C 5876 £436 £305  
  HD25C 65 £493 £345  
  HD26C 850 £351 £246  
 M01.x HD23C 1403 £480 £336 £305 
Dysmenorrhea N94.4-N94.6 MB03B 2583 £405 £264  
Earache (otalgia) H92.x CZ21Y 3319 £368 £258  
Myalgia (muscle pain) M79.1 HD21C 1515 £367 £257  
Neuropathic pain (e.g., jaw pain, neurologic 
pain, phantom limb pain, 
post-infectious neuralgia, or painful 
neuropathies) 
M79.2 AA26Z 4580 £525 £368  
Pevic Pain R10.x FC05C 5545 £474 £332  
Pleuritic pain R07.3 EB01Z 5396 £508 £356  
Rectal or perirectal pain (proctalgia) K59.4 FC11C 3266 £532 £372  
    £463 £324  
Fever  R50.x WA04U 30 £390 £273  
Infection Bacterial  A49 WA09Y 29 £394 £276  
Fungal B35-B49 WA09Y 29 £394 £276  
Viral B34 WA06Y 87 £529 £370  
    £475 £332  
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Appendix 6.5 The summary of unit cost list for complication 
 
 Adverse event Cost Total Cost 
Cardiovascular Unspecified  £364 
Arrhythmia £314  
Hypertension £365  
Hypotension £356  
Congestive heart failure (CHF) £641  
Local Oedema £444  
Weight gain / loss £122  
Dermatology / skin Unspecified  £272 
Alopecia £264  
Rash £251  
Gastrointestinal 
disorder 
Unspecified  £300 
Anorexia £122  
Diarrhea £130  
Nausea / Vomiting £120  
Stomatitis £97  
Mucositis £300  
Hepatic disorder Unspecified  £224 
Bilirubinemia £215  
Liver failure £286  
Pulmonary disorder Unspecified  £301 
Dyspnoea £277  
Apnea £277  
Renal / genitourinary 
disorder 
Unspecified  £94 
Creatiniemia £218  
Renal failure £644  
dialysis £93  
Neurology Unspecified  £272 
General £286  
Fatigue, malaise £282  
Sensory £333  
Motor £415  
Paralysis £458  
Cortical £250  
Dizziness £368  
Seizure (convulsion) £368  
Cerebellar £393  
Hemarrhage £652  
Mood £139  
Anxiety £139  
Depression £139  
Pain   Unspecified  £324 
Headache £162  
Bone pain £305  
Fever Unspecified  £273 
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Appendix 6.6 The summary of the unit cost list for non-infection complications 
 
 Incidence rate Unit Cost Cost Total cost 
ADE    £188 
  Severe fever 10% £273 £27  
  Severe pain 3% £324 £10  
  Severe Nausea / vomiting 34.5% £120 £41  
  Severe Diarrhea 11.3% £130 £15  
  Severe Stomatitis 7% £97 £7  
  Severe Cardiac disorder 1.3% £364 £5  
  Severe Hepatic disorder 10.1% £224 £23  
Neurologic disorder (Severe) 22% £272 £60  
  Severe Cerebellum disorder 0.7% £393   
AraC (LD)    £115 
  Severe Diarrhea 7.6% £130 £10  
  Severe Malaise 1% £282 £3  
  Severe mucositis 8% £300 £24  
  Severe alopecia 8% £264 £21  
  Severe cardiac disorder 14% £364 £51  
  Severe Renal disorder 6.6% £94 £6  
AraC (HD)    £184 
  Severe neurotoxicity 3% £398 £12  
  Severe cerebellar toxcitity 5% £561 £29  
  Severe liver disorder 16% £320 £51  
  Severe cardiac disorder 16% £520 £83  
  Renal disorder 7% £134 £9  
DA (C100)    £292 
  Severe Fever 24.6% £273 £67  
  Severe Mucositis 3.8% £300 11  
Digestive system     
  Severe Nausea / vomiting 2.3% £120 £3  
  Severe Diarrhea 4.9% £130 £6  
  Severe Anorexia 21% £122 £26  
Skin and appendages     
  Severe Alopecia 27.4% £264 £72  
  Severe Rash 0.4% £251 £1  
Cardiovascular system (severe) 8.4% £364 £31  
  Severe heart failure 4%    
Renal disorder (severe) 4% £94 £4  
  Severe Dialysis 13%    
Hepatic disorder (severe) 20.6% £224 £46  
  Severe Bilirubinemia 7.5%    
  Severe Creatinine 0.3%    
Neurologic disorder (severe) 9% £272 £25  
DA (C200)    £356 
  Severe Fever 11% £273 £30  
  Severe Malaise 16% £282 £45  
  Severe Pain 5.7% £324 £19  
Digestive system     
  Severe Nausea / vomiting 2.9% £120 £4  
  Severe Diarrhea 9% £130 £12  
  Severe Stomatitis 10.9% £97 £11  
Skin and appendages     
  Severe Rash 45% £251 £113  
Respiratory system     
  Severe Dyspnea 18% £277 £50  
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Cardiovascular system (severe) 12.9% £364 £47  
Severe Hypotension 7%    
Renal disorder     
  Severe Dialysis 3% £93 £3  
Hepatic disorder (severe) 7.4% £224 £17  
  Severe Bilirubinemia 16%    
Neurologic disorder (severe) 2% £272 £5  
  Severe CNS toxicity 4.8%    
HAM    £248 
  Severe Fever 38% £273 £104  
  Severe Mucositis 9% £300 £27  
Digestive system     
  Severe Nausea / vomiting 13.9% £120 £17  
  Severe Diarrhea 15.9% £130 £21  
Hepatic disorder (severe) 8% £224 £18  
  Severe Bilirubinemia 17.7%    
  Severe Creatinine 4%    
Cardiovascular system (severe) 1% £364 £4  
Neurocortical disorder (severe) 21% £272 £57  
  Severe CNS toxicity 7%    
MidAC    £59 
Digestive system     
     Severe Nausea / vomiting 17.2% £120 £21  
     Severe Diarrhea 7.8% £130 £10  
     Severe Stomatitis 6.8% £97 £7  
Cardiovascular system (severe) 4.2% £364 £15  
Neurocortical disorder     
     Severe CNS toxicity 1.6% £393 £6  
FA    £147 
  Severe Fever 33% £273 £90  
Renal disorder (severe) 4% £94 £4  
Hepatic disorder (severe) 22% £224 £49  
Cardiovascular system (severe) 1% £364 £4  
FLAG    £409 
  Severe Fever 28% £273 £76  
   Severe Mucositis 7% £300 £21  
  Severe Pain 14% £324 £45  
Digestive system     
  Severe Nausea / vomiting 32% £120 £38  
  Severe Diarrhea 8% £130 £10  
Metabolic disorder     
  Severe Edema 1% £444 £4  
Respiratory system     
  Severe Dyspnea 50% £277 £139  
Renal disorder (severe) 0% £94 £0  
Hepatic disorder (severe) 12.6% £224 £28  
  Severe Bilirubinemia 12%    
  Severe creatinine 0%    
Cardiovascular system (severe) 8% £364 £29  
Neurocortical disorder (severe) 7% £272 £19  
     
FLAG-Ida    £353 
  Severe Fever 28% £273 £76  
  Severe Severe Mucositis 65% £300 £195  
Digestive system     
  Severe Nausea / vomiting 10.7% £130 £14  
  Severe Diarrhea 5% £120 £6  
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Hepatic disorder     
  Severe Bilirubinemia 22% £215 £47  
Cardiovascular system (Severe) 4% £364 £15  
MACE    £103 
  Severe Headache 10% £162 £16  
Digestive system      
  Severe Nausea / vomiting 29% £130 £38  
Hepatic disorder (severe) 1% £224 £2  
Neurocortical disorder      
  Severe Cerebellar toxicity 12% £393 £47  
Mylotarg    £197 
  Severe Fever 6.3% £273 £17  
  Severe Mucositis 4% £300 £12  
Digestive system     
  Severe Nausea / vomiting 11% £130 £14  
Respiratory system     
  Severe Dyspnea 10% £277 £28  
Hepatic disorder     
  Severe Bilirubinemia 21% £215 £45  
  Severe Creatinine 0.5% £218 £1  
Cardiovascular system     
  Severe Hypertension 10% £365 £37  
  Severe Hypotension 7.7% £356 £27  
Neurocortical disorder     
  Severe CNS toxicity 4% £393 £16  
G-CSF    £202 
  Severe Fever 24% £273 £66  
Severe Mucositis 15% £300 £45  
  Severe Pain 0.8% £324 £3  
Digestive system     
  Severe Nausea / vomiting 20% £130 £26  
  Severe Diarrhea 5% £120 £6  
Skin and appendages     
  Severe Rash 3.3% £251 £8  
Hepatic disorder (severe) 4% £224 £9  
  Severe Bilirubinemia 6%    
Cardiovascular system (severe) 8.6% £364 £31  
  Severe Hypotension 3.4%    
Neurocortical disorder (severe) 3% £272 £8  
ATRA    £165 
RAS 24% £194 £47  
Severe Nausea / Vomiting 6% £130 £8  
Severe Diarrhea 3% £120 £4  
Severe Stomitis 7% £97 £7  
Skin disorder (severe) 5% £272 £14  
Liver disorder (severe) 13% £224 £29  
Cardiovascular disorder (severe) 11% £364 £40  
  Severe hypertension 7%    
Neurocortical disorder (severe) 6% £272 £16  
MRC Approach    £29 
  RAS 15% £194 £29  
Spanish Approach    £187 
  RAS 18% £194 £35  
  Severe Mucositis 19% £300 £57  
  Severe edema 10% £444 £44  
  Severe Nausea / vomiting 5% £130 £15  
  Severe Diarrhea 2% £120 £2  
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  Severe stomatitis 6% £97 £6  
Skin disorder (severe) 2% £272 £5  
Liver disorder (severe) 3% £224 £7  
Cardiac disorder (severe) 3% £364 £11  
Neurocortical disorder (severe) 2% £272 £5  
Clofarabine    £115 
  Severe Mucositis 6% £300 £18  
Digestive system     
  Severe Nausea / vomiting 2.5% £130 £3  
  Severe Diarrhea 0% £0 £0  
Skin and appendages     
  Severe Rash 10% £251 £25  
Respiratory system     
  Severe Bilirubinemia 19% £215 £41  
  Severe Creatinine 13% £218 £28  
Hydroxyurea    £52 
Severe Mucositis 3% £300 £9  
Digestive system (severe) 9% £300 £27  
  Severe Nausea / vomiting 8%    
  Severe Diarrhea 20%    
Skin and appendages     
  Severe Alopecia 5% £264 £13  
Renal disorder (severe) 3% £94 £3  
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Appendix 6.7 The cost lists of complication cost for each treatment 
 
 
 
Complication cost Antibiotics Cost Total cost 
Type  1   
(derived from literatures) 
Type 2 
(derived from expert 
opinions) 
Antibiotics days Day cost Antibiotics cost Type 1 Type 2 
Chemotherapy        
Inpatient         
ADE 10+3+5 £188 £115.1 12 / course ×81.8 £1964 £2152 £2079 
Course 1 (10+3+5) £94 £57.6 14 ×81.8 £1145 £1239 £1203 
Course 2 (8+3+5) £94 £57.6 7 ×81.8 £573 £667 £631 
ADE + Mylotarg £188 £115.1 12 / course ×81.8 £1964 £2152 £2079 
Course 1 (10+3+5) £94 £57.6 14 ×81.8 £1145 £1239 £1203 
Course 2 (8+3+5) £94 £57.6 7 ×81.8 £573 £667 £631 
AraC (HD) £184 £115.1 8 / course ×81.8 £1308 £1492 £1423 
Course 1  £92 £57.6 10 ×81.8 £818 £910 £876 
Course 2 £92 £57.6 8 ×81.8 £654 £746 £712 
AraC (HD) + Mylotarg £184 £115.1 8 /course ×81.8 £1308 £1492 £1423 
Course 1 £92 £57.6 10 ×81.8 £818 £910 £876 
Course 2 £92 £57.6 8 ×81.8 £654 £746 £712 
AraC (LD) £115 £115.1 9 / course ×81.8 £1472 £1587 £1530 
Course 1 £57.5 £57.6 11 ×81.8 £890 £957 £957 
Course 2-4 £57.5 £57.6 7 ×81.8 £573 £630 £630 
DA   £356 £115.1 14 / course ×81.8 £2290 £2646 £2405 
Course 1 £178 £57.6 16 ×81.8 £1309 £1487 £1367 
Course 2 £178 £57.6 12 ×81.8 £982 £1160 £1040 
DA + Mylotarg £356 £115.1 14 / course ×81.8 £2290 £2646 £2405 
Course 1 £178 £57.6 16 ×81.8 £1309 £1487 £1367 
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Course 2 £178 £57.6 12 ×81.8 £982 £1160 £1040 
FLA £147 £115.1 24 / course ×81.8 £3926 £4073 £4041 
Course 1 £73.5 £57.6 21 * ×81.8 £1718 £1792 £1776 
Course 2 £73.5 £57.6 26 * ×81.8 £2127 £2200 £2185 
FLAG £409 £115.1 24 / course ×81.8 £3926 £4073 £4041 
Course 1 £204.5 £57.6 21 ×81.8 £1718 £1792 £1776 
Course 2 £204.5 £57.6 26 ×81.8 £2127 £2200 £2185 
FLAG-Ida £353 £115.1 22 / course ×81.8 £3599 £3952 £3714 
Course 1 £176.5 £57.6 15 ×81.8 £1227 £1404 £1285 
Course 2 £176.5 £57.6 29 ×81.8 £2372 £2549 £2430 
FLAG-Ida + Mylotarg £353 £115.1 22 / course ×81.8 £3599 £3952 £3714 
Course 1 £176.5 £57.6 15 ×81.8 £1227 £1404 £1285 
Course 2 £176.5 £57.6 29 ×81.8 £2372 £2549 £2430 
HAM £248 £115.1 10 (MidAC) ×81.8 £818 £1066 £933 
MidAC £59 £115.1 10 ×81.8 £818 £877 £933 
Mini MidAC £59 £115.1 10 ×81.8 £818 £877 £933 
MACE £103 £115.1 12 ×81.8 £982 £1085 £1097 
Spanish approach £187 £115.1 14 / course ×81.8 £4581 £4768 £4696 
Course 1 £46.75 £28.78 14 ×81.8 £1145 £1192 £1174 
Course 2 £46.75 £28.78 14 ×81.8 £1145 £1192 £1174 
Course 3 £46.75 £28.78 14 * ×81.8 £1145 £1192 £1174 
Course 3 £46.75 £28.78 14 * ×81.8 £1145 £1192 £1174 
MRC approach £29 (+350) £115.1 13 / course ×81.8 £4254 £4633 £4369 
Course 1 £7.25 (+94) £28.78 13 ×81.8 £1063 £1165 £2155 
Course 2 £7.25 (+94) £28.78 23 ×81.8 £1881 £1983 £1910 
Course 3 £7.25(+103) £28.78 7 ×81.8 £573 £683 £602 
Course 4 £7.25(+59) £28.78 16 ×81.8 £1309 £1375 £1338 
Clofarabine £115 £115 14 ** ×81.8 £1145 £1260 £1260 
Inpatient (Mild)        
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Amsacrine - £115 14 ** ×81.8 £1145 £1145 £1260 
Campath - £115 14 ** ×81.8 £1145 £1145 £1260 
Arsenic trioxide - £115 14 ** ×81.8 £1145 £1145 £1260 
Outpatient (Intensive)        
Cyclophosphamid - - - - - - - 
Cyclophosphamid/MESNA - - - - - - - 
Daunorubicin        
ETI - - - - - - - 
FC - - - - - - - 
Fludarabine - - - - - - - 
Etoposide - - - - - - - 
Melphalan - - - - - - - 
Vincristine - - - - - - - 
ATRA £165 - - - £165 £165 - 
Mylotarg £197 - - - £197 £197 - 
Anagrelide - - - - - - - 
Clopidogrel - - - - - - - 
Outpatient (Mild)        
Aspirin - - - - - - - 
Hydroxycarbamide £122 - - - £122 £122 - 
Hydroxycarbamide + Aspirin £122 - - - £122 £122 - 
Chelating agents - - - - - - - 
Clinical Trial        
AML 14 AraC £115 £115.1 9 / course ×81.8 £1472 £1587 £1530 
Course 1 £57.5 £57.6 11 ×81.8 £890 £957 £957 
Course 2-4 £57.5 £57.6 7 ×81.8 £573 £630 £630 
AML 14 AraC + Mylotarg £115 £115.1 9 / course ×81.8 £1472 £1587 £1530 
Course 1 £57.5 £57.6 11 ×81.8 £890 £957 £957 
Course 2-4 £57.5 £57.6 7 ×81.8 £573 £630 £630 
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AML 14 D35 C200 £356 £115.1 14 / course ×81.8 £2290 £2646 £2405 
Course 1 £178 £57.6 16 ×81.8 £1309 £1487 £1367 
Course 2 £178 £57.6 12 ×81.8 £982 £1160 £1040 
AML 14 D35 C400 £356 £115.1 14 / course ×81.8 £2290 £2646 £2405 
Course 1 £178 £57.6 16 ×81.8 £1309 £1487 £1367 
Course 2 £178 £57.6 12 ×81.8 £982 £1160 £1040 
AML 14 D50 C200 £356 £115.1 14 / course ×81.8 £2290 £2646 £2405 
Course 1 £178 £57.6 16 ×81.8 £1309 £1487 £1367 
Course 2 £178 £57.6 12 ×81.8 £982 £1160 £1040 
AML 15 ADE £188 £115.1 12 / course ×81.8 £1964 £2152 £2079 
Course 1 £94 £57.6 14 ×81.8 £1145 £1239 £1203 
Course 2 £94 £57.6 7 ×81.8 £573 £667 £631 
AML 15 ADE + Mylotarg £188 £115.1 12 / course ×81.8 £1964 £2152 £2079 
Course 1 £94 £57.6 14 ×81.8 £1145 £1239 £1203 
Course 2 £94 £57.6 7 ×81.8 £573 £667 £631 
AML 15 AraC £184 £115.1 8 / course ×81.8 £1308 £1492 £1423 
Course 1 £92 £57.6 10 ×81.8 £818 £910 £876 
Course 2 £92 £57.6 8 ×81.8 £654 £746 £712 
AML 15 AraC + Mylotarg £184 £115.1 8 / course ×81.8 £1308 £1492 £1423 
Course 1 £92 £57.6 10 ×81.8 £818 £910 £876 
Course 2 £92 £57.6 8 ×81.8 £654 £746 £712 
AML 15 DA £356 £115.1 14 / course ×81.8 £2290 £2646 £2405 
Course 1 £178 £57.6 16 ×81.8 £1309 £1487 £1367 
Course 2 £178 £57.6 12 ×81.8 £982 £1160 £1040 
AML 15 DA + Mylotarg £356 £115.1 14 / course ×81.8 £2290 £2646 £2405 
Course 1 £178 £57.6 16 ×81.8 £1309 £1487 £1367 
Course 2 £178 £57.6 12 ×81.8 £982 £1160 £1040 
AML 15 FLAG-Ida £353 £115.1 22 / course ×81.8 £3599 £3952 £3714 
Course 1 £176.5 £57.6 15 ×81.8 £1227 £1404 £1285 
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Course 2 £176.5 £57.6 29 ×81.8 £2372 £2549 £2430 
AML 15 FLAG-Ida + Mylotarg £353 £115.1 22 / course ×81.8 £3599 £3952 £3714 
Course 1 £176.5 £57.6 15 ×81.8 £1227 £1404 £1285 
Course 2 £176.5 £57.6 29 ×81.8 £2372 £2549 £2430 
AML 15 MidAC £59 £115.1 10 ×81.8 £818 £877 £933 
AML 15 MACE £103 £115.1 12 ×81.8 £982 £1085 £1097 
AML 15 MACE + Mylotarg £103 £115.1 12 ×81.8 £982 £1085 £1097 
APML 15 Spanish approach £187 £115.1 14 / course ×81.8 £4581 £4768 £4696 
Course 1 £46.75 £28.78 14 ×81.8 £1145 £1192 £1174 
Course 2 £46.75 £28.78 14 * ×81.8 £1145 £1192 £1174 
Course 3 £46.75 £28.78 14 * ×81.8 £1145 £1192 £1174 
Course 4 £46.75 £28.78 14 * ×81.8 £1145 £1192 £1174 
APML Spanish Maintenance - - - - - - - 
APML 15 MRC approach £29 £115.1 13 / course ×81.8 £4254 £4633 £4369 
Course 1 £7.25 £28.78 13 ×81.8 £1063 £1165 £2155 
Course 2 £7.25 £28.78 23 ×81.8 £1881 £1983 £1910 
Course 3 £7.25 £28.78 7 ×81.8 £573 £683 £602 
Course 4 £7.25 £28.78 16 ×81.8 £1309 £1375 £1338 
Other treatment Group 1        
Supportive care - - - - - - - 
Transfusion - - - - - - - 
Erythropoietin - - - - - - - 
Steroids - - - - - - - 
G-CSF - - - - - - - 
Venesection - - - - - - - 
Immunosupressive therapy - - - - - - - 
Palliative Care        
Duration < 21 - - - - - - - 
Duration > 21 - - - - - - - 
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Follow-up - - - - - - - 
Other treatment Group 2        
Splenectomy - - - - - - - 
Transplant - - - - - - - 
Auto BMT - - - - - - - 
Allo BMT - - - - - - - 
Radiotherapy - - - - - - - 
TBI -  - - - - - 
Non-TBI - - - - - - - 
 
* The estimate derived from the value of similar treatment 
** The estimate derived from expert survey 
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Appendix 7.1 International price and data source list of Mylotarg 
 
Country Resource Year Price Price in UK 
(£) 
USA http://content.ecast.wyeth.com/msgs/105/April_PI_20090401_1.pdf 2009/03 2,524.24 USD £1,764.06 
Canada http://www.saverxcanada.com/drugs/Mylotarg/solution/5mg 2009/05 2,833.97 USD £1,913.55 
Chile http://www.cenabast.cl/ConsultaPrecios/index.asp 2009 - - 
Germany www.rote-liste.de/Online 2009 - [195] - 
France http://www.vidalpro.net 2009 - [195] - 
Spain http://www.buenasalud.com/enc/ 2009 - [195] - 
Belgium http://www.bcfi.be/ 2009 - [195] - 
Greece http://www.mednet.gr/app/index.php 2009 - [195] - 
Switzerland http://www.kompendium.ch/app/search_d.cfm 2009 - [195] - 
Sweden http://www.fass.se/LIF/produktfakta/fakta_lakare.jsp 2009 - [195] - 
Japan http://www.irxmedicine.com/products/pdt.asp?p_unitid=29174 2008/03 310,000 YEN £1,492.16 
 http://www.mhlw.go.jp/shingi/2005/08/txt/s0831-2.txt 2007 241,154 YEN £1,039.25 
Taiwan http://homepage.vghtpe.gov.tw/~pharm/newdrugreport/96/S-1231.pdf 2009 77,385 TWD £1,579.23 
Korea www.dailyinfo.co.kr 
sdic.sookmyung.ac.kr 
2007 2,780,000 KRW £1,507.00 
China www.2007.org.cn/product/Leukemianewspecial/200709/product_32.html 2009/05 3,200 USD £2,160.70 
Thailand No public website 2009 - - 
Malaysia http://www.bpfk.gov.my/Search/advsearch.asp 2009 - - 
Australia www.pbs.gov.au 2009 - - 
New Zealand http://www.pharmac.govt.nz/Schedule 2009 - - 
Israel http://www.ima.org.il/imaj/ar06sep-1.pdf 2009 2,213.17 USD £1,494.38 
South Africa http://www.sapma.co.za/assets/attachments/PIASA/Wyeth_Price_List_2009-02.PDF 2009 20,409.26 Rand £1,623.90 
Average    £1,619.36 
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Appendix 7.2 Detailed cost list of drug items for each treatment (Assumed that an average patient surface area is 1.8 m2)   
 
 Dose Unit cost Frequency Cost 
Intensive Inpatient treatment     
ADE 10+3+5 Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡1158.58 / course 
 Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD (1 dose) ￡2.15 Once  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
ADE 8+3+5 Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡1121.90 / course 
 Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD (1 dose) ￡2.15 Once  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
ADE + Mylotarg course 1 Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡2779.87 / course 
 Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD (1 does) ￡2.15 Once  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Mylotarg 5 mg (1 dose) ￡1619.39 Once  
      
ADE course 2 Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡1121.90 / course 
 Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
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 Allopurinol  300mg oral OD (1 dose) ￡2.15 Once  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
      
AraC (HD): course 1 Cytarabine  3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡1699.97 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol 0.5% eye drops 1 drop QDS (1 dose) ￡2.35 4 times daily  
      
AraC (HD): course 2 Cytarabine 3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡1699.97 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol 1 drop QDS (1 does) ￡2.35 4 timesdaily  
      
AraC (HD) + Mylotarg: course 1 Cytarabine 3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡3321.26 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
 Metoclopramide 10 mg oral QDS prn ￡0.07 Once daily  
 Predsol 1 drop QDS ￡2.35 Once daily  
 Chlorphenamine 10 mg IV Bolus ￡1.90 Once daily  
 Mylotarg 5 mg ￡1619.39 Once  
      
AraC (HD): course 2 Cytarabine 3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡1699.97 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol 1 drop QDS (1 dose) ￡2.35 4 times daily  
      
AraC (LD): course 1 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡9.16 / day (￡91.6 / course) 
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AraC (LD): course 2-4 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡9.16 / day (￡91.6 / course) 
      
AraC (LD) +Mylotarg: course 1 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡9.16 (1630.45) / day 
 Chlorphenamine 10 mg IV Bolus (1 dose) ￡1.90 Once ￡1712.96 / course 
 Mylotarg 5 mg (1 dose) ￡1619.39 Once  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
AraC (LD) +Mylotarg: course 2-4 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡9.16 / day (￡91.6 / course) 
      
Clofarabine Clofarabine 20 mg/m2 in 100ml N/Saline (5 doses) ￡2160 Once daily ￡10879.82 / course 
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
DA 3+10 Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡1015.83 / course 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once   
      
DA 3+8 Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡979.15 / course 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once   
      
DA (3+10)+Mylotarg Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡2637.12 / course 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once  
 - 375- 
 
 Mylotarg 5 mg ￡1619.39 Once  
      
DA (3+8)+Mylotarg Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡979.15 / course 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once   
      
FLA : course 1 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily ￡1978.65 / course 
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (3 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
      
FLA: course 2 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily ￡1978.65 / course 
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (3 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
      
FLAG: course 1 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡2557.83 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS (1op) (1 dose) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Daily  
      
FLAG: course 2 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡2557.83 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
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 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS (1op) (1 dose) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Daily  
      
FLAG-Ida: course 1 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡3789.60 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) (1 dose) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Daily  
      
FLAG-Ida: course 2 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡3789.60 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) (1 dose) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Daily  
      
FLAG-Ida + Mylotarg: course 1 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡5410.89 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) (1 dose) ￡0.07 4 times daily  
 Chlorphenamine 10 mg iv Bolus(1 dose) ￡1.90 Once  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Daily  
 Mylotarg 5 mg (1 dose) ￡1619.39 Once  
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FLAG-Ida: course 2 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡3789.60 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) (1 dose) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Once  
      
HAM Cytarabine 3000 mg/m2 BD day 1-4 (8 doses) ￡549.9 Every 12 hours ￡2830.82 / course 
 Mitoxantrone 10 mg/m2 iv day 2-6 (5 doses) ￡36.17 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Once  
      
MACE Amsacrine 100 mg/m2 od day 1-5 (5 doses) ￡173.32 Once daily ￡1180.82 / course 
 Cytarabine 200 mg/m2 od day 1-5 (5 doses) ￡18.33 Once daily  
 Etoposide 100 mg/m2 od day 1-5 (5 doses) ￡28.55 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
MidAC Mitoxantrone 10 mg/m2 in 100ml N/Saline (5 doses) ￡117.50 Once daily ￡1204.19 / course 
 Cytarabine 1000 mg/m2 iv day 1, 3, 5 (6 doses) ￡91.65 Every 12 hours  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) (1 dose) ￡2.35 Daily  
      
Mini-MidAC  As full dose of MidAC   ￡1204.19 / course 
      
Mild Inpatient Treatment      
Amsacrine Amsacrine 100 mg/m2 iv ￡155.75 Daily ￡155.75 / day 
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Arsenic trioxide (ATO): course 1 Arsenic trioxide 0.15 mg/kg/day in 100ml dextrose 5% ￡250.90 25 days every course ￡250.90 / day 
      
Campath Campath 
(alemtuzumab) 
30 mg intravenously ￡322.93 3 days weekly ￡991.22 / week 
 Dexamethasone 8 mg oral stat ￡0.56 3 days weekly  
 Chlorphenamine 10 mg iv Bolus ￡1.90 3 days weekly  
 Allopurinol  300 mg oral od ￡2.15 Once daily  
      
Intensive Outpatient treatment      
Mylotarg Mylotarg 5 mg (i.v) ￡1619.39 weekly ￡1619.39 / week 
(weekly) 
      
Daunorubicin Daunorubicin 60 mg/m2 in 100ml N/ Saline  ￡315.56 Once every 21 days ￡315.56 / day 
      
Cyclophosphamide Cyclophosphamide 500mg oral stat weekly ￡2.88 weekly ￡69.78 / week 
 Granisetron 3 mg oral stat dose ￡23.09 Once daily (weekly) 
 Metoclopramide 10 mg QDS oral (1op) ￡0.07 Daily  
 Prednisolone 40 mg/m2 oral alt days ￡44.75 Alternative days  
      
Cyclophosphamide (HD) Cyclophosphamide 3000mg/m2 in 500ml N/S daily (2 doses) ￡28.08 Once daily ￡132.06 
 Granisetron 2 mg oral stat dose ￡15.39 Once daily (one off) 
 Dexamethasone 8 mg oral stat dose ￡0.56 Once daily  
 Dexamethasone 2 mg oral (8 tabs) ￡1.12 Once daily  
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 Once daily  
 Allopurinol 300 mg oral OD (1op) ￡2.15 Once daily  
 Mesna 6000mg/m2 in 1000ml N/S (i.v) ￡56.61 Once daily  
      
ETI Etoposide, capsules,  80mg/m2 bd  ￡24.9 Every 12 hours ￡40.77 / day 
 Tioguanine 100mg/m2 bd  ￡10.9 Every 12 hours (5 days every 26 days) 
 Idarubicin 15mg/m2 od day ￡4.97 5 days every 26 days  
      
FC Fludarabine 40 mg/m2 oral OD  ￡153 5 days every 28 days ￡157.13 / day 
 Cyclophosphamide 250 mg/m2 oral OD  ￡0.96 5 days every 28 days (5 days every 28 days) 
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 Granisetron 1mg BD oral ￡3.1 5 days every 28 days  
 Metoclopramide 10 mg QDS oral (1op) ￡0.07 5 days every 28 days  
 
      
Etoposide Etoposide 100mg oral daily  ￡12.45 7 days every 28 days ￡12.52 / day 
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 7 days every 28 days (7 days every 28 days) 
      
Fludarabine Fludarabine 40mg/m2 oral od daily ￡153 5 days every 33 days ￡153.07 / day 
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 5 days every 33 days (5 days every 33 days) 
      
Vincristine Vincristine 2 mg/m2 once every week (i.v) ￡24.87 Once every 7 days ￡24.87 / week 
(weekly) 
      
Melphalan Melphalan 7 mg/m2 oral OD daily ￡3.23 Once daily ￡5.01 / day 
 Prednisolone 40 mg/m2 oral days ￡1.78 Once daily  
      
ATRA ATRA 45mg/m2 daily ￡16.03 Once daily ￡16.03 / day 
      
Anagrelide Anagrelide 1 mg 4 times a day ￡3.37 Once daily ￡13.48 / day 
      
Clopidogrel Clopidogrel 75 mg daily ￡1.21 Once daily ￡1.21 / day 
      
Mild Outpatient Treatment      
Aspirin Aspirin 75mg oral for 3 doses daily ￡0.0339 3 times daily ￡0.1 / day 
      
Hydroxycarbamide Hydroxycarbamide 2 g Oral OD daily ￡0.44 Once daily ￡0.72 / day 
 Metoclopramide 10 mg oral QDS (four times daily) pm ￡0.07 4 times daily  
      
Hydroxycarbamide + Aspirin Hydroxycarbamide 2 g Oral OD daily ￡0.44 Once daily ￡0.82 / day 
 Metoclopramide 10 mg oral QDS (four times daily) pm ￡0.07 4 times daily  
 Aspirin 75mg oral 3 doses daily ￡0.0339 3 times daily  
      
Chelating agent Desferprioxamine 500 mg daily intramuscularly for 1 week ￡4.44 Once Daily ￡31.08 / first week 
 Deferiprone 25mg/kg, oral, 3 times a day ￡5.33 Daily ￡5.33 / day 
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Clinical trial      
AML 14 AraC: course 1 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡ ￡9.16 / day ( 91.6 / course) 
      
AML 14 AraC: course 2 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡ ￡9.16 / day ( 91.6 / course) 
      
AML 14 AraC + Mylotarg: course 1 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡9.16 (1630.45) / day 
 Chlorphenamine 10 mg IV Bolus (1 dose) ￡1.90 Once ￡1712.96 / course 
 Mylotarg 5 mg (1 dose) ￡1619.39 Once  
      
AML 14 AraC + Mylotarg: course 2 Cytarabine  20mg PFS (bd for 10 days – 20 doses) ￡4.58 Every 12 hours ￡9.16 / day 
      
AML 14 D35 C200 (10+3) Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡889.59 / course 
 Daunorubicin 35 mg/m2 iv od day 1,3,5 (3 doses) ￡220.89 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once  
      
AML 14 D35 C200 (8+3) Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡852.91 / course 
 Daunorubicin 35 mg/m2 iv od day 1,3,5 (3 doses) ￡220.89 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once daily  
      
AML 14 D35 C400 (10+3) Cytarabine 200 mg/m2 iv bd day 1-10 (20 doses) ￡18.33 Every 12 hours ￡1072.79 
 Daunorubicin 35 mg/m2 iv od day 1,3,5 (3 doses) ￡220.89 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once daily  
      
AML 14 D35 C400 (8+3) Cytarabine 200 mg/m2 iv bd day 1-8 (16 doses) ￡18.33 Every 12 hours ￡999.47 
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 Daunorubicin 35 mg/m2 iv od day 1,3,5 (3 doses) ￡220.89 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once daily  
      
AML 14 D50 C200 (10+3) Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡1015.83 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once daily  
      
AML 14 D50 C200 (8+3) Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡979.15 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once daily  
      
AML 15 ADE (10+3+5) Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡1158.58 / course 
 Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD ￡2.15 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
AML 15 ADE (8+3+5) Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡1121.90 / course 
 Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD ￡2.15 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
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 Metoclopramide 10 mg oral QDS prn ￡0.07 Once daily  
      
AML 15 ADE + Mylotarg  Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡2777.97 / course 
    (course1)  Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD ￡2.15 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Mylotarg 5 mg (1 dose) ￡1619.39 Once  
      
AML 15 ADE + Mylotarg Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡1121.90 / course 
    (course  2)  Daunorubicin 50 mg/m2 iv day 1, 3, 5 (3 doses) ￡262.97 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD ￡2.15 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
AML 15 AraC: course 1 Cytarabine  3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡1699.97 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol 0.5% eye drops 1 drop QDS (1 dose) ￡2.35 Once daily  
      
AML 15 AraC: course 2 Cytarabine 3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡1699.97 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol 1 drop QDS (1 dose) ￡2.35 Once daily  
      
AML 15 AraC + Mylotarg: course 1 Cytarabine 3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡3323.05 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
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 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 Once daily  
 Predsol 1 drop QDS (1 dose) ￡2.35 4 times daily  
 Chlorphenamine 10 mg IV Bolus (1 dose) ￡1.90 Once daily  
 Mylotarg 5 mg (1 dose) ￡1619.39 Once  
      
AML 15 AraC + Mylotarg: course 2 Cytarabine 3000m g/m2 iv bd day 1, 3, 5 (6 doses) ￡274.95 Alternative days ￡1699.97 / course 
 Dexamethasone 8 mg oral stat (3 doses) ￡0.56 Alternative days  
 Granisetron 2 mg oral stat (3 doses) ￡15.39 Alternative days  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Predsol 1 drop QDS (1 dose) ￡2.35 Once daily  
      
AML 15 DA (10+3) Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡1015.83 / course 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once daily  
      
AML 15 DA (8+3) Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡979.15 / course 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
 Allopurinol  300 mg oral od (1 dose) ￡2.15 Once daily  
      
AML 15 DA + Mylotarg: course 1 Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡2637.12 / course 
 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn ￡0.07 4 times daily  
 Allopurinol  300 mg oral od ￡2.15 Once daily  
 Mylotarg 5 mg ￡1619.39 Once  
      
AML 15 DA + Mylotarg: course 2 Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡979.15 / course 
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 Daunorubicin 50 mg/m2 iv od day 1,3,5 (3 doses) ￡262.97 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Alternative day  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Alternative day  
 Metoclopramide 10 mg oral QDS prn ￡0.07 4 times daily  
 Allopurinol  300 mg oral od ￡2.15 Once daily  
      
AML 15 FLAG-Ida: course 1 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡3789.60 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
      
AML 15 FLAG-Ida: course 2 G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡3789.60 / course 
 Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
      
AML 15 FLAG-Ida + Mylotarg G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡5410.89 / course 
    (course1)  Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 4 times daily  
 Chlorphenamine 10 mg iv Bolus ￡1.90 Once Daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
 Mylotarg 5 mg ￡1619.39 Once  
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AML 15 FLAG-Ida + Mylotarg G-CSF 300 microgram OD for 7 days ￡562.67 Once daily ￡3789.60 / course 
    (course2)  Fludarabine 30mg/m2 iv. od day 1-5 (5 doses) ￡366.60 Once daily  
 Cytarabine 2000mg/m2 iv od day 1-5 (5 doses) ￡23.69 Once daily  
 Idarubicin 10 mg/m2 od day 4-6 (3 doses) ￡410.59 Alternative day  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.70 Once daily  
 Metoclopramide 10 mg oral QDS (1op) ￡0.07 4 times daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
      
AML 15 MACE Amsacrine 100 mg/m2 od day 1-5 (5 doses) ￡173.32 Once daily ￡1180.82 / course 
 Cytarabine 200 mg/m2 od day 1-5 (5 doses) ￡18.33 Once daily  
 Etoposide 100 mg/m2 od day 1-5 (5 doses) ￡28.55 Once daily  
 Dexamethasone 8 mg oral stat ￡0.56 Once daily  
 Granisetron 2 mg oral stat ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn ￡0.07 4 times daily  
      
AML 15 MACE + Mylotarg Amsacrine 100 mg/m2 od day 1-5 (5 doses) ￡173.32 Once daily ￡2802.11 / course 
 Cytarabine 200 mg/m2 od day 1-5 (5 doses) ￡18.33 Once daily  
 Etoposide 100 mg/m2 od day 1-5 (5 doses) ￡28.55 Once daily  
 Mylotarg 5mg (1 dose) ￡1619.39 Once  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn ￡0.07 4 times daily  
 Chlorphenamine 10 mg iv Bolus ￡1.90 Once Daily  
      
AML 15 MidAC Mitoxantrone 10 mg/m2 in 100ml N/Saline (5 doses) ￡117.50 Once daily ￡1204.19 / course 
 Cytarabine 1000 mg/m2 (6 doses) ￡91.65 Every 12 hours  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn ￡0.07 Once daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
      
APML 15 Spanish: course 1 ATRA 45mg/m2 for 28 days (28 doses) ￡448.81 Once daily ￡2978.42 / course 
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 Idarubicin 12 mg/m2 (4 doses) ￡615.89 First 4 days  
 Allopurinol  300mg oral OD ￡2.15 Daily  
 Dexamethasone 8mg oral stat (4 doses) ￡0.56 First 4 days  
 Granisetron 2mg oral stat (4 doses) ￡15.39 First 4 days  
 Metoclopramide 10mg oral QDS prn ￡0.07 4 times daily  
      
APML 15 Spanish: course 2 ATRA 45mg/m2 for 15 days (15doses) ￡240.43 Once daily ￡1915.92 / course 
 Idarubicin 7 mg/m2 (4 doses) ￡410.59 First 4 days  
 Dexamethasone 8mg oral stat (4 doses) ￡0.56 First 4 days  
 Granisetron 1mg oral stat (4 doses) ￡7.70 First 4 days  
 Metoclopramide 10mg oral QDS prn ￡0.07 4 times daily  
      
APML 15 Spanish: course 3 ATRA 45mg/m2 for 15 days (15 doses) ￡240.43 Once daily ￡869.32 / course 
 Mitozantrone 10 mg/m2 (5 doses) ￡117.50 First 5 days  
 Dexamethasone 8mg oral stat (5 doses) ￡0.56 First 5 days  
 Granisetron 1mg oral stat (5 doses) ￡7.70   
 Metoclopramide 10mg oral QDS prn ￡0.07   
      
APML 15 Spanish: course 4 ATRA 45mg/m2 for 15 days (15doses) ￡240.43 Once daily ￡864.60 / course 
 Idarubicin 12 mg/m2 (1 doses) ￡615.89 Once  
 Dexamethasone 8mg oral stat (4 doses) ￡0.56 First 4 days  
 Granisetron 1mg oral stat (4 doses) ￡7.70 First 4 days  
      
    Maintenance (1-3 month) Mercaptopurine 50 mg/m2 oral daily £1.675 Once daily ￡14.81 / week 
 Methotrexate 15 mg/m2 IM bolus (weekly) £3.08 Weekly  
      
    Maintenance (4-24 month) Mercaptopurine 50 mg/m2 oral daily  £1.675   
 Methotrexate 15 mg/m2 IM bolus (weekly) £3.08   
 ATRA 45 mg/m2 per day for 15 days every 3 
months 
£240.45   
      
APML 15 MRC: ADE+ATRA Cytarabine 100 mg/m2 iv bd day 1-10 (20 doses) ￡9.17 Every 12 hours ￡1607.42 / course 
 Daunorubicin 100 mg/m2 iv day 1, 3, 5 (3 doses) ￡473.34 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
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 ATRA 45mg/m2 for 28 days (28 doses) ￡448.81 Once daily  
 Allopurinol  300mg oral OD (1 dose) ￡2.15 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
APML 15 MRC : ADE Cytarabine 100 mg/m2 iv bd day 1-8 (16 doses) ￡9.17 Every 12 hours ￡1121.90 / course 
 Daunorubicin 100 mg/m2 iv day 1, 3, 5 (3 doses) ￡473.34 Alternative days  
 Etoposide 100 mg/m2/d iv day 1-5 (5 doses) ￡28.55 Once daily  
 Allopurinol  300mg oral OD (1 dose) ￡2.15 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 1 mg oral stat (5 doses) ￡7.7 Once daily  
 Metoclopramide 10 mg oral QDS prn (1 dose) ￡0.07 4 times daily  
      
APML 15 MRC : MACE Amsacrine 100 mg/m2 od day 1-5 (5 doses) ￡173.32 Once daily ￡1180.2/ course 
 Cytarabine 200 mg/m2 od day 1-5 (5 doses) ￡18.33 Once daily  
 Etoposide 100 mg/m2 od day 1-5 (5 doses) ￡28.55 Once daily  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn ￡0.07 Once daily  
      
APML 15 MRC : MidAC Mitoxantrone 10 mg/m2 in 100ml N/Saline (5 doses) ￡117.50 Once daily ￡1204.19 / course 
 Cytarabine 1000 mg/m2 (6 doses) ￡91.65 Every 12 hours  
 Dexamethasone 8 mg oral stat (5 doses) ￡0.56 Once daily  
 Granisetron 2 mg oral stat (5 doses) ￡15.39 Once daily  
 Metoclopramide 10 mg oral QDS prn ￡0.07 Once daily  
 Predsol  0.5% eye drops (1op) ￡2.35 Daily  
      
Other treatments      
Supportive Care      
Erythropoietin Aranesp 0.45 mcg/kg weekly (injection) ￡46.76 weekly ￡46.76 / week 
      
Steroids      
Dexamethasone Dexamethasone 4 mg, twice a day ￡0.29 Daily ￡0.58 / day 
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Prednisolone Prednisolone 20 mg, oral OD ￡0.14 Daily ￡0.14 / day 
Hydrocortisone Hydrocortisone 20 mg, oral OD ￡1.4 Daily ￡1.4 / day 
      
G-CSF G-CSF 300 microgram OD daily ￡80.38 4 days after chemo ￡80.38 / day (4 days after chemo) 
(once every 25 days) 
      
Transfusion Red blood  2 unit (mean) ￡261  ￡414 / transfusion 
 Platelet 1 unit (mean) ￡153   
      
Immunosuppresive      
 Cyclosporin Neoral: 12.5mg/kg oral OD ￡23.4 Daily ￡23.5 / day 
 Prednisolone 10 mg oral OD ￡0.08 Daily  
      
Venesection - - - monthly ￡132.1 / venesection 
      
Palliative care - - - 3 times weekly ￡336.3 / day 
      
Transplantation (allo)    Once ￡45558 / transplantation 
      
Radiotherapy      
TBI    Once ￡651 / radiotherapy 
Non-TBI    Once ￡635 / radiotherapy 
      
Splenectomy - - - Once ￡4010 / spenectomy 
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Appendix 7.3 Detailed drug item cost lists  
 
Detailed drug item cost list for ADE related regimen (by day)  
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
ADE 10+3+5 Day 1 Granisetron 1mg Oral stat £7.7 £320 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1 mg mg Oral stat £7.7 £376 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £694 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1 mg mg Oral stat £7.7 £749 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £1067 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1085 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1104 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1122 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 9 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1140 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 10 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1159 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
ADE 10+3+8 Day 1 Granisetron 1mg Oral stat £7.7 £320 
  Dexamethasone 8 mg Oral stat £0.56  
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  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1 mg mg Oral stat £7.7 £376 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £694 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1 mg mg Oral stat £7.7 £749 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £1067 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1085 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1104 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1122 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
      
ADE + Mylotarg Day 1 Granisetron 1mg Oral stat £7.7 £1942 
(Course 1)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
  Chlorphenamine 10 mg IV Bolus £1.90  
  Mylotarg 3 mg protein/m2 £1619  
 Day 2 Granisetron 1 mg mg Oral stat £7.7 £1997 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
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  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £2315 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1 mg mg Oral stat £7.7 £2370 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £2688 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2707 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2725 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2743 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 9 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2762 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 10 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2780 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
ADE + Mylotarg Day 1 Granisetron 1mg Oral stat £7.7 £320 
(Course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1 mg mg Oral stat £7.7 £376 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £694 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1 mg mg Oral stat £7.7 £749 
  Dexamethasone 8 mg Oral stat £0.56  
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  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £1067 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1085 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1104 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1122 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
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Detailed drug item cost list for AraC (HD) related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
AraC (HD) Day 1 Granisetron 2 mg Oral stat £15.4 £568 
(course 1 and 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Predsol 1 drop QDS £2.35  
 Day 3 Granisetron 2 mg Oral stat £15.4 £1134 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
 Day 5 Granisetron 2 mg Oral stat £15.4 £1700 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
AraC (HD) Day 1 Granisetron 2 mg Oral stat £15.4 £568 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Predsol 1 drop QDS £2.35  
 Day 3 Granisetron 2 mg Oral stat £15.4 £1134 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
 Day 5 Granisetron 2 mg Oral stat £15.4 £1700 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
      
AraC (HD) + Mylotarg Day 1 Granisetron 2 mg Oral stat £15.4 £2190 
(course 1)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Predsol 1 drop QDS £2.35  
  Chlorphenamine 10 mg IV Bolus £1.90  
  Mylotarg 3 mg protein/m2 £1619  
 Day 3 Granisetron 2 mg Oral stat £15.4 £2755 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
 Day 5 Granisetron 2 mg Oral stat £15.4 £3321 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
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  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
AraC (HD) + Mylotarg Day 1 Granisetron 2 mg Oral stat £15.4 £568 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Predsol 1 drop QDS £2.35  
 Day 3 Granisetron 2 mg Oral stat £15.4 £1134 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
 Day 5 Granisetron 2 mg Oral stat £15.4 £1700 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £275  
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Detailed drug item cost list for AraC (LD) related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
AraC (LD) Day 1 Cytarabine 20 mg injection £4.58 £9 
  Cytarabine 20 mg injection £4.58  
 Day 2 Cytarabine 20 mg injection £4.58 £18 
  Cytarabine 20 mg injection £4.58  
 Day 3 Cytarabine 20 mg injection £4.58 £28 
  Cytarabine 20 mg injection £4.58  
 Day 4 Cytarabine 20 mg injection £4.58 £37 
  Cytarabine 20 mg injection £4.58  
 Day 5 Cytarabine 20 mg injection £4.58 £46 
  Cytarabine 20 mg injection £4.58  
 Day 6 Cytarabine 20 mg injection £4.58 £55 
  Cytarabine 20 mg injection £4.58  
 Day 7 Cytarabine 20 mg injection £4.58 £64 
  Cytarabine 20 mg injection £4.58  
 Day 8 Cytarabine 20 mg injection £4.58 £73 
  Cytarabine 20 mg injection £4.58  
 Day 9 Cytarabine 20 mg injection £4.58 £82 
  Cytarabine 20 mg injection £4.58  
 Day 10 Cytarabine 20 mg injection £4.58 £92 
  Cytarabine 20 mg injection £4.58  
AraC (LD) + Mylotarg Day 1 Cytarabine 20 mg injection £4.58 £1631 
(course 1)  Cytarabine 20 mg injection £4.58  
  Chlorphenamine 10 mg IV Bolus £1.90  
  Mylotarg 3 mg protein/m2 £1619  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Cytarabine 20 mg injection £4.58 £1640 
  Cytarabine 20 mg injection £4.58  
 Day 3 Cytarabine 20 mg injection £4.58 £1649 
  Cytarabine 20 mg injection £4.58  
 Day 4 Cytarabine 20 mg injection £4.58 £1658 
  Cytarabine 20 mg injection £4.58  
 Day 5 Cytarabine 20 mg injection £4.58 £1668 
  Cytarabine 20 mg injection £4.58  
 Day 6 Cytarabine 20 mg injection £4.58 £1676 
  Cytarabine 20 mg injection £4.58  
 Day 7 Cytarabine 20 mg injection £4.58 £1686 
  Cytarabine 20 mg injection £4.58  
 Day 8 Cytarabine 20 mg injection £4.58 £1695 
  Cytarabine 20 mg injection £4.58  
 Day 9 Cytarabine 20 mg injection £4.58 £1704 
  Cytarabine 20 mg injection £4.58  
 Day 10 Cytarabine 20 mg injection £4.58 £1713 
  Cytarabine 20 mg injection £4.58  
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Detailed drug item cost list for Clofarabine related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated c
ost 
Clofarabine Day 1 Granisetron 2 mg Oral stat £15.4 £2176 
  Dexamethasone 8 mg Oral stat £0.56  
  Clofarabine 20 mg/m2 in 100ml N/Saline £2160  
 Day 2 Granisetron 2 mg Oral stat £15.4 £4352 
  Dexamethasone 8 mg Oral stat £0.56  
  Clofarabine 20 mg/m2 in 100ml N/Saline £2160  
 Day 3 Granisetron 2 mg Oral stat £15.4 £6528 
  Dexamethasone 8 mg Oral stat £0.56  
  Clofarabine 20 mg/m2 in 100ml N/Saline £2160  
 Day 4 Granisetron 2 mg Oral stat £15.4 £8704 
  Dexamethasone 8 mg Oral stat £0.56  
  Clofarabine 20 mg/m2 in 100ml N/Saline £2160  
 Day 5 Granisetron 2 mg Oral stat £15.4 £10880 
  Dexamethasone 8 mg Oral stat £0.56  
  Clofarabine 20 mg/m2 in 100ml N/Saline £2160  
  Metoclopramide 10 mg oral QDS prn £0.07  
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Detailed drug item cost list for DA related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
DA 3+10 Day 1 Granisetron 1mg Oral stat £7.7 £292 
(course 1)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1mg Oral stat £7.7 £318 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £608 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1mg Oral stat £7.7 £635 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £924 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £943 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £961 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £979 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 9 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £998 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 10 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1016 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
DA 3+8 Day 1 Granisetron 1mg Oral stat £7.7 £292 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1mg Oral stat £7.7 £318 
  Dexamethasone 8 mg Oral stat £0.56  
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  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £608 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1mg Oral stat £7.7 £635 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £924 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £943 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £961 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £979 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
      
DA + Mylotarg  Day 1 Granisetron 1mg Oral stat £7.7 £1913 
(course 1)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
  Chlorphenamine 10 mg IV Bolus £1.90  
  Mylotarg 3 mg protein/m2 £1619  
 Day 2 Granisetron 1mg Oral stat £7.7 £1940 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £2229 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1mg Oral stat £7.7 £2256 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £2545 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
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  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2564 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2582 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2600 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 9 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2619 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 10 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £2637 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
DA + Mylotarg Day 1 Granisetron 1mg Oral stat £7.7 £292 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1mg Oral stat £7.7 £318 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £608 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1mg Oral stat £7.7 £635 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £924 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £943 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £961 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £979 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
DA (D35 C400) Day 1 Granisetron 1mg Oral stat £7.7 £268 
(course 1)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
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 Day 2 Granisetron 1mg Oral stat £7.7 £313 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 3 Granisetron 1mg Oral stat £7.7 £579 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 4 Granisetron 1mg Oral stat £7.7 £624 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 5 Granisetron 1mg Oral stat £7.7 £890 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 6 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £926 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 7 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £963 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 8 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £1000 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 9 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £1036 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 10 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £1073 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
DA (D35 C400) Day 1 Granisetron 1mg Oral stat £7.7 £268 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1mg Oral stat £7.7 £313 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 3 Granisetron 1mg Oral stat £7.7 £579 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 4 Granisetron 1mg Oral stat £7.7 £624 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 5 Granisetron 1mg Oral stat £7.7 £890 
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  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 6 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £926 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 7 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £963 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
 Day 8 Cytarabine 200 mg/m2 in 100ml N/Saline £18.33 £1000 
  Cytarabine 200 mg/m2 in 100ml N/Saline £18.33  
      
DA (D35 C200) Day 1 Granisetron 1mg Oral stat £7.7 £250 
(course 1)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1mg Oral stat £7.7 £276 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £524 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1mg Oral stat £7.7 £550 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £798 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £816 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £835 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £853 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 9 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £871 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 10 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £890 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
DA (D35 C200) Day 1 Granisetron 1mg Oral stat £7.7 £250 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
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  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1mg Oral stat £7.7 £276 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £524 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1mg Oral stat £7.7 £550 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £798 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 35 mg/m2 in 100ml N/Saline £221  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £816 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £835 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £853 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
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Detailed drug item cost list for FLA related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
FLA Day 1 Granisetron 1mg Oral stat £7.7 £401 
(course 1)  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Fludarabine 30 mg/m2 in 100ml N/S £366.6 £791 
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 3 Granisetron 1mg Oral stat £7.7 £1190 
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 4 Fludarabine 30 mg/m2 in 100ml N/S £366.6 £1580 
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 5 Granisetron 1mg Oral stat £7.7 £1979 
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
FLA Day 1 Granisetron 1mg Oral stat £7.7 £401 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Fludarabine 30 mg/m2 in 100ml N/S £366.6 £791 
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 3 Granisetron 1mg Oral stat £7.7 £1190 
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 4 Fludarabine 30 mg/m2 in 100ml N/S £366.6 £1580 
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 5 Granisetron 1mg Oral stat £7.7 £1979 
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
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Detailed drug item cost list for FLAG related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
FLAG Day 1 G-CSF 300 microgram OD £80.38 £481 
(course 1& 2)  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 G-CSF 300 microgram OD £80.38 £960 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 3 G-CSF 300 microgram OD £80.38 £1439 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 4 G-CSF 300 microgram OD £80.38 £1918 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 5 G-CSF 300 microgram OD £80.38 £2397 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 6 G-CSF 300 microgram OD £80.38 £2478 
 Day 7 G-CSF 300 microgram OD £80.38 £2558 
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Detailed drug item cost list for FLAG-Ida related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated 
cost 
FLAG-Ida   Day 1 G-CSF 300 microgram OD £80.38 £892 
(course 1 & 2)  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 2 G-CSF 300 microgram OD £80.38 £1371 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 3 G-CSF 300 microgram OD £80.38 £2260 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 4 G-CSF 300 microgram OD £80.38 £2739 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 5 G-CSF 300 microgram OD £80.38 £3629 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 6 G-CSF 300 microgram OD £80.38 £3709 
 Day 7 G-CSF 300 microgram OD £80.38 £3790 
FLAG-Ida Day 1 G-CSF 300 microgram OD £80.38 £892 
(course 2)  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 2 G-CSF 300 microgram OD £80.38 £1371 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
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  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 3 G-CSF 300 microgram OD £80.38 £2260 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 4 G-CSF 300 microgram OD £80.38 £2739 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 5 G-CSF 300 microgram OD £80.38 £3629 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 6 G-CSF 300 microgram OD £80.38 £3709 
 Day 7 G-CSF 300 microgram OD £80.38 £3790 
      
FLAG-Ida + 
Mylotarg 
Day 1 G-CSF 300 microgram OD £80.38 £2513 
(course 1)  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
  Chlorphenamine 10 mg IV Bolus £1.90  
  Mylotarg 3 mg protein/m2 £1619  
 Day 2 G-CSF 300 microgram OD £80.38 £2992 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 3 G-CSF 300 microgram OD £80.38 £3882 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 4 G-CSF 300 microgram OD £80.38 £4361 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 5 G-CSF 300 microgram OD £80.38 £5250 
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  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 6 G-CSF 300 microgram OD £80.38 £5331 
 Day 7 G-CSF 300 microgram OD £80.38 £5411 
FLAG-Ida + 
Mylotarg 
Day 1 G-CSF 300 microgram OD £80.38 £892 
(course 2)  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 2 G-CSF 300 microgram OD £80.38 £1371 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 3 G-CSF 300 microgram OD £80.38 £2260 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 4 G-CSF 300 microgram OD £80.38 £2739 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
 Day 5 G-CSF 300 microgram OD £80.38 £3629 
  Granisetron 1mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Fludarabine 30 mg/m2 in 100ml N/S £366.6  
  Cytarabine 2000 mg/m2 in 500ml N/Saline £23.69  
  Idarubicin 10 mg/m2 in 100 ml £410.6  
 Day 6 G-CSF 300 microgram OD £80.38 £3709 
 Day 7 G-CSF 300 microgram OD £80.38 £3790 
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Detailed drug item cost list for MidAC related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
MidAC Day 1 Granisetron 2 mg Oral stat £15.4 £319 
Mini-MidAC  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Granisetron 2 mg Oral stat £15.4 £636 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
 Day 3 Granisetron 2 mg Oral stat £15.4 £953 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
 Day 4 Granisetron 2 mg Oral stat £15.4 £1078 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
 Day 5 Granisetron 2 mg Oral stat £15.4 £1204 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
      
HAM Day 1 Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95 £552.32 
  Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Granisetron 1 mg Oral stat £7.7 £1228 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95  
 Day 3 Granisetron 1 mg Oral stat £7.7 £1904 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95  
 Day 4 Granisetron 1 mg Oral stat £7.7 £2579 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95  
  Cytarabine 3000 mg/m2 in 500ml N/Saline £274.95  
 Day 5 Granisetron 1 mg Oral stat £7.7 £2705 
 - 409- 
 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
 Day 6 Granisetron 1 mg Oral stat £7.7 £2831 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
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Detailed drug item cost list for MACE related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
MACE Day 1 Granisetron 2 mg Oral stat £15.4 £236 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Granisetron 2 mg Oral stat £15.4 £472 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 3 Granisetron 2 mg Oral stat £15.4 £709 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 4 Granisetron 2 mg Oral stat £15.4 £945 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 5 Granisetron 2 mg Oral stat £15.4 £1181 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
      
MACE + Mylotarg Day 1 Granisetron 2 mg Oral stat £15.4 £1858 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Chlorphenamine 10 mg IV Bolus £1.90  
  Mylotarg 3 mg protein/m2 £1619  
 Day 2 Granisetron 2 mg Oral stat £15.4 £2094 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 3 Granisetron 2 mg Oral stat £15.4 £2330 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
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  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 4 Granisetron 2 mg Oral stat £15.4 £2566 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 5 Granisetron 2 mg Oral stat £15.4 £2802 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
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Detailed drug item cost list for Spanish approach related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
Spanish approach Day 1 ATRA 45 mg/m2 per day £16.03 £650 
(course 1)  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
  Granisetron 2 mg Oral stat £15.4  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 12 mg/m2 in 100 ml N/S £615.89  
 Day 2 ATRA 45 mg/m2 per day £16.03 £1298 
  Granisetron 2 mg Oral stat £15.4  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 12 mg/m2 in 100 ml N/S £615.89  
 Day 3 ATRA 45 mg/m2 per day £16.03 £1946 
  Granisetron 2 mg Oral stat £15.4  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 12 mg/m2 in 100 ml N/S £615.89  
 Day 4 ATRA 45 mg/m2 per day £16.03 £2594 
  Granisetron 2 mg Oral stat £15.4  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 12 mg/m2 in 100 ml N/S £615.89  
 Day 5-28 ATRA 45 mg/m2 per day £320.60 £2978 
Spanish approach  Day 1 ATRA 45 mg/m2 per day £16.03 £435 
(course 2)  Granisetron 1 mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 7 mg/m2 in 100 ml N/S £410.59  
 Day 2 ATRA 45 mg/m2 per day £16.03 £870 
  Granisetron 1 mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 7 mg/m2 in 100 ml N/S £410.59  
 Day 3 ATRA 45 mg/m2 per day £16.03 £1305 
  Granisetron 1 mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 7 mg/m2 in 100 ml N/S £410.59  
 Day 4 ATRA 45 mg/m2 per day £16.03 £1740 
  Granisetron 1 mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 7 mg/m2 in 100 ml N/S £410.59  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 5-15 ATRA 45 mg/m2 per day (for 11 days) £176.33 £1916 
Spanish approach  Day 1 Granisetron 1 mg Oral stat £7.7 £142 
(course 3)  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  ATRA 45 mg/m2 per day £16.03  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Granisetron 1 mg Oral stat £7.7 £284 
  Dexamethasone 8 mg Oral stat £0.56  
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  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  ATRA 45 mg/m2 per day £16.03  
 Day 3 Granisetron 1 mg Oral stat £7.7 £425 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  ATRA 45 mg/m2 per day £16.03  
 Day 4 Granisetron 1 mg Oral stat £7.7 £567 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  ATRA 45 mg/m2 per day £16.03  
 Day 5 Granisetron 1 mg Oral stat £7.7 £709 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  ATRA 45 mg/m2 per day £16.03  
 Day 6-15 ATRA 45 mg/m2 per day (for 10 days) £160.3 £869 
Spanish approach  Day 1 ATRA 45 mg/m2 per day £16.03 £640 
(course 4)  Granisetron 1 mg Oral stat £7.7  
  Dexamethasone 8 mg Oral stat £0.56  
  Idarubicin 12 mg/m2 in 100 ml N/S £615.89  
 Day 2-15 ATRA 45 mg/m2 per day (for 14 days) £224.42 £865 
Spanish maintenance  Mercaptopurine 50 mg/m2 OD for 84 days £148.29  
(Month 1-3) Week 1 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 2 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 3 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 4 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 5 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 6 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 7 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 8 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 9 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 10 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 11 Methotrexate 15 mg/m2 IM bolus £3.08  
 Week 12 Methotrexate 15 mg/m2 IM bolus £3.08  
Spanish Maintenance  Mercaptopurine 50 mg/m2 OD for 84 days £148.29  
(month 4-24 per 3 
months) 
 Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  Methotrexate 15 mg/m2 IM bolus £3.08  
  ATRA 45 mg/m2 per day for 15 days £240.43  
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Detailed drug item cost list for MRC approach related regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated
 cost 
MRC approach  Day 1 Granisetron 1mg Oral stat £7.7 £337 
(course 1)  Dexamethasone 8 mg Oral stat £0.56  
(ADE 10+3+5)  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
  ATRA 45 mg/m2 per day £16.03  
 Day 2 Granisetron 1 mg mg Oral stat £7.7 £406 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 3 Granisetron 1mg Oral stat £7.7 £742 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 4 Granisetron 1 mg mg Oral stat £7.7 £813 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 5 Granisetron 1mg Oral stat £7.7 £1147 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1181 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1216 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1250 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
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 Day 9 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1285 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 10 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1319 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  ATRA 45 mg/m2 per day £16.03  
 Day 
11-28 
ATRA 45 mg/m2 per day (18 days) £288.54 £1607 
MRC approach Day 1 Granisetron 1mg Oral stat £7.7 £320 
(course 2)  Dexamethasone 8 mg Oral stat £0.56  
(ADE 8+3+5)  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Metoclopramide 10 mg oral QDS prn £0.07  
  Allopurinol 300 mg Oral OD £2.15  
 Day 2 Granisetron 1 mg mg Oral stat £7.7 £376 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 3 Granisetron 1mg Oral stat £7.7 £694 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 4 Granisetron 1 mg mg Oral stat £7.7 £749 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 5 Granisetron 1mg Oral stat £7.7 £1067 
  Dexamethasone 8 mg Oral stat £0.56  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
  Daunorubicin 50 mg/m2 in 100ml N/Saline £263  
  Etoposide 100 mg/m2 in 500ml N/Saline £28.55  
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 6 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1085 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 7 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1104 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
 Day 8 Cytarabine 100 mg/m2 in 100ml N/Saline £9.17 £1122 
  Cytarabine 100 mg/m2 in 100ml N/Saline £9.17  
MRC approach Day 1 Granisetron 2 mg Oral stat £15.4 £236 
(course 3: MACE)  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
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  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Granisetron 2 mg Oral stat £15.4 £472 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 3 Granisetron 2 mg Oral stat £15.4 £709 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 4 Granisetron 2 mg Oral stat £15.4 £945 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
 Day 5 Granisetron 2 mg Oral stat £15.4 £1181 
  Dexamethasone 8 mg Oral stat £0.56  
  Etoposide 100 mg/m2 in 500 ml N/S £28.55  
  Amsacrine 100 mg/m2 in 500 ml Dextrose 5% £173.32  
  Cytarabine 200 mg/m2 in 1000 ml N/S £18.33  
MRC approach  Day 1 Granisetron 2 mg Oral stat £15.4 £319 
(course 4: MidAC)  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Prednisolone 0.5% 1op £2.35  
  Metoclopramide 10 mg oral QDS prn £0.07  
 Day 2 Granisetron 2 mg Oral stat £15.4 £636 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
 Day 3 Granisetron 2 mg Oral stat £15.4 £953 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
  Cytarabine 1000 mg/m2 in 500ml N/Saline £91.65  
 Day 4 Granisetron 2 mg Oral stat £15.4 £1078 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
 Day 5 Granisetron 2 mg Oral stat £15.4 £1204 
  Dexamethasone 8 mg Oral stat £0.56  
  Mitozantrone 10 mg/m2 in 100 ml N/S £117.5  
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Detailed drug item cost list for mild inpatient regimen (by day) 
 
Regimen Day Drug item Dosage Unit cost 
Accumulated c
ost 
Amsacrine Day 1 Amsacrine 100 mg/m2 iv £155.75 £156 / day 
      
Daunorubicin Day 1 Daunorubicin 60 mg/m2 in 100ml N/S £315.56 £316 / day 
      
Arsenic trioxide Day 1 Arsenic trioxide 0.25 mg/kg/day  £615.89 £616 / day 
      
Campath Day 1 Campath 30 mg iv £322.93 £328 
  Dexamethasone 8 mg oral stat £0.56  
  Chlorphenamine 10 mg iv bolus £1.90  
  Allopurinol 300 mg oral OD £2.15  
 Day 2 Allopurinol 300 mg oral OD £2.15 £330 
 Day 3 Campath 30 mg iv £322.93 £657 
  Dexamethasone 8 mg oral stat £0.56  
  Chlorphenamine 10 mg iv bolus £1.90  
  Allopurinol 300 mg oral OD £2.15  
 Day 4 Allopurinol 300 mg oral OD £2.15 £659 
 Day 5 Campath 30 mg iv £322.93 £987 
  Dexamethasone 8 mg oral stat £0.56  
  Chlorphenamine 10 mg iv bolus £1.90  
  Allopurinol 300 mg oral OD £2.15  
 Day 6 Allopurinol 300 mg oral OD £2.15 £989 
 Day 7 Allopurinol 300 mg oral OD £2.15 £991 
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Appendix 7.4 The treatment cost list for chemotherapy 
 
 
 
Treatment cost 
Drug cost Personnel cost Overheads cost Ward/clinic cost Complication 
(incl. antibiotic 
cost) 
Per Day Quantity Per Day Qauntity Per Day Quantity Per Day Quantity 
Chemotherapy          
Inpatient           
ADE           
    10+3+5 £1158.46 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
    8+3+5  £1121.90 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £667 
ADE + Mylotarg         
Course 1 £2779.87 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
Course 2 £1121.90 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £667 
AraC (HD)         
Course 1 £1699.97 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £910 
Course 2 £1699.97 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £746 
AraC (HD) + Mylotarg         
Course 1 £3321.12 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £910 
Course 2 £1699.97 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £746 
AraC (LD)         
Course 1 £91.60 × treatment time £116.2 × treatment time £20.4 × treatment time £67 × hospital stay £957 
Course 2 + £91.60 × treatment time £116.2 × treatment time £20.4 × treatment time £67 × hospital stay £630 
Clofarabine £17879.82 (full course) £140.2 × treatment time £22.4 × treatment time £67 × hospital stay £1260 
DA           
Course 1 £1015.83 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1487 
Course 2 £979.15 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1160 
DA + Mylotarg         
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Course 1 £2637.12 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1487 
Course 2 £979.15 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1160 
FLA         
Course 1 £1978.65 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £1792 
Course 2 £1978.65 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £2200 
FLAG         
Course 1 £2557.83 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £1792 
Course 2 £2557.83 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £2200 
FLAG-Ida         
Course 1 £3789.60 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £1404 
Course 2 £3789.60 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £2549 
FLAG-Ida + Mylotarg         
Course 1 £5410.89 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £1404 
Course 2 £3789.60 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £2549 
HAM £2830.82 (full course) £140.2 × treatment time £22.4 × treatment time £67 × hospital stay £1066 
MidAC £1204.19 (full course) £140.2 × treatment time £22.4 × treatment time £67 × hospital stay £877 
Mini MidAC £1204.19 (full course) £140.2 × treatment time £22.4 × treatment time £67 × hospital stay £877 
MACE £1180.82 (full course) £107.3 × treatment time £18.8 × treatment time £67 × hospital stay £1085 
Spanish approach         
Course 1 £2978.42 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
Course 2 £1915.92 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
Course 3 £869.32 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
Course 4 £864.60 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
MRC approach         
Course 1 £1607.42 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £1165 
Course 2 £1121.90 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £1983 
Course 3 £1180.2 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £683 
Course 4 £1204.19 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £1375 
Inpatient (Mild          
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Amsacrine £155.75 × treatment time £134.2 × treatment time £20.4 × treatment time £67 × treatment time £1145 
Arsenic trioxide £250 × treatment time £134.2 × treatment time £20.4 × treatment time £67 × treatment time £1145 
Campath £991.22 × treatment time/7d £134.2 × treatment time/7d £20.4 × treatment time/7d £67 × treatment time/7d £1145 
Outpatient (Intensive)          
Cyclophosphamid £69.78 × treatment time /7 d £26.6 × treatment time /7 d £6.05 × treatment time /7 d £19 × treatment time /7 d - 
Cyclophosphamid/MESNA £132.06  £26.6  £6.05  £19  - 
Daunorubicin £315.56 × treatment time /21d £134.2 × treatment time /21d £20.4 × treatment time/21d £19 × treatment time /21d - 
ETI £203.85 × treatment time /26d £133 × treatment time /26d £30.25 × treatment time /26d £95 × treatment time /26d - 
FC £157.13 × treatment time /28d £133 × treatment time /28d £30.25 × treatment time /28d £95 × treatment time /28d - 
Fludarabine £765.35 × treatment time /33d £133 × treatment time /33d £30.25 × treatment time /33d £95 × treatment time /33d - 
Etoposide £87.64 × treatment time /28d £186.2 × treatment time /28d £42.35 × treatment time /28d £133 × treatment time /28d - 
Melphalan £5.01 × treatment time £26.6 × treatment time £6.05 × treatment time £19 × treatment time - 
Vincristine £24.87 × treatment time /7d £26.6 × treatment time /7d £6.05 × treatment time /7d £19 × treatment time /7d - 
ATRA £16.03 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d £165 
Mylotarg £1619.36 × treatment time /7d £134.2 × treatment time /7d £20.4 × treatment time /7d £19 × treatment time /7d £197 
Anagrelide £3.37 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
Clopidogrel £1.21 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
Outpatient (Mild)          
Aspirin £0.1 × treatment time £26.6 × treatment time/28d £6.05 × treatment time/28d £19 × treatment time/28d - 
Hydroxycarbamide £0.72 × treatment time £26.6 × treatment time/28d £6.05 × treatment time/28d £19 × treatment time/28d £122 
Hydroxycarbamide + Aspirin £0.82 × treatment time £26.6 × treatment time/28d £6.05 × treatment time/28d £19 × treatment time/28d £122 
Chelating agents          
First week £31.08 × treatment time £26.6 × treatment time £6.05 × treatment time £67 × treatment time - 
After 8 days £5.33 × treatment time £26.6 × treatment time/28d £6.05 × treatment time/28d £19 × treatment time/28d - 
Clinical Trial          
AML 14 AraC         
   Course  1  £91.60 × treatment time £116.2 × treatment time £20.4 × treatment time £67 × hospital stay £957 
   Course  2  £91.60 × treatment time £116.2 × treatment time £20.4 × treatment time £67 × hospital stay £630 
AML 14 AraC + Mylotarg         
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   Course  1  £91.60 × treatment time+£1619 £116.2 × treatment time £20.4 × treatment time £67 × hospital stay £957 
   Course  2  £91.60 × treatment time £116.2 × treatment time £20.4 × treatment time £67 × hospital stay £630 
AML 14 D35 C200         
   Course  1  £889.59 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1487 
   Course  2  £852.91 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1160 
AML 14 D35 C400         
   Course  1  £1072.79 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1487 
   Course  2  £999.47 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1160 
AML 14 D50 C200         
   Course  1  £1015.83 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1487 
   Course  2  £979.15 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1160 
AML 15 ADE         
   10+3+5 £1158.46 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
   8+3+5 £1121.90 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £667 
AML 15 ADE + Mylotarg         
   10+3+5 £1158.46 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
   8+3+5 £1158.46 (full course) £135.6 × treatment time £20.5 × treatment time £67 × hospital stay £1239 
AML 15 AraC         
   Course  1  £1699.97 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £910 
   Course  2  £1699.97 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £746 
AML 15 AraC + Mylotarg         
   Course  1  £3321.12 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £910 
   Course  2  £1699.97 (full course) £122.5 × treatment time £21.3 × treatment time £67 × hospital stay £746 
AML 15 DA         
   10+3 £1015.83 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1487 
   8+3  £979.15 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1160 
AML 15 DA + Mylotarg         
   10+3 £2637.12 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1487 
   8+3  £979.15 (full course) £130.4 × treatment time £18.6 × treatment time £67 × hospital stay £1160 
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AML 15 FLAG-Ida         
   Course  1  £3789.60 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £1404 
   Course  2  £3789.60 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £2549 
AML 15 FLAG-Ida + Mylotarg         
   Course  1  £5410.89 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £1404 
   Course  2  £3789.60 (full course) £101.6 × treatment time £14.6 × treatment time £67 × hospital stay £2549 
AML 15 MidAC £1204.19 (full course) £140.2 × treatment time £22.4 × treatment time £67 × hospital stay £877 
AML 15 MACE £1180.82 (full course) £107.3 × treatment time £18.8 × treatment time £67 × hospital stay £1085 
AML 15 MACE + Mylotarg £2799.82 (full course) £107.3 × treatment time £18.8 × treatment time £67 × hospital stay £1085 
APML 15 Spanish approach         
   Course  1  £2978.42 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
   Course  2  £1915.92 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
   Course  3  £869.32 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
   Course  4  £864.60 (full course) £116 × treatment time £16.9 × treatment time £67 × hospital stay £1192 
APML Spanish Maintenance £425.66 £26.6 × duration / 14 d £6.05 × duration / 14 d £19 × duration / 28d  
         
APML 15 MRC approach         
   Course  1  £1607.42 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £1165 
   Course  2  £1121.90 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £1983 
   Course  3  £1180.2 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £683 
   Course  4  £1204.19 (full course) £157.6 × treatment time £22.8 × treatment time £67 × hospital stay £1375 
Supportive care          
Erythropoietin £46.76 × treatment time /7d £45.3 × treatment time /7d £9.95 × treatment time /7d £19 × treatment time /7d - 
Transfusion          
Duration < 100 days £414 × treatment time/4d £41.9 × treatment time/4d £6.2 ×treatment time/4d £67 × treatment time/4d - 
Duration > 100 days £414 × treatment time/14d £41.9 × treatment time/14d £6.2 × treatment time/14d £67 × treatment time/14d - 
G-CSF £322 × frequency £40.8 × frequency £8.9 × frequency £268 × frequency - 
Steroids          
Dexamethasone: £0.58 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
 - 423- 
 
Prednisdone £0.14 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
Hydrocortisone £1.4 × treatment time £26.6 × treatment time /28d £6.05 × treatment time /28d £19 × treatment time /28d - 
Other treatment Group 1          
Venesection £0 once £41.9 once   £9.4 once £19 once - 
Immunosupressive therapy £23.5 × treatment time £32.1 × treatment time /28d £6.95 × treatment time /28d £19 × treatment time /28d - 
Other treatment Group 2  
Palliative Care  
Duration <30 £336 × 3× treatment time /7d 
Duration >30 Follow-up 
End of life £938 for 14 days 
Follow-up £53 × gap between treatments / 28 day 
Other treatment Group 3  
Splenectomy £4,010 
Transplant £45558 
Radiotherapy  
TBI £635 
Non-TBI £651 
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Appendix 9.1 The detailed cost results of each treatment 
 
Events No 
Cost 1 (exclude complication cost) Cost 2 (include complication cost) 
Mean Min Max Mean Min Max 
Average cost  239 pts £26081 £193 £236310 £28584 £193 £248227 
Chemotherapy 329 courses £3440 £59 £13770 £4284 £60 £15030 
Clinical trial 265 courses £5010 £914 £7997 £6220 £914 £10131 
Chemo+trial 594 courses £4140 £59 £13770 £5148 £60 £15030 
Inpatient chemotherapy 516 courses £4678 £638 £13770 £5829 £729 £5112 
Outpatient chemotherapy 78 events £587 £59 £5112 £640 £60 £5112 
    ADE  47 courses £4367 £4797 £2553 £5284 £2677 £6036 
Course 1 23 courses £4625 £2553 £4797 £5799 £2677 £6036 
Course 2 24 courses £4120 £3938 £4287 £4790 £4522 £5037 
Chemotherapy 26 courses £4395 £2553 £4797 £5361 £2677 £6036 
Course 1 16 courses £4562 £2553 £4797 £5708 £2677 £6036 
Course 2 10 courses £4310 £4113 £4287 £4805 £4779 £5037 
AML 15 21 courses £4331 £3938 £4797 £5189 £4522 £6036 
Course 1 7 courses £4768 £4596 £4797 £6007 £5835 £6036 
Course 2 14 courses £4113 £3938 £4287 £4779 £4522 £5037 
    ADE  +  Mylotarg  10 courses £6132 £4113 £6418 £7290 £4779 £7657 
Chemotherapy - - - - - - - 
AML 15 10 courses £6132 £4113 £6418 £7290 £4779 £7657 
Course 1 9 courses £6357 £6069 £6418 £7568 £7060 £7657 
Course 2 1 course £4113 - - £4779 - - 
    AraC (HD) 40 courses £4091 £3092 £4405 £4919 £3689 £5315 
Course 1 21 courses £4389 £4202 £4405 £5299 £5114 £5315 
Course 2 19 courses £3761 £3092 £3802 £4499 £3689 £4548 
Chemotherapy 15 courses £4199 £3735 £4405 £5055 £4481 £5315 
Course 1 10 courses £4405 £4405 £4405 £5315 £5315 £5315 
Course 2 + 5 courses £3788 £3735 £3802 £4535 £4481 £4548 
AML 15 25 courses £4025 £3092 £4405 £4838 £3689 £5315 
Course 1 11 courses £4374 £4204 £4405 £5284 £5114 £5315 
Course 2 14 courses £3751 £3092 £3802 £4487 £3689 £4548 
    AraC(HD) + Mylotarg 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Chemotherapy - - - - - - - 
AML 15 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Course 1 7 courses £5926 £5316 £6028 £6810 £6044 £6938 
Course 2 - - - - - - - 
    AraC (LD) 83 courses £3396 £638 £4895 £4088 £729 £5852 
Course 1 39 courses £3226 £638 £4895 £4002 £729 £5852 
Course 2 44 courses £3547 £1285 £4359 £4164 £1348 £4989 
Chemotherapy 72 courses £3267 £638 £4895 £3951 £729 £5852 
Course 1 35 courses £3096 £638 £4895 £3851 £729 £5852 
Course 2+ 37 courses £3430 £1285 £4359 £4045 £1348 £4989 
AML 14 11 course £4237 £3019 £4359 £4986 £3649 £5316 
Course 1 4 courses £4359 £4359 £4359 £5316 £5316 £5316 
Course 2+ 7 courses £4168 £3019 £4359 £4798 £3649 £4989 
    AraC (LD) + Mylotarg 2 courses £5170 £4359 £5980 £5963 £4989 £6938 
Chemotherapy - - - - - - - 
AML 14 2 courses £5170 £4359 £5980 £5963 £4989 £6938 
Course 1 1 course £5980 - - £6938 - - 
Course 2 1 course £4359 - - £4989 - - 
    DA  91 courses £4458 £750 £4918 £5738 £819 £6405 
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Course 1 52 courses £4559 £750 £4918 £5913 £819 £6405 
Course 2 39 courses £4322 £2774 £4751 £5501 £3688 £6055 
    DA (D50 C200) 85 courses £4454 £750 £4918 £5726 £819 £6405 
Chemotherapy 57 courses £4349 £750 £4918 £5591 £819 £6405 
Course 1 34 courses £4397 £750 £4918 £5689 £819 £6405 
Course 2 + 23 courses £4279 £2774 £4751 £5447 £3688 £6055 
AML 14 7 courses £4631 £4248 £4918 £5977 £5408 £6405 
Course 1 4 courses £4918 £4918 £4918 £6405 £6405 £6405 
Course 2 3 courses £4248 £4248 £4248 £5408 £5408 £5408 
AML 15 21 courses £4679 £4248 £4918 £6008 £5408 £6405 
Course 1 10 courses £4884 £4751 £4918 £6341 £6089 £6405 
Course 2 11 courses £4492 £4248 £4751 £5704 £5408 £6055 
DA (D35 C200) 5 courses £4470 £3854 £4792 £5826 £5014 £6278 
AML 14 5 courses £4470 £3854 £4792 £5826 £5014 £6278 
Course 1 3 courses £4792 £4792 £4792 £6278 £6278 £6278 
Course 2 2 courses £3988 £3854 £4122 £5148 £5014 £5282 
DA (D35 C400) 1 course £4707 - - £6194 - - 
AML 14 1 course £4707 - - £6194 - - 
Course 1 1 course £4707 - - £6194 - - 
Course 2 - - - - - - - 
    DA+Mylotarg  8 courses £6253 £4248 £6539 £7699 £5408 £8026 
Chemotherapy 1 course £6539 - - £8026 - - 
Course 1 1 course £6539 - - £8026 - - 
Course 2 + - - - - - - - 
AML 15 7 courses £6212 £4248 £6539 £7652 £5408 £8026 
Course 1 6 courses £6539 £6539 £6539 £8025 £8025 £8025 
Course 2 1 course £4248 - - £5408 - - 
    Clofarabine 3 courses £13256 £12631 £13770 £14516 £13891 £15030 
Chemotherapy 3 courses £13256 £12631 £13770 £14516 £13891 £15030 
Course 1 2 courses £13200 £12631 £13770 £14461 £13891 £15030 
Course 2  1 course £13368 - - £14628 - - 
    FLA  7 courses £4713 £3565 £5709 £6551 £4865 £7909 
Chemotherapy 7 courses £4713 £3565 £5709 £6551 £4865 £7909 
Course 1 4 courses £4503 £4503 £4503 £6294 £6294 £6294 
Course 2  3 courses £4994 £3565 £5709 £6894 £4865 £7909 
    FLAG  25 courses £5305 £4474 £6283 £7100 £5759 £8615 
Chemotherapy 25 courses £5305 £4474 £6283 £7100 £5759 £8615 
Course 1 16 courses £5303 £4661 £5479 £6951 £5759 £7402 
Course 2  9 courses £5308 £4474 £6283 £7365 £6233 £8615 
    FLAG-Ida  40 courses £6575 £5505 £7582 £8403 £6909 £10131 
Course 1 21 courses £6243 £5505 £6376 £7551 £6909 £7780 
Course 2 19 courses £6943 £5572 £7582 £9344 £7139 £10131 
Chemotherapy 6 courses £6503 £6153 £7582 £7963 £7155 £10131 
Course 1 5 courses £6287 £6153 £6376 £7530 £7155 £7780 
Course 2 + 1 course £7582 - - £10131 - - 
AML 15 34 courses £6588 £5505 £7582 £8480 £6909 £10131 
Course 1 16 courses £6230 £5505 £6376 £7558 £6909 £7780 
Course 2 18 courses £6907 £5572 £7582 £9300 £7139 £10131 
    FLAG-Ida + Mylotarg 19 courses £7807 £7037 £7998 £9449 £8040 £10131 
Chemotherapy 1 course £7774 - - £8777 - - 
Course 1 1 course £7774 - - £8777 - - 
Course 2 + - - - - - - - 
AML 15 18 courses £7809 £7037 £7997 £9486 £8040 £10131 
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Course 1 13 courses £7896 £7037 £7997 £9238 £8040 £9401 
Course 2 5 courses £7582 £7582 £7582 £10131 £10131 £10131 
    MACE  21 courses £3519 £2829 £3553 £4583 £3480 £4638 
Chemotherapy 11 courses £3488 £2829 £3553 £4533 £3480 £4638 
Course 1 10 courses £3481 £2829 £3553 £4522 £3480 £4638 
Course 2 + 1 course £3553 - - £4638 - - 
AML 15 10 courses £3553 £3553 £3553 £4638 £4638 £4638 
Course 1 10 courses £3553 £3553 £3553 £4638 £4638 £4638 
Course 2 - - - - - - - 
    MACE + Mylotarg 9 courses £5175 £5175 £5175 £6259 £6259 £6259 
AML 15 9 courses £5175 £5175 £5175 £6259 £6259 £6259 
Course 1 9 courses £5175 £5175 £5175 £6259 £6259 £6259 
Course 2 - - - - - - - 
    MidAC  31 courses £3967 £3038 £4094 £4771 £3389 £4971 
Chemotherapy 17 courses £3913 £3038 £4094 £4687 £3389 £4971 
Course 1 15 courses £3889 £3038 £4094 £4649 £3389 £4971 
Course 2 + 2 courses £4094 £4094 £4094 £4971 £4971 £4971 
AML 15 14 courses £4032 £3518 £4094 £4872 £4044 £4971 
Course 1 14 courses £4032 £3518 £4094 £4872 £4044 £4971 
Course 2 - - - - - - - 
    HAM  1 courses £5883 - - £6949 - - 
Chemotherapy 1 courses £5883 - - £6949 - - 
Course 1 1 courses £5883 - - £6949 - - 
Course 2 + - - - - - - - 
    Spanish  33 courses £4636 £3339 £6403 £5799 £3964 £7595 
Course 1 10 courses £5975 £3508 £6403 £7094 £3964 £7595 
Course 2 9 courses £4579 £3339 £4734 £5743 £4285 £5926 
Course 3 7 courses £4019 £3789 £4057 £5211 £4981 £5249 
Course 4 7 courses £3416 £3377 £3645 £4608 £4569 £4837 
Spanish like 6 courses £4951 £3645 £6403 £6143 £4837 £7595 
Course 1 2 courses £6403 £6403 £6403 £7595 £7595 £7595 
Course 2 2 course £4734 £4734 £4734 £5926 £5926 £5926 
Course 3 1 course £3789 - - £4981 - - 
Course 4 1 course £3645 - - £4837 - - 
AML 15 27 courses £4566 £3339 £6403 £5722 £3964 £7595 
Course 1 8 courses £5868 £3508 £6403 £6968 £3964 £7595 
Course 2 7 courses £4534 £3339 £4734 £5691 £4285 £5926 
Course 3 6 courses £4057 £4057 £4057 £5249 £5249 £5249 
Course 4 6 courses £3377 £3377 £3377 £4569 £4569 £4569 
    MRC  35 courses £4283 £3511 £5500 £5606 £4300 £6795 
Course 1 10 courses £5301 £3511 £5500 £6575 £4594 £6795 
Course 2 9 courses £4160 £4041 £4175 £6143 £6024 £6158 
Course 3 9 courses £3617 £3617 £3617 £4300 £4300 £4300 
Course 4 7 courses £3841 £3841 £3841 £5216 £5216 £5216 
AML 15 31 courses £4283 £3511 £5500 £5606 £4300 £6795 
Course 1 9 courses £5279 £3511 £5500 £6550 £4594 £6795 
Course 2 8 courses £4159 £4041 £4175 £6141 £6024 £6158 
Course 3 8 courses £3617 £3617 £3617 £4300 £4300 £4300 
Course 4 6 courses £3841 £3841 £3841 £5216 £5216 £5216 
MRC-like 4 courses £4283 £3617 £5500 £5617 £4300 £6795 
Course 1 1 course £5500 - - £6795 - - 
Course 2 1 course £4175 - - £6158   
Course 3 1 course £3617 - - £4300 - - 
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Course 4 1 course £3841 - - £5216 - - 
    Amsacrine  1 courses £2155 - - £3300 - - 
    Arsenic  trioxide  2 courses £10391 £10391 £10391 £11537 £11537 £11537 
    Campath  1 courses £2211 - - £3357 - - 
    ATRA  3 £334 £106 £757 £405 £124 £922 
    Anagrelide 1 £152 - - £152 - - 
    Clopidogrel 1 £92 - - £92 - - 
    Cyclophosphamide 6 £128 £128 £128 £128 £128 £128 
    Cyclophosphamide + MESNA 1 £173 - - £173 - - 
    Daunorubicin 1 £768 - - £768 - - 
    ETI  2 £1440 £786 £2095 £1440 £786 £2095 
    Etoposide 0 - - - - - - 
    FC  6 £775 £215 £1687 £775 £215 £1687 
    Fludarabine 2 £594 £364 £823 £594 £364 £823 
    Mylotarg  1 £1712 - - £1909 - - 
    Melphalan  3 £228 £128 £382 £228 £128 £382 
    Aspirin  2 £90 £60 £120 £90 £60 £120 
    Hydroxycarbamide 39 £132 £59 £384 £226 £63 £506 
    Hydroxycarbamide / Aspirin 1 £2244 - - £2366 - - 
    Chelating agents 2 £3874 £2636 £5112 £3874 £2636 £5112 
    Vincristine  1 £374 - - £374 - - 
    Spanish maintenance 5 £3165 £914 £4563 £3165 £914 £4563 
Supportive care        
Transfusion 267 courses £8861 £530 £67282 £8861 £530 £67282 
 190 events £12453 £530 £75229 £12453 £530 £75229 
Erythropoietin 3 £1628 £111 £4440 1628 £111 £4440 
G-CSF 62 £827 £197 £4765 £827 £197 £4765 
 55 IP events £748 £197 £1182 £748 £197 £1182 
 7 OP events £1447 £596 £4765 £1447 £596 £4765 
Steroids 13 £300 £59 £1733 £300 £59 £1733 
Dexamethasone 5 £110 £62 £289 £110 £62 £289 
Prednisolone 7 £467 £59 £1733 £467 £59 £1733 
Hydrocortisone 1 £79 - - £79 - - 
Palliative care 33 patients £2223 £336 £6313 £2223 £336 £6313 
End of life care 66 patients £938 - - £938 - - 
splenectomy 2 £4010 - - £4010 - - 
venesection 3 £1168 £280 £2102 £1168 £280 £2102 
immunosuppressive 6 £5302 £82 £16684 £5302 £82 £16684 
stem cell transplant 13 £44199 - - £44199 - - 
radiotherapy 14 £1318 £635 £2771 £1318 £635 £2771 
Observation 135 pts £1326 £53 £4416    
   When no treatment 10 pts £335 £53 £1649    
   Refused treatment 2 pts £80 £53 £106    
Follow-up 123 pts £1427 £53 £4416    
 269 events £653 £53 £3564    
Lab cost 239 pts £1662 £140 £12288 £1662 £140 £12288 
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